"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016 on the Investors page of the bd.com website or by phone at (800) 585-8367 f",79,"Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016 on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 20775429. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Cristy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",409,"Thank you, Cristy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com. 
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first fiscal quarter press release and in the MD&A sections of our recent SEC filings. 
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures in the financial schedule, in our press release or the appendix of the Investor Relations slides. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Bill Kozy, Executive Vice President and Chief Operating Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. It is now my pleasure to turn the call over to Vince."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our",449,"Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our expectations. Strong underlying margin expansion was driven by the achievement of operational efficiencies and continuous improvement, coupled with the positive impact of synergies. 
As we move through the first quarter, we continue to make progress with the strategic review of our portfolio. Many of you already know, we recently announced Fresenius Kabi has acquired the BD Simplist portfolio. We believe Fresenius is a better owner of the BD Rx business as it complements their existing products and capabilities in the injectable pharmaceutical industry. In addition, we are excited that we are initiating a long-term collaboration for Fresenius to supply us with a portfolio of competitive ID solutions in the U.S. This transaction is intended to enable BD to be responsive to our customers' needs and is complementary to our end-to-end Medication Management Solutions for our customers and their patients. 
Since we provided guidance in November, there have been a number of new dynamics that will affect our results this year. As most of you already know, several weeks ago there was a bipartisan agreement to suspend the Medical Device Tax. This critical relief is extremely important to BD as well as the patients, providers and research communities we serve. While some of the specifics are still being analyzed, we plan to reinvest this tax back into the business which further supports our innovation strategy. 
In summary, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We're also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year.
Moving on to Slide 5, I will review our first quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company revenues grew 1.8%, which is in line with our prior guidance of 1% to 2% growth that we had anticipated and communicated on our last earnings call. Adjusting for tough comparisons for the prior year, this reflects solid underlying growth in both segments. 
Adjusted EPS was $1.96 driven by the solid underlying performance of the segments. Earnings were ahead of our expectations as the quarter also benefited from product mix that was incremental to already strong gross margin performance and some timing of expenses and below the line items. 
Now I'd like to turn things over to Chris for a more detailed discussion of our first quarter financial performance and our updated fiscal year 2016 guidance."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with o",1857,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with our previously disclosed guidance. Our growth rate this quarter reflects a tough comparison to strong prior year results of 6.7% organic growth, which includes CareFusion's final quarter as a stand-alone company growing at 10% organically. As a reminder, our results last year were driven by robust performance in the legacy CareFusion businesses, the impact of timing of orders in Pharmaceutical Systems, a very strong flu season, timing of tenders and strong emerging market performance. As a result, these items negatively impacted our first quarter growth rate by over 240 basis points. On an underlying basis, we are pleased with the solid performance of our segments and the momentum in our businesses.
BD Medical first quarter revenues increased 1.9%, reflecting the aforementioned items. Medication & Procedural Solutions or MPS growth was 2.0%, which reflects strength in pharmacy solutions, Infusion Therapy and safety-engineered products. Very strong results in the prior year negatively impacted the MPS growth rate by approximately 250 basis points. 
Despite extremely strong results in the prior year in Medication Management Solutions, revenues grew 4.3%, driven by both strong infusion and dispensing capital installations. Respiratory Solutions revenues declined 6.8%, reflecting the tough comparisons of prior year results due to the strong final quarter as part of legacy CareFusion. Growth in Diabetes Care was 3.9%, driven by solid growth in pen needles. 
Pharmaceutical Systems growth of 2.6% reflects strong growth in SAIS, partially offset by the impact of timing of orders, which we expect to occur later this fiscal year. 
BD Life Sciences first quarter revenues increased 1.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Preanalytical Systems growth of 4.4% was driven by safety-engineered products in both the U.S. and Europe and also reflects strong growth in emerging markets. BD Biosciences growth of 1.2% reflects clinical tendered delays in emerging markets and a difficult comparison to the prior year when sequestration ended. This was offset by strong sales that were driven by an increased demand of high-end instruments and growth in research reagents. The Diagnostic Systems decline of 0.8% reflects a mild flu season, which impacted growth by approximately 400 basis points. Growth was also negatively impacted by a slowdown of capital spending in China. Solid microbiology growth as well as growth in molecular led by BD MAX and international growth in Women's Health partially offset the impact from the flu.
Moving to Slide 8, I'll walk you through our geographic revenues for the first quarter on a currency-neutral basis. U.S. growth of 1.5% reflects the aforementioned prior year comparisons and timing impacts with BD Medical growing 1.9% and BD Life Sciences growing 0.3%. BD Medical's performance reflects strength in pharmacy solutions, infusion therapy pumps and related consumables and strength in Diabetes Care. This was partially offset by Respiratory Solutions. BD Life Sciences growth reflects the impact of a light of flu season this year and a difficult comparison to the prior year due to a strong flu season and the ending of sequestration. Offsetting these impacts was strong performance in the Biosciences business driven by research reagent sales, solid performance in our Preanalytical Systems unit, growth in microbiology and growth from BD MAX.
Moving on to international, revenues grew 2.2%. This is below our normal growth rate, which reflects timing of tenders and capital installations. International revenues also reflect the moderation of growth in China in the quarter, and I'll provide more color on China in just a moment.
Medical segment grew 1.9%. This reflects solid performance in Pharmaceutical Systems and Medication Management Solutions, partially offset by a tough comparison due to large tenders in Brazil and the MA in the prior year as well as timing of capital installations in the dispensing business. 
Our Life Sciences segment grew 2.7%, which reflects strong growth in Diagnostic Systems driven by core microbiology, Women's Health and an expanded BD MAX menu in Europe. We also saw strong growth in the Preanalytical Systems unit. This was partially offset by a decline in the Biosciences business due to tender delays in emerging markets.
On Slide 9, emerging market revenues grew 2.4% currency-neutral, with developed markets growing 1.7%. The first quarter growth rate in emerging markets reflects a very difficult comparison to the prior-year period, both the BD and CareFusion legacy businesses and a moderation of growth in China. 
China growth for the first quarter was 4.5% compared with growth of over 23% in the first quarter of last year. This difficult comparison was in line with our expectations. Beyond the difficult comparison, we also experienced a continued slowdown of capital spending in Diagnostic Systems, which resulted in inventory adjustments. Inventory adjustments negatively impacted growth in the quarter by approximately 350 basis points. While there are pockets of pressure, millions of patients are entering the healthcare system and, overall, emerging markets continue to be an important growth driver. For the total year, we expect China to grow in the low double-digit range and total emerging markets to grow 9% to 10%.
Moving to global safety on Slide 10, currency-neutral sales increased 4.9% and grew to $737 million in the quarter. Safety revenues in the U.S. grew 3.8%, while international sales grew 6.5% currency-neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 10.9% in emerging markets. Medical Safety sales grew 5.4%, primarily driven by safety catheters and a range of products in Pharmaceutical Systems. Life Science safety sales, which are driven by our Preanalytical Systems unit, grew 4.1% in the quarter.
Slide 11 recaps the first quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 1.8% on a comparable currency-neutral basis. Pricing was about flat in the quarter. 
Moving down the P&L, I will focus on the comparable basis figures, which include CareFusion results in the prior year, in order to give a better indication of our performance. 
Gross profit improved by 3.6%. I'll provide more color on gross profit in the next slide when we look at underlying performance and the impact of currency. 
SSG&A as a percentage of revenue was 24.9%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenues was 6.3% as we continue to invest in new products and innovation. 
Operating income grew 12%, reflecting strong P&L leverage, which I'll also address in more detail in the next slide. 
Our tax rate increased slightly. However, it continues to improve versus our initial deal model expectations. 
As discussed earlier, adjusted earnings per share were $1.96, which is a 45.8% increase versus the prior year. This reflects solid underlying performance from the segments, positive product mix that was incremental to already strong gross margin performance, some timing of expenses and below-the-line items.
Slide 12 illustrates our gross profit and operating margin for the first quarter presented on a comparable basis. Strong gross profit margin performance of 130 basis points was primarily driven by continuous improvement initiatives and product mix and, to a lesser extent, favorable raw material prices. Building off the strong momentum in fiscal year 2015 of 100 basis points of underlying operating margin expansion, operating margins grew 220 basis points year-over-year, driven by gross margin expansion combined with the achievement of operational efficiencies, continuous improvement and the positive impact of cost synergies. Currency had a negative impact on both gross profit margin and operating margins.
Moving on to Slide 14. Since we provided guidance in November, there have been a number of new dynamics that we anticipate will affect our results. Some of these items include the sale of BD Rx, the suspension of the Medical Device Tax,, the reinstatement of the R&D tax credit, lower oil prices, a milder flu season and additional FX pressure. As a result of these new dynamics, in combination with our first quarter results, we are raising our currency-neutral adjusted EPS guidance by 4 percentage points from $8.73 to $8.80 to a range of $9.01 to $9.08. The increased currency-neutral guidance is offset by incremental FX pressures of approximately $0.28 due to the continued strengthening of the U.S. dollar. Therefore, we are maintaining our adjusted EPS guidance of $8.37 to $8.44. We are extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 15, I'd like to walk you through additional elements of our guidance for the full fiscal year 2016. In summary, we continue to expect comparable revenue growth of 4.5% to 5% on a currency-neutral basis. On a reported basis, revenue growth for the total year is expected to be between 20% and 20.5%, which reflects a currency headwind of about 450 basis points. U.S. dollar has strengthened further against most currencies since we last provided guidance in November. Our guidance assumes a euro to dollar exchange rate of 1.09. We expect this unfavorable impact to be acute again in the second quarter with a revenue headwind of over 400 basis points on a comparable basis. We expect our currency-neutral revenue growth to be back in line with our guidance range of 4.5% to 5%. In the second half of the year, we expect the currency impact on revenue to moderate. 
We continue to expect growth in BD Medical of 4.5% to 5%. In our Life Sciences segment, we are revising our guidance to 4% to 4.5% to reflect the mild flu season in combination with lower sales in China. 
Based on the current view of the environment, we continue expect pricing to be about flat for the year. We continue to expect gross profit margin to be between 52% and 52.5% as the benefit from operating efficiencies, the sale of BD Rx and lower resin prices are expected to be partially offset by increased currency pressure. SSG&A as a percentage of sales is expected to be between 24% and 24.5%. This is slightly better than our previous forecast as a result of the suspension of the Medical Device Tax, which was recorded within SSG&A. As we reinvest the medical device tax, we now expect R&D investment of about 6% to 6.5% of revenues. The reinvestment will help us to accelerate the strategies in both of our segments. 
Operating margin is expected to be between 21% and 22% of revenues as a result of the items I just reviewed. Excluding the unfavorable impact of foreign currency, we are raising our underlying operating margin guidance to 170 to 190 basis points. Once again, we are very pleased with our performance in driving margin expansion. 
We are broadening our tax rate to be between 21% and 22%. 
Our full-year guidance ranges for operating cash flow, capital expenditures, interest/other and share count remain unchanged from our November guidance. 
Now I would like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each",825,"Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each quarter. The product update slides that you are accustomed to seeing will remain in the appendix of the presentation for reference. 
Starting with new product innovation, within our Life Sciences business, we are very pleased with the early access customer response to the BD FACSSymphony, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell. BD FACSSymphony  offers high-speed analysis that is 20x faster than other nonflow platforms. When combined with our BD Horizon Brilliant or the sirige and reagent portfolio, these capabilities will allow researchers improve identification and analysis of rare cell types and events. 
In early December, we successfully launched our FACSCelesta instrument, a mid-level cell analyzer with a very positive market reception. The new FACSCelesta system offers simultaneous measurement of up to 14 different single cell characteristics. The FACSCelesta system is also designed to leverage our broad BD Horizon Brilliant reagent portfolio. 
In our Diagnostic Systems business, we continue to focus on menu expansion and anticipate launching new assays on the BD MAX platform in fiscal year 2016, including CT/GC and Vaginitis. 
Within our strategic and business initiatives, as we discussed earlier, we have divested the BD Rx business and are excited to be adding IV solutions to our medication management portfolio. 
We continue to make progress with our portfolio strategic review process and will provide you with updates as we move forward. 
In January, we launched our new BD branded captures the new BD and our rearticulated purpose, advancing the world of health, which is more relevant than ever in a dynamic and ever-changing industry. 
And in an equally important area of partnerships and collaborations, we remain on track with our collaboration with Medtronic. The insulin infusion sets in our Diabetes Care business have an expected product launch in the middle of the fiscal year 2016, so this year. We believe this product will improve the consistency of insulin delivery by significantly reducing silent occlusions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We continue to see strong growth in opportunities in our IDAST business, where we have built a comprehensive solution offering, which includes the BD Bruker Maldi Biotyper. This is a result of the collaboration with Bruker Corporation. We've seen success over the past several years with the BD Bruker MBT instrument due to its ability to provide rapid and accurate microbial identification and its adoption in new geographic markets. As you can see, we continue to have strong opportunities that drive growth and innovation, and we look forward to updating you as we make progress throughout the year.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the first quarter, and we made progress with our back office functions and with harmonizing our IT infrastructure. We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs as we discussed earlier. The consistent solid performance of our business, combined with operating efficiencies, cost leverage and cost synergy capture is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion in fiscal year 2015, we expect another 170 to 190 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid start to fiscal year 2016, both segments performed well, and we delivered very strong earnings growth. 
Second, our margin profile has improved significantly. We are driving operational efficiencies and continuous improvement in addition to delivering on our synergy commitments. This is manifesting in our financial results with 200 basis points of operating margin expansion this quarter and increased guidance for the total year. 
Third, we continue to evaluate and optimize our portfolio and focus on the appropriate strategic initiatives. In doing so, we are positioning ourselves in higher-growth areas, which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. 
Finally, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We are also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year. 
We believe we are well-positioned to continue our track record of delivering value to our customers and shareholders and I look to the future with enthusiasm. Thank you. We will now open the call to questions."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank. Your next question is from Mike Weinstein of JPMorgan.",22,"[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank. Your next question is from Mike Weinstein of JPMorgan."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth this quarter over a tougher comp discrete heard you but didn't good job of reflecting the numbers. But you're maintaining your FX",101,"So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth this quarter over a tougher comp discrete heard you but didn't good job of reflecting the numbers. But you're maintaining your FX-neutral guidance for the year, which effectively implies that over the balance of the next 3 quarters you'll grow the top line 5.5% to 6% FX-neutral. So, a, is that correct? And then, b, can you just walk us through your confidence in the top line outlook for the rest of the year?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very diffi",225,"Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very difficult comps, a strong flu season last year. We had CareFusion's last final quarter, and we talked in our prepared remarks about the 6.7% growth that we were jumping over, including the CareFusion 10% growth. And then we had a number of items like in pharmacy solutions, where we have the typical timing compares. All that goes away. In fact, it reverses in the second half. So if you remember, the CareFusion businesses actually grew minus 2% in the third quarter. So actually, we expect the second quarter to be back in basically the range that we normally have, the 4.5 to 5. And you'll start picking up more in the back half of the year against that CareFusion compare. Don't forget, we had the AVEA recall in respiratory, so that becomes an easier compare. Emerging markets actually start comparing to more normalized results. You saw China this year, first quarter of last year was 23% growth, we had a jumpover. So all that starts reversing. And so we are confident in our full-year guidance."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Lewis of Morgan Stanley.",10,"Your next question is from David Lewis of Morgan Stanley."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How congested did you see the updated EM guidance? And I guess just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind of w",69,"Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How congested did you see the updated EM guidance? And I guess just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind of weakness in Tier 1 hospitals in China? And where are inventory levels now for you in some of these broader emerging markets?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the audi",212,"Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the auditing of large capital purchases. So we're seeing that in China, and we expect that to continue for the rest of the year. On the disposable side, we did fine. And these are products that sustain the healthcare system. And so we expect stability in China on that side. That's really the difference as we look around the emerging markets. That's the biggest difference. If I talk about Latin America, Latin America is basically -- Brazil is where we said it was and then stronger performance in the other countries. So in terms of inventory, as you heard, we made inventory adjustments on the Medical side last time. And coming back to the Diagnostic piece, we actually thought that it was more of a timing issue, this audit issue. We're not saying that's going away, so we came back and we did make the inventory adjustment on the Diagnostic side because of the change in the situation. Chris, anything else you would add?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","That about nails it.",4,"That about nails it."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initia",94,"I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initiatives maybe materializing? And when you think we could start to see that drive revenue uptick, particularly in the context of the 4.5% to 5% is pretty much where the business has been growing the past couple of years and what it takes to sort of accelerate that number?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, overall, I would stick with what we said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that.",42,"Well, overall, I would stick with what we said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","David, this is Tom. So I think, as been said, we've always commented that it would take us some time to get products registered for particularly the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several dozen",109,"David, this is Tom. So I think, as been said, we've always commented that it would take us some time to get products registered for particularly the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several dozen products actively under regulatory review that we've already submitted. We have taken a few products that were already approved and put those through our channels i n markets like China and we are seeing some early positive signs. But we've always said it'll take some time to ramp and that we would see that more in FY '17 and we're right on track to that."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise of Stifel.",9,"Your next question is from Rick Wise of Stifel."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start off with the margin expansion. If I -- you -- maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost syn",72,"Let me start off with the margin expansion. If I -- you -- maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synergies now with CareFusion. Am I understanding that correctly? And maybe just in general, how much more is there to go? I mean, is that accelerating?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 3",404,"Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 30. And so whether you call those synergies or -- it's all good. I mean what I would point to on that chart is that, that 9.01 to 9.08 represents a 37% to 38% increase over where we have been on a BDX legacy guidance basis. And so how you characterize that, whether it's just accretion or synergies, that's somewhat semantics. I mean, we were growing over the expectation that we would have grown 9% to 10% anyway. So we've stayed pure on that. The tax rate improvements, are those synergies? Yes, they're synergies as well, it's just not what we had originally contemplated in the deal. So we've tried to keep a very clear and transparent view of what is synergies and what's accretion. And that 4%, as I said, I wouldn't call those synergies. We are not raising our synergy guidance as we did last quarter because these are just kind of other things that are benefiting our cost structure and bottom line that hadn't been contemplated in November. So for what we control, we're really executing extremely well, very pleased with it. But obviously, the FX drag is worse. In that regard, since November, the euro has stabilized at 1.09. Of that 4% drag additional in FX, 1% comes from the euro remaining at that 1.09. And then another percent from other major currencies like Canada, for example, it's down 8% or 7% since November. Mexico is down 8%. China is down 3%. So that's another percent of that 4. The other 2 is every other currency in the world is weak against the U.S. dollar compared to where it was in November. And so that's another 2%. So an additional 4% drag. So we don't really have a lot of control over that. We do everything we can to mitigate that. So what we control, we're really feeling good about, but we are going against significant FX headwinds. But we really feel good about the fact that we were able to still meet our commitment of 8 37 to 8 44 despite those significant FX headwinds."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Lawrence Keusch of Raymond James.",10,"Your next question is from Lawrence Keusch of Raymond James."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just 2 things here. Number one, sounds like from the prepared comments that the CareFusion large volume infusion pump is quite well. I'm wondering if you could provide a little color on that and some of the dynamics. I think you said capital sales were",108,"So just 2 things here. Number one, sounds like from the prepared comments that the CareFusion large volume infusion pump is quite well. I'm wondering if you could provide a little color on that and some of the dynamics. I think you said capital sales were up. And I'm asking in reference to some strong results from a competitor yesterday. And then just on China, I think you also said low double-digit growth for the year. You're obviously starting much lower than that. So you've touched on this, but how do you really accelerate through the course of the year to get to that low double-digit China growth?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Tom will start with the infusion.",8,"Okay. So Tom will start with the infusion."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, we have just comment on the U.S. which is by far the largest market. We did have high single-digit growth in o",91,"Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, we have just comment on the U.S. which is by far the largest market. We did have high single-digit growth in our infusion business in the U.S., which in a market that's growing low single digits, we certainly see that as reflecting continued strengthening of our position in our business. So we are very pleased with our results and the momentum that we continue in that business."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?",27,"I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Exactly. Chris, you want to take China?",7,"Exactly. Chris, you want to take China?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the f",164,"Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the first quarter. As I said on the overall BD, revenue growth to come, the comparison to prior year eases in the second half of the year significantly. We have, for example, respiratory wasn't even shipping in China towards the second half of last year, so that makes it an easier compare as well. So that's where we get the low double digits. We are getting a little bit of a lift. We talked about most of the CareFusion synergies coming next year. But there is a little bit connect there's some things like that, that help us, actually an easy compare against CareFusion's China performance last year that gives us a little bit of a lift as well."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess first question is just on safety and I guess specifically around Europe, I guess there's been a couple of quarters since you've given us an update here in terms of how far through that opportunity we are penetrated and how much more this have to g",48,"I guess first question is just on safety and I guess specifically around Europe, I guess there's been a couple of quarters since you've given us an update here in terms of how far through that opportunity we are penetrated and how much more this have to go?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, it's fairly highly converted on in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical side, and Tom wil",48,"So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, it's fairly highly converted on in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical side, and Tom will talk about that."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","This is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a Medical perspective, as we think a",119,"This is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a Medical perspective, as we think about infusion, I'd say we're probably in the fifth, sixth -- fifth inning let's say there, as that's typically the first area that people convert to. And then the injection business, which is generally a low -- can proceed as a lower risk procedure, we're in even much earlier innings on that side of the business. So overall, we still have a ways to go, certainly several years to go, when it comes to the European safety conversion."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Matt Taylor of Barclays.",9,"Your next question is from Matt Taylor of Barclays."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott brought earlier this week, so does that change your view on point-of-care testin",63,"I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott brought earlier this week, so does that change your view on point-of-care testing? Sorry for the multipart question, but I had a few things to get in there."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","That's okay. I don't think Abbott's buying changes our view on point of care testing. But Linda will be happy to update you on the flu and what's going on out there.",33,"That's okay. I don't think Abbott's buying changes our view on point of care testing. But Linda will be happy to update you on the flu and what's going on out there."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. As we have seen on the flu, we had a tough jump over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platfor",93,"Sure. As we have seen on the flu, we had a tough jump over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platform, we feel very good about our position both in terms of accuracy, turnaround time and throughput. This is being reflected in our share position, now over 19,000 instruments placed globally. And we're very excited about the new wireless connectivity we'll introduce this quarter."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Brian Weinstein of William Blair.",10,"Your next question is from Brian Weinstein of William Blair."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Question on new products. Vince, you used to talk about kind of percentage of revenue that your products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in li",73,"Question on new products. Vince, you used to talk about kind of percentage of revenue that your products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in light of putting more money into R&D from the medical device tax reinvestment? Where are you putting that specifically? What types of projects should we be thinking about?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the Care",217,"Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the CareFusion product line coming in, and we're not quite there yet. But if I look at the portfolio and the number of new products, I would say we're in a strong position. I mean, it's across both the segments and it's over the next 3-year period. And so both portfolios on the Medical side and the Life Science side appear good. As I mentioned on the call, we feel very excited about the launch of the infusion set, the FlowSmart set. We haven't talked much about it lately, but SAIS is making progress with their micro infuser, and we have signed up a number of customers is there. And so we're starting to see some nice momentum in SAIS. I'm not going to try to walk through all of the new products across MPS, MMS, but there is a nice portfolio, and Tom would tell you, in addition, that the backlog for Pyxis remains very robust. And Tom, I think it continues to actually get a little larger, right?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high.",27,"Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, it would increase the number. And then on Linda side of the business, I went through those new flow products but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays ou",58,"Yes, it would increase the number. And then on Linda side of the business, I went through those new flow products but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays out soon in terms of chlamydia and Vaginitis. What's your expectation there?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4, Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu.",51,"Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4, Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Manage",115,"And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Management and on the Life Science side. And both I would say they are both the core business as we continue to elaborate things like KIESTRA and drive that into the market place and drive the genomic stuff that we just started. I think we're in a situation where a lot of these things haven't launched yet, but they launch over the next couple of years. So thanks, Brian, for the question."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Jon Groberg of UBS.",9,"Your next question is from Jon Groberg of UBS."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can I just maybe one kind of clarification and then a quick question. So I just put 2 on here. But one in China, I guess maybe Vince or , can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital purchases. It see",146,"Can I just maybe one kind of clarification and then a quick question. So I just put 2 on here. But one in China, I guess maybe Vince or , can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital purchases. It seems like about 12 months later than what most Life Science companies have been seeing or most of them saw a year ago and reported pretty good results in China this year. So just curious kind of why you think you're seeing those delays more significantly than others in the Life Sciences space? And then I just wanted on the new products on Totalys, I think in your presentation you are still launching in the U.S. in '16. I'm just curious what you're seeing with that in Europe and whether that strong track for '16?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda, do you want to take that?",9,"Sure. So Linda, do you want to take that?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So maybe on your first question on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China specifically. So as we were putting those instruments into the market, really",182,"Yes. So maybe on your first question on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China specifically. So as we were putting those instruments into the market, really starting in our first quarter fiscal year '15, we had expectations on those that clearly in the first quarter we saw that the overall number of tenders being issued were not at the level that we were expecting. So that would explain the delay because of the Bruker exclusivity. We are seeing though very good progress competitively in that space with now more expanded solution to offer. And as you know, we are seeing great performance ex U.S. now with a more expanded platform that includes our Totalys and focal point system for full liquid cytology solution. So we saw this quarter high double-digit growth ex U.S. on those platforms. And the anticipated launch date for us in the U.S. is in FY '16. I don't have the exact quarter sitting in front of me, but..."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","But later in the year, anyway.",6,"But later in the year, anyway."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Q3 would be a safe bet for us.",9,"Yes. Q3 would be a safe bet for us."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Vijay Kumar of Evercore ISI.",10,"Your next question is from Vijay Kumar of Evercore ISI."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the [indiscernible] of EPS, and I guess off [ph] margins a",98,"Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the [indiscernible] of EPS, and I guess off [ph] margins are going to come up at the higher end of the guidance range. I want to make sure I got that right. And when you look at below the line, I think other income, you had some hedging gains. Why would those sort of gains reverse in the back half?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first q",172,"Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first quarter, favorable timing of expenses as well. And then below the line there is a little bit in tax rate. So the 21.5 is a little bit better than expectations, and we see that flowing through the total year. We were slightly better in interest income and slightly less in interest expense. You put all those things in and that flows through to the full year. Of course, it's overwhelmed by the items that I talked about with the oil prices being down, will benefit the second half of the year as well as the sale of BD Rx. So you put all that together and we get to the 9 01 to 9 08 and the 8 37 to 8 44 all-in with FX."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Richard Newitter of Leerink Partners.",10,"Your next question is from Richard Newitter of Leerink Partners."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wanted to ask, actually 2 quick ones. One, is the full MedTech tax reversal benefit getting reinvested such as a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted Chi",76,"Just wanted to ask, actually 2 quick ones. One, is the full MedTech tax reversal benefit getting reinvested such as a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted China growth rate to be if you kind of look at it the way you said low teens, I think in the past 2 quarters but if you back out the inventory."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on medical device tax, just to put it in perspective, last year we had about or in our budget we had about $60 million for the full year, don't forget we only picked up 3 quarters of that this year, so that's about $45 million. Right now, we have",195,"Okay. So on medical device tax, just to put it in perspective, last year we had about or in our budget we had about $60 million for the full year, don't forget we only picked up 3 quarters of that this year, so that's about $45 million. Right now, we have about 1/3 of that being executed against the other 2/3 we are still getting the projects in place and we do fully expect to spend that this year. There might be a little bit of timing issue. Obviously, in the month of January, we're getting the benefit and we're only executing on the 1/3. So we'll probably just naturally pick up a little bit in timing, but not a lot, and that's already in the guidance. But we fully expect to reinvest, and we want to reinvest and we're going through that process now. 
And then the second question was China. I think I'd bring you back to -- if you adjust for the difficult compare in the first quarter and you adjust for the inventory adjustments that we took in Life Sciences, it brings you back up to a double-digit number in China."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we said low double digits for the year.",9,"And we said low double digits for the year."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ...",22,"Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ..."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Easier compare and a little bit of momentum out of some CareFusion products.",13,"Easier compare and a little bit of momentum out of some CareFusion products."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Doug Schenkel of Cowen and Company.",11,"Your next question is from Doug Schenkel of Cowen and Company."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation see",128,"So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation seems to be a bit more material than we would've expected just given what we've seen from life science tools Pierce. Others have talked about academic government starting to pick up. It sounds like biopharma continues to be strong. So as all that said, 2 questions. One, can you describe what you saw on the quarter in terms of demand from biopharma and economic government in the U.S.? And two, what's embedded into your guidance for contributions from new products and the potential benefit associated with a more robust NIH budget?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Bioscience's business continues to do very well. We did mention that in first quarter '15, we had a tough",232,"Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Bioscience's business continues to do very well. We did mention that in first quarter '15, we had a tough jumpover. We had high double-digit growth primarily in our research instrument base. So we still managed to grow off that base, but it was a difficult compare. So for this quarter, we did see very good growth in our biopharma side, particularly in our Advanced Bioprocessing business, a business we do not talk about a lot but is doing very, very well for us. So that was a tremendous area of growth. And then as we've been talking about for the past several quarters, led by the U.S., our total research solutions platform now, we feel very good about the prospects for that business. Of course, this past quarter, launching both FACSSymphony and FACSCelesta, and we think across the range of low mid and high-end analyzers now, combined with our platforms, so really now starting to work that full solution between our instrument base and our solutions base. We see the U.S. research market as being an area that has, if you look at our last quarter report, with very strong for us and an area moving forward that is in our guidance."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","How do you feel about new products, Linda? I know you can't exactly quantify it but. . .",18,"How do you feel about new products, Linda? I know you can't exactly quantify it but. . ."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so new products overall, starting with biosciences, the research solutions, feel very strong about the genomic side of course coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about that. An",67,"Yes, so new products overall, starting with biosciences, the research solutions, feel very strong about the genomic side of course coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about that. And then of course PAS with their new products and DS with the expansion of the MAX menu, we're really starting to see this kick in."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So we should start to see some traction in the back half of the year basically? Okay, thanks.",18,"So we should start to see some traction in the back half of the year basically? Okay, thanks."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Derik De Bruin of Bank of America.",12,"Your next question is from Derik De Bruin of Bank of America."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So could you talk a little bit about sort of looking at the overall portfolio, I mean you've trimmed Simplist and there have been some talk about respiratory earlier on in the process of maybe doing some [indiscernible] has that business rebounded to the",61,"So could you talk a little bit about sort of looking at the overall portfolio, I mean you've trimmed Simplist and there have been some talk about respiratory earlier on in the process of maybe doing some [indiscernible] has that business rebounded to the point now that you'll be recoverable that part of the portfolio and it's not potentially divestiture candidate?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business.",102,"So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business. I would tell you, we are making some progress on that, but we are not to the finish line yet. There are a couple of other small pieces that we are continuing to work on also in terms of that strategic review process, and you'll hear more from us as we move forward."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Today's final question is coming from Kristen Stewart of Deutsche Bank.",12,"Today's final question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I was just wondering if you could expand a little bit more upon the relationship with solutions and also if there's any additional updates on the CME relationship with the pumps and anything about bringing that in-house to BD and the timing of launch that",52,"I was just wondering if you could expand a little bit more upon the relationship with solutions and also if there's any additional updates on the CME relationship with the pumps and anything about bringing that in-house to BD and the timing of launch that, that could go into emerging markets?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Go ahead, Tom.",3,"Go ahead, Tom."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the. So we are very pleased obviously with the long-term collaboration that we've entered into with Fresenius for a broad line of ID solutions in the U.S. marketplace. We cert",205,"Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the. So we are very pleased obviously with the long-term collaboration that we've entered into with Fresenius for a broad line of ID solutions in the U.S. marketplace. We certainly see that these opportunities aligned with ours customers feedback to have additional options available to them and how they buy IV solutions. And we expect to begin launching that line in the very back half of FY '16. So I think that's probably the most to say about that there, but we see it very much in line in supporting and helping to advance our overall medication management strategy, and we've gotten very positive feedback from customers after that announcement. Related to CME, we do sell CME products in certain markets today, primarily in Europe. No new news to update in terms of an acquisition or integration of CME into BD. As you know, we already own 40% of CME, and we've talked about options of that going forward. No new news to share there. We continue to promote and grow their products though in the market, particularly in Europe, that we have had since the beginning of the year."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is from Brandon Couillard of Jefferies.",9,"Your final question is from Brandon Couillard of Jefferies."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of test available on the menu and to what extent is the LDT capability contributing to growth?",47,"Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of test available on the menu and to what extent is the LDT capability contributing to growth?"
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis",138,"Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis. In terms of the menu, of course, the expansion that we saw in the menu in both and CT/GC, what we're seeing now in Europe is very strong double-digit growth and very positive feedback from our U.S. customer base, again starting to see very good growth in placements on our Mac system. And of course when we get the CT/GC and Vaginitis, we are anticipating stronger growth there. On the LDC side in terms of what we see in terms of opportunity for us moving forward, are you speaking about the..."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Open channel.",2,"Open channel."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportuni",79,"Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportunity for us. I would say that the big opportunity that we see this with the differentiated menu that we are already seeing on the and we look forward to on the CT/GC and Vaginitis."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks.",16,"Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much.",41,"Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks a lot.",3,"Thanks a lot."
103678,321567599,925239,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. That does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. That does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367",79,"Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 20775429. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Cristy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",409,"Thank you, Cristy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures in the financial schedule, in our press release or the appendix of the Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Bill Kozy, Executive Vice President and Chief Operating Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. It is now my pleasure to turn the call over to Vince."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our",451,"Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our expectations. Strong underlying margin expansion was driven by the achievement of operational efficiencies and continuous improvement, coupled with the positive impact of synergies.
As we move through the first quarter, we continue to make progress with the strategic review of our portfolio. Many of you already know, we recently announced that Fresenius Kabi has acquired the BD Simplist portfolio. We believe Fresenius is a better owner of the BD Rx business as it complements their existing products and capabilities in the injectable pharmaceutical industry. In addition, we are excited that we are initiating a long-term collaboration for Fresenius to supply us with a portfolio of competitive IV solutions in the U.S. This transaction is intended to enable BD to be responsive to our customers' needs and is complementary to our end-to-end Medication Management Solutions for our customers and their patients.
Since we provided guidance in November, there have been a number of new dynamics that will affect our results this year. As most of you already know, several weeks ago, there was a bipartisan agreement to suspend the Medical Device Tax. This critical relief is extremely important to BD as well as the patients, providers and research communities we serve. While some of the specifics are still being analyzed, we plan to reinvest this tax back into the business, which further supports our innovation strategy. 
In summary, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We're also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year.
Moving on to Slide 5, I will review our first quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company revenues grew 1.8%, which is in line with our prior guidance of 1% to 2% growth that we had anticipated and communicated on our last earnings call. Adjusting for tough comparisons for the prior year, this reflects solid underlying growth in both the segments. 
Adjusted EPS was $1.96, driven by the solid underlying performance of the segments. Earnings were ahead of our expectations as the quarter also benefited from product mix that was incremental to already strong gross margin performance and some timing of expenses and below the line items.
Now I'd like to turn things over to Chris for a more detailed discussion of our first quarter financial performance and our updated fiscal year 2016 guidance."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with o",1862,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with our previously disclosed guidance. Our growth rate this quarter reflects a tough comparison to strong prior year results of 6.7% organic growth, which includes CareFusion's final quarter as a stand-alone company, growing at 10% organically. As a reminder, our results last year were driven by robust performance in the legacy CareFusion businesses, the impact of timing of orders in Pharmaceutical Systems, a very strong flu season, timing of tenders and strong emerging market performance. As a result, these items negatively impacted our first quarter growth rate by over 240 basis points. On an underlying basis, we are pleased with the solid performance of our segments and the momentum in our businesses.
BD Medical first quarter revenues increased 1.9%, reflecting the aforementioned items. Medication & Procedural Solutions or MPS growth was 2.0%, which reflects strength in pharmacy solutions, Infusion Therapy and safety-engineered products. Very strong results in the prior year negatively impacted the MPS growth rate by approximately 250 basis points. 
Despite extremely strong results in the prior year in Medication Management Solutions, revenues grew 4.3%, driven by both strong infusion and dispensing capital installations. Respiratory Solutions revenues declined 6.8%, reflecting the tough comparisons of prior year results due to the strong final quarter as part of legacy CareFusion. Growth in Diabetes Care was 3.9%, driven by solid growth in pen needles. 
Pharmaceutical Systems growth of 2.6% reflect strong growth in SAIS, partially offset by the impact of timing of orders, which we expect to occur later this fiscal year. 
BD Life Sciences first quarter revenues increased 1.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Preanalytical Systems growth of 4.4% was driven by safety-engineered products in both the U.S. and Europe and also reflects strong growth in emerging markets. BD Biosciences growth of 1.2% reflects clinical tendered delays in emerging markets and a difficult comparison to the prior year when sequestration ended. This was offset by strong sales that were driven by an increased demand of high-end instruments and growth in research reagents. The Diagnostic Systems decline of 0.8% reflects a mild flu season, which impacted growth by approximately 400 basis points. Growth was also negatively impacted by a slowdown of capital spending in China. Solid microbiology growth as well as growth in molecular led by BD MAX and international growth in Women's Health partially offset the impact from the flu.
Moving to Slide 8, I'll walk you through our geographic revenues for the first quarter on a currency-neutral basis. U.S. growth of 1.5% reflects the aforementioned prior year comparisons and timing impacts with BD Medical growing 1.9% and BD Life Sciences growing 0.3%. BD Medical's performance reflects strength in pharmacy solutions, infusion therapy pumps and related consumables and strength in Diabetes Care. This was partially offset by Respiratory Solutions. BD Life Sciences growth reflects the impact of a light flu season this year and a difficult comparison to the prior year due to a strong flu season and the ending of sequestration. Offsetting these impacts was strong performance in the Biosciences business driven by research reagent sales, solid performance in our Preanalytical Systems unit, growth in microbiology and growth from BD MAX.
Moving on to International, revenues grew 2.2%. This is below our normal growth rate, which reflects timing of tenders and capital installations. International revenues also reflect the moderation of growth in China in the quarter, and I'll provide more color on China in just a moment.
The medical segment grew 1.9%. This reflects solid performance in Pharmaceutical Systems and Medication Management Solutions, partially offset by a tough comparison due to large tenders in Brazil and EMA in the prior year as well as timing of capital installations in the dispensing business.
Our Life Sciences segment grew 2.7%, which reflects strong growth in Diagnostic Systems driven by core microbiology, Women's Health and an expanded BD MAX menu in Europe. We also saw strong growth in the Preanalytical Systems unit. This was partially offset by a decline in the Biosciences business due to tender delays in emerging markets.
On Slide 9, emerging market revenues grew 2.4% currency-neutral, with developed markets growing 1.7%. The first quarter growth rate in emerging markets reflects a very difficult comparison to the prior year period, both the BD and CareFusion legacy businesses and a moderation of growth in China.
China growth for the first quarter was 4.5% compared with growth of over 23% in the first quarter of last year. This difficult comparison was in line with our expectations. Beyond the difficult comparison, we also experienced a continued slowdown of capital spending in Diagnostic Systems, which resulted in inventory adjustments. Inventory adjustments negatively impacted growth in the quarter by approximately 350 basis points. While there are pockets of pressure, millions of patients are entering the health care system and, overall, emerging markets continue to be an important growth driver. For the total year, we expect China to grow in the low double-digit range and total emerging markets to grow 9% to 10%.
Moving to global safety on Slide 10, currency-neutral sales increased 4.9% and grew to $737 million in the quarter. Safety revenues in the U.S., grew 3.8%, while international sales grew 6.5% currency-neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 10.9% in emerging markets. Medical Safety sales grew 5.4%, primarily driven by safety catheters and a range of products in Pharmaceutical Systems. Life Science safety sales, which are driven by our Preanalytical Systems unit, grew 4.1% in the quarter.
Slide 11 recaps the first quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 1.8% on a comparable currency-neutral basis. Pricing was about flat in the quarter.
Moving down the P&L, I will focus on the comparable basis figures, which includes CareFusion results in the prior year, in order to give a better indication of our performance. 
Gross profit improved by 3.6%. I'll provide more color on gross profit in the next slide when we look at underlying performance and the impact of currency.
SSG&A as a percentage of revenue was 24.9%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenues was 6.3% as we continue to invest in new products and innovation. 
Operating income grew 12%, reflecting strong P&L leverage, which I'll also address in more detail in the next slide. 
Our tax rate increased slightly. However, it continues to improve versus our initial deal model expectations. 
As discussed earlier, adjusted earnings per share were $1.96, which is a 45.8% increase versus the prior year. This reflects solid underlying performance from the segments, positive product mix that was incremental to already strong gross margin performance, some timing of expenses and below the line items.
Slide 12 illustrates our gross profit and operating margin for the first quarter presented on a comparable basis. Strong gross profit margin performance of 130 basis points was primarily driven by continuous improvement initiatives and product mix and to a lesser extent, favorable raw material prices. Building off the strong momentum in fiscal year 2015 of 100 basis points of underlying operating margin expansion, operating margins grew 220 basis points year-over-year, driven by gross margin expansion, combined with the achievement of operational efficiencies, continuous improvement and the positive impact of cost synergies. Currency had a negative impact on both gross profit margin and operating margins.
Moving on to Slide 14. Since we provided guidance in November, there have been a number of new dynamics that we anticipate will affect our results. Some of these items include the sale of BD Rx, the suspension of the Medical Device Tax, the reinstatement of the R&D tax credit, lower oil prices, a milder flu season and additional FX pressure. As a result of these new dynamics, in combination with our first quarter results, we are raising our currency-neutral adjusted EPS guidance by 4 percentage points from $8.73 to $8.80 to a range of $9.01 to $9.08. The increased currency-neutral guidance is offset by incremental FX pressures of approximately $0.28 due to the continued strengthening of the U.S. dollar. Therefore, we are maintaining our adjusted EPS guidance of $8.37 to $8.44. We are extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 15, I'd like to walk you through additional elements of our guidance for the full fiscal year 2016. In summary, we continue to expect comparable revenue growth of 4.5% to 5% on a currency-neutral basis. On a reported basis, revenue growth for the total year is expected to be between 20% and 20.5%, which reflects a currency headwind of about 450 basis points. U.S. dollar has strengthened further against most currencies since we last provided guidance in November. Our guidance assumes a euro to dollar exchange rate of 1.09. We expect this unfavorable impact to be acute again in the second quarter with a revenue headwind of over 400 basis points on a comparable basis. We expect our currency-neutral revenue growth to be back in line with our guidance range of 4.5% to 5%. In the second half of the year, we expect the currency impact on revenue to moderate.
We continue to expect growth in BD Medical of 4.5% to 5%. In our Life Sciences segment, we are revising our guidance to 4% to 4.5% to reflect the mild flu season in combination with lower sales in China. 
Based on the current view of the environment, we continue to expect pricing to be about flat for the year. We continue to expect gross profit margin to be between 52% and 52.5% as the benefit from operating efficiencies, the sale of BD Rx and lower resin prices are expected to be partially offset by increased currency pressure. SSG&A as a percentage of sales is expected to be between 24% and 24.5%. This is slightly better than our previous forecast as a result of the suspension of the Medical Device Tax, which was recorded within SSG&A. As we reinvest the medical device tax, we now expect R&D investments of about 6% to 6.5% of revenues. The reinvestment will help us to accelerate the strategies in both of our segments.
Operating margin is expected to be between 21% and 22% of revenues as a result of the items I just reviewed. Excluding the unfavorable impact of foreign currency, we are raising our underlying operating margin guidance to 170 to 190 basis points. Once again, we are very pleased with our performance in driving margin expansion. 
We are broadening our tax rate to be between 21% and 22%. 
Our full-year guidance range is for operating cash flow, capital expenditures, interest/other and share count remain unchanged from our November guidance. 
Now I would like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each",827,"Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each quarter. The product update slides that you are accustomed to seeing will remain in the appendix of the presentation for reference.
Starting with new product innovation, within our Life Sciences business, we are very pleased with the early access customer response to the BD FACSSymphony, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell. BD FACSSymphony  offers high-speed analysis that is 20x faster than other nonflow platforms. When combined with our BD Horizon Brilliant over the Sirigen Reagent portfolio, these capabilities will allow researchers improve the identification and analysis of rare cell types and events.
In early December, we successfully launched our FACSCelesta instrument, a mid-level cell analyzer with a very positive market reception. The new FACSCelesta system offers simultaneous measurement of up to 14 different single cell characteristics. The FACSCelesta system is also designed to leverage our broad BD Horizon Brilliant reagent portfolio. 
In our Diagnostic Systems business, we continue to focus on menu expansion and anticipate launching new assays on the BD MAX platform in fiscal year 2016, including CT/GC and Vaginitis. 
Within our strategic and business initiatives, as we discussed earlier, we have divested the BD Rx business and are excited to be adding IV solutions to our Medication Management portfolio. 
We continue to make progress with our portfolio strategic review process and will provide you with updates as we move forward.
In January, we launched our new BD brand that captures the new BD and our rearticulated purpose, advancing the world of health, which is more relevant than ever in a dynamic and ever-changing industry.
And in an equally important area of partnerships and collaborations, we remain on track with our collaboration with Medtronic. The insulin infusion sets in our Diabetes Care business have an expected product launch in the middle of the fiscal year 2016, so this year. We believe this product will improve the consistency of insulin delivery by significantly reducing silent occlusions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We continue to see strong growth in opportunities in our IDAST business, where we have built a comprehensive solution offering, which includes the BD Bruker Maldi Biotyper. This is a result of the collaboration with Bruker Corporation. We've seen success over the past several years with the BD Bruker MBT instrument due to its ability to provide rapid and accurate microbial identification and its adoption in new geographic markets. As you can see, we continue to have strong opportunities that drive growth and innovation, and we look forward to updating you as we make progress throughout the year.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the first quarter, and we made progress with our back office functions and with harmonizing our IT infrastructure. We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. 
Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs as we discussed earlier. The consistent solid performance of our business, combined with operating efficiencies, cost leverage and cost synergy capture is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion in fiscal year 2015, we expect another 170 to 190 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid start to fiscal year 2016, both segments performed well, and we delivered very strong earnings growth.  Second, our margin profile has improved significantly. We are driving operational efficiencies and continuous improvement in addition to delivering on our synergy commitments. This is manifesting in our financial results with 200 basis points of operating margin expansion this quarter and increased guidance for the total year.  Third, we continue to evaluate and optimize our portfolio and focus on the appropriate strategic initiatives. In doing so, we are positioning ourselves in higher growth areas, which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers.  Finally, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We are also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year.  We believe we are well-positioned to continue our track record of delivering value to our customers and shareholders and I look to the future with enthusiasm. Thank you. 
We will now open the call to questions."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank.",13,"[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We don't hear you Kristen if you're there.",9,"We don't hear you Kristen if you're there."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Let's come back to Kristen.",6,"Let's come back to Kristen."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Are you on mute Kristen.",5,"Are you on mute Kristen."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Mike Weinstein of JPMorgan.",9,"Your next question is from Mike Weinstein of JPMorgan."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth this quarter over a tougher comp. The Street, they heard you, but didn't do a good job of reflecting at the numbers. But you're m",108,"So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth this quarter over a tougher comp. The Street, they heard you, but didn't do a good job of reflecting at the numbers. But you're maintaining your FX neutral guidance for the year, which effectively implies that over the balance of the next 3 quarters you'll grow the top line 5.5% to 6% FX neutral. So, a, is that correct? And then, b, can you just walk us through your confidence in the top line outlook for the rest of the year?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very diffi",228,"Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very difficult comps, a strong flu season last year. We had CareFusion's last final quarter, and we talked in our prepared remarks about the 6.7% growth that we were jumping over, including the CareFusion 10% growth. And then we had a number of items like in pharmacy solutions, where we have the typical timing compares. All of that goes away. In fact, it reverses in the second half. So if you remember, the CareFusion businesses actually grew minus 2% in the third quarter. So actually, we expect the second quarter to be back in basically the range that we normally have, the 4.5% to 5%. And you'll start picking up more in the back half of the year against that CareFusion compare. Don't forget, we had the AVEA recall in respiratory, so that becomes an easier compare. Emerging markets actually start comparing to more normalized results. You saw China this year, first quarter of last year was 23% growth, we had a jumpover. So all of that starts reversing. And so we are confident in our full year guidance."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Lewis of Morgan Stanley.",10,"Your next question is from David Lewis of Morgan Stanley."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How congested did you see the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind",70,"Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How congested did you see the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind of weakness in Tier 1 hospitals in China? And where are inventory levels now for you in some of these broader emerging markets?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the audi",214,"Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the auditing of large capital purchases. So we're seeing that in China, and we expect that to continue for the rest of the year. On the disposable side, we did fine. And these are products that sustain the health care system. And so we expect stability in China on that side. That's really the difference as we look around the emerging markets. That's the biggest difference. If I talk about Latin America, Latin America is basically -- Brazil is where we said it was and then with stronger performance in the other countries. So in terms of inventory, as you heard, we made inventory adjustments on the Medical side last time. And coming back to the Diagnostic piece, we actually thought that it was more of a timing issue, this audit issue. We're not saying that's going away, so we came back and we did make the inventory adjustment on the Diagnostic side because of the change in the situation. Chris, anything else you would add?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think that [indiscernible] about nails it.",8,"No, I think that [indiscernible] about nails it."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initia",95,"I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initiatives maybe materializing? And when you think we could start to see that drive revenue uptick, particularly in the context of the 4.5% to 5% is pretty much where the business has been growing in the past couple of years and what it takes to sort of accelerate that number?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And, Tom can comment on that.",42,"Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And, Tom can comment on that."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David, this is Tom. So I think, as been said, we've always commented that it would take us some time to get products registered for particularly the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several",109,"Sure, David, this is Tom. So I think, as been said, we've always commented that it would take us some time to get products registered for particularly the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several dozen products actively under regulatory review that we've already submitted. We have taken a few products that were already approved and put those through our channels in markets like China and we are seeing some early positive signs. But we've always said it'd take some time to ramp and that we would see that more in FY '17 and we're right on track to that."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise of Stifel.",9,"Your next question is from Rick Wise of Stifel."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start off with the margin expansion. If I -- you -- maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost syn",72,"Let me start off with the margin expansion. If I -- you -- maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synergies now with CareFusion. Am I understanding that correctly? And maybe just in general, how much more is there to go? I mean, is that accelerating?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 3",404,"Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 30. And so whether you call those synergies or -- it's all good. I mean what I would point to one that chart is that, that $9.01 to $9.08 represents a 37% to 38% increase over where we would have been on a BDX legacy guidance basis. And so how you characterize that, whether it's just accretion or synergies, that's somewhat semantics. I mean, we were growing over the expectation that we would have grown 9% to 10% anyway. So we've stayed pure on that. But the tax rate improvements, are those synergies? Yes, they're synergies as well, it's just not what we had originally contemplated in the deal. So we've tried to keep a very clear and transparent view of what is synergies and what's accretion. And that 4%, as I said, I wouldn't call those synergies. We are not raising our synergy guidance as we did last quarter because these are just kind of other things that are benefiting our cost structure and bottom line that hadn't been contemplated in November. So for what we control, we're really executing extremely well, very pleased with it. But obviously, the FX drag is worse. In that regard, since November, the euro had stabilized at 1.09. Of that 4% drag additional in FX, 1% comes from the euro remaining at that 1.09. And then another percent from other major currencies like Canada, for example, it's down 8% or 7% since November. Mexico is down 8%. China is down 3%. So that's another percent of that 4%. The other 2% is every other currency in the world is weak against the U.S. dollar compared to where it was in November. And so that's another 2%. So the additional 4% drag. So we don't really have a lot of control over that. We do everything we can to mitigate that. So what we control, we're really feeling good about, but we are going against significant FX headwinds. But we really feel good about the fact that we were able to still meet our commitment of $8.37 to $8.44 despite those significant FX headwinds."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just 2 things here. Number one, it sound like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of that dynamics. I think you said cap",111,"So just 2 things here. Number one, it sound like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of that dynamics. I think you said capital sales were up, and I'm asking in reference to some strong results from a competitor yesterday. And then just on China, I think you also said low double-digit growth for the year. You're obviously starting much lower than that. So you've touched on this, but how do you really accelerate through the course of the year to get to that low double-digit China growth?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Tom will start with the infusion.",8,"Okay. So Tom will start with the infusion."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, we have just comment on the U.S., which is by far the largest market. We did have high single-digit growth in",92,"Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, we have just comment on the U.S., which is by far the largest market. We did have high single-digit growth in our infusion business in the U.S., which in a market that's growing low single digits. We certainly see that as reflecting continued strengthening of our position in our Alaris business. So we are very pleased with our results and the momentum that we continue in that business."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?",28,"Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Exactly.",1,"Exactly."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Chris, you want to take China?",6,"Chris, you want to take China?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the f",163,"Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the first quarter. As I said on the overall BD, revenue growth to come, the comparison to prior year eases in the second half of the year significantly. We have, for example, respiratory wasn't even shipping in China, towards the second half of last year, so that makes it an easier compare as well. So that's where we get the low double digits. We are getting a little bit of a lift. We talked about most of the CareFusion synergies coming next year. But there is a little bit connectors and things like that, that help us, actually an easy compare against CareFusion's China performance last year that gives us a little bit of a lift as well."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess first question is just on safety and I guess specifically around Europe, I guess it's been a couple of quarters since you've given us an update here in terms of how far through that opportunity we are penetrated and how much more this have to go?",48,"I guess first question is just on safety and I guess specifically around Europe, I guess it's been a couple of quarters since you've given us an update here in terms of how far through that opportunity we are penetrated and how much more this have to go?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical si",52,"So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical side, and Tom will talk about that."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we t",121,"Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we think about infusion, I'd say we're probably in the fifth, sixth -- fifth inning let's say there, as that's typically the first area that people convert to. And then in the injection business, which is generally a low -- can proceed as a lower risk procedure, we're in even much earlier innings on that side of the business. So overall, we still have a ways to go, certainly several years to go, when it comes to the European safety conversion."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Matt Taylor of Barclays.",9,"Your next question is from Matt Taylor of Barclays."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing?",63,"I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing? Sorry for the multipart question, but I had a few things to get in there."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there.",32,"That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. As we have seen on the flu, we had a tough jump over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platfor",93,"Sure. As we have seen on the flu, we had a tough jump over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platform, we feel very good about our position, both in terms of accuracy, turnaround time and throughput. This is being reflected in our share position, now over 19,000 instruments placed globally. And we're very excited about the new wireless connectivity we'll introduce this quarter."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Brian Weinstein of William Blair.",10,"Your next question is from Brian Weinstein of William Blair."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in lig",73,"Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in light of putting more money into R&D from the medical device tax reinvestment? Where are you putting that specifically? What types of projects should we be thinking about?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the Care",217,"Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the CareFusion product line coming in, and we're not quite there yet. But if I look at the portfolio and the number of new products, I would say we're in a strong position. I mean, it's across both the segments and it's over the next 3-year period. And so both portfolios on the Medical side and the Life Science side appear good. As I mentioned on the call, we feel very excited about the launch of the infusion set, the FlowSmart set. We haven't talked much about it lately, but SAIS is making progress with their micro infuser, and we have signed up a number of customers there. And so we're starting to see some nice momentum in SAIS. I'm not going to try to walk through all of the new products across MPS and MMS, but there is a nice portfolio, and Tom would tell you, in addition, that the backlog for Pyxis remains very robust. And Tom, I think it continues to actually get a little larger, right?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products, sales and certainly continues to keep that number up very high.",27,"Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products, sales and certainly continues to keep that number up very high."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, we would increase the number. And then on Linda side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays o",58,"Yes, we would increase the number. And then on Linda side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays out soon in terms of chlamydia and vaginitis. What's your expectation there?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4, Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu.",51,"Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4, Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Manage",114,"And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Management and on the Life Science side. In both, I would say, they are both the core business as we continue to elaborate things like KIESTRA and drive that into the marketplace, and drive the genomics stuff that we just started. I think we're in a situation where a lot of these things haven't launched yet, but they launch over the next couple of years. So thanks, Brian, for the question."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Jon Groberg of UBS.",9,"Your next question is from Jon Groberg of UBS."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can I just maybe to -- one kind of clarification and then a quick question. So I'll just put 2 on here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital pur",148,"Can I just maybe to -- one kind of clarification and then a quick question. So I'll just put 2 on here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital purchases. It seems like about 12 months later than what most Life Science companies have been seeing or most of them saw a year ago and reported pretty good results in China this year. So just curious kind of why you think you're seeing those delays more significantly than others in the Life Sciences space? And then I just wanted on the new products on Totalys, I think in your presentation, you are still launching in the U.S. in '16. I'm just curious what you're seeing with that in Europe and whether that strong track for '16?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda, do you want to take that?",9,"Sure. So Linda, do you want to take that?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China specifically. So as we are putting those instruments into the market, really",184,"Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China specifically. So as we are putting those instruments into the market, really starting in our first quarter fiscal year '15, we had expectations on those that clearly in the first quarter, we saw that the overall number of tenders being issued were not at the level that we are expecting. So that would explain the delay because of the Bruker exclusivity. We are seeing though very good progress competitively in that space with now and more expanded solution to offer. And then as you know, we are seeing great performance ex U.S. now with a more expanded platform that includes our Totalys and focal point system for full liquid cytology solution. So we saw this quarter high double-digit growth ex U.S. on those platforms. And the anticipated launch date for us in the U.S. is in FY '16. I don't have the exact quarter sitting in front of me, but..."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","But later in the year, anyway.",6,"But later in the year, anyway."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Q3 would be a safe bet for us.",9,"Yes. Q3 would be a safe bet for us."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Vijay Kumar of Evercore ISI.",10,"Your next question is from Vijay Kumar of Evercore ISI."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the recreation [ph] of EPS, and I guess off margins are go",98,"Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the recreation [ph] of EPS, and I guess off margins are going to come up at the high end of the guidance range. I want to make sure I got that right. And when you look at below the line, I think other income, you had some hedging gains. Why would those sort of gains reverse in the back half?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first q",168,"Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first quarter, favorable timing of expenses as well. And then below the line, there is a little bit in tax rate. So the 21.5% is a little bit better than expectations, and we see that flowing through the total year. We were slightly better in interest income and slightly less in interest expense. You put all those things in and that flows through to the full year. Of course, it's overwhelmed by the items that I talked about with the oil prices being down, will benefit the second half of the year as well as the sale of BD Rx. So you put all that together and we get to the $9.01 to $9.08 and the $8.37 to $8.44 all-in with FX."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Richard Newitter of Leerink Partners.",10,"Your next question is from Richard Newitter of Leerink Partners."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wanted to ask, actually 2 quick ones. One, is the full MedTech tax reversal benefit getting reinvested such as a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted Chi",75,"Just wanted to ask, actually 2 quick ones. One, is the full MedTech tax reversal benefit getting reinvested such as a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted China growth rate to be if you kind of look at it the way you said low teens, I think in the past 2 quarters that you back out the inventory."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on medical device tax, just to put it in perspective, last year we had about or in our budget, we had about $60 million for the full year, don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we have",197,"Okay. So on medical device tax, just to put it in perspective, last year we had about or in our budget, we had about $60 million for the full year, don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we have about 1/3 of that being executed against the other 2/3 we are still getting the projects in place and we do fully expect to spend that this year. There might be a little bit of timing issue. Obviously, in the month of January, we're getting the benefit and we're only executing on the 1/3. So we'll probably just naturally pick up a little bit in timing, but not a lot, and that's already in the guidance. But we fully expect to reinvest, and we want to reinvest and we're going through that process now. 
And then the second question was China. I think that I'd bring you back to -- if you adjust for the difficult compare in the first quarter and you adjust for the inventory adjustments that we took in Life Sciences, it brings you back up to a double digit number in China."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we said low double digits for the year.",9,"And we said low double digits for the year."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ...",22,"Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ..."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Easier compares and a little bit of momentum out of some CareFusion products.",13,"Easier compares and a little bit of momentum out of some CareFusion products."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Doug Schenkel of Cowen and Company.",11,"Your next question is from Doug Schenkel of Cowen and Company."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation see",128,"So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation seems to be a bit more material than we would've expected just given what we've seen from Life Science tools peers. Others have talked about academic government starting to pick up. It sounds like biopharma continues to be strong. So it's all that said, 2 questions. One, can you describe what you saw on the quarter in terms of demand from biopharma and academic government in the U.S.? And two, what's embedded into your guidance for contributions from new products and the potential benefit associated with a more robust NIH budget?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Bioscience's business continues to do very well. We did mention that in first quarter '15, we had a tough",234,"Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Bioscience's business continues to do very well. We did mention that in first quarter '15, we had a tough jumpover. We had high double-digit growth, primarily in our research instrument base. So we still manage to grow off that base, but it was a difficult compare. So for this quarter, we did see very good growth in our biopharma side, particularly in our Advanced Bioprocessing business, a business we do not talk about a lot, but is doing very, very well for us. So that was a tremendous area of growth. And then as we've been talking about for the past several quarters, led by the U.S., our Total Research Solutions platform now, we feel very good about the prospects for that business. Of course, this past quarter, launching both FACSSymphony and FACSCelesta, and we think across the range of low mid and high-end analyzers now, combined with our Sirigen platform, so really now starting to work out that full solution between our instrument base and our solutions base. We see the U.S. research market as being an area that has, if you look at our last quarter report, with very strong for us and an area moving forward that is in our guidance."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","How do you feel about new products, Linda? I know you can't exactly quantify it, but. . .",18,"How do you feel about new products, Linda? I know you can't exactly quantify it, but. . ."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about",68,"Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about that. And then of course PAS with their new products and DS with the expansion of the MAX menu, we're really starting to see these kick in."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So we should start to see some traction in the back half of the year basically? Okay, thanks.",18,"So we should start to see some traction in the back half of the year basically? Okay, thanks."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Derik De Bruin of Bank of America.",12,"Your next question is from Derik De Bruin of Bank of America."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So could you talk a little bit about sort of looking at the overall portfolio, I mean you've trimmed Simplist and there had been some talk about respiratory earlier on in the process of maybe doing some [indiscernible] has that business rebounded to the p",69,"So could you talk a little bit about sort of looking at the overall portfolio, I mean you've trimmed Simplist and there had been some talk about respiratory earlier on in the process of maybe doing some [indiscernible] has that business rebounded to the point now that or you feel comfortable with it that it's -- you feel it's part of the portfolio and it's not potentially divestiture candidate?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business.",102,"So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business. I would tell you, we are making some progress on that, but we are not to the finish line yet. There are a couple of other small pieces that we are continuing to work on also in terms of that strategic review process, and you'll hear more from us as we move forward."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Today's final question is coming from Kristen Stewart of Deutsche Bank.",12,"Today's final question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I'll let you back in Kristen.",7,"I'll let you back in Kristen."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Sorry to miss you there for a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the Solutions. And also if there's any additional updates on the CME relationship with the pumps and anyth",63,"Sorry to miss you there for a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the Solutions. And also if there's any additional updates on the CME relationship with the pumps and anything about bringing that in-house to BD and the timing of launch that, that could go into emerging markets?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Go ahead, Tom.",3,"Go ahead, Tom."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased obviously with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. We",206,"Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased obviously with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. We certainly see that these opportunities aligned with ours customers feedback to have additional options available to them and how they buy IV solutions. And we expect to begin launching that line in the very back half of FY '16. So I think that's probably the most to say about that there, but we see it very much in line in supporting and helping to advance our overall medication management strategy, and we've gotten very positive feedback from customers after that announcement. Related to CME, we do sell CME products in certain markets today, primarily in Europe. No new news to update in terms of an acquisition or integration of CME into BD. As you know, we already own 40% of CME, and we've talked about options of that going forward. No new news to share there. We continue to promote and grow their products though in the market, particularly in Europe, that we have had since the beginning of the year."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is from Brandon Couillard of Jefferies.",9,"Your final question is from Brandon Couillard of Jefferies."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of test available on the menu and to what extent is the LDCT capability contributing to growth?",47,"Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of test available on the menu and to what extent is the LDCT capability contributing to growth?"
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis",140,"Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis. In terms of the menu, of course, the expansions that we saw in the menu in both Enterics and CT/GC, what we're seeing now in Europe is very strong double digit growth and very positive feedback from our U.S. customer base, again starting to see very good growth in placements on our Mac system. And of course when we get the CT/GC and Vaginitis, we are anticipating stronger growth there. On the LDCT side in terms of what we see in terms of opportunity for us moving forward, are you speaking about the..."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Open channel.",2,"Open channel."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportuni",80,"Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportunity for us. I would say that the big opportunity that we see is, with the differentiated menu that we are already seeing on the Enterics and we'll look forward to on the CT/GC and Vaginitis."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Linda. Okay.",3,"Thanks, Linda. Okay."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks.",16,"Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much.",41,"Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks a lot.",3,"Thanks a lot."
103678,321567599,925519,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367",79,"Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 20775429. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",408,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures, in the financial schedules, in our press release or the appendix of the Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Bill Kozy, Executive Vice President and Chief Operating Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. It is now my pleasure to turn the call over to Vince."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our",450,"Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our expectations. Strong underlying margin expansion was driven by the achievement of operational efficiencies and continuous improvement, coupled with the positive impact of synergies.
As we move through the first quarter, we continue to make progress with the strategic review of our portfolio. Many of you already know, we recently announced that Fresenius Kabi has acquired the BD Simplist portfolio. We believe Fresenius is a better owner of the BD Rx business as it complements their existing products and capabilities in the injectable pharmaceutical industry. In addition, we are excited that we are initiating a long-term collaboration for Fresenius to supply us with a portfolio of competitive IV solutions in the U.S. This transaction is intended to enable BD to be responsive to our customers' needs and is complementary to our end-to-end Medication Management Solutions for our customers and their patients.
Since we provided guidance in November, there have been a number of new dynamics that will affect our results this year. As most of you already know, several weeks ago, there was a bipartisan agreement to suspend the Medical Device Tax. This critical relief is extremely important to BD as well as the patients, providers and research communities we serve. While some of the specifics are still being analyzed, we plan to reinvest this tax back into the business, which further supports our innovation strategy. 
In summary, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We're also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year.
Moving on to Slide 5, I will review our first quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company revenues grew 1.8%, which is in line with our prior guidance of 1% to 2% growth that we had anticipated and communicated on our last earnings call. Adjusting for tough comparisons for the prior year, this reflects solid underlying growth in both segments. 
Adjusted EPS was $1.96, driven by the solid underlying performance of the segments. Earnings were ahead of our expectations as the quarter also benefited from product mix that was incremental to already strong gross margin performance and some timing of expenses and below the line items.
Now I'd like to turn things over to Chris for a more detailed discussion of our first quarter financial performance and our updated fiscal year 2016 guidance."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with o",1863,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with our previously disclosed guidance. Our growth rate this quarter reflects a tough comparison to strong prior year results of 6.7% organic growth, which includes CareFusion's final quarter as a stand-alone company, growing at 10% organically. As a reminder, our results last year were driven by robust performance in the legacy CareFusion businesses, the impact of timing of orders in Pharmaceutical Systems, a very strong flu season, timing of tenders and strong emerging market performance. As a result, these items negatively impacted our first quarter growth rate by over 240 basis points. On an underlying basis, we are pleased with the solid performance of our segments and the momentum in our businesses.
BD Medical first quarter revenues increased 1.9%, reflecting the aforementioned items. Medication & Procedural Solutions or MPS growth was 2.0%, which reflects strength in Pharmacy Solutions, Infusion Therapy and safety-engineered products. Very strong results in the prior year negatively impacted the MPS growth rate by approximately 250 basis points. 
Despite extremely strong results in the prior year in Medication Management Solutions, revenues grew 4.3%, driven by both strong infusion and dispensing capital installations. Respiratory Solutions revenues declined 6.8%, reflecting the tough comparison to prior year results due to the strong final quarter as part of legacy CareFusion. Growth in Diabetes Care was 3.9%, driven by solid growth in pen needles. 
Pharmaceutical Systems growth of 2.6% reflect strong growth in SAIS, partially offset by the impact of timing of orders, which we expect to occur later this fiscal year. 
BD Life Sciences first quarter revenues increased 1.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Preanalytical Systems growth of 4.4% was driven by safety-engineered products in both the U.S. and Europe and also reflects strong growth in emerging markets. BD Biosciences growth of 1.2% reflects clinical tendered delays in emerging markets and a difficult comparison to the prior year when sequestration ended. This was offset by strong sales that were driven by an increased demand of high-end instruments and growth in research reagents. The Diagnostic Systems decline of 0.8% reflects a mild flu season, which impacted growth by approximately 400 basis points. Growth was also negatively impacted by a slowdown of capital spending in China. Solid microbiology growth as well as growth in molecular led by BD MAX and international growth in Women's Health partially offset the impact from the flu.
Moving to Slide 8, I'll walk you through our geographic revenues for the first quarter on a currency-neutral basis. U.S. growth of 1.5% reflects the aforementioned prior year comparisons and timing impacts with BD Medical growing 1.9% and BD Life Sciences growing 0.3%. BD Medical's performance reflects strength in Pharmacy Solutions, Infusion Therapy pumps and related consumables and strength in Diabetes Care. This was partially offset by Respiratory Solutions. BD Life Sciences growth reflects the impact of a light flu season this year and a difficult comparison to the prior year due to a strong flu season and the ending of sequestration. Offsetting these impacts was strong performance in the Biosciences business driven by research reagent sales, solid performance in our Preanalytical Systems unit, growth in microbiology and growth from BD MAX.
Moving on to International, revenues grew 2.2%. This is below our normal growth rate, which reflects timing of tenders and capital installations. International revenues also reflect the moderation of growth in China in the quarter, and I'll provide more color on China in just a moment.
The medical segment grew 1.9%. This reflects solid performance in Pharmaceutical Systems and Medication Management Solutions, partially offset by a tough comparison due to large tenders in Brazil and EMA in the prior year as well as timing of capital installations in the dispensing business.
Our Life Sciences segment grew 2.7%, which reflects strong growth in Diagnostic Systems driven by core microbiology, Women's Health and an expanded BD MAX menu in Europe. We also saw strong growth in the Preanalytical Systems unit. This was partially offset by a decline in the Biosciences business due to tender delays in emerging markets.
On Slide 9, emerging market revenues grew 2.4% currency-neutral, with developed markets growing 1.7%. The first quarter growth rate in emerging markets reflects a very difficult comparison to the prior year period, both the BD and CareFusion legacy businesses and a moderation of growth in China.
China growth for the first quarter was 4.5% compared with growth of over 23% in the first quarter of last year. This difficult comparison was in line with our expectations. Beyond the difficult comparison, we also experienced a continued slowdown of capital spending in Diagnostic Systems, which resulted in inventory adjustments. Inventory adjustments negatively impacted growth in the quarter by approximately 350 basis points. While there are pockets of pressure, millions of patients are entering the health care system and, overall, emerging markets continue to be an important growth driver. For the total year, we expect China to grow in the low double-digit range and total emerging markets to grow 9% to 10%.
Moving to global safety on Slide 10, currency-neutral sales increased 4.9% and grew to $737 million in the quarter. Safety revenues in the U.S., grew 3.8%, while international sales grew 6.5% currency-neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 10.9% in emerging markets. Medical Safety sales grew 5.4%, primarily driven by safety catheters and a range of products in Pharmaceutical Systems. Life Science safety sales, which are driven by our Preanalytical Systems unit, grew 4.1% in the quarter.
Slide 11 recaps the first quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 1.8% on a comparable currency-neutral basis. Pricing was about flat in the quarter.
Moving down the P&L, I will focus on the comparable basis figures, which includes CareFusion results in the prior year, in order to give a better indication of our performance. 
Gross profit improved by 3.6%. I'll provide more color on gross profit in the next slide when we look at underlying performance and the impact of currency.
SSG&A as a percentage of revenue was 24.9%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenues was 6.3% as we continue to invest in new products and innovation. 
Operating income grew 12%, reflecting strong P&L leverage, which I'll also address in more detail on the next slide. 
Our tax rate increased slightly. However, it continues to improve versus our initial deal model expectations. 
As discussed earlier, adjusted earnings per share were $1.96, which is a 45.8% increase versus the prior year. This reflects solid underlying performance from the segments, positive product mix that was incremental to already strong gross margin performance, some timing of expenses and below the line items.
Slide 12 illustrates our gross profit and operating margin for the first quarter presented on a comparable basis. Strong gross profit margin performance of 130 basis points was primarily driven by continuous improvement initiatives and product mix and to a lesser extent, favorable raw material prices. Building off the strong momentum in fiscal year 2015 of 100 basis points of underlying operating margin expansion, operating margins grew 220 basis points year-over-year, driven by gross margin expansion, combined with the achievement of operational efficiencies, continuous improvement and the positive impact of cost synergies. Currency had a negative impact on both gross profit margin and operating margins.
Moving on to Slide 14. Since we provided guidance in November, there have been a number of new dynamics that we anticipate will affect our results. Some of these items include the sale of BD Rx, the suspension of the Medical Device Tax, the reinstatement of the R&D tax credit, lower oil prices, a milder flu season and additional FX pressure. As a result of these new dynamics, in combination with our first quarter results, we are raising our currency-neutral adjusted EPS guidance by 4 percentage points from $8.73 to $8.80 to a range of $9.01 to $9.08. The increased currency-neutral guidance is offset by incremental FX pressures of approximately $0.28 due to the continued strengthening of the U.S. dollar. Therefore, we are maintaining our adjusted EPS guidance of $8.37 to $8.44. We are extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 15, I'd like to walk you through additional elements of our guidance for the full fiscal year 2016. In summary, we continue to expect comparable revenue growth of 4.5% to 5% on a currency-neutral basis. On a reported basis, revenue growth for the total year is expected to be between 20% and 20.5%, which reflects a currency headwind of about 450 basis points. The U.S. dollar has strengthened further against most currencies since we last provided guidance in November. Our guidance assumes a euro to dollar exchange rate of 1.09. We expect this unfavorable impact to be acute again in the second quarter with a revenue headwind of over 400 basis points on a comparable basis. We expect our currency-neutral revenue growth to be back in line with our guidance range of 4.5% to 5%. In the second half of the year, we expect the currency impact on revenue to moderate.
We continue to expect growth in BD Medical of 4.5% to 5%. In our Life Sciences segment, we are revising our guidance to 4% to 4.5% to reflect the mild flu season in combination with lower sales in China. 
Based on the current view of the environment, we continue to expect pricing to be about flat for the year. We continue to expect gross profit margin to be between 52% and 52.5% as the benefit from operating efficiencies, the sale of BD Rx and lower resin prices are expected to be partially offset by increased currency pressure. SSG&A as a percentage of sales is expected to be between 24% and 24.5%. This is slightly better than our previous forecast as a result of the suspension of the Medical Device Tax, which was recorded within SSG&A. As we reinvest the medical device tax, we now expect R&D investment of about 6% to 6.5% of revenues. The reinvestment will help us to accelerate the strategies in both of our segments.
Operating margin is expected to be between 21% and 22% of revenues as a result of the items I just reviewed. Excluding the unfavorable impact of foreign currency, we are raising our underlying operating margin guidance to 170 to 190 basis points. Once again, we are very pleased with our performance in driving margin expansion. 
We are broadening our tax rate to be between 21% and 22%. 
Our full-year guidance range is for operating cash flow, capital expenditures, interest/other and share count remain unchanged from our November guidance. 
Now I would like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each",825,"Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each quarter. The product update slides that you are accustomed to seeing will remain in the appendix of the presentation for reference.
Starting with new product innovation, within our Life Sciences business, we are very pleased with the early access customer response to BD FACSSymphony, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell. BD FACSSymphony offers high-speed analysis that is 20x faster than other nonflow platforms. When combined with our BD Horizon Brilliant or the Sirigen reagent portfolio, these capabilities will allow researchers improved identification and analysis of rare cell types and events.
In early December, we successfully launched our FACSCelesta instrument, a mid-level cell analyzer with a very positive market reception. The new FACSCelesta system offers simultaneous measurement of up to 14 different single cell characteristics. The FACSCelesta system is also designed to leverage our broad BD Horizon Brilliant reagent portfolio. 
In our Diagnostic Systems business, we continue to focus on menu expansion and anticipate launching new assays on the BD MAX platform in fiscal year 2016, including CT/GC and Vaginitis. 
Within our strategic and business initiatives, as we discussed earlier, we have divested the BD Rx business and are excited to be adding IV solutions to our Medication Management portfolio. 
We continue to make progress with our portfolio strategic review process and will provide you with updates as we move forward.
In January, we launched our new BD brand that captures the new BD and our rearticulated purpose, advancing the world of health, which is more relevant than ever in a dynamic and ever-changing industry.
And in the equally important area of partnerships and collaborations, we remain on track with our collaboration with Medtronic. The insulin infusion sets in our Diabetes Care business have an expected product launch in the middle of the fiscal year 2016, so this year. We believe this product will improve the consistency of insulin delivery by significantly reducing silent occlusions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We continue to see strong growth in opportunities in our IDAST business, where we have built a comprehensive solution offering, which includes the BD Bruker MALDI Biotyper. This is a result of the collaboration with Bruker Corporation. We've seen success over the past several years with the BD Bruker MBT instrument due to its ability to provide rapid and accurate microbial identification and its adoption in new geographic markets. As you can see, we continue to have strong opportunities that drive growth and innovation, and we look forward to updating you as we make progress throughout the year.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the first quarter, and we made progress with our back office functions and with harmonizing our IT infrastructure. We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. 
Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs as we discussed earlier. The consistent solid performance of our business, combined with operating efficiencies, cost leverage and cost synergy capture is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion in fiscal year 2015, we expect another 170 to 190 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid start to fiscal year 2016. Both segments performed well, and we delivered very strong earnings growth. Second, our margin profile has improved significantly. We are driving operational efficiencies and continuous improvement in addition to delivering on our synergy commitments. This is manifesting in our financial results with 200 basis points of operating margin expansion this quarter and increased guidance for the total year. Third, we continue to evaluate and optimize our portfolio and focus on the appropriate strategic initiatives. In doing so, we are positioning ourselves in higher growth areas, which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. Finally, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We are also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year. We believe we are well-positioned to continue our track record of delivering value to our customers and shareholders and I look to the future with enthusiasm. Thank you. 
We will now open the call to questions."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank.",13,"[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We don't hear you Kristen if you're there.",9,"We don't hear you Kristen if you're there."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Not working. We'll have to come back to Kristen.",9,"Not working. We'll have to come back to Kristen."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Are you on mute Kristen?",5,"Are you on mute Kristen?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Mike Weinstein of JPMorgan.",9,"Your next question is from Mike Weinstein of JPMorgan."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth for this quarter over a tougher comp. The Street heard you but didn't do a good job of reflecting that in the numbers. But you're",113,"So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth for this quarter over a tougher comp. The Street heard you but didn't do a good job of reflecting that in the numbers. But you're maintaining your FX neutral guidance for the year, which effectively implies that over the balance of the year -- over the next 3 quarters you grow the top line 5.5% to 6% FX neutral. So, a, is that correct? And then, b, can you just walk us through your confidence in the top line outlook for the rest of the year?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very diffi",229,"Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very difficult comps, a strong flu season last year. We had CareFusion's last final quarter, and we talked in our prepared remarks about the 6.7% growth that we were jumping over, including the CareFusion 10% growth. And then we had a number of items like in Pharmacy Solutions, where we have the typical timing compares. All of that goes away. In fact, it reverses in the second half. So if you remember, the CareFusion businesses actually grew minus 2% in the third quarter. So actually, we expect the second quarter to be back in basically the range that we normally have, the 4.5% to 5%. And you'll start picking up more in the back half of the year against that CareFusion compare. Don't forget, we had the AVEA recall in respiratory, so that becomes an easier compare. Emerging markets actually start comparing to more normalized results. You saw China this year; the first quarter of last year was 23% growth, we had a jump-over. So all of that starts reversing. And so we are confident in our full year guidance."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Lewis of Morgan Stanley.",10,"Your next question is from David Lewis of Morgan Stanley."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How much congested did you see in the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing",72,"Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How much congested did you see in the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind of weakness in Tier 1 hospitals in China? And where are inventory levels now for you in some of these broader emerging markets?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the audi",214,"Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the auditing of large capital purchases. So we're seeing that in China, and we expect that to continue for the rest of the year. On the disposable side, we did fine. And these are products that sustain the health care system. And so we expect stability in China on that side. That's really the difference as we look around the emerging markets. That's the biggest difference. If I talk about Latin America, Latin America is basically -- Brazil is where we said it was and then with stronger performance in the other countries. So in terms of inventory, as you heard, we made inventory adjustments on the Medical side last time. And coming back to the Diagnostic piece, we actually thought that it was more of a timing issue, this audit issue. We're now saying that's going away, so we came back and we did make the inventory adjustment on the Diagnostic side because of the change in the situation. Chris, anything else you would add?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think that about nails it.",7,"No, I think that about nails it."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initia",97,"I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initiatives may be materializing? And when you think we could start to see that drive a revenue uptick, particularly in the context of the 4.5% to 5% is pretty much where the business has been growing in the past couple of years and what it takes to sort of accelerate that number?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that.",42,"Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David, this is Tom. So I think, as Vince said, we've always commented that it would take us some time to get products registered for, particularly, the ex U.S. markets, to put through our channels. Those registrations are well underway. We have seve",110,"Sure, David, this is Tom. So I think, as Vince said, we've always commented that it would take us some time to get products registered for, particularly, the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several dozen products actively under regulatory review that we've already submitted. We have taken a few products that were already approved and put those through our channels in markets like China and we are seeing some early positive signs. But we've always said it would take some time to ramp and that we would see that more in FY '17, and we're right on track to that."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise of Stifel.",9,"Your next question is from Rick Wise of Stifel."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start off with the margin expansion. If I -- you maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synerg",71,"Let me start off with the margin expansion. If I -- you maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synergies now with CareFusion. Am I understanding that correctly? And maybe just in general, how much more is there to go? I mean, is this accelerating?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 3",404,"Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 30. And so whether you call those synergies or -- it's all good. I mean what I would point to on that chart is that, that $9.01 to $9.08 represents a 37% to 38% increase over where we would have been on a BDX legacy guidance basis. And so how you characterize that, whether it's just accretion or synergies, that's somewhat semantics. I mean, we were growing over the expectation that we would have grown 9% to 10% anyway. So we've stayed pure on that. But the tax rate improvements, are those synergies? Yes, they're synergies as well, it's just not what we had originally contemplated in the deal. So we've tried to keep a very clear and transparent view of what is synergies and what's accretion. And that 4%, as I said, I wouldn't call those synergies. We are not raising our synergy guidance as we did last quarter because these are just kind of other things that are benefiting our cost structure and bottom line that hadn't been contemplated in November. So for what we control, we're really executing extremely well, very pleased with it. But obviously, the FX drag is worse. In that regard, since November, the euro has stabilized at 1.09. Of that 4% drag additional in FX, 1% comes from the euro remaining at that 1.09. And then another percent from other major currencies like Canada, for example, it's down 8% or 7% since November. Mexico is down 8%. China is down 3%. So that's another percent of that 4%. The other 2% is every other currency in the world is weak against the U.S. dollar compared to where it was in November. And so that's another 2%. So the additional 4% drag. So we don't really have a lot of control over that. We do everything we can to mitigate that. So what we control, we're really feeling good about, but we are going against significant FX headwinds. But we really feel good about the fact that we were able to still meet our commitment of $8.37 to $8.44 despite those significant FX headwinds."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just 2 things here. Number one, it sounded like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of the dynamics. I think you said ca",111,"So just 2 things here. Number one, it sounded like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of the dynamics. I think you said capital sales were up, and I'm asking in reference to some strong results from a competitor yesterday. And then just on China, I think you also said low double-digit growth for the year. You're obviously starting much lower than that. So you've touched on this, but how do you really accelerate through the course of the year to get to that low double-digit China growth?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Tom will start with the infusion -- capital.",10,"Okay. So Tom will start with the infusion -- capital."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, maybe I'll just comment on the U.S., which is by far the largest market. We did have high single-digit growth",92,"Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, maybe I'll just comment on the U.S., which is by far the largest market. We did have high single-digit growth in our infusion business in the U.S., which, in a market that's growing low single digits, we certainly see that as reflecting continued strengthening of our position in our Alaris business. So we are very pleased with our results and the momentum that we continue in that business."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?",28,"Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Exactly.",1,"Exactly."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Chris, you want to take China?",6,"Chris, you want to take China?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the f",163,"Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the first quarter. As I said on the overall BD revenue growth to come, the comparison to prior year eases in the second half of the year significantly. We have, for example, respiratory wasn't even shipping in China, towards the second half of last year, so that makes it an easier compare as well. So that's where we get the low double digits. We are getting a little bit of a lift. We talked about most of the CareFusion synergies coming next year. But there is a little bit connectors and things like that, that help us. Actually an easy compare against CareFusion's China performance last year that gives us a little bit of a lift as well."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess first question is just on safety and I guess specifically around Europe. I guess it's been a couple of quarters since you've given us an update here in terms of kind of how far through that opportunity we are penetrated and how much more does this",51,"I guess first question is just on safety and I guess specifically around Europe. I guess it's been a couple of quarters since you've given us an update here in terms of kind of how far through that opportunity we are penetrated and how much more does this have to go?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical si",52,"So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical side, and Tom will talk about that."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we t",121,"Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we think about infusion, I'd say we're probably in the fifth, sixth -- fifth inning let's say there, as that's typically the first area that people convert to. And then in the injection business, which is generally a low -- can proceed as a lower risk procedure, we're in even much earlier innings on that side of the business. So overall, we still have a ways to go, certainly several years to go, when it comes to the European safety conversion."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Matt Taylor of Barclays.",9,"Your next question is from Matt Taylor of Barclays."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing?",63,"I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing? Sorry for the multipart question, but I had a few things to get in there."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there.",32,"That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. As we have seen on the flu, we had a tough jump-over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platfor",92,"Sure. As we have seen on the flu, we had a tough jump-over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platform, we feel very good about our position, both in terms of accuracy, turnaround time and throughput. This is being reflected in our share position, now over 19,000 instruments placed globally. And we're very excited about the new wireless connectivity we'll introduce this quarter."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Brian Weinstein of William Blair.",10,"Your next question is from Brian Weinstein of William Blair."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in lig",73,"Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in light of putting more money into R&D from the medical device tax reinvestment? Where are you putting that specifically? What types of projects should we be thinking about?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the Care",217,"Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the CareFusion product line coming in, and we're not quite there yet. But if I look at the portfolio and the number of new products, I would say we're in a strong position. I mean, it's across both the segments and it's over the next 3-year period. And so both portfolios on the Medical side and the Life Science side appear good. As I mentioned on the call, we feel very excited about the launch of the infusion set, the FlowSmart set. We haven't talked much about it lately, but SAIS is making progress with their micro infuser, and we have signed up a number of customers there. And so we're starting to see some nice momentum in SAIS. I'm not going to try to walk through all of the new products across MPS and MMS, but there is a nice portfolio, and Tom would tell you, in addition, that the backlog for Pyxis remains very robust. And Tom, I think it continues to actually get a little larger, right?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high.",27,"Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, we would increase the number. And then on Linda's side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays",58,"Yes, we would increase the number. And then on Linda's side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays out soon in terms of chlamydia and vaginitis. What's your expectation there?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4 -- Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu.",52,"Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4 -- Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Manage",114,"And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Management and on the Life Science side. In both, I would say, they are both the core business as we continue to elaborate things like KIESTRA and drive that into the marketplace, and drive the genomics stuff that we just started. I think we're in a situation where a lot of these things haven't launched yet, but they launch over the next couple of years. So thanks, Brian, for the question."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Jon Groberg of UBS.",9,"Your next question is from Jon Groberg of UBS."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can I just maybe do one kind of clarification and then a quick question. So I'll just put it into 2 here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital p",151,"Can I just maybe do one kind of clarification and then a quick question. So I'll just put it into 2 here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital purchases? It seems like about 12 months later than what most Life Science companies have been seeing. Or most of them saw it a year ago and reported pretty good results in China this year. So just curious kind of why you think you're seeing those delays more significantly than others in the Life Sciences space? And then I just wanted on the new products on Totalys, I think in your presentation, you have that still launching in the U.S. in '16. I'm just curious what you're seeing with that in Europe and whether that still on track for '16?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda, do you want to take that?",9,"Sure. So Linda, do you want to take that?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China, specifically. So as we are putting those instruments into the market, reall",185,"Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China, specifically. So as we are putting those instruments into the market, really starting in our first quarter fiscal year '15, we had expectations on those that clearly in the first quarter, we saw that the overall number of tenders being issued were not at the level that we were expecting. So that would explain the delay because of the Bruker exclusivity. We are seeing, though, very good progress competitively in that space with now a more expanded solution to offer. And then as you note, we are seeing great performance ex U.S. now with a more expanded platform that includes our Totalys and focal point system for a full liquid cytology solution. So we saw this quarter high double-digit growth ex U.S. on those platforms. And the anticipated launch date for us in the U.S. is in FY '16. I don't have the exact quarter sitting in front of me, but..."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","But later in the year, anyway.",6,"But later in the year, anyway."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Q3 would be a safe bet for us.",9,"Yes. Q3 would be a safe bet for us."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Vijay Kumar of Evercore ISI.",10,"Your next question is from Vijay Kumar of Evercore ISI."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the reiteration [ph] of EPS, and I guess off margins are g",98,"Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the reiteration [ph] of EPS, and I guess off margins are going to come up at the high end of the guidance range. I want to make sure I got that right. And when you look at below the line, I think other income, you had some hedging gains. Why would those sort of gains reverse in the back half?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first q",170,"Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first quarter, favorable timing of expenses as well. And then below the line, there is a little bit in tax rate. So the 21.5% is a little bit better than expectations, and we see that flowing through to the total year. We were slightly better in interest income and slightly less in interest expense. You put all those things in and that flows through to the full year. Of course, it's overwhelmed by the items that I talked about with -- the oil prices being down will benefit the second half of the year as well as the sale of BD Rx. So you put all that together and we get to the $9.01 to $9.08 and the $8.37 to $8.44 all-in with FX."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Richard Newitter of Leerink Partners.",10,"Your next question is from Richard Newitter of Leerink Partners."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wanted to ask, actually, 2 quick ones. One, is the full med tech tax reversal benefit getting reinvested? So it's just a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adju",78,"Just wanted to ask, actually, 2 quick ones. One, is the full med tech tax reversal benefit getting reinvested? So it's just a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted China growth rate to be if you kind of look at it the way -- you said low teens, I think in the past 2 quarters if you back out the inventory."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on medical device tax, just to put it in perspective, last year we had about -- or in our budget, we had about $60 million for the full year. Don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we h",198,"Okay. So on medical device tax, just to put it in perspective, last year we had about -- or in our budget, we had about $60 million for the full year. Don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we have about 1/3 of that being executed against. The other 2/3 we are still getting the projects in place and we do fully expect to spend that this year. There might be a little bit of timing issue. Obviously, in the month of January, we're getting the benefit and we're only executing on the 1/3. So we'll probably just naturally pick up a little bit in timing, but not a lot, and that's already in the guidance. But we fully expect to reinvest, and we want to reinvest and we're going through that process now. 
And then the second question was China. I think that I'd bring you back to -- if you adjust for the difficult compare in the first quarter and you adjust for the inventory adjustments that we took in Life Sciences, it brings you back up to a double digit number in China."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we said low double digits for the year.",9,"And we said low double digits for the year."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ...",22,"Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ..."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Easier compares and a little bit of momentum out of some CareFusion products.",13,"Easier compares and a little bit of momentum out of some CareFusion products."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Doug Schenkel of Cowen and Company.",11,"Your next question is from Doug Schenkel of Cowen and Company."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation see",128,"So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation seems to be a bit more material than we would've expected just given what we've seen from Life Science tools peers. Others have talked about academic government starting to pick up. It sounds like biopharma continues to be strong. So with all that said, 2 questions. One, can you describe what you saw in the quarter in terms of demand from biopharma and academic government in the U.S.? And two, what's embedded into your guidance for contributions from new products and the potential benefit associated with a more robust NIH budget?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Biosciences business continues to do very well. We did mention that in first quarter '15, we had a tough j",235,"Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Biosciences business continues to do very well. We did mention that in first quarter '15, we had a tough jump-over. We had high double-digit growth, primarily in our research instrument base. So we still managed to grow off that base, but it was a difficult compare. So for this quarter, we did see very good growth in our biopharma side, particularly in our Advanced Bioprocessing business, a business we do not talk about a lot but is doing very, very well for us. So that was a tremendous area of growth. And then as we've been talking about for the past several quarters, led by the U.S., our Total Research Solutions platform now, we feel very good about the prospects for that business. Of course, this past quarter, launching both FACSSymphony and FACSCelesta and we think across the range of low mid and high-end analyzers now, combined with our Sirigen platform, so really now starting to work out that full solution between our instrument base and our solutions base. We see the U.S. research market as being an area that has, if you look at our last quarter report -- was very strong for us and an area moving forward that is in our guidance."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","How do you feel about new products, Linda? I know you can't exactly quantify it, but. . .",18,"How do you feel about new products, Linda? I know you can't exactly quantify it, but. . ."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about",68,"Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about that. And then of course PAS with their new products and DS with the expansion of the MAX menu, we're really starting to see these kick in."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So we should start to see some traction in the back half of the year basically. Okay, thanks.",18,"So we should start to see some traction in the back half of the year basically. Okay, thanks."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Derik De Bruin of Bank of America.",12,"Your next question is from Derik De Bruin of Bank of America."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So could you talk a little bit about sort of looking at the overall portfolio. I mean you've trimmed Simplist, and there had been some talk about respiratory earlier on in the process of maybe doing something with that. Has that business rebounded to the",72,"So could you talk a little bit about sort of looking at the overall portfolio. I mean you've trimmed Simplist, and there had been some talk about respiratory earlier on in the process of maybe doing something with that. Has that business rebounded to the point now that -- or you feel comfortable with it that it's -- you feel it's part of the portfolio and it's not, potentially, a divestiture candidate?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business.",102,"So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business. I would tell you, we are making some progress on that, but we are not to the finish line yet. There are a couple of other small pieces that we are continuing to work on also in terms of that strategic review process, and you'll hear more from us as we move forward."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Today's final question is coming from Kristen Stewart of Deutsche Bank.",12,"Today's final question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We let you back in Kristen.",6,"We let you back in Kristen."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Sorry to miss you there before. It was a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the solutions. And also if there's any additional updates on the CME relationship with the pump",65,"Sorry to miss you there before. It was a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the solutions. And also if there's any additional updates on the CME relationship with the pumps and anything about bringing that in-house to BD and the timing of launch that, that could go into emerging markets?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Go ahead, Tom.",3,"Go ahead, Tom."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased, obviously, with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. W",206,"Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased, obviously, with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. We certainly see that these opportunities aligned with our customers feedback to have additional options available to them in how they buy IV solutions. And we expect to begin launching that line in the very back half of FY '16. So I think that's probably the most to say about that there. But we see it very much in line and supporting and helping to advance our overall medication management strategy, and we've gotten very positive feedback from customers after that announcement. Related to CME, we do sell CME products in certain markets today, primarily in Europe. No new news to update in terms of an acquisition or integration of CME into BD. As you know, we already own 40% of CME, and we've talked about options of that going forward. No new news to share there. We continue to promote and grow their products though in the markets, particularly in Europe, that we have had since the beginning of the year."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is from Brandon Couillard of Jefferies.",9,"Your final question is from Brandon Couillard of Jefferies."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of tests available on the menu, and to what extent is the LDT capability contributing to growth?",47,"Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of tests available on the menu, and to what extent is the LDT capability contributing to growth?"
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis",140,"Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis. In terms of the menu, of course, the expansions that we saw in the menu in both Enterics and CT/GC, what we're seeing now in Europe is very strong double digit growth and very positive feedback from our U.S. customer base. Again, starting to see very good growth in placements on our Mac system. And of course when we get the CT/GC and Vaginitis, we are anticipating stronger growth there. On the LDCT side in terms of what we see in terms of opportunity for us moving forward, are you speaking about the..."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Open channel.",2,"Open channel."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportuni",80,"Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportunity for us. I would say that the big opportunity that we see is, with the differentiated menu that we are already seeing on the Enterics and we'll look forward to on the CT/GC and Vaginitis."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Linda. Okay.",3,"Thanks, Linda. Okay."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks.",16,"Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much.",41,"Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks a lot.",3,"Thanks a lot."
103678,321567599,925763,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367",79,"Hello, and welcome to BD's First Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through February 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 20775429. [Operator Instructions] 
Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",408,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our first fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures, in the financial schedules, in our press release or the appendix of the Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Bill Kozy, Executive Vice President and Chief Operating Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. It is now my pleasure to turn the call over to Vince."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our",450,"Thank you, Monique, and good morning, everyone. As we stated in our press release, we are pleased with our solid start to fiscal year 2016. Performance from both the Medical and Life Science segments contributed to revenue growth that was in line with our expectations. Strong underlying margin expansion was driven by the achievement of operational efficiencies and continuous improvement, coupled with the positive impact of synergies.
As we move through the first quarter, we continue to make progress with the strategic review of our portfolio. Many of you already know, we recently announced that Fresenius Kabi has acquired the BD Simplist portfolio. We believe Fresenius is a better owner of the BD Rx business as it complements their existing products and capabilities in the injectable pharmaceutical industry. In addition, we are excited that we are initiating a long-term collaboration for Fresenius to supply us with a portfolio of competitive IV solutions in the U.S. This transaction is intended to enable BD to be responsive to our customers' needs and is complementary to our end-to-end Medication Management Solutions for our customers and their patients.
Since we provided guidance in November, there have been a number of new dynamics that will affect our results this year. As most of you already know, several weeks ago, there was a bipartisan agreement to suspend the Medical Device Tax. This critical relief is extremely important to BD as well as the patients, providers and research communities we serve. While some of the specifics are still being analyzed, we plan to reinvest this tax back into the business, which further supports our innovation strategy. 
In summary, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We're also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year.
Moving on to Slide 5, I will review our first quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company revenues grew 1.8%, which is in line with our prior guidance of 1% to 2% growth that we had anticipated and communicated on our last earnings call. Adjusting for tough comparisons for the prior year, this reflects solid underlying growth in both segments. 
Adjusted EPS was $1.96, driven by the solid underlying performance of the segments. Earnings were ahead of our expectations as the quarter also benefited from product mix that was incremental to already strong gross margin performance and some timing of expenses and below the line items.
Now I'd like to turn things over to Chris for a more detailed discussion of our first quarter financial performance and our updated fiscal year 2016 guidance."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with o",1864,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, performance in both segments contributed to a solid start to fiscal 2016. Total first quarter revenues of approximately $3 billion grew 1.8% on a comparable basis, which is in line with our previously disclosed guidance. Our growth rate this quarter reflects a tough comparison to strong prior year results of 6.7% organic growth, which includes CareFusion's final quarter as a stand-alone company, growing at 10% organically. As a reminder, our results last year were driven by robust performance in the legacy CareFusion businesses, the impact of timing of orders in Pharmaceutical Systems, a very strong flu season, timing of tenders and strong emerging market performance. As a result, these items negatively impacted our first quarter growth rate by over 240 basis points. On an underlying basis, we are pleased with the solid performance of our segments and the momentum in our businesses.
BD Medical first quarter revenues increased 1.9%, reflecting the aforementioned items. Medication & Procedural Solutions or MPS growth was 2.0%, which reflects strength in Pharmacy Solutions, Infusion Therapy and safety-engineered products. Very strong results in the prior year negatively impacted the MPS growth rate by approximately 250 basis points. 
Despite extremely strong results in the prior year in Medication Management Solutions, revenues grew 4.3%, driven by both strong infusion and dispensing capital installations. Respiratory Solutions revenues declined 6.8%, reflecting the tough comparison to prior year results due to the strong final quarter as part of legacy CareFusion. Growth in Diabetes Care was 3.9%, driven by solid growth in pen needles. 
Pharmaceutical Systems growth of 2.6% reflect strong growth in SAIS, partially offset by the impact of timing of orders, which we expect to occur later this fiscal year. 
BD Life Sciences first quarter revenues increased 1.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Preanalytical Systems growth of 4.4% was driven by safety-engineered products in both the U.S. and Europe and also reflects strong growth in emerging markets. BD Biosciences growth of 1.2% reflects clinical tendered delays in emerging markets and a difficult comparison to the prior year when sequestration ended. This was offset by strong sales that were driven by an increased demand of high-end instruments and growth in research reagents. The Diagnostic Systems decline of 0.8% reflects a mild flu season, which impacted growth by approximately 400 basis points. Growth was also negatively impacted by a slowdown of capital spending in China. Solid microbiology growth as well as growth in molecular led by BD MAX and international growth in Women's Health partially offset the impact from the flu.
Moving to Slide 8, I'll walk you through our geographic revenues for the first quarter on a currency-neutral basis. U.S. growth of 1.5% reflects the aforementioned prior year comparisons and timing impacts with BD Medical growing 1.9% and BD Life Sciences growing 0.3%. BD Medical's performance reflects strength in Pharmacy Solutions, Infusion Therapy pumps and related consumables and strength in Diabetes Care. This was partially offset by Respiratory Solutions. BD Life Sciences growth reflects the impact of a light flu season this year and a difficult comparison to the prior year due to a strong flu season and the ending of sequestration. Offsetting these impacts was strong performance in the Biosciences business driven by research reagent sales, solid performance in our Preanalytical Systems unit, growth in microbiology and growth from BD MAX.
Moving on to International, revenues grew 2.2%. This is below our normal growth rate, which reflects timing of tenders and capital installations. International revenues also reflect the moderation of growth in China in the quarter, and I'll provide more color on China in just a moment.
The medical segment grew 1.9%. This reflects solid performance in Pharmaceutical Systems and Medication Management Solutions, partially offset by a tough comparison due to large tenders in Brazil and EMA in the prior year as well as timing of capital installations in the dispensing business.
Our Life Sciences segment grew 2.7%, which reflects strong growth in Diagnostic Systems driven by core microbiology, Women's Health and an expanded BD MAX menu in Europe. We also saw strong growth in the Preanalytical Systems unit. This was partially offset by a decline in the Biosciences business due to tender delays in emerging markets.
On Slide 9, emerging market revenues grew 2.4% currency-neutral, with developed markets growing 1.7%. The first quarter growth rate in emerging markets reflects a very difficult comparison to the prior year period, both the BD and CareFusion legacy businesses and a moderation of growth in China.
China growth for the first quarter was 4.5% compared with growth of over 23% in the first quarter of last year. This difficult comparison was in line with our expectations. Beyond the difficult comparison, we also experienced a continued slowdown of capital spending in Diagnostic Systems, which resulted in inventory adjustments. Inventory adjustments negatively impacted growth in the quarter by approximately 350 basis points. While there are pockets of pressure, millions of patients are entering the health care system and, overall, emerging markets continue to be an important growth driver. For the total year, we expect China to grow in the low double-digit range and total emerging markets to grow 9% to 10%.
Moving to global safety on Slide 10, currency-neutral sales increased 4.9% and grew to $737 million in the quarter. Safety revenues in the U.S., grew 3.8%, while international sales grew 6.5% currency-neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 10.9% in emerging markets. Medical Safety sales grew 5.4%, primarily driven by safety catheters and a range of products in Pharmaceutical Systems. Life Science safety sales, which are driven by our Preanalytical Systems unit, grew 4.1% in the quarter.
Slide 11 recaps the first quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 1.8% on a comparable currency-neutral basis. Pricing was about flat in the quarter.
Moving down the P&L, I will focus on the comparable basis figures, which includes CareFusion results in the prior year, in order to give a better indication of our performance. 
Gross profit improved by 3.6%. I'll provide more color on gross profit in the next slide when we look at underlying performance and the impact of currency.
SSG&A as a percentage of revenue was 24.9%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenues was 6.3% as we continue to invest in new products and innovation. 
Operating income grew 12%, reflecting strong P&L leverage, which I'll also address in more detail on the next slide. 
Our tax rate increased slightly. However, it continues to improve versus our initial deal model expectations. 
As discussed earlier, adjusted earnings per share were $1.96, which is a 45.8% increase versus the prior year. This reflects solid underlying performance from the segments, positive product mix that was incremental to already strong gross margin performance, some timing of expenses and below the line items.
Slide 12 illustrates our gross profit and operating margin for the first quarter presented on a comparable basis. Strong gross profit margin performance of 130 basis points was primarily driven by continuous improvement initiatives and product mix and to a lesser extent, favorable raw material prices. Building off the strong momentum in fiscal year 2015 of 100 basis points of underlying operating margin expansion, operating margins grew 220 basis points year-over-year, driven by gross margin expansion, combined with the achievement of operational efficiencies, continuous improvement and the positive impact of cost synergies. Currency had a negative impact on both gross profit margin and operating margins.
Moving on to Slide 14. Since we provided guidance in November, there have been a number of new dynamics that we anticipate will affect our results. Some of these items include the sale of BD Rx, the suspension of the Medical Device Tax, the reinstatement of the R&D tax credit, lower oil prices, a milder flu season and additional FX pressure. As a result of these new dynamics, in combination with our first quarter results, we are raising our currency-neutral adjusted EPS guidance by 4 percentage points from $8.73 to $8.80 to a range of $9.01 to $9.08. The increased currency-neutral guidance is offset by incremental FX pressures of approximately $0.28 due to the continued strengthening of the U.S. dollar. Therefore, we are maintaining our adjusted EPS guidance of $8.37 to $8.44. We are extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 15, I'd like to walk you through additional elements of our guidance for the full fiscal year 2016. In summary, we continue to expect comparable revenue growth of 4.5% to 5% on a currency-neutral basis. On a reported basis, revenue growth for the total year is expected to be between 20% and 20.5%, which reflects a currency headwind of about 450 basis points. The U.S. dollar has strengthened further against most currencies since we last provided guidance in November. Our guidance assumes a euro to dollar exchange rate of 1.09. We expect this unfavorable impact to be acute again in the second quarter with a revenue headwind of over 400 basis points on a comparable basis. We expect our currency-neutral revenue growth to be back in line with our guidance range of 4.5% to 5%. In the second half of the year, we expect the currency impact on revenue to moderate.
We continue to expect growth in BD Medical of 4.5% to 5%. In our Life Sciences segment, we are revising our guidance to 4% to 4.5% to reflect the mild flu season in combination with lower sales in China. 
Based on the current view of the environment, we continue to expect pricing to be about flat for the year. We continue to expect gross profit margin to be between 52% and 52.5% as the benefit from operating efficiencies, the sale of BD Rx and lower resin prices are expected to be partially offset by increased currency pressure. SSG&A as a percentage of sales is expected to be between 24% and 24.5%. This is slightly better than our previous forecast as a result of the suspension of the Medical Device Tax, which was recorded within SSG&A. As we reinvest the medical device tax, we now expect R&D investment of about 6% to 6.5% of revenues. The reinvestment will help us to accelerate the strategies in both of our segments.
Operating margin is expected to be between 21% and 22% of revenues as a result of the items I just reviewed. Excluding the unfavorable impact of foreign currency, we are raising our underlying operating margin guidance to 170 to 190 basis points. Once again, we are very pleased with our performance in driving margin expansion. 
We are broadening our tax rate to be between 21% and 22%. 
Our full year guidance range is for operating cash flow, capital expenditures, interest/other and share count remain unchanged from our November guidance. 
Now I would like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each",825,"Thank you, Chris. Moving on to Slide 17, we are presenting a new slide that includes updates on our new product innovation, strategic and business initiatives and partnerships and collaborations. With this new format, we will provide business updates each quarter. The product update slides that you are accustomed to seeing will remain in the appendix of the presentation for reference.
Starting with new product innovation, within our Life Sciences business, we are very pleased with the early access customer response to BD FACSSymphony, a novel cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell. BD FACSSymphony offers high-speed analysis that is 20x faster than other nonflow platforms. When combined with our BD Horizon Brilliant or the Sirigen reagent portfolio, these capabilities will allow researchers improved identification and analysis of rare cell types and events.
In early December, we successfully launched our FACSCelesta instrument, a mid-level cell analyzer with a very positive market reception. The new FACSCelesta system offers simultaneous measurement of up to 14 different single cell characteristics. The FACSCelesta system is also designed to leverage our broad BD Horizon Brilliant reagent portfolio. 
In our Diagnostic Systems business, we continue to focus on menu expansion and anticipate launching new assays on the BD MAX platform in fiscal year 2016, including CT/GC and Vaginitis. 
Within our strategic and business initiatives, as we discussed earlier, we have divested the BD Rx business and are excited to be adding IV solutions to our Medication Management portfolio. 
We continue to make progress with our portfolio strategic review process and will provide you with updates as we move forward.
In January, we launched our new BD brand that captures the new BD and our rearticulated purpose, advancing the world of health, which is more relevant than ever in a dynamic and ever-changing industry.
And in the equally important area of partnerships and collaborations, we remain on track with our collaboration with Medtronic. The insulin infusion sets in our Diabetes Care business have an expected product launch in the middle of the fiscal year 2016, so this year. We believe this product will improve the consistency of insulin delivery by significantly reducing silent occlusions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We continue to see strong growth in opportunities in our IDAST business, where we have built a comprehensive solution offering, which includes the BD Bruker MALDI Biotyper. This is a result of the collaboration with Bruker Corporation. We've seen success over the past several years with the BD Bruker MBT instrument due to its ability to provide rapid and accurate microbial identification and its adoption in new geographic markets. As you can see, we continue to have strong opportunities that drive growth and innovation, and we look forward to updating you as we make progress throughout the year.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the first quarter, and we made progress with our back office functions and with harmonizing our IT infrastructure. We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. 
Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs as we discussed earlier. The consistent solid performance of our business, combined with operating efficiencies, cost leverage and cost synergy capture is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion in fiscal year 2015, we expect another 170 to 190 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid start to fiscal year 2016. Both segments performed well, and we delivered very strong earnings growth. Second, our margin profile has improved significantly. We are driving operational efficiencies and continuous improvement in addition to delivering on our synergy commitments. This is manifesting in our financial results with 200 basis points of operating margin expansion this quarter and increased guidance for the total year. Third, we continue to evaluate and optimize our portfolio and focus on the appropriate strategic initiatives. In doing so, we are positioning ourselves in higher growth areas, which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. Finally, we are confident in our outlook and are maintaining our currency-neutral revenue guidance. We are also maintaining our adjusted EPS guidance despite significant currency headwinds and are raising our currency-neutral adjusted EPS guidance for the full fiscal year. We believe we are well-positioned to continue our track record of delivering value to our customers and shareholders and I look to the future with enthusiasm. Thank you. 
We will now open the call to questions."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank.",13,"[Operator Instructions] Our first question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We don't hear you Kristen if you're there.",9,"We don't hear you Kristen if you're there."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Not working. We'll have to come back to Kristen.",9,"Not working. We'll have to come back to Kristen."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Are you on mute Kristen?",5,"Are you on mute Kristen?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Mike Weinstein of JPMorgan.",9,"Your next question is from Mike Weinstein of JPMorgan."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth for this quarter over a tougher comp. The Street heard you but didn't do a good job of reflecting that in the numbers. But you're",113,"So let me ask you a couple of items. So number one, you guys in the last call had guided to 1% to 2% constant currency growth for this quarter over a tougher comp. The Street heard you but didn't do a good job of reflecting that in the numbers. But you're maintaining your FX neutral guidance for the year, which effectively implies that over the balance of the year -- over the next 3 quarters you grow the top line 5.5% to 6% FX neutral. So a, is that correct? And then, b, can you just walk us through your confidence in the top line outlook for the rest of the year?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very diffi",229,"Sure, thanks, Mike. Yes, so we did have results that were right in line in the first quarter with what we guided, the 1% to 2%, it came in at 1.8%, which does imply greater growth for the rest of the year. Just to remind everyone that there was very difficult comps, a strong flu season last year. We had CareFusion's last final quarter, and we talked in our prepared remarks about the 6.7% growth that we were jumping over, including the CareFusion 10% growth. And then we had a number of items like in Pharmacy Solutions, where we have the typical timing compares. All of that goes away. In fact, it reverses in the second half. So if you remember, the CareFusion businesses actually grew minus 2% in the third quarter. So actually, we expect the second quarter to be back in basically the range that we normally have, the 4.5% to 5%. And you'll start picking up more in the back half of the year against that CareFusion compare. Don't forget, we had the AVEA recall in respiratory, so that becomes an easier compare. Emerging markets actually start comparing to more normalized results. You saw China this year; the first quarter of last year was 23% growth, we had a jump-over. So all of that starts reversing. And so we are confident in our full year guidance."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Lewis of Morgan Stanley.",10,"Your next question is from David Lewis of Morgan Stanley."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How much congested did you see in the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing",72,"Vince or Chris, I just -- I wanted to talk about emerging markets for a second here. How much congested did you see in the updated EM guidance? And I guess, and just drilling down here, is the pressure largely capital in select businesses? Are you seeing any kind of weakness in Tier 1 hospitals in China? And where are inventory levels now for you in some of these broader emerging markets?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the audi",214,"Sure. So taking China first, the weakness was really on the capital side. It was in Life Science. And it does not appear to be driven so much by the financial situation as it was driven more by this issue that we brought up last quarter, which is the auditing of large capital purchases. So we're seeing that in China, and we expect that to continue for the rest of the year. On the disposable side, we did fine. And these are products that sustain the health care system. And so we expect stability in China on that side. That's really the difference as we look around the emerging markets. That's the biggest difference. If I talk about Latin America, Latin America is basically -- Brazil is where we said it was and then with stronger performance in the other countries. So in terms of inventory, as you heard, we made inventory adjustments on the Medical side last time. And coming back to the Diagnostic piece, we actually thought that it was more of a timing issue, this audit issue. We're now saying that's going away, so we came back and we did make the inventory adjustment on the Diagnostic side because of the change in the situation. Chris, anything else you would add?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think that about nails it.",7,"No, I think that about nails it."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initia",97,"I wanted just to follow up on the CareFusion integration. Clearly, the cost synergy side of the equation is progressing at a rate faster than you had initially provided. But can you give us a little bit more clarity on how some of the cross-selling initiatives may be materializing? And when you think we could start to see that drive a revenue uptick, particularly in the context of the 4.5% to 5% is pretty much where the business has been growing in the past couple of years and what it takes to sort of accelerate that number?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that.",42,"Well, overall, I would stick with what we've said. You're really going to see the revenue synergies starting in '17. That doesn't mean that we haven't done some work already in terms of aligning our organizations. And Tom can comment on that."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David, this is Tom. So I think, as Vince said, we've always commented that it would take us some time to get products registered for, particularly, the ex U.S. markets, to put through our channels. Those registrations are well underway. We have seve",110,"Sure, David, this is Tom. So I think, as Vince said, we've always commented that it would take us some time to get products registered for, particularly, the ex U.S. markets, to put through our channels. Those registrations are well underway. We have several dozen products actively under regulatory review that we've already submitted. We have taken a few products that were already approved and put those through our channels in markets like China and we are seeing some early positive signs. But we've always said it would take some time to ramp and that we would see that more in FY '17, and we're right on track to that."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise of Stifel.",9,"Your next question is from Rick Wise of Stifel."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start off with the margin expansion. If I -- you maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synerg",71,"Let me start off with the margin expansion. If I -- you maybe, Chris, if I looked at the slide correctly, your bridging commentary, you had 22% cost synergies last quarter. This quarter, you updated it by adding 4%. So really talking about 26% cost synergies now with CareFusion. Am I understanding that correctly? And maybe just in general, how much more is there to go? I mean, is this accelerating?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 3",404,"Well, you're on the right point, Rick. If you look at Chart 14, it really lays that out. The one thing that I would say is that 4% additional is things like the sale of BD Rx. Oil prices continue to give us a lift as the price per barrel went from 50 to 30. And so whether you call those synergies or -- it's all good. I mean what I would point to on that chart is that, that $9.01 to $9.08 represents a 37% to 38% increase over where we would have been on a BDX legacy guidance basis. And so how you characterize that, whether it's just accretion or synergies, that's somewhat semantics. I mean, we were growing over the expectation that we would have grown 9% to 10% anyway. So we've stayed pure on that. But the tax rate improvements, are those synergies? Yes, they're synergies as well, it's just not what we had originally contemplated in the deal. So we've tried to keep a very clear and transparent view of what is synergies and what's accretion. And that 4%, as I said, I wouldn't call those synergies. We are not raising our synergy guidance as we did last quarter because these are just kind of other things that are benefiting our cost structure and bottom line that hadn't been contemplated in November. So for what we control, we're really executing extremely well, very pleased with it. But obviously, the FX drag is worse. In that regard, since November, the euro has stabilized at 1.09. Of that 4% drag additional in FX, 1% comes from the euro remaining at that 1.09. And then another percent from other major currencies like Canada, for example, it's down 8% or 7% since November. Mexico is down 8%. China is down 3%. So that's another percent of that 4%. The other 2% is every other currency in the world is weak against the U.S. dollar compared to where it was in November. And so that's another 2%. So the additional 4% drag. So we don't really have a lot of control over that. We do everything we can to mitigate that. So what we control, we're really feeling good about, but we are going against significant FX headwinds. But we really feel good about the fact that we were able to still meet our commitment of $8.37 to $8.44 despite those significant FX headwinds."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just 2 things here. Number one, it sounded like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of the dynamics. I think you said ca",111,"So just 2 things here. Number one, it sounded like from the prepared comments that the CareFusion large volume infusion pump business did quite well. I was wondering if you could provide a little color on that and some of the dynamics. I think you said capital sales were up, and I'm asking in reference to some strong results from a competitor yesterday. And then just on China, I think you also said low double-digit growth for the year. You're obviously starting much lower than that. So you've touched on this, but how do you really accelerate through the course of the year to get to that low double-digit China growth?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Tom will start with the infusion -- capital.",10,"Okay. So Tom will start with the infusion -- capital."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, maybe I'll just comment on the U.S., which is by far the largest market. We did have high single-digit growth",92,"Sure. This is Tom. So we did have another solid quarter for the overall MMS business and, certainly, in our infusion business. And particularly, maybe I'll just comment on the U.S., which is by far the largest market. We did have high single-digit growth in our infusion business in the U.S., which, in a market that's growing low single digits, we certainly see that as reflecting continued strengthening of our position in our Alaris business. So we are very pleased with our results and the momentum that we continue in that business."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?",28,"Yes, I think, Tom, we grew last year in MMS was what, 40-something percent in the first quarter? So the 4% growth was on top of that, right?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Exactly.",1,"Exactly."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Chris, you want to take China?",6,"Chris, you want to take China?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the f",163,"Yes, so for China, if you look at the first quarter growth, we talked about the difficult compare against the 23% and we talked about the inventory adjustments in diagnostics. If you normalize for both of those, you'd be in double digits in China in the first quarter. As I said on the overall BD revenue growth to come, the comparison to prior year eases in the second half of the year significantly. We have, for example, respiratory wasn't even shipping in China, towards the second half of last year, so that makes it an easier compare as well. So that's where we get the low double digits. We are getting a little bit of a lift. We talked about most of the CareFusion synergies coming next year. But there is a little bit connectors and things like that, that help us. Actually an easy compare against CareFusion's China performance last year that gives us a little bit of a lift as well."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess first question is just on safety and I guess specifically around Europe. I guess it's been a couple of quarters since you've given us an update here in terms of kind of how far through that opportunity we are penetrated and how much more does this",51,"I guess first question is just on safety and I guess specifically around Europe. I guess it's been a couple of quarters since you've given us an update here in terms of kind of how far through that opportunity we are penetrated and how much more does this have to go?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical si",52,"So I think Tom can talk to that. It's mostly on the Medical side. As you may recall, that -- it's fairly highly converted on the -- in the PAS business and they're really moving to second-generation products, but there's more opportunity on the Medical side, and Tom will talk about that."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we t",121,"Bill, this is Tom. Safety does continue to perform well internationally overall and certainly in Europe as compliance with the regulation continues to support our safety growth. Maybe just to break it into 2 categories, from a medical perspective, as we think about infusion, I'd say we're probably in the fifth, sixth -- fifth inning let's say there, as that's typically the first area that people convert to. And then in the injection business, which is generally a low -- can proceed as a lower risk procedure, we're in even much earlier innings on that side of the business. So overall, we still have a ways to go, certainly several years to go, when it comes to the European safety conversion."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Matt Taylor of Barclays.",9,"Your next question is from Matt Taylor of Barclays."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing?",63,"I guess I wanted to just get a sense of your views about flu and you haven't updated us on your footprint there in a while. Could you speak to that? And interestingly, Abbott bought Alere this week, so does that change your view on point-of-care testing? Sorry for the multipart question, but I had a few things to get in there."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there.",32,"That's okay. I don't think Abbott's buying Alere changes our view on point-of-care testing. But Linda will be happy to update you on the flu and what's going on out there."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. As we have seen on the flu, we had a tough jump-over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platfor",92,"Sure. As we have seen on the flu, we had a tough jump-over versus a strong flu season last year and not seeing anything that would indicate we're going to get any sort of a flu season this year. As for our position in point-of-care, on our Veritor platform, we feel very good about our position, both in terms of accuracy, turnaround time and throughput. This is being reflected in our share position, now over 19,000 instruments placed globally. And we're very excited about the new wireless connectivity we'll introduce this quarter."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Brian Weinstein of William Blair.",10,"Your next question is from Brian Weinstein of William Blair."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in lig",73,"Question on new products. Vince, you used to talk about kind of percentage of revenue that new products were driving. Can you kind of update us where the new products are and kind of what your thoughts are going forward for new products, especially in light of putting more money into R&D from the medical device tax reinvestment? Where are you putting that specifically? What types of projects should we be thinking about?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the Care",217,"Yes. Sure, Brian. We moved from about 8% to up to the 14%, 15% range last year, and that included Nano kind of starting to come out of that calculation. We're trying to get our arms around how we're going to do this calculation going forward with the CareFusion product line coming in, and we're not quite there yet. But if I look at the portfolio and the number of new products, I would say we're in a strong position. I mean, it's across both the segments and it's over the next 3-year period. And so both portfolios on the Medical side and the Life Science side appear good. As I mentioned on the call, we feel very excited about the launch of the infusion set, the FlowSmart set. We haven't talked much about it lately, but SAIS is making progress with their micro infuser, and we have signed up a number of customers there. And so we're starting to see some nice momentum in SAIS. I'm not going to try to walk through all of the new products across MPS and MMS, but there is a nice portfolio, and Tom would tell you, in addition, that the backlog for Pyxis remains very robust. And Tom, I think it continues to actually get a little larger, right?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high.",27,"Correct. It continues. Obviously, Pyxis ES is a major contributor to that percentage of new products sales and certainly continues to keep that number up very high."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, we would increase the number. And then on Linda's side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays",58,"Yes, we would increase the number. And then on Linda's side of the business, I went through those new flow products, but also the BD MAX menu expanding, you're seeing the impact of that in Europe already. And Linda, we should be getting those other assays out soon in terms of chlamydia and vaginitis. What's your expectation there?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4 -- Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu.",52,"Yes. So both products are in process right now at FDA. So we would expect both of those products to be on the market in the U.S. in Q3 and Q4 -- Q3 or Q4. We are very encouraged by the growth that we are seeing in Europe with the expanded menu."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Manage",114,"And then of course, Barricor, which we mentioned on our last call. Now coming back to the investment on the medical device tax. I think it's an opportunity for us to really accelerate the strategies that we've articulated to you, both in Medication Management and on the Life Science side. In both, I would say, they are both the core business as we continue to elaborate things like KIESTRA and drive that into the marketplace, and drive the genomics stuff that we just started. I think we're in a situation where a lot of these things haven't launched yet, but they launch over the next couple of years. So thanks, Brian, for the question."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Jon Groberg of UBS.",9,"Your next question is from Jon Groberg of UBS."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can I just maybe do one kind of clarification and then a quick question. So I'll just put it into 2 here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital p",151,"Can I just maybe do one kind of clarification and then a quick question. So I'll just put it into 2 here. But one in China, I guess maybe Vince or Linda, can you maybe talk a little bit more on the Life Sciences weakness on the auditing of large capital purchases? It seems like about 12 months later than what most Life Science companies have been seeing. Or most of them saw it a year ago and reported pretty good results in China this year. So just curious kind of why you think you're seeing those delays more significantly than others in the Life Sciences space? And then I just wanted on the new products on Totalys, I think in your presentation, you have that still launching in the U.S. in '16. I'm just curious what you're seeing with that in Europe and whether that still on track for '16?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda, do you want to take that?",9,"Sure. So Linda, do you want to take that?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China, specifically. So as we are putting those instruments into the market, reall",185,"Yes. So maybe on your first question, on why the delay in China. If you recall, we mentioned last year that we signed an exclusive partnership with Bruker on the ID side in China, specifically. So as we are putting those instruments into the market, really starting in our first quarter fiscal year '15, we had expectations on those that clearly in the first quarter, we saw that the overall number of tenders being issued were not at the level that we were expecting. So that would explain the delay because of the Bruker exclusivity. We are seeing, though, very good progress competitively in that space with now a more expanded solution to offer. And then as you note, we are seeing great performance ex U.S. now with a more expanded platform that includes our Totalys and focal point system for a full liquid cytology solution. So we saw this quarter high double-digit growth ex U.S. on those platforms. And the anticipated launch date for us in the U.S. is in FY '16. I don't have the exact quarter sitting in front of me, but..."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","But later in the year, anyway.",6,"But later in the year, anyway."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Q3 would be a safe bet for us.",9,"Yes. Q3 would be a safe bet for us."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Vijay Kumar of Evercore ISI.",10,"Your next question is from Vijay Kumar of Evercore ISI."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the reiteration [ph] of EPS, and I guess off margins are g",98,"Just maybe going back on the guidance, I wanted to make sure sort of if we have the math right. So it looks like the reported revenues came down by 300 basis points, but the implicit assumption on the reiteration [ph] of EPS, and I guess off margins are going to come up at the high end of the guidance range. I want to make sure I got that right. And when you look at below the line, I think other income, you had some hedging gains. Why would those sort of gains reverse in the back half?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first q",170,"Okay. So I think I got you right, yes, operating margins have been increased in the back half of the year. When we look at the Q1 compared to expectations, I think what we're seeing is, as you pointed out, favorable gross margin performance in the first quarter, favorable timing of expenses as well. And then below the line, there is a little bit in tax rate. So the 21.5% is a little bit better than expectations, and we see that flowing through to the total year. We were slightly better in interest income and slightly less in interest expense. You put all those things in and that flows through to the full year. Of course, it's overwhelmed by the items that I talked about with -- the oil prices being down will benefit the second half of the year as well as the sale of BD Rx. So you put all that together and we get to the $9.01 to $9.08 and the $8.37 to $8.44 all-in with FX."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Richard Newitter of Leerink Partners.",10,"Your next question is from Richard Newitter of Leerink Partners."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wanted to ask, actually, 2 quick ones. One, is the full med tech tax reversal benefit getting reinvested? So it's just a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adju",78,"Just wanted to ask, actually, 2 quick ones. One, is the full med tech tax reversal benefit getting reinvested? So it's just a swap between SG&A? Or are you allowing some flow-through? And then the second question is, what would you expect the kind of adjusted China growth rate to be if you kind of look at it the way -- you said low teens, I think in the past 2 quarters if you back out the inventory."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on medical device tax, just to put it in perspective, last year we had about -- or in our budget, we had about $60 million for the full year. Don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we h",198,"Okay. So on medical device tax, just to put it in perspective, last year we had about -- or in our budget, we had about $60 million for the full year. Don't forget, we only pick up 3 quarters of that this year, so that's about $45 million. Right now, we have about 1/3 of that being executed against. The other 2/3 we are still getting the projects in place and we do fully expect to spend that this year. There might be a little bit of timing issue. Obviously, in the month of January, we're getting the benefit and we're only executing on the 1/3. So we'll probably just naturally pick up a little bit in timing, but not a lot, and that's already in the guidance. But we fully expect to reinvest, and we want to reinvest and we're going through that process now. And then the second question was China. I think that I'd bring you back to -- if you adjust for the difficult compare in the first quarter and you adjust for the inventory adjustments that we took in Life Sciences, it brings you back up to a double digit number in China."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we said low double digits for the year.",9,"And we said low double digits for the year."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ...",22,"Yes, for the full year, it's low double digits and we get the benefit of a little bit of easier compare ..."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Easier compares and a little bit of momentum out of some CareFusion products.",13,"Easier compares and a little bit of momentum out of some CareFusion products."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Doug Schenkel of Cowen and Company.",11,"Your next question is from Doug Schenkel of Cowen and Company."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation see",128,"So U.S. bioscience revenue growth moderated sequentially from, I think, around 15% year-over-year last quarter to around 6% year-over-year this quarter. Recognizing that comparison was a bit more difficult relative to the prior quarter, the moderation seems to be a bit more material than we would've expected just given what we've seen from Life Science tools peers. Others have talked about academic government starting to pick up. It sounds like biopharma continues to be strong. So with all that said, 2 questions. One, can you describe what you saw in the quarter in terms of demand from biopharma and academic government in the U.S.? And two, what's embedded into your guidance for contributions from new products and the potential benefit associated with a more robust NIH budget?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Biosciences business continues to do very well. We did mention that in first quarter '15, we had a tough j",235,"Okay, so that was a multipart question. Let me see if I can get at this. So first, let me just comment on the performance of the U.S. business. U.S. Biosciences business continues to do very well. We did mention that in first quarter '15, we had a tough jump-over. We had high double-digit growth, primarily in our research instrument base. So we still managed to grow off that base, but it was a difficult compare. So for this quarter, we did see very good growth in our biopharma side, particularly in our Advanced Bioprocessing business, a business we do not talk about a lot but is doing very, very well for us. So that was a tremendous area of growth. And then as we've been talking about for the past several quarters, led by the U.S., our Total Research Solutions platform now, we feel very good about the prospects for that business. Of course, this past quarter, launching both FACSSymphony and FACSCelesta and we think across the range of low mid and high-end analyzers now, combined with our Sirigen platform, so really now starting to work out that full solution between our instrument base and our solutions base. We see the U.S. research market as being an area that has, if you look at our last quarter report -- was very strong for us and an area moving forward that is in our guidance."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","How do you feel about new products, Linda? I know you can't exactly quantify it, but. . .",18,"How do you feel about new products, Linda? I know you can't exactly quantify it, but. . ."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about",68,"Yes, so new products overall, starting with biosciences, the research solutions piece feel very strong about the genomics side, of course, coming with our full launches on both the gen cell side and Cellular Research coming this quarter. So excited about that. And then of course PAS with their new products and DS with the expansion of the MAX menu, we're really starting to see these kick in."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So we should start to see some traction in the back half of the year basically. Okay, thanks.",18,"So we should start to see some traction in the back half of the year basically. Okay, thanks."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Derik De Bruin of Bank of America.",12,"Your next question is from Derik De Bruin of Bank of America."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So could you talk a little bit about sort of looking at the overall portfolio. I mean you've trimmed Simplist, and there had been some talk about respiratory earlier on in the process of maybe doing something with that. Has that business rebounded to the",72,"So could you talk a little bit about sort of looking at the overall portfolio. I mean you've trimmed Simplist, and there had been some talk about respiratory earlier on in the process of maybe doing something with that. Has that business rebounded to the point now that -- or you feel comfortable with it that it's -- you feel it's part of the portfolio and it's not, potentially, a divestiture candidate?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business.",102,"So what I would tell you about respiratory is we're running it like -- we own this business. So we run it to optimize the business and like we do with all of our businesses. Having said that, we are proceeding with our strategic analysis of that business. I would tell you, we are making some progress on that, but we are not to the finish line yet. There are a couple of other small pieces that we are continuing to work on also in terms of that strategic review process, and you'll hear more from us as we move forward."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Today's final question is coming from Kristen Stewart of Deutsche Bank.",12,"Today's final question is coming from Kristen Stewart of Deutsche Bank."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We let you back in Kristen.",6,"We let you back in Kristen."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Sorry to miss you there before. It was a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the solutions. And also if there's any additional updates on the CME relationship with the pump",65,"Sorry to miss you there before. It was a technical glitch. I was just wondering if you could expand a little bit more upon the relationship with Fresenius over the solutions. And also if there's any additional updates on the CME relationship with the pumps and anything about bringing that in-house to BD and the timing of launch that, that could go into emerging markets?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Go ahead, Tom.",3,"Go ahead, Tom."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased, obviously, with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. W",206,"Kristen, this is Tom. Let me start off with the Fresenius one then I'll address the CME. So we are very pleased, obviously, with the long-term collaboration that we've entered into with Fresenius for a broad line of IV solutions in the U.S. marketplace. We certainly see that these opportunities aligned with our customers feedback to have additional options available to them in how they buy IV solutions. And we expect to begin launching that line in the very back half of FY '16. So I think that's probably the most to say about that there. But we see it very much in line and supporting and helping to advance our overall medication management strategy, and we've gotten very positive feedback from customers after that announcement. Related to CME, we do sell CME products in certain markets today, primarily in Europe. No new news to update in terms of an acquisition or integration of CME into BD. As you know, we already own 40% of CME, and we've talked about options of that going forward. No new news to share there. We continue to promote and grow their products though in the markets, particularly in Europe, that we have had since the beginning of the year."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is from Brandon Couillard of Jefferies.",9,"Your final question is from Brandon Couillard of Jefferies."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of tests available on the menu, and to what extent is the LDT capability contributing to growth?",47,"Just one more for Linda. Any chance can give us an update on where BD MAX stands in terms of its global installed base? And remind us of the number of tests available on the menu, and to what extent is the LDT capability contributing to growth?"
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis",140,"Okay. So on the overall MAX platform, in terms of overall numbers of placements, I'm not going to go into the overall number for the quarter, but safe to say that our total overall global systems now are close to 1,000 placements overall on a global basis. In terms of the menu, of course, the expansions that we saw in the menu in both Enterics and CT/GC, what we're seeing now in Europe is very strong double digit growth and very positive feedback from our U.S. customer base. Again, starting to see very good growth in placements on our Mac system. And of course when we get the CT/GC and Vaginitis, we are anticipating stronger growth there. On the LDCT side in terms of what we see in terms of opportunity for us moving forward, are you speaking about the..."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Open channel.",2,"Open channel."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportuni",80,"Yes. So for us, we see that in Europe being a great advantage, European customers are really adapting that as a strong advantage. And in the U.S., again, it's seen as an area for us versus our competition that really differentiates MAX. So great opportunity for us. I would say that the big opportunity that we see is, with the differentiated menu that we are already seeing on the Enterics and we'll look forward to on the CT/GC and Vaginitis."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Linda. Okay.",3,"Thanks, Linda. Okay."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks.",16,"Thank you. With that, I'll turn the floor back over to Vince Forlenza for closing remarks."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much.",41,"Well, thank you very much for all of your questions. We are very pleased to update you on our quarterly results and to raise our FX-neutral EPS guidance. We look forward to updating you as the year progresses. Thanks very much."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks a lot.",3,"Thanks a lot."
103678,321567599,926012,"Becton, Dickinson and Company, Q1 2016 Earnings Call, Feb 03, 2016",2016-02-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for",77,"Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 83710101. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is pos",399,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. 
As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at BD.com. 
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second fiscal quarter press release and in the MD&A sections of our recent SEC filings. 
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the BD.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. 
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures in the financial schedules, in our press release or the appendix of the Investor Relations slides. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. 
It is now my pleasure to turn the call over to Vince."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic and prod",669,"Thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic and product portfolio with both segments contributing to revenue growth. We continue to drive strong underlying margin expansion through the achievement of operational efficiencies and continuous improvement coupled with the positive impact of cost synergies. 
As many of you already know, in March, we celebrated the 1 year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration, and a significant amount of work has been driven by the integration teams across the businesses. 
In terms of talent retention, we have a strong team that's in place that's comprised of both legacy CareFusion and legacy BD associates. They've been helping drive the company through our next phase of growth as a combined entity. 
In terms of our customers, we are becoming increasingly more relevant as they look -- as they are looking for providers that can really help them improve the quality, efficiency and safety processes. We have made good progress on this front 12 months postclose, and feedback from our customers has been a fairly positive. 
Also we had been actively working to create new growth opportunities for CareFusion products and expanding their global reach by leveraging BD's global infrastructure. We are well into the registration process with dozens of products across multiple geographies. I will provide more details on this later in the presentation. 
Lastly, we are seeing strong productivity as we are overdelivering on our initial cost synergy capture commitments. As you already know, we have increased our total cost synergy target by about $100 million over the deal's horizon. We are clearly advancing our strategy to improve medication management. The value we bring to customers around the world has become increasingly evident as we make progress integrating these 2 great companies. 
We're also pleased to inform you that the annual strategic review of our portfolio is now complete. In March, we announced that BD and Apax Partners, a private equity firm, will form a joint venture with Respiratory Solutions business. Apax will establish and stand up a newco, enabling more strategic focus and investment to build a leading global respiratory company. 
And more recently, we announced the divestiture of our vertebral augmentation solutions business. This product line was not aligned with our strategy, and we believe it can see more robust investment in growth under a different owner. The completion of our current strategic review process enables the company to remain focused on the areas we believe are high growth and aligned with our core capabilities. 
In addition, during our last call, we let you know about our intent to reinvest the savings from the suspension of the medical device tax that went into effect in January. Since that time, we have already allocated increased R&D dollars to highly strategic initiatives. Not only will this help to fund drive future growth for the company, but it will also enable better outcomes for our customers and their patients. 
Looking forward to the total year, we are confident in our outlook and are maintaining our fiscal 2016 currency-neutral revenue and EPS guidance. We are also increasing our adjusted guidance to reflect lower currency headwinds due to the weakening of the U.S. dollar relative to the euro and other currencies. 
Moving to Slide 5. I will review our second quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company revenues grew 5.3% or 5.2% on a combined organic basis. Adjusted EPS of $2.18 was ahead of our expectations as the quarter benefited in part from some timing within the year. 
Now I'd like to turn things over to Chris for a more detailed discussion of our second quarter financial performance and our updated fiscal year 2016 guidance."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to a very solid second quarter results. Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comp",1857,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to a very solid second quarter results. 
Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comparable basis or 5.2% on a combined organic basis. This was slightly ahead of our expectations as the quarter benefited by about 50 basis points from the timing of revenues, which occurred earlier than expected. I'll discuss this as I take you through the business results. 
BD Medical's second quarter revenues increased 6.1%, reflecting solid growth across the segment. Medication and Procedural Solutions growth was 4%, which reflects strength in Infusion Therapy, safety-engineered products and infection prevention. Medication Management Solutions revenues grew 6%, driven by strong dispensing capital installations with our Pyxis platform. Pyxis ES demand was strong in the quarter, driven by several large customer conversions, and we saw a positive impact from our efforts to simplify the installation process. 
We also saw a solid growth in the infusion business, where we continue to expand our leadership position. Growth in Diabetes Care was 3.6%, driven by pen needles and syringes. Pharmaceutical Systems growth of 11% reflects a strong growth in SAIS. Performance in this business also reflected the favorable timing of customer orders that occurred 1 quarter earlier than we initially intended. 
Respiratory Solutions revenues increased 10.9%, reflecting the timing of capital placements, which similarly benefited the quarter as the placements were expected to occur later in the fiscal year. BD Life Sciences second quarter revenues increased 3.4%, driven by solid growth in Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 5.7% was driven by safety-engineered products in the U.S. and solid growth in Europe and emerging markets. 
Diagnostic Systems growth of 4.6% was a result of strong growth in core microbiology, including IDAST and BD MAX assays. Growth was also aided in part by an increase in flu activity in the U.S. While the flu season is still mild in comparison to the prior year, the timing of the late flu season had a positive benefit year-over-year in the quarter of 10 basis points. 
Biosciences revenues were about flat when compared with last year's second quarter. Strong double-digit growth in the U.S. was driven by continued increased demand for high parameter instruments and growth in research reagents. This was offset by a 7% decline in Europe due to a difficult comparison related to timing of orders in the prior year. 
In addition, growth was negatively impacted by clinical tender delays in Africa associated with our HIV monitor related to the World Health Organization guidelines. 
Moving to Slide 8. I'll walk you through our geographic revenues for the second quarter on a currency-neutral basis. U.S. revenues increased 5.7%. This was primarily driven by strength in Medication Management Solutions, Medication and Procedural Solutions, Biosciences and Diagnostics and was aided in part by the aforementioned timing of revenues. 
BD Medical's performance reflects strong dispensing capital installations and solid growth in the infusion business as well as strength in infection prevention and interventional specialties. BD Life Sciences growth reflects continued strong performance in the Biosciences business, driven by demand for high parameter research instruments and reagents sales. 
Diagnostic Systems had strong growth in microbiology, including KIESTRA and blood culture, BD MAX as well as a benefit from the increase in flu activity during the quarter. 
Moving on to international revenues grew 4.8%. This is below our normal growth rate and primarily reflects the aforementioned clinical tender delays in Africa. I'll provide more details on this in a moment. 
The Medical segment grew 6.9%. This reflects solid performance in Medication and Procedural Solutions, driven by sales of safety-engineered products, particularly in China and strong dispensing installations in Medication Management Solutions. Growth was aided in part by the aforementioned timing of customer ordering patterns and capital placements. 
The Life Sciences segment grew 1.4%. This reflects strong growth in Preanalytical Systems in Western Europe and Asia Pacific and strong growth in Western Europe and Latin America in Diagnostic Systems, driven by core microbiology. This was partially offset by the aforementioned tender delays in Africa and the difficult comparison in Europe in Biosciences. 
On Slide 9, emerging market revenues grew 5.1% currency neutral, with developed markets growing 5.3%. The second quarter growth rate in emerging market reflects solid growth in China and Latin America, partially offset by a decline in EMEA. China growth for the second quarter was 9.4%. Double-digit revenue growth in our Medical segment was driven by continued strong demand for consumables across all of our businesses in the segment. 
Within our Life Sciences segment, strength in Preanalytical Systems was offset by the slowdown of capital spending in Diagnostic Systems as communicated on our call last quarter. For the total year, we continue to expect China to grow in the low double-digit range. 
We now expect total emerging markets to grow in the high single-digit range compared to our previous guidance of 9% to 10% growth. This is offset by stronger performance in developed markets, growing between 4% and 4.5% for the second half of the year. 
Our revised guidance for emerging markets reflects the aforementioned impact in Africa to our Biosciences unit from the WHO guidelines. In addition, since we last provided guidance in February, the government of Saudi Arabia announced a new austerity measures, which affect the health care industry. This has begun to impact our business in that particular region, and we saw a small impact in the second quarter. We view this situation in Saudi Arabia as temporary though the timing of reversal may not occur within this fiscal year. Our new guidance range contemplates emerging markets growing between 10% and 12% for the second half of the year. 
Moving to global safety on Slide 10. Currency-neutral sales increased 6.7%. Safety revenues in the U.S. grew 4.5%, and international sales also grew 9.9% currency neutral, with continued strength in Europe as compliance with safety legislation continues. 
Safety revenues grew 15.6% in emerging markets. Medical Safety sales grew 8%, primarily driven by safety catheters. Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 4.6% in the quarter. 
Slide 11 recaps the second quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 5.3% on a comparable currency-neutral basis. Pricing was slightly positive in the quarter. 
Moving down the P&L, I will focus on the comparable basis figures, which include CareFusion's results in the prior year in order to give a better indication of our performance. Gross profit improved by 7.9%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency. 
SSG&A as a percentage of revenue was 24.5%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. R&D as a percentage of revenue was 5.9%. Our expenditures in the quarter were slightly lower than our full year expectation of 6% to 6.5% of revenues due to the timing of spending. We continue to invest in new products and innovation and expect to further reinvest the benefits from the medical device tax suspension in the back half of the year. 
Operating income grew 24.8%, reflecting strong P&L leverage. In addition, as we had previously discussed, there were a number of items that negatively impacted operating margin in the prior year in the CareFusion business. I'll address the underlying growth in operating profit in more detail on the next slide. 
Our tax rate declined 70 basis points to 20.6%, below our full year expectation of 21% to 22% as the quarter included some timing benefits. As Vince discussed earlier, adjusted earnings per share were $2.18, which is a 44.7% increase versus the prior year. This reflects our solid growth profile and strong underlying margin expansion. In addition, growth benefited from the timing of renewals earlier in the year than expected as well as timing within the year related to R&D expenditures and tax as we just discussed. 
Slide 12 illustrates our gross profit and operating margin for the second quarter presented on a comparable basis. Strong gross profit margin performance of 170 basis points was primarily driven by robust operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. Strong operating margin performance of 370 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. 
In addition, timing of R&D expenses and the benefit of the medical device tax suspension aided operating margin in the quarter. Also you will recall, several items drove low second quarter operating margins for CareFusion in the prior year. Currency had a slightly negative impact on both gross profit margin and operating margins. 
Moving on to Slide 14. Since we provided guidance in February, the U.S. dollar has weakened against the euro and other currencies. As a result, we are raising our adjusted EPS guidance by 2% -- percentage points or $0.13 from a range of $8.37 to $8.44 to a range of $8.50 to $8.57. We are maintaining our currency neutral adjusted EPS guidance of $9.01 to $9.08 as we expect the second quarter tax timing to reverse and R&D spend to ramp over the back half of the year, which includes reinvestment of the medical device tax. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments. 
Turning to Slide 15. I'd like you to walk you through the additional elements of our guidance for the full fiscal year 2016. In summary, we continue to expect comparable organic revenue growth of 4.5% to 5% on a currency-neutral basis, with the back half of the year growing between 5.5% and 6.5%. This contemplates the third quarter growth rate to be slightly lower than our full year guidance range and the fourth quarter to be well above the full year guidance range. 
On a reported basis, revenue growth for the total year is expected to be between 21.5% and 22%, which reflects a currency headwind of about 300 basis points, an improvement from our prior guidance of about 450 basis points of currency headwinds. The U.S. dollar has weakened against the euro and most currencies since we last provided guidance in February. While our guidance assumes a euro-to-dollar exchange rate of $1.13 for the rest of the year, which is better than the actual rate from the second half of last year, we see some remaining FX headwinds over the second half as noneuro currencies remain unfavorable year-over-year. 
We continue to expect growth of 4.5% to 5% in BD Medical and 4% to 4.5% in our Life Sciences segment. Based on our current view of the environment, we continue to expect pricing to be about flat for the year. Beyond revenue and EPS, all other P&L guidance from February remains unchanged. 
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation, within our Life Sciences business, our Preanalytical Systems b",735,"Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation, within our Life Sciences business, our Preanalytical Systems business launched 2 new products this quarter: the UltraTouch Push Button Blood Collection Sets will deliver significant improvements in patient outcomes and lab efficiency. The BD Barricor tubes used gel-free technology, which significantly improves sample quality and lab turnaround time. The initial market feedback on both these products has been extremely positive. 
In our Bioscience business, as evidenced by our U.S. growth rate this quarter, we have seen very positive market uptake of our high parameter instrumentation, the FACSSymphony X-50 and X-20. In our genomics business, we anticipate launching our GenCell click library preparation platform and our FACSseq Cell Sorter designed specifically for genomics applications later this year -- this fiscal year. 
Within strategic and business initiatives, as we discussed earlier, we have completed our current portfolio review, having recently announced the Respiratory Solutions joint venture and sale of the vertebral augmentation solutions business. We remain focused on the areas we believe are high growth and aligned with our core capabilities. 
We have also made progress with our product registrations, having successfully registered more than 50 CareFusion products in over 20 countries. In addition, we have submitted registrations and are awaiting approval for an additional 25 products. This is consistent with our plans to achieve revenue synergies, and we remain on track for them to begin to materialize in fiscal year 2017. 
And in the areas of partnerships and collaborations, we remain excited for the launch of our infusion set, which we expect will move to broad commercial release with Medtronic in early fiscal year 2017. We believe this product will improve the consistency of insulin delivery by significantly reducing flow interruptions, simplify the user's experience and increase the patient's overall satisfaction with insulin pumping. 
We recently entered into a strategic partnership with the Parker Institute for Cancer Immunotherapy, and we'll play a part in the Institute's vision of reducing cancer to a manageable disease. Support from the Parker Institute will help us advance our new cell sorter program while bringing our high parameter cell analysis solutions to these researchers as they work to discover the next breakthrough in cancer immunotherapy. As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you as we continue to make progress.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the second quarter, and we made progress with our back-office functions and with harmonizing our IT infrastructure. 
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs as we discussed earlier. 
The consistent, solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 170 to 190 basis points of expansion this fiscal year. 
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid second quarter. Both segments performed well, and our performance highlights the benefits of our diverse portfolio, both from a product and geographic standpoint. 
Second, we have made significant progress on the acquisition of CareFusion. The value we can bring to customers around the world has become increasingly evident as we integrate these 2 great companies. 
Third, we have taken steps to optimize our portfolio. In doing so, we are positioning ourselves in higher-growth areas, which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. 
Finally, we are confident in our outlook for the full fiscal year. We're maintaining our currency-neutral revenue guidance and raising our adjusted EPS. We believe we are well positioned to continue our track record of delivering value to our customers and shareholders. I look to the future with optimism. 
Thank you. We will now open the call to questions."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley.",13,"[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, 2 questions, maybe one for you and one for Chris. I guess, the first one is the theme that you're showing the last several quarters is one  that the whole device industry is showing this quarter, which is this polarization better U.S. performance a",90,"Vince, 2 questions, maybe one for you and one for Chris. I guess, the first one is the theme that you're showing the last several quarters is one  that the whole device industry is showing this quarter, which is this polarization better U.S. performance and slightly softer ex U.S. performance, specifically emerging markets. Talk to us about how much of this in your mind is the quarter or just the trend that BD has been seeing for several quarters, and what's driving that strength in the U.S. in your opinion?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care",356,"Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care coverage, especially the expansion of Medicaid. But the other thing that you are seeing is that our businesses are performing quite well. You heard us talk about in the Bioscience business, the launch of those new products. We have a whole series of new products coming out, and I mentioned specifically the high parameter work that's going on. So yes, that showed up in this quarter right now, but that's going to continue as we move through the year. You also saw good performance in Diagnostics because we're getting some traction, blood culture and KIESTRA, that is moving forward, KIESTRA moving forward in the U.S. and then good performance across the Medical businesses, where we -- we're improving our competitive position in MMS, and so you see all of that coming together. Europe, I think, once again, I think, has stabilized, and it's really, of course, you have to drop out the CareFusion factors, but there was negative timing in Biosciences, but you've got the same product launches that are occurring there. Quite frankly, Japan is forming -- is performing better for us as well. Now on the other side of the coin, the situation in China seems to have stabilized. We're seeing good performance on the medical device side of the business, and the situation really hasn't changed all that much on Diagnostics on the capital side, but it had stabilized, and so we're getting good growth in China. We didn't mention it, we continue to get good growth in India. We're getting good growth in Latin America. There was some onetime events this quarter, which you heard in terms of Africa and Saudi Arabia, and Saudi Arabia is more of an impact in the back half of the year. So yes, this is slightly less in emerging markets, yes. But the mix is quite good."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Mike Weinstein of JPMorgan.",10,"Your next question is coming from Mike Weinstein of JPMorgan."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start if you went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic, and The Street was worried just about the ability to see the acceleration. Now we're 3 months later, and you g",137,"Let me start if you went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic, and The Street was worried just about the ability to see the acceleration. Now we're 3 months later, and you grew 5.3% organic this quarter. So essentially what you said would happen, happened. Can you just talk a little bit as you go into the back half of the year, I just want to make sure I understand the commentary on the cadence of the quarters. I know the comp in some different respects from the fourth quarter is easier than the third quarter, but I just want to understand just the commentary relative to third quarter being a bit below the full year guidance and the fourth quarter being materially above."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike. I'll have Chris walk you through that because there's some complications here. You've got to go back to last year to understand, but Chris will walk you through.",30,"Yes, Mike. I'll have Chris walk you through that because there's some complications here. You've got to go back to last year to understand, but Chris will walk you through."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter b",171,"Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter because in terms of absolute dollars, that was our highest quarter last year. So you've got to really look at those absolute dollars. Looking at growth rates is a little misleading because the growth rate last year was negative in CareFusion and the third quarter, but that was more about the comparative prior year. But the absolute dollars are the grow over. And then as you model out the year, based on the guidance that we just gave you in terms of growth rates for the third and fourth quarter, you'll see steadily improving sequential revenue dollars for all 4 quarters this year. We really feel good about the trajectory, particularly on a sequential basis this year, it's all about the compare to last year revenue dollars."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, if you think about it, there were 2 events in CareFusion, 2 different compensation events that caused the pattern to be highly fluctuate for the first quarter being very high, the third quarter being very high. And then we have the flu. So you'",94,"Yes, Mike, if you think about it, there were 2 events in CareFusion, 2 different compensation events that caused the pattern to be highly fluctuate for the first quarter being very high, the third quarter being very high. And then we have the flu. So you've got to go back and look at those absolute numbers, as Chris was saying, and then you'll see our growth this year actually as we look at the whole year is actually quite smooth. But the growth rates jump around because of that. Thanks for your question, Mike."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess, firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then",116,"Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess, firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then how we should start to evaluate the impact on a go-forward basis? And then for Chris, can you maybe help us understand why given the changing currency, there's not a positive impact on the margin profile? It looks like you just flowed the dollars right down to EPS at the corporate margin guidance that you previously provided. So why don't we see an uplift in profitability associated with the changing rates?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So let me ask Tom to comment first, and we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about.",43,"Sure. So let me ask Tom to comment first, and we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David. This is Tom. So as Vince mentioned before, we registered more than 50 products over 20 countries, got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2 bu",247,"Sure, David. This is Tom. So as Vince mentioned before, we registered more than 50 products over 20 countries, got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2 businesses that are -- came from legacy CareFusion, and the majority of those products are actually within MPS. So think disposables, and this is right in line with what we had talked about over the last several quarters that as we think about the first products that would be able to help drive incremental revenue growth, it would be things like infusion sets, ChloraPrep, the consumables that fit very well with BD's traditional sales channels and market approaches and presence in the marketplaces, and those are the products that we focused on getting registration for first. So I would say we're seeing some early signs of success as we've been launching these products, which is very consistent with our plans to achieve revenue synergies and really remain on track to start seeing them materialize more in 2017, but we do see sales now and obviously, on a company the size of BD and a segment of Medical, we'll see those start showing up more materially as we roll into '17, but they have started. And I would just say that obviously, we're going to continue those product registration work. We're continuing to the sales and marketing investments to support those initiatives, but overall, we're on track."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And to your second question, David, we did still see a little bit of a drag in the second quarter on both the gross profit, it's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is although the",142,"And to your second question, David, we did still see a little bit of a drag in the second quarter on both the gross profit, it's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is although the euro has improved, the noneuro currencies year-over-year are still providing a bit of a drag. And then secondly, and probably more importantly, is the phenomenon of the profit and inventory that we've talked about in the past so didn't quite catch up in the second quarter. Certainly, not much of a drag, and it's starting to level off and that, in my prepared remarks, was the commentary for the second half of the year. It doesn't really turn positive because of that phenomenon, but it certainly lightens up in terms of headwinds."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Our next question comes from Larry Keusch of Raymond James.",10,"Our next question comes from Larry Keusch of Raymond James."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess, for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also as alluded to in the prepared comments, it sounds like the installa",92,"I guess, for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also as alluded to in the prepared comments, it sounds like the installation process for med station ES is improving. I know there've been a number of software tweaks for that ES system over the past couple of years, and just also wanted to understand if you're kind of getting to a point where that system is now stable."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure, Larry. This is Tom. So let me start with the Pyxis question, and I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis. As we actually just released another new version of the software, which",419,"Yes, sure, Larry. This is Tom. So let me start with the Pyxis question, and I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis. As we actually just released another new version of the software, which we think really, it makes some very significant progress and actually addresses -- we'll make a big step forward in terms of installation efficiency, and so as we've shared in the past, we were really focused on improving the installation process. We had shared that there's quite large backlog at the time of the acquisition. And to really address that backlog, we needed to improve the installation efficiency process, and we've been working on that, applying some of our lean expertise as well as making some adjustments in the software that would automate a lot of that and simplify the other workload in the field. So we're seeing a lot of those efforts come to fruition. We did have very strong placements in Q2 that was part of the driver of MMS growth. We continue to see strong demand for the Pyxis ES platform, and we're equally looking forward to continued strong growth in the second half of the year in that as Vince alluded to earlier. So on the infusion side, we also are very pleased with the growth that we saw in the quarter here and have similar expectations for the back half of the year. As you know, we are the market leader in that space. We continue to strengthen our position over the last several years. We expect to continue to strengthen our position in the market by about the same amount this year as we have over the last couple of years. We do see customers continue to select the BD Alaris pumps in the incremental way really based on that interoperability and the power of one to be able to do all their infusion needs across both large volume infusions, syringes and narcotics, all in one product, the only item that can do that. So we're happy there. I would point out as well that as you look at our safety sales, particularly in the U.S., that was largely driven by growth in our -- in some of the connectors that are associated with our dedicated sets in the infusion category, and that's really a reflection of that strong performance in that infusion category and that renewing consumable stream that comes as we place pumps incrementally. Thank you."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities in CareFusion. Can you talk a little bit about the pace of identifying new opportunities, either in terms of additional cost syn",91,"Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities in CareFusion. Can you talk a little bit about the pace of identifying new opportunities, either in terms of additional cost synergies or on the revenue side and obviously, you alluded to some of the products in registration. And then secondly, just on China. Looks like based on the numbers, we're going to need about some sort of teens acceleration, easier comps, can you just elaborate on that?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll ask Chris to talk about the cost synergies.",11,"So I'll ask Chris to talk about the cost synergies."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So just as a reminder, we raised the cost synergies earlier.[Technical Difficulty]",14,"Sure. So just as a reminder, we raised the cost synergies earlier.
[Technical Difficulty]"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Is anybody able to hear us?",6,"Is anybody able to hear us?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Yes, we can hear you now.",6,"Yes, we can hear you now."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So let me start again on that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the 3 25 to 3 50, and that was identification of some new synergies from our recent or our original",231,"Okay. So let me start again on that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the 3 25 to 3 50, and that was identification of some new synergies from our recent or our original model. I would also remind you that we increased the overall synergies from the standpoint of the tax rate improvements that we saw that we originally didn't contemplate, and that's another 3% accretion that we had mentioned. Really, when you think about the synergies, we get initial synergies of duplicate public company costs. Then you move into the integration of systems and infrastructure, and we've gotten good traction on that, and that led to the last increase. And then towards the end are the more difficult synergies to get, which are the distribution centers and manufacturing plants, and we actually saw some good initial improvements in that area or traction in that area that led to our last increase. So we really feel great about what we're driving. All in, all in, it's significantly higher than our original expectations, particularly when you add the tax synergy. You see this year, the EPS quarter-over-quarter was over 44%, I think, is an indication of that. So we really feel good about our ability to drive those of synergies and executing on those synergies."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for China, growth is going to be driven by the Medical side of the company, and there are multiple business is on the Medical side that are doing well in China. And then in addition, there was several million dollars of inventory that came out of",75,"And then for China, growth is going to be driven by the Medical side of the company, and there are multiple business is on the Medical side that are doing well in China. And then in addition, there was several million dollars of inventory that came out of the chain last year. So there is a favorable comparison in the fourth quarter. But Tom, do you want to comment on any of the product lines?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","I think as you said, we see on the consumables across the board are holding in strongly. We do have again while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from CareFusion",78,"I think as you said, we see on the consumables across the board are holding in strongly. We do have again while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from CareFusion, and so we are seeing some good traction in some of those items, particularly as we think about connectors and some of the oncology products coming away from CareFusion."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And we don't talk about it much, but we also have launched Flush in China. So that's another piece that has been growing quite nicely for us.",28,"And we don't talk about it much, but we also have launched Flush in China. So that's another piece that has been growing quite nicely for us."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","And our next question is from Rick Wise with Stifel.",10,"And our next question is from Rick Wise with Stifel."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess, I'll ask sort of a 2-part question. Maybe first, big picture, Vince, you can talk a little bit about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next, and what y",100,"I guess, I'll ask sort of a 2-part question. Maybe first, big picture, Vince, you can talk a little bit about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next, and what you're thinking about and maybe just one for Chris. On operating margin expansion, you've addressed it a little bit, but this acceleration in operating margin expansion can't go on forever. How do we think about the -- not for guidance, but how do we think about fiscal '17 beyond, what's possible in terms of further operating margin expansions just directionally?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, that's fine. I'll start out and guys get really good at your single questions, really fantastic. Let me just say from capital deployment standpoint, of course, short run, we're still working to get down to the 3x leverage, and we're making excellent",150,"Okay, that's fine. I'll start out and guys get really good at your single questions, really fantastic. Let me just say from capital deployment standpoint, of course, short run, we're still working to get down to the 3x leverage, and we're making excellent progress there. And so in the short run, we still have the flexibility to do plug-in acquisitions. And then as we have been stating, we're going to be really strategy driven, and we challenge both segments to look at their strategies. And as we look at the -- our ability to provide solutions to the marketplace and have a broader impact, that's what's going to drive our strategy. It'll be a mix of both internal development and continued looking on the outside, and we'll be very, very balanced here. But ultimately, it's about strategic impact plus value creation for shareholders, and that's how we're thinking about it."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","On the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies and cont",272,"On the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies and continuous improvement, a little bit of benefit from raw material prices as we talked in the past from oil. But on the operating side, SSG&A really reflective of getting on the synergies. It was a little bit of an easier compare in the second quarter because of the operating margin challenges in CareFusion that quarter last year. So you won't expect 370. In fact, we expect about 170 to 190 for the year on the operating margin basis. I'd remind you that's on top of of 100 basis of margin improvement last year. So really, improving the margins as you point out. As we think about going forward, as we execute on synergies, you would expect to see above normal. So we usually think 40 to 50 basis points of margin improvement. You're going to get more of that as we execute on the synergies in '17 and '18. You would also get a little bit of a lift from the fact that as we exit respiratory, which had challenging margins, you get a little bit of a lift. So not to give guidance on '17, but you're absolutely right. Directionally, we're going to see improved margins going forward in '17 and '18. And then as you start lapping those synergies, I think somewhere beyond that, you start going back to that 40 to 50 basis points. That's a few years out."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Derik De Bruin of Bank of America.",13,"Your next question is coming from Derik De Bruin of Bank of America."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio, but can you sort of talk about is this a '17 organic revenue growth question sort of what the impact of all these moving parts",66,"Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio, but can you sort of talk about is this a '17 organic revenue growth question sort of what the impact of all these moving parts are on it? And do you still feel good about a 4% to 5% longer-term organic revenue growth rate for the company?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, when we did the deal, and we discussed what our revenue aspirations were we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal is to bring the entire company up to about 5%. I think we're making excellent prog",90,"Yes, when we did the deal, and we discussed what our revenue aspirations were we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal is to bring the entire company up to about 5%. I think we're making excellent progress. I think you see the performance of the CareFusion businesses is quite strong. I think that the portfolio moves that we have made have been the right ones, so that still is our goal, and I think we're making excellent progress."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can you guys hear me? Can you guys timing question on a few items. I guess, one, is the infusion set, do you have kind of a specific launch for that ID infusion set? And then on the BD Simplist and the respiratory, I guess, when exactly expect all those t",76,"Can you guys hear me? Can you guys timing question on a few items. I guess, one, is the infusion set, do you have kind of a specific launch for that ID infusion set? And then on the BD Simplist and the respiratory, I guess, when exactly expect all those to close? And you have any updated views on the EPS and that kind of impact from an EPS standpoint for the rest of this year."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So Tom can talk to those things, but respiratory, I think, we're expecting to close at the end of this fiscal year and then...",25,"Yes. So Tom can talk to those things, but respiratory, I think, we're expecting to close at the end of this fiscal year and then..."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed.",3,"Simplist is closed."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is done.",3,"Simplist is done."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","We don't expect impact on sales from that at all, small and the other opportunities we'll make up for that. In terms of the infusion set launch as Vince mentioned, we expect broad commercialization in early FY '17. We are tracking towards by the end of th",149,"We don't expect impact on sales from that at all, small and the other opportunities we'll make up for that. In terms of the infusion set launch as Vince mentioned, we expect broad commercialization in early FY '17. We are tracking towards by the end of this fiscal year, within this fiscal year, we will be doing a limited launch, and we talked about this in the past, in which Medtronic will start providing the product to a set group of patients. So that they can really understand the user insight at another level before they do the full scale launch, and so we're moving forward preparing to ship out the first product for that limited scale launch in the back half of this fiscal year. That will occur, and then it would open up for a full commercial launch, we expect, at the start of FY '17."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16, but for '17, it's $0.10 to $0.14.",44,"And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16, but for '17, it's $0.10 to $0.14."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks very much.",4,"Okay. Thanks very much."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein with William Blair.",10,"Your next question comes from Brian Weinstein with William Blair."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","On R&D, it did step down sequentially. You said that obviously you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current pr",74,"On R&D, it did step down sequentially. You said that obviously you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current projects? Is it really putting that money to work in new projects? And any specific areas of focus that you would like to focus on with those dollars?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that timing -- that money is going to get spent, and I'm talking before the medic",164,"Yes, sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that timing -- that money is going to get spent, and I'm talking before the medical device tax in the back half of the year. Timing of things like clinical trials and whatnot, and so -- but in addition, the money that is being spent on the medical device tax is being spent in both segments, and it is a combination of some new things that we're already doing, but mostly, it's current strategies where we are accelerating those strategies, where we had platforms, where we could push them faster, and part of that, which is a bit new for us is moving the informatics side of things quicker. So if you can think of major platforms going faster and informatics piece on top of that, both sides of the company."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Richard Newitter with Leerink Partners.",10,"Your next question comes from Richard Newitter with Leerink Partners."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is kind of like an inning question, what inning are you in for 2 parts of your business that we talk about, particularly with ES. Can you just update us on where you are with the kind of the opportunity there to kind of get upgrades for that product",100,"This is kind of like an inning question, what inning are you in for 2 parts of your business that we talk about, particularly with ES. Can you just update us on where you are with the kind of the opportunity there to kind of get upgrades for that product cycle? And then the second innings question just the -- in your cytology business, liquid Pap testing, can you just tell us what the trend is there, are we kind of through in impact mostly at this point, and just comment on any pricing or volume trends for that business."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, let's start with the Pap first, and Linda, can talk to you about that.",15,"Sure, let's start with the Pap first, and Linda, can talk to you about that."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing we think we're mostly through. Outside the U.S., we're actually seeing a strong double-d",103,"Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing we think we're mostly through. Outside the U.S., we're actually seeing a strong double-digit performance. And then the entire platform, both in the U.S. and ex U.S. is being helped by the tool automation we are doing across both our point and our Totalys system. So complete control of the sample from collection through the results. So that's a driving a lot of growth both in the U.S. and ex U.S. for us."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks Linda.",3,"Okay. Thanks Linda."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And on Pyxis ES, so we're about 25% of our base business has been converted over to ES, and so we continue to see strong demand there, and we still do have certainly a quite a wide runway ahead, yes.",40,"And on Pyxis ES, so we're about 25% of our base business has been converted over to ES, and so we continue to see strong demand there, and we still do have certainly a quite a wide runway ahead, yes."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks for the question.",5,"Okay, thanks for the question."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. Good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth. Th",153,"So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. Good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth. That would seemingly imply there's a positive offset for developed market growth. I believe this change in mix should benefit operating margin. It doesn't seem like your guidance reflects that margin mix dynamic. Am I wrong? And if not, why? And then the second question is for Tom. Regarding your plans for the 25 or so additional CareFusion product registrations, what's the time line for those? And can you walk us through why those products take a bit longer to get registered? I'm just trying to get a better handle on the profile of those products versus the first 50 that are close to or have been registered."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Chris?",2,"Okay. Chris?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, just you're not wrong, but at this point in the year, the impact that it has still within the range of guidance that we gave. So we had a fairly broad range, and it's still in that range. So arguably, it's the higher end of the range.",48,"Yes, just you're not wrong, but at this point in the year, the impact that it has still within the range of guidance that we gave. So we had a fairly broad range, and it's still in that range. So arguably, it's the higher end of the range."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Tom?",2,"Okay. Tom?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact that it's really combination of just think about, of course, we couldn't submit all file simultaneously. So it just takes time to work through those. So Think about those o",152,"Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact that it's really combination of just think about, of course, we couldn't submit all file simultaneously. So it just takes time to work through those. So Think about those ones we submitted recently and didn't work through certain regulatory processes. In other cases, it's a combination of they're in certain countries that have longer registration. China has longer registration processes than most of Europe as an example, and then the other one is that certain product categories. So for example is registered at a drug in many markets, particularly, let's say, Latin America it's registered as a drug. Those typically sit in the regulatory process longer than medical devices. So it's kind of a combination of those 3 items, not one thing specific and not unexpected at all. It's right in line with our projection."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And you have to pull together the data for these files, and so certain product lines that may not have done that kind of clinical trial for China. So we have to do some prework to get them into the final. That's all that it is. Okay. Thanks very much.",50,"And you have to pull together the data for these files, and so certain product lines that may not have done that kind of clinical trial for China. So we have to do some prework to get them into the final. That's all that it is. Okay. Thanks very much."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar with Evercore ISI.",10,"Your next question comes from Vijay Kumar with Evercore ISI."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by about 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure sort of is tha",84,"Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by about 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure sort of is that a bit of conservatism on the part of management just because FX has been moving all over the place when you think about Medtronic with the Q in context of FX improving in the back half?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side, and then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right",269,"Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side, and then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right, we were up around $0.14 to $0.16, but we see that as timing, and the timing buckets are the medical device tax spending, which we know, where we want to spend it. But because of the timing, don't forget, it happened in January, and we couldn't ramp that quickly. So that past quarter, we really got a lift from that, but we fully intend to spend that in the back half of the year. Then you had timing on the rate. So the tax rate was lower than our 21 to 22, and that's just lumpy throughout the year. We expect that to fall back within the rest of the year. So you have that piece. And then we had to pull forward of some of the revenues from the third quarter to the second quarter, and the impact of that. So all of that accounts for the bulk of that 14 to 16 on an FXN basis. The other thing I would point out is we actually raised the FX EPS guidance last quarter by $0.28. It was loss from the standpoint that at that point, FX was getting worse across the world and offset that but the FXN was raised prior. So you really got to think about this in those 2 buckets."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Our final question is coming from Matt Taylor of Barclays.",10,"Our final question is coming from Matt Taylor of Barclays."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to see if you could touch on a couple of kind of interesting projects that you talked about in the last couple of quarters. One is the solutions that you bringing in with the swap in the Simplist business and the other is diabetes partnership wit",65,"I wanted to see if you could touch on a couple of kind of interesting projects that you talked about in the last couple of quarters. One is the solutions that you bringing in with the swap in the Simplist business and the other is diabetes partnership with Medtronic. You talk a little bit about those opportunities and maybe help us quantify the upside there?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Tom will address those. Tom, you want to start with diabetes?",13,"Sure. So Tom will address those. Tom, you want to start with diabetes?"
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we said all year, we were expecting to get the product into some early stage release in a controlled patient group this fiscal year and then really see mo",226,"Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we said all year, we were expecting to get the product into some early stage release in a controlled patient group this fiscal year and then really see more of the impact in the Diabetes Care business in FY '17. That remains unchanged. So we remain very excited about that opportunity. It's, of course, our first venture outside of the pen needles and syringes for the Diabetes Care business, moving into a fast growing market with a market leader, Medtronic, and we're, I think, equally excited about the product technology and what it can do to help patients and the partnership and what the power of us working together can do to make an impact there. So think about solutions. So as we, of course, shared before, we have announced a solutions partnership with Fresenius. We are looking at launching that, not necessary now in Q4 of '16 but more in early FY '17 just based on regulatory approval time lines there, but that does continue to move forward. And again we had not shared a specific number there, but we said it would certainly make up for any reduction in BD Rx sales that we have planned over the coming horizon, and that remains right on track."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for any closing remarks.",15,"I will now turn the floor back over to Vince Forlenza for any closing remarks."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thank you very much for your participation on the call today. It was real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and pro",136,"Okay, thank you very much for your participation on the call today. It was real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and progress with those businesses, the synergies, the teams in place and then lastly, the strategic partnerships that we're doing, including the Parker Institute relationship, the new products that are being launched. We didn't spend a lot of time on the Life Science business today. There weren't that many questions, but with BD MAX, with KIESTRA, all these things happening over there, very, very exciting and of course, the new products on the Medical side. So thank you very much for your time and look forward to updating you next quarter."
103678,329827360,973576,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for",79,"Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 83710101. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is po",399,"Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. 
As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com. 
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second fiscal quarter press release and in the MD&A sections of our recent SEC filings. 
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. 
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules, in our press release or the appendix of the Investor Relations slides. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. 
It is now my pleasure to turn the call over to Vince."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic an",673,"Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic and product portfolio with both segments contributing to revenue growth. We continue to drive strong underlying margin expansion through the achievement of operational efficiencies and continuous improvement coupled with the positive impact of cost synergies. 
As many of you already know, in March we celebrated the 1 year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration and a significant amount of work has been driven by the integration teams across the businesses. 
In terms of talent retention, we have a strong team that's in place that's comprised of both legacy CareFusion and legacy BD associates. They've been helping drive the company through our next phase of growth as a combined entity. 
In terms of our customers, we are becoming increasingly more relevant as they look -- as they are looking for providers that can really help them improve the quality, efficiency and safety of processes. We have made good progress on this front 12 months post close, and feedback from our customers has been extremely positive. 
Also, we had been actively working to create new growth opportunities for CareFusion products and expanding their global reach by leveraging BD's global infrastructure. We are well into the registration process with dozens of products across multiple geographies. I will provide more details on this later in the presentation. 
Lastly, we are seeing strong productivity as we are overdelivering on our initial cost synergy capture commitments. As you already know, we have increased our total cost synergy target by about $100 million over the deal's horizon. We are clearly advancing our strategy to improve medication management. The value we bring to customers around the world has become increasingly evident as we make progress integrating these 2 great companies. 
We're also pleased to inform you that the annual strategic review of our portfolio is now complete. In March, we announced that BD and Apax Partners, a private equity firm, will form a joint venture with the Respiratory Solutions business. Apax will establish and stand up a NewCo, enabling more strategic focus and investment to build a leading global respiratory company. 
And more recently, we announced the divestiture of our vertebral augmentation solutions business. This product line was not aligned with our strategy and we believe it can see more robust investment in growth under a different owner. 
The completion of our current strategic review process enables the company to remain focused on the areas we believe are high growth and aligned with our core capabilities. 
In addition, during our last call, we let you know about our intent to reinvest the savings from the suspension of the medical device tax that went into effect in January. Since that time, we have already allocated increased R&D dollars to highly strategic initiatives. Not only will this help to fund -- drive future growth for the company, but it will also enable better outcomes for our customers and their patients. 
Looking forward to the total year, we are confident in our outlook and are maintaining our fiscal 2016 currency-neutral revenue and EPS guidance. We are also increasing our adjusted guidance to reflect lower currency headwinds due to the weakening of the U.S. dollar relative to the euro and other currencies. 
Moving to Slide 5. I will review our second quarter revenue and EPS results, which I will speak to on a currency-neutral basis. 
Total company revenues grew 5.3% or 5.2% on a combined organic basis. 
Adjusted EPS of $2.18 was ahead of our expectations as the quarter benefited in part from some timing within the year. 
Now I'd like to turn things over to Chris for a more detailed discussion of our second quarter financial performance and our updated fiscal year 2016 guidance."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to a very solid second quarter results. Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comp",1856,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to a very solid second quarter results. 
Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comparable basis or 5.2% on a combined organic basis. This was slightly ahead of our expectations as the quarter benefited by about 50 basis points from the timing of revenues, which occurred earlier than expected. I'll discuss this as I take you through the business results. 
BD Medical's second quarter revenues increased 6.1%, reflecting solid growth across the segment. Medication and Procedural Solutions growth was 4%, which reflects strength in Infusion Therapy, safety-engineered products and infection prevention. 
Medication Management Solutions revenues grew 6%, driven by strong dispensing capital installations with our Pyxis platform. Pyxis ES demand was strong in the quarter, driven by several large customer conversions, and we saw a positive impact from our efforts to simplify the installation process. 
We also saw solid growth in the infusion business, where we continued to expand our leadership position. Growth in Diabetes Care was 3.6%, driven by pen needles and syringes. Pharmaceutical Systems growth of 11% reflects a strong growth in SAIS. Performance in this business also reflected the favorable timing of customer orders that occurred 1 quarter earlier than we initially anticipated.  Respiratory Solutions revenues increased 10.9%, reflecting the timing of capital placements, which similarly benefited the quarter as the placements were expected to occur later in the fiscal year. 
BD Life Sciences second quarter revenues increased 3.4%, driven by solid growth in Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 5.7% was driven by safety-engineered products in the U.S. and solid growth in Europe and emerging markets. 
Diagnostic Systems growth of 4.6% was the result of strong growth in core microbiology, including IDAST and BD MAX assays. Growth was also aided in part by an increase in flu activity in the U.S. While the flu season is still mild in comparison to the prior year, the timing of the late flu season had a positive benefit year-over-year in the quarter of 10 basis points. Biosciences revenues were about flat when compared with last year's second quarter. Strong double-digit growth in the U.S. was driven by continued increased demand for high-parameter instruments and growth in research reagents. This was offset by a 7% decline in Europe due to a difficult comparison related to timing of orders in the prior year. In addition, growth was negatively impacted by clinical tender delays in Africa associated with our HIV monitor related to the World Health Organization guidelines. 
Moving to Slide 8. I'll walk you through our geographic revenues for the second quarter on a currency-neutral basis. 
U.S. revenues increased 5.7%. This was primarily driven by strength in Medication Management Solutions, Medication and Procedural Solutions, Biosciences and Diagnostics and was aided in part by the aforementioned timing of revenues. 
BD Medical's performance reflects strong dispensing capital installations and solid growth in the infusion business as well as strength in infection prevention and interventional specialties. 
BD Life Sciences growth reflects continued strong performance in the Biosciences business, driven by demand for high parameter research instruments and reagents sales. Diagnostic Systems had strong growth in microbiology, including KIESTRA and blood culture, BD MAX as well as a benefit from the increase in flu activity during the quarter. 
Moving on to international. Revenues grew 4.8%. This is below our normal growth rate and primarily reflects the aforementioned clinical tender delays in Africa. I'll provide more details on this in a moment. 
The Medical segment grew 6.9%. This reflects solid performance in Medication and Procedural Solutions driven by sales of safety-engineered products, particularly in China, and strong dispensing installations in Medication Management Solutions. Growth was aided in part by the aforementioned timing of customer ordering patterns and capital placements. 
The Life Sciences segment grew 1.4%. This reflects strong growth in Preanalytical Systems in Western Europe and Asia Pacific and strong growth in Western Europe and Latin America in Diagnostic Systems driven by core microbiology. This was partially offset by the aforementioned tender delays in Africa and the difficult comparison in Europe in Biosciences. 
On Slide 9, emerging market revenues grew 5.1%, currency neutral, with developed markets growing 5.3%. The second quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by a decline in EMA. China growth for the second quarter was 9.4%. Double-digit revenue growth in our Medical segment was driven by continued strong demand for consumables across all of our businesses in the segment. Within our Life Sciences segment, strength in Preanalytical Systems was offset by the slowdown of capital spending in Diagnostic Systems as communicated on our call last quarter. For the total year, we continue to expect China to grow in the low double-digit range. 
We now expect total emerging markets to grow in the high single-digit range compared to our previous guidance of 9% to 10% growth. This is offset by stronger performance in developed markets, growing between 4% and 4.5% for the second half of the year. 
Our revised guidance for emerging markets reflects the aforementioned impact in Africa to our Biosciences unit from the WHO guidelines. In addition, since we last provided guidance in February, the government of Saudi Arabia announced the new austerity measures, which affect the health care industry. This has begun to impact our business in that particular region, and we saw a small impact in the second quarter. We view this situation in Saudi Arabia as temporary, though the timing of reversal may not occur within this fiscal year. 
Our new guidance range contemplates emerging markets growing between 10% and 12% for the second half of the year. 
Moving to global safety on Slide 10. Currency-neutral sales increased 6.7%. Safety revenues in the U.S. grew 4.5% and international sales also grew 9.9%, currency neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 15.6% in emerging markets. Medical Safety sales grew 8%, primarily driven by safety catheters. Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 4.6% in the quarter. 
Slide 11 recaps the second quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 5.3% on a comparable currency-neutral basis. Pricing was slightly positive in the quarter. 
Moving down the P&L, I will focus on the comparable basis figures, which include CareFusion's results in the prior year in order to give a better indication of our performance. 
Gross profit improved by 7.9%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency. 
SSG&A as a percentage of revenue was 24.5%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenue was 5.9%. Our expenditures in the quarter were slightly lower than our full year expectation of 6% to 6.5% of revenues due to the timing of spending. We continue to invest in new products and innovation and expect to further reinvest the benefit from the medical device tax suspension in the back half of the year. 
Operating income grew 24.8%, reflecting strong P&L leverage. In addition, as we had previously discussed, there were a number of items that negatively impacted operating margin in the prior year in the CareFusion business. I'll address the underlying growth in operating profit in more detail on the next slide. 
Our tax rate declined 70 basis points to 20.6%, below our full year expectation of 21% to 22% as the quarter included some timing benefits. 
As Vince discussed earlier, adjusted earnings per share were $2.18, which is a 44.7% increase versus the prior year. This reflects our solid growth profile and strong underlying margin expansion. In addition, growth benefited from the timing of revenues earlier than -- in the year than expected as well as timing within the year related to R&D expenditures and tax, as we just discussed. 
Slide 12 illustrates our gross profit and operating margin for the second quarter presented on a comparable basis. Strong gross profit margin performance of 170 basis points was primarily driven by robust operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. 
Strong operating margin performance of 370 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. In addition, timing of R&D expenses and the benefit of the medical device tax suspension aided operating margin in the quarter. Also, you will recall, several items drove lower second quarter operating margins for CareFusion in the prior year. 
Currency had a slightly negative impact on both gross profit margin and operating margins. 
Moving on to Slide 14. Since we provided guidance in February, the U.S. dollar has weakened against the euro and other currencies. As a result, we are raising our adjusted EPS guidance by 2% -- percentage points or $0.13 from a range of $8.37 to $8.44 to a range of $8.50 to $8.57. We are maintaining our currency-neutral adjusted EPS guidance of $9.01 to $9.08 as we expect the second quarter tax timing to reverse and R&D spend to ramp over the back half of the year, which includes reinvestment of the medical device tax. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments. 
Turning to Slide 15. I'd like you to walk you through the additional elements of our guidance for the full fiscal year 2016. 
In summary, we continue to expect comparable organic revenue growth of 4.5% to 5% on a currency-neutral basis with the back half of the year growing between 5.5% and 6.5%. This contemplates the third quarter growth rate to be slightly lower than our full year guidance range and the fourth quarter to be well above the full year guidance range. 
On a reported basis, revenue growth for the total year is expected to be between 21.5% and 22%, which reflects a currency headwind of about 300 basis points, an improvement from our prior guidance of about 450 basis points of currency headwinds. 
The U.S. dollar has weakened against the euro and most currencies since we last provided guidance in February. While our guidance assumes a euro-to-dollar exchange rate of $1.13 for the rest of the year, which is better than the actual rate from the second half of last year, we see some remaining FX headwinds over the second half as non-euro currencies remain unfavorable year-over-year. 
We continue to expect growth of 4.5% to 5% in BD Medical and 4% to 4.5% in our Life Sciences segment. Based on our current view of the environment, we continue to expect pricing to be about flat for the year. Beyond revenue and EPS, all other P&L guidance from February remains unchanged. 
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems",733,"Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. 
Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems business launched 2 new products this quarter: the UltraTouch Push Button Blood Collection sets will deliver significant improvements in patient outcomes and lab efficiency. The BD Barricor tubes use gel-free technology, which significantly improves sample quality and lab turnaround time. The initial market feedback on both these products has been extremely positive. 
In our Bioscience business, as evidenced by our U.S. growth rate this quarter, we have seen very positive market uptake of our high-parameter instrumentation, the FACSSymphony X-50 and X-20. In our genomics business, we anticipate launching our GenCell CLiC library preparation platform and our FACSseq Cell Sorter designed specifically for genomics applications later this year -- this fiscal year. 
Within strategic and business initiatives, as we discussed earlier, we have completed our current portfolio review, having recently announced the Respiratory Solutions joint venture and sale of the vertebral augmentation solutions business. We remain focused on the areas we believe are high growth and aligned with our core capabilities. 
We have also made progress with our product registrations, having successfully registered more than 50 CareFusion products in over 20 countries. In addition, we have submitted registrations and are awaiting approval for an additional 25 products. This is consistent with our plans to achieve revenue synergies, and we remain on track for them to begin to materialize in fiscal year 2017. 
And in the areas of partnerships and collaborations, we remain excited for the launch of our infusion set, which we expect will move to broad commercial release with Medtronic in early fiscal year 2017. We believe this product will improve the consistency of insulin delivery by significantly reducing flow interruptions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We recently entered into a strategic partnership with the Parker Institute for Cancer Immunotherapy, and we'll play a part in the Institute's vision of reducing cancer to a manageable disease. Support from the Parker Institute will help us advance our new cell sorter program while bringing our high-parameter cell analysis solutions to these researchers as they work to discover the next breakthrough in cancer immunotherapy. As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you as we continue to make progress.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the second quarter, and we made progress with our back-office functions and with harmonizing our IT infrastructure. 
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs, as we discussed earlier. 
The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 170 to 190 basis points of expansion this fiscal year. 
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid second quarter. Both segments performed well and our performance highlights the benefits of our diverse portfolio, both from a product and geographic standpoint. 
Second, we have made significant progress on the acquisition of CareFusion. The value we can bring to customers around the world has become increasingly evident as we integrate these 2 great companies. 
Third, we have taken steps to optimize our portfolio. In doing so, we are positioning ourselves in higher-growth areas which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. 
Finally, we are confident in our outlook for the full fiscal year. We're maintaining our currency-neutral revenue guidance and raising our adjusted EPS. We believe we are well positioned to continue our track record of delivering value to our customers and shareholders. I look to the future with optimism. 
Thank you. We will now open the call to questions."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley.",13,"[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one  that the whole device industry is showing this quarter, which is this polarization. We've seen better U.S. p",92,"Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one  that the whole device industry is showing this quarter, which is this polarization. We've seen better U.S. performance and slightly softer ex U.S. performance, specifically emerging markets. Talk to us about how much of this in your mind is the quarter or just the trend that BD has been seeing for several quarters? And what's driving that strength in the U.S. in your opinion?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care",363,"Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care coverage, especially the expansion of Medicaid. But the other thing that you are seeing is that our businesses are performing quite well. You heard us talk about in the Bioscience business the launch of those new products. We have a whole series of new products coming out, and I mentioned -- and specifically the high-parameter work that's going on. So yes, that showed up in this quarter right now, but that's going to continue as we move through the year. You also saw good performance in Diagnostics because we're getting some traction in blood culture and KIESTRA, that is moving forward -- KIESTRA moving forward in the U.S. And then good performance across the Medical businesses, where we -- we're improving our competitive position in MMS. And so you see all of that coming together. And Europe, I think -- once again, I think, has stabilized, and it's really -- of course, you have to drop out the CareFusion factors, but there was negative timing in Biosciences. But you've got the same product launches that are occurring there. And quite frankly, Japan is forming -- is performing better for us as well. Now on the other side of the coin, the situation in China seems to have stabilized. We're seeing good performance on the medical device side of the business. And the situation really hasn't changed all that much on Diagnostics, on the capital side, but it had stabilized. And so we're getting good growth in China. We didn't mention it, we continue to get good growth in India. We're getting good growth in Latin America. There were some onetime events this quarter, which you heard in terms of Africa and Saudi Arabia. And Saudi Arabia is more of an impact in the back half of the year. So yes, this is slightly less in emerging markets, yes, but the mix is quite good."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Mike Weinstein of JPMorgan.",10,"Your next question is coming from Mike Weinstein of JPMorgan."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're -- 3 months later and you",140,"Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're -- 3 months later and you grew 5.3% organic this quarter. So essentially, what you said would happen happened. Can you just talk a little bit as you go into the back half of the year? I just want to make sure I understand the commentary on the cadence of the quarters. I know the comp, in some different respects, for the fourth quarter is easier than the third quarter, but I just want to understand the -- just the commentary relative to third quarter being a bit below the full year guidance and the fourth quarter being materially above."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through.",34,"Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter b",173,"Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter because in terms of absolute dollars, that was our highest quarter last year. So you got to really look at those absolute dollars. Looking at growth rates is a little misleading because the growth rate last year was negative in CareFusion in the third quarter, but that was more about the compare to prior year. But yes, absolute dollars are the grow over. And then as you model out the year, based on the guidance that we just gave you in terms of growth rates for the third and fourth quarter, you'll see steadily improving sequential revenue dollars for all 4 quarters this year. So we really feel good about the trajectory, particularly on a sequential basis this year. It's all about the compare to last year revenue dollars."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, if you think about it, there were 2 events with CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate with the first quarter being very high and the third quarter being very high. And then we had the flu.",92,"Yes, Mike, if you think about it, there were 2 events with CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate with the first quarter being very high and the third quarter being very high. And then we had the flu. So you got to go back and look at those absolute numbers, as Chris was saying, and then you'll see that our growth this year actually, as we look at the whole year, is actually quite smooth. But the growth rates jump around because of that."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks for your question, Mike.",5,"Thanks for your question, Mike."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then h",117,"Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then how we should start to evaluate the impact on a go-forward basis? And then for Chris, can you maybe help us understand why given the change in currency there's not a positive impact on the margin profile? It looks like you just flowed the dollars right down to EPS at the corporate margin guidance you previously provided. So why wouldn't we see an uplift in profitability associated with the change in rates?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?",43,"Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2",247,"Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2 businesses that are -- came from legacy CareFusion, and a majority of those products are actually within MPS. So think disposables. And this is right in line with what we had talked about over the last several quarters that as we think about the first products that would be able to help drive incremental revenue growth, it would be things like infusion sets, ChloraPrep, the consumables that fit very well with BD's traditional sales channels and market approaches and presence in the marketplaces, and those are the products that we focused on getting registration for first. So I would say we're seeing some early signs of success as we've been launching these products, which is very consistent with our plans to achieve revenue synergies and really remain on track to start seeing them materialize more in 2017. But we do see sales now. And obviously, on a company the size of BD and a segment of Medical, we'll see those start showing up more materially as we roll on to '17. But they have started. And I would just say that obviously, we're going to continue those product registration work. We're continuing the sales and marketing investments to support those initiatives. But overall, we're on track."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, althoug",148,"And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, although the euro hasn't (sic) [ has ] improved, the non-euro currencies year-over-year are still providing a bit of a drag. And then secondly, and probably more importantly, is the phenomenon of the profit and inventory that we've talked about in the past. So it didn't quite catch up in the second quarter. Certainly not much of a drag and it's starting to level off, and that, in my prepared remarks, was the commentary for the second half of the year. It doesn't really turn positive because of that phenomena, but it certainly lightens up in terms of headwinds."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Larry Keusch of Raymond James.",10,"Your next question comes from Larry Keusch of Raymond James."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installa",93,"I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installation process for MedStation ES is improving. I know there have been a number of software tweaks for that ES system over the past couple of years, and just also I want to understand if you're kind of getting to a point where that system is now stable."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the sof",424,"Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the software, which we think really it makes some very significant progress and actually addresses -- will make a big step forward in terms of installation efficiency. And so as we've shared in the past, we were really focused on improving the installation process. We had shared that there was a quite large backlog at the time of the acquisition. And to really address that backlog, we needed to improve the installation efficiency process, and we've been working on that, applying some of our lean expertise as well as making some adjustments in the software that would automate a lot of that and simplify the workload in the field. So we're seeing a lot of those efforts come to fruition. We did have very strong placements in Q2. That was part of the driver of MMS growth. We continue to see strong demand for the Pyxis ES platform, and we're equally looking forward to continued strong growth in the second half of the year in that, as Vince alluded to earlier. Then on the infusion side, we also are very pleased with the growth that we saw in the quarter here and have similar expectations for the back half of the year. As you know, we are the market leader in that space. We've continued to strengthen our position over the last several years. We expect to continue to strengthen our position in the market by about the same amount this year, as we have over the last couple of years. We do see customers continue to select the BD Alaris pumps in an incremental way really based on that interoperability and the power of one to be able to do all of their infusion needs across both large-volume infusions, syringes and narcotics, all in one product. It's the only item that can do that. So we're happy there. I would point out as well that as you look at our safety sales, particularly in the U.S., that was largely driven by growth in our -- in some of the connectors that are associated with our dedicated sets in the infusion category. And that's really a reflection of that strong performance in that infusion category and that renewing consumable stream that comes as we place pumps incrementally. Thank you."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost sy",93,"Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost synergies or on the revenue side? And obviously, you alluded to some of the products and registration. And then secondly, just on China, looks like, based on the numbers, we're going to need about -- some sort of teens acceleration, easier comps. But can you just elaborate on that?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, okay so I'll ask Chris to talk about the cost synergies.",12,"Yes, okay so I'll ask Chris to talk about the cost synergies."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So just a reminder, the -- we raised the cost synergies earlier, assuming that...[Technical Difficulty]",17,"Sure. So just a reminder, the -- we raised the cost synergies earlier, assuming that...
[Technical Difficulty]"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Is anybody able to hear us?",6,"Is anybody able to hear us?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Yes, we can hear you now.",6,"Yes, we can hear you now."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our",233,"Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our recent -- or our original model. I would also remind you that we increased the overall synergies from the standpoint of the tax rate improvements that we saw that we originally didn't contemplate, and that's another 3% accretion that we had mentioned. Really, the -- when you think about the synergies, we get initial synergies of duplicate public company costs. Then you move into the integration of systems and infrastructure, and we've gotten good traction on that and that led to the last increase. And then towards the end are the more difficult synergies to get, which are the distribution centers and manufacturing plants, and we actually saw some good initial improvements in that area or traction in that area that led to our last increase. So we really feel great about what we're driving. All in-all in, it's significantly higher than our original expectations, particularly when you add the tax synergy. You see this year the EPS quarter-over-quarter was over 44%, I think, is an indication of that. So we really feel good about our ability to drive those synergies and executing on those synergies."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of",74,"And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of the chain last year, so there is a favorable comparison in the fourth quarter. But Tom, do you want to comment on any of the product lines?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from",80,"No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from CareFusion. And then we're seeing some good traction in some of those items, particularly as we think about connectors and some of the oncology products coming on from CareFusion."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us.",28,"And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise with Stifel.",9,"Your next question is from Rick Wise with Stifel."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and what yo",101,"I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and what you're thinking about? And maybe just one for Chris on operating margin expansion. You've addressed a little bit, but this acceleration in operating margin expansion can't go on forever. How do we think about the -- not for guidance, but how do we think about fiscal '17 and beyond? What's possible in terms of further operating margin expansion just directionally?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- but it's importance [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get dow",160,"Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- but it's importance [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get down to the 3x leverage, and we're making excellent progress there. And so in the short run, we still have the flexibility to do plug-in acquisitions. And then as we have been stating, we're going to be really strategy driven. And we challenge both segments to look at their strategies. And as we look at the -- our ability to provide solutions to the marketplace and have a broader impact, that's what's going to drive our strategy. It'll be a mix of both internal development and continued looking on the outside, and we'll be very, very balanced here. But ultimately, it's about strategic impact plus value creation for shareholders, and that's how we're thinking about it."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies",277,"And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies and continuous improvement, a little bit of benefit from raw material prices, as we've talked in the past, from oil. But then, on the operating side, SSG&A really reflective of hitting on the synergies. It was a little bit of an easier compare in the second quarter because of the operating margin challenges in CareFusion in that quarter last year. So you won't expect 370. In fact, we expect about 170 to 190 for the year on the operating margin basis. I'd remind you that's on top of a 100 basis of margin improvement last year. So really improving the margins, as you point out. And as we think about going forward, as we execute on synergies, you would expect to see above normal. So we usually think 40 to 50 basis points of margin improvement. You're going to get more of that as we execute on the synergies in '17 and '18. You would also get a little bit of a lift from the fact that as we exit respiratory, which had challenging margins, you get a little bit of a lift. So not to give guidance on '17, but you're absolutely right. Directionally, we're going to see improved margins going forward in '17 and '18. And then, as you start lapping those synergies, I think somewhere beyond that, you start going back to that 40 to 50 basis points. That's a few years out."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Derik De Bruin of Bank of America.",13,"Your next question is coming from Derik De Bruin of Bank of America."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these movi",68,"Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these moving parts are on it? And do you still feel good about a 4% to 5% longer-term organic revenue growth rate for the company?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent pro",90,"Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent progress. I think you see the performance of the CareFusion businesses is quite strong. I think that the portfolio moves that we have made have been the right ones. So that still is our goal and I think we're making excellent progress."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can you guys hear me? So guys, kind of a sort of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist in the respiratory, I guess",83,"Can you guys hear me? So guys, kind of a sort of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist in the respiratory, I guess when exactly do you expect all those to close? And if you have any updated views on the EPS and that kind of impact from an EPS standpoint for those initiatives."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then...",25,"Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then..."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed.",3,"Simplist is closed."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is done.",3,"Simplist is done."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad",161,"Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad commercialization in early FY '17. We are tracking towards by the end of this fiscal year, within this fiscal year. We will be doing a limited launch, and we've talked about this in the past, in which Medtronic will start providing the product to a set group of patients so that they can really understand the user insight at another level before they do the full-scale launch. And so we're moving forward, preparing to ship out the first product for that limited-scale launch in the back half of this fiscal year. That will occur, and then it would open up for a full commercial launch, we expect, at the start of FY '17."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14.",44,"And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks very much.",4,"Okay, thanks very much."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein with William Blair.",10,"Your next question comes from Brian Weinstein with William Blair."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current p",74,"On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current projects? Is it really putting that money to work in new projects? And any specific areas of focus that you would like to focus on with those dollars?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before",167,"Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before the medical device tax in the back half of the year. It's the timing of things like clinical trials and whatnot. And so -- but in addition, the money that is being spent on the medical device tax is being spent in both segments, and it is a combination of some new things that we are doing. But mostly, it's current strategies where we are accelerating those strategies, where we had platforms where we could push them faster. And part of that, which is a bit new for us, is moving the informatics side of things quicker. So you can think of major platforms going faster and the informatics piece on top of that. Both sides of the company."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Richard Newitter with Leerink Partners.",10,"Your next question comes from Richard Newitter with Leerink Partners."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is kind of like an inning question, what innings are you in for 2 parts of your business that figure we'll talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades f",105,"This is kind of like an inning question, what innings are you in for 2 parts of your business that figure we'll talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades for that product cycle? And then the second innings question, just the -- in your cytology business, your liquid-based Pap testing, can you just tell us what the trend is there? Are we kind of through the interval expansion impacts mostly at this point? And just comment on any pricing or volume trends for that business."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, let's start with the Pap first, and Linda can talk to you about that.",15,"Sure, let's start with the Pap first, and Linda can talk to you about that."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So if you look at the liquid cytology business in the U.S., as you mentioned we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-dig",100,"Yes. So if you look at the liquid cytology business in the U.S., as you mentioned we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-digit performance. And then the entire platform, both in the U.S. and ex U.S., is being held by the Total automation we're doing across both our FocalPoint and our Totalys system. So complete control of the sample from collection through the result. So that's driving a lot of growth both in the U.S. and ex U.S. for us."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Linda. Okay.",4,"Okay. Thanks, Linda. Okay."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes.",42,"And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks for the question.",5,"Okay, thanks for the question."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth",152,"So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth. That would seemingly imply there's a positive offset for developed market growth. I believe this change in mix should benefit operating margin. It doesn't seem like your guidance reflects that margin mix dynamic. Am I wrong? And if not, why? And then the second question is for Tom. Regarding your plans for the 25-or-so additional CareFusion product registrations, what's the time line for those? And can you walk us through why those products take a bit longer to get registered? I'm just trying to get a better handle on the profile of those products versus the first 50 that are close to or have been registered."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Chris?",2,"Okay. Chris?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range.",49,"Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Tom?",2,"Okay. Tom?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really  a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think ab",163,"And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really  a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think about those as being ones that we submitted more recently and didn't work through certain regulatory processes. In other cases, it's a combination of they're in certain countries that have longer registration. China has longer registration processes than most of Europe, as an example. And then the other one is, is that certain product categories -- so ChloraPrep, for example, is registered as a drug in many markets. Particularly, let's say, Latin America, it's registered as a drug. Those typically sit in the regulatory process longer than medical devices. So it's kind of a combination of those 3 items, not one thing specific, and not unexpected at all. It's right in line with our projection."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much.",50,"And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar with Evercore ISI.",10,"Your next question comes from Vijay Kumar with Evercore ISI."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure sort of is that a li",88,"Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure sort of is that a little bit of conservatism on the part of management just because FX has been moving all over the place when you think about -- and they're trying to put the Q in context of FX improving in the back half?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right",270,"Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right, we were up around $0.14 to $0.16. But we see that as timing, and the timing buckets are the medical device tax spending, which we know where we want to spend it, but because of the timing -- don't forget it happened in January and we couldn't ramp that quickly. So that past quarter, we really got a lift from that. But we fully intend to spend that in the back half of the year. Then you had timing on the tax rate. So the tax rate was lower than our 21% to 22%, and that's just lumpy throughout the year. We expect that to fall back within the rest of the year. So you had that piece. And then we had the pull-forward of some of the revenues from the third quarter to the second quarter and the impact of that. So all of that accounts for the bulk of that $0.14 to $0.16 on an FXN basis. The other thing I'd point out is we actually raised the FXN EPS guidance last quarter by $0.28. It was loss from the standpoint that at that point, FX was getting worse across the world and it offset that, but the FXN was raised prior. So you really got to think about it in those 2 buckets."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Our final question is coming from Matt Taylor of Barclays.",10,"Our final question is coming from Matt Taylor of Barclays."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes",69,"I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes partnership with Medtronic. Can you talk a little bit about those opportunities and maybe help us quantify the upside there?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Tom will address those. Tom, you want to start with diabetes?",13,"Sure. So Tom will address those. Tom, you want to start with diabetes?"
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see",228,"Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see more of the impact in the Diabetes Care business in FY '17. That remains unchanged. So we remain very excited about that opportunity. It's, of course, our first venture outside of the pen needles and syringes for the Diabetes Care business, moving into a fast-growing market with the market leader, Medtronic, and we're, I think, equally excited about the product technology and what it can do to help patients and the partnership and what the power of us working together can do to make an impact there. If you think about solutions, so we -- as we had, of course, shared before, we have announced the solutions partnership with Fresenius. We are looking at launching that not necessarily now in Q4 of '16 but more in early FY '17 just based on regulatory approval time lines there, but that does continue to move forward. And again, we had not shared a specific number there, but we said it would certainly make up for any reduction in BD Rx sales that we had planned over the coming horizon, and that remains right on track."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for any closing remarks.",15,"I will now turn the floor back over to Vince Forlenza for any closing remarks."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thank you very much for your participation on the call today. It was real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and pro",136,"Okay, thank you very much for your participation on the call today. It was real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and progress with those businesses, the synergies, the teams in place and then lastly the strategic partnerships that we're doing, including the Parker Institute relationship, the new products that are being launched. We didn't spend a lot of time on the Life Science business today. There weren't that many questions. But with BD MAX, with KIESTRA, all these things happening over there, very, very exciting. And of course, the new products on the Medical side. So thank you very much for your time and look forward to updating you next quarter."
103678,329827360,973926,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for",79,"Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 83710101. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is po",399,"Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. 
As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com. 
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second fiscal quarter press release and in the MD&A sections of our recent SEC filings. 
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. 
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules, in our press release or the appendix of the Investor Relations slides. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. 
It is now my pleasure to turn the call over to Vince."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic an",671,"Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic and product portfolio with both segments contributing to revenue growth. We continue to drive strong underlying margin expansion through the achievement of operational efficiencies and continuous improvement coupled with the positive impact of cost synergies. 
As many of you already know, in March we celebrated the 1-year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration, and a significant amount of work has been driven by the integration teams across the businesses. 
In terms of talent retention, we have a strong team that's in place that's comprised of both legacy CareFusion and legacy BD associates. They've been helping drive the company through our next phase of growth as a combined entity. 
In terms of our customers, we are becoming increasingly more relevant as they look -- as they are looking for providers that can really help them improve the quality, efficiency and safety of processes. We have made good progress on this front 12 months post-close, and feedback from our customers has been extremely positive. 
Also, we have been actively working to create new growth opportunities for CareFusion products and expanding their global reach by leveraging BD's global infrastructure. We are well into the registration process with dozens of products across multiple geographies. I will provide more details on this later in the presentation. 
Lastly, we are seeing strong productivity as we are overdelivering on our initial cost synergy capture commitments. As you already know, we have increased our total cost synergy target by about $100 million over the deal's horizon. We are clearly advancing our strategy to improve medication management. The value we bring to customers around the world has become increasingly evident as we make progress integrating these 2 great companies. 
We're also pleased to inform you that the annual strategic review of our portfolio is now complete. In March, we announced that BD and Apax Partners, a private equity firm, will form a joint venture with the Respiratory Solutions business. Apax will establish and stand up a newco, enabling more strategic focus and investment to build a leading global respiratory company. 
And more recently, we announced the divestiture of our vertebral augmentation solutions business. This product line was not aligned with our strategy and we believe it can see more robust investment in growth under a different owner. 
The completion of our current strategic review process enables the company to remain focused on the areas we believe are high growth and aligned with our core capabilities. 
In addition, during our last call, we let you know about our intent to reinvest the savings from the suspension of the medical device tax that went into effect in January. Since that time, we have already allocated increased R&D dollars to highly strategic initiatives. Not only will this help to fund -- drive future growth for the company, but it will also enable better outcomes for our customers and their patients. 
Looking forward to the total year, we are confident in our outlook and are maintaining our fiscal 2016 currency-neutral revenue and EPS guidance. We are also increasing our adjusted guidance to reflect lower currency headwinds due to the weakening of the U.S. dollar relative to the euro and other currencies. 
Moving to Slide 5. I will review our second quarter revenue and EPS results, which I will speak to on a currency-neutral basis. 
Total company revenues grew 5.3% or 5.2% on a combined organic basis. 
Adjusted EPS of $2.18 was ahead of our expectations as the quarter benefited in part from some timing within the year. 
Now I'd like to turn things over to Chris for a more detailed discussion of our second quarter financial performance and our updated fiscal year 2016 guidance."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to our very solid second quarter results. Total second quarter revenues of approximately $3.1 billion grew 5.3% on a co",1855,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to our very solid second quarter results. 
Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comparable basis or 5.2% on a combined organic basis. This was slightly ahead of our expectations as the quarter benefited by about 50 basis points from the timing of revenues, which occurred earlier than expected. I'll discuss this as I take you through the business results. 
BD Medical's second quarter revenues increased 6.1%, reflecting solid growth across the segment. Medication and Procedural Solutions growth was 4%, which reflects strength in Infusion Therapy, safety-engineered products and infection prevention. 
Medication Management Solutions revenues grew 6%, driven by strong dispensing capital installations with our Pyxis platform. Pyxis ES demand was strong in the quarter, driven by several large customer conversions, and we saw a positive impact from our efforts to simplify the installation process. 
We also saw solid growth in the infusion business, where we continue to expand our leadership position. Growth in Diabetes Care was 3.6%, driven by pen needles and syringes. Pharmaceutical Systems growth of 11% reflects a strong growth in SAIS. Performance in this business also reflected the favorable timing of customer orders that occurred 1 quarter earlier than we initially anticipated.  Respiratory Solutions revenues increased 10.9%, reflecting the timing of capital placements, which similarly benefited the quarter as the placements were expected to occur later in the fiscal year. 
BD Life Sciences second quarter revenues increased 3.4%, driven by solid growth in Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 5.7% was driven by safety-engineered products in the U.S. and solid growth in Europe and emerging markets. 
Diagnostic Systems growth of 4.6% was the result of strong growth in core microbiology, including IDAST and BD MAX assays. Growth was also aided in part by an increase in flu activity in the U.S. While the flu season is still mild in comparison to the prior year, the timing of the late flu season had a positive benefit year-over-year in the quarter of 10 basis points. Biosciences revenues were about flat when compared with last year's second quarter. Strong double-digit growth in the U.S. was driven by continued increased demand for high-parameter instruments and growth in research reagents. This was offset by a 7% decline in Europe due to a difficult comparison related to timing of orders in the prior year. In addition, growth was negatively impacted by clinical tender delays in Africa associated with our HIV monitoring related to the World Health Organization guidelines. 
Moving to Slide 8. I'll walk you through our geographic revenues for the second quarter on a currency-neutral basis. 
U.S. revenues increased 5.7%. This was primarily driven by strength in Medication Management Solutions, Medication and Procedural Solutions, Biosciences and Diagnostics and was aided in part by the aforementioned timing of revenues. 
BD Medical's performance reflects strong dispensing capital installations and solid growth in the infusion business as well as strength in infection prevention and interventional specialties. 
BD Life Sciences growth reflects continued strong performance in the Biosciences business, driven by demand for high-parameter research instruments and reagent sales. Diagnostic Systems had strong growth in microbiology, including KIESTRA and blood culture, BD MAX as well as a benefit from the increase in flu activity during the quarter. 
Moving on to international. Revenues grew 4.8%. This is below our normal growth rate and primarily reflects the aforementioned clinical tender delays in Africa. I'll provide more details on this in a moment. 
The Medical segment grew 6.9%. This reflects solid performance in Medication and Procedural Solutions driven by sales of safety-engineered products, particularly in China, and strong dispensing installations in Medication Management Solutions. Growth was aided in part by the aforementioned timing of customer ordering patterns and capital placements. 
The Life Sciences segment grew 1.4%. This reflects strong growth in Preanalytical Systems in Western Europe and Asia Pacific and strong growth in Western Europe and Latin America in Diagnostic Systems, driven by core microbiology. This was partially offset by the aforementioned tender delays in Africa and the difficult comparison in Europe in Biosciences. 
On Slide 9, emerging market revenues grew 5.1%, currency neutral, with developed markets growing 5.3%. The second quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by a decline in EMA. China growth for the second quarter was 9.4%. Double-digit revenue growth in our Medical segment was driven by continued strong demand for consumables across all of our businesses in the segment. Within our Life Sciences segment, strength in Preanalytical Systems was offset by the slowdown of capital spending in Diagnostic Systems as communicated on our call last quarter. For the total year, we continue to expect China to grow in the low double-digit range. 
We now expect total emerging markets to grow in the high single-digit range compared to our previous guidance of 9% to 10% growth. This is offset by stronger performance in developed markets, growing between 4% and 4.5% for the second half of the year. 
Our revised guidance for emerging markets reflects the aforementioned impact in Africa to our Biosciences unit from the WHO guidelines. In addition, since we last provided guidance in February, the government of Saudi Arabia announced the new austerity measures, which affect the health care industry. This has begun to impact our business in that particular region, and we saw a small impact in the second quarter. We view this situation in Saudi Arabia as temporary, though the timing of reversal may not occur within this fiscal year. 
Our new guidance range contemplates emerging markets growing between 10% and 12% for the second half of the year. 
Moving to global safety on Slide 10. Currency-neutral sales increased 6.7%. Safety revenues in the U.S. grew 4.5% and international sales also grew 9.9%, currency neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 15.6% in emerging markets. Medical Safety sales grew 8%, primarily driven by safety catheters. Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 4.6% in the quarter. 
Slide 11 recaps the second quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 5.3% on a comparable currency-neutral basis. Pricing was slightly positive in the quarter. 
Moving down the P&L, I will focus on the comparable basis figures, which include CareFusion's results in the prior year in order to give a better indication of our performance. 
Gross profit improved by 7.9%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency. 
SSG&A as a percentage of revenue was 24.5%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenue was 5.9%. Our expenditures in the quarter were slightly lower than our full year expectation of 6% to 6.5% of revenues due to the timing of spending. We continue to invest in new products and innovation and expect to further reinvest the benefit from the medical device tax suspension in the back half of the year. 
Operating income grew 24.8%, reflecting strong P&L leverage. In addition, as we had previously discussed, there were a number of items that negatively impacted operating margin in the prior year in the CareFusion business. I'll address the underlying growth in operating profit in more detail on the next slide. 
Our tax rate declined 70 basis points to 20.6%, below our full year expectation of 21% to 22% as the quarter included some timing benefits. 
As Vince discussed earlier, adjusted earnings per share were $2.18, which is a 44.7% increase versus the prior year. This reflects our solid growth profile and strong underlying margin expansion. In addition, growth benefited from the timing of revenues earlier than -- in the year than expected as well as timing within the year related to R&D expenditures and tax, as we just discussed. 
Slide 12 illustrates our gross profit and operating margin for the second quarter presented on a comparable basis. Strong gross profit margin performance of 170 basis points was primarily driven by robust operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. 
Strong operating margin performance of 370 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. In addition, timing of R&D expenses and the benefit of the medical device tax suspension aided operating margin in the quarter. Also, you will recall, several items drove lower second quarter operating margins for CareFusion in the prior year. 
Currency had a slightly negative impact on both gross profit margin and operating margins. 
Moving on to Slide 14. Since we provided guidance in February, the U.S. dollar has weakened against the euro and other currencies. As a result, we are raising our adjusted EPS guidance by 2% -- percentage points or $0.13 from a range of $8.37 to $8.44 to a range of $8.50 to $8.57. We are maintaining our currency-neutral adjusted EPS guidance of $9.01 to $9.08 as we expect the second quarter tax timing to reverse and R&D spend to ramp over the back half of the year, which includes reinvestment of the medical device tax. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments. 
Turning to Slide 15. I'd like you to walk you through the additional elements of our guidance for the full fiscal year 2016. 
In summary, we continue to expect comparable organic revenue growth of 4.5% to 5% on a currency-neutral basis, with the back half of the year growing between 5.5% and 6.5%. This contemplates the third quarter growth rate to be slightly lower than our full year guidance range and the fourth quarter to be well above the full year guidance range. 
On a reported basis, revenue growth for the total year is expected to be between 21.5% and 22%, which reflects a currency headwind of about 300 basis points, an improvement from our prior guidance of about 450 basis points of currency headwinds. 
The U.S. dollar has weakened against the euro and most currencies since we last provided guidance in February. While our guidance assumes a euro-to-dollar exchange rate of $1.13 for the rest of the year, which is better than the actual rate from the second half of last year, we see some remaining FX headwinds over the second half as non-euro currencies remain unfavorable year-over-year. 
We continue to expect growth of 4.5% to 5% in BD Medical and 4% to 4.5% in our Life Sciences segment. Based on our current view of the environment, we continue to expect pricing to be about flat for the year. Beyond revenue and EPS, all other P&L guidance from February remains unchanged. 
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems",733,"Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. 
Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems business launched 2 new products this quarter. The UltraTouch Push Button Blood Collection sets will deliver significant improvements in patient outcomes and lab efficiency. The BD Barricor tubes use gel-free technology, which significantly improves sample quality and lab turnaround time. The initial market feedback on both these products has been extremely positive. 
In our Bioscience business, as evidenced by our U.S. growth rate this quarter, we have seen very positive market uptake of our high-parameter instrumentation, the FACSSymphony X-50 and X-20. In our genomics business, we anticipate launching our GenCell CLiC library preparation platform and our FACSseq Cell Sorter designed specifically for genomics applications later this year -- this fiscal year. 
Within strategic and business initiatives, as we discussed earlier, we have completed our current portfolio review, having recently announced the Respiratory Solutions joint venture and sale of the vertebral augmentation solutions business. We remain focused on the areas we believe are high growth and aligned with our core capabilities. 
We have also made progress with our product registrations, having successfully registered more than 50 CareFusion products in over 20 countries. In addition, we have submitted registrations and are awaiting approval for an additional 25 products. This is consistent with our plans to achieve revenue synergies, and we remain on track for them to begin to materialize in fiscal year 2017. 
And in the areas of partnerships and collaborations, we remain excited for the launch of our infusion set, which we expect will move to broad commercial release with Medtronic in early fiscal year 2017. We believe this product will improve the consistency of insulin delivery by significantly reducing flow interruptions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We recently entered into a strategic partnership with the Parker Institute for Cancer Immunotherapy, and we'll play a part in the Institute's vision of reducing cancer to a manageable disease. Support from the Parker Institute will help us advance our new cell sorter program while bringing our high-parameter cell analysis solutions to these researchers as they work to discover the next breakthrough in cancer immunotherapy. As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you as we continue to make progress.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the second quarter, and we made progress with our back-office functions and with harmonizing our IT infrastructure. 
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs, as we discussed earlier. 
The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 170 to 190 basis points of expansion this fiscal year. 
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid second quarter. Both segments performed well and our performance highlights the benefits of our diverse portfolio, both from a product and geographic standpoint. 
Second, we have made significant progress on the acquisition of CareFusion. The value we can bring to customers around the world has become increasingly evident as we integrate these 2 great companies. 
Third, we have taken steps to optimize our portfolio. In doing so, we are positioning ourselves in higher-growth areas which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. 
Finally, we are confident in our outlook for the full fiscal year. We're maintaining our currency-neutral revenue guidance and raising our adjusted EPS. We believe we are well positioned to continue our track record of delivering value to our customers and shareholders. I look to the future with optimism. 
Thank you. We will now open the call to questions."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley.",13,"[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one that the whole device industry is showing this quarter, which is this polarization between better U.S. perfor",91,"Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one that the whole device industry is showing this quarter, which is this polarization between better U.S. performance and slightly softer ex U.S. performance, specifically emerging markets. Talk to us about how much of this in your mind is the quarter or just the trend that BD has been seeing for several quarters? And what's driving that strength in the U.S. in your opinion?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care",363,"Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care coverage, especially the expansion of Medicaid. But the other thing that you are seeing is that our businesses are performing quite well. You heard us talk about in the Bioscience business, the launch of those new products. We have a whole series of new products coming out, and I mentioned -- and specifically the high-parameter work that's going on. So yes, that showed up in this quarter right now, but that's going to continue as we move through the year. You also saw good performance in Diagnostics because we're getting some traction in blood culture and KIESTRA, that is moving forward -- KIESTRA moving forward in the U.S. And then good performance across the Medical businesses, where we -- we're improving our competitive position in MMS. And so you see all of that coming together. And Europe, I think -- once again, I think, has stabilized, and it's really -- of course, you have to drop out the CareFusion factors, but there was negative timing in Biosciences. But you've got the same product launches that are occurring there. And quite frankly, Japan is forming -- is performing better for us as well. Now on the other side of the coin, the situation in China seems to have stabilized. We're seeing good performance on the medical device side of the business. And the situation really hasn't changed all that much on Diagnostics, on the capital side, but it has stabilized. And so we're getting good growth in China. We didn't mention it, we continue to get good growth in India. We're getting good growth in Latin America. There were some onetime events this quarter, which you heard in terms of Africa and Saudi Arabia. And Saudi Arabia is more of an impact in the back half of the year. So yes, this is slightly less in emerging markets, yes, but the mix is quite good."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Mike Weinstein of JPMorgan.",10,"Your next question is coming from Mike Weinstein of JPMorgan."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're 3 months later and you gre",139,"Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're 3 months later and you grew 5.3% organic this quarter. So essentially, what you said would happen happened. Can you just talk a little bit as you go into the back half of the year? I just want to make sure I understand the commentary on the cadence of the quarters. I know the comp, in some different respects, for the fourth quarter is easier than the third quarter, but I just want to understand the -- just the commentary relative to third quarter being a bit below the full year guidance and the fourth quarter being materially above."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through.",34,"Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter b",173,"Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter because in terms of absolute dollars, that was our highest quarter last year. So you got to really look at those absolute dollars. Looking at growth rates is a little misleading because the growth rate last year was negative in CareFusion in the third quarter, but that was more about the compare to prior year. But the absolute dollars are the grow over. And then as you model out the year, based on the guidance that we just gave you in terms of growth rates for the third and fourth quarter, you'll see steadily improving sequential revenue dollars for all 4 quarters this year. So we really feel good about the trajectory, particularly on a sequential basis. This year, it's all about the compare to last year revenue dollars."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, if you think about it, there were 2 events at CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate, with the first quarter being very high and the third quarter being very high. And then we had the flu.",92,"Yes, Mike, if you think about it, there were 2 events at CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate, with the first quarter being very high and the third quarter being very high. And then we had the flu. So you got to go back and look at those absolute numbers, as Chris was saying, and then you'll see that our growth this year actually, as we look at the whole year, is actually quite smooth. But the growth rates jump around because of that."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks for your question, Mike.",5,"Thanks for your question, Mike."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then h",117,"Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then how we should start to evaluate the impact on a go-forward basis? And then for Chris, can you maybe help us understand why given the change in currency there's not a positive impact on the margin profile? It looks like you just flowed the dollars right down to EPS at the corporate margin guidance you previously provided. So why wouldn't we see an uplift in profitability associated with the change in rates?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?",43,"Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2",246,"Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2 businesses that are -- came from legacy CareFusion, and the majority of those products are actually within MPS. So think disposables. And this is right in line with what we had talked about over the last several quarters, that as we think about the first products that would be able to help drive incremental revenue growth, it would be things like infusion sets, ChloraPrep, the consumables that fit very well with BD's traditional sales channels and market approaches and presence in the marketplaces, and those are the products that we focused on getting registrations for first. So I would say we're seeing some early signs of success as we've been launching these products, which is very consistent with our plans to achieve revenue synergies and really remain on track to start seeing them materialize more in 2017. But we do see sales now. And obviously, on a company the size of BD and a segment of Medical, we'll see those start showing up more materially as we roll into '17. But they have started. And I would just say that obviously, we're going to continue those product registration work. We're continuing the sales and marketing investments to support those initiatives. But overall, we're on track."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, althoug",144,"And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, although the euro has improved, the non-euro currencies year-over-year are still providing a bit of a drag. And then secondly, and probably more importantly, is the phenomenon of the profit and inventory that we've talked about in the past. So it didn't quite catch up in the second quarter. Certainly not much of a drag and it's starting to level off, and that, in my prepared remarks, was the commentary for the second half of the year. It doesn't really turn positive because of that phenomena, but it certainly lightens up in terms of headwinds."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Larry Keusch of Raymond James.",10,"Your next question comes from Larry Keusch of Raymond James."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installa",93,"I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installation process for MedStation ES is improving. I know there have been a number of software tweaks for that ES system over the past couple of years, and just also I want to understand if you're kind of getting to a point where that system is now stable."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the sof",424,"Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the software, which we think really it makes some very significant progress and actually addresses -- will make a big step forward in terms of installation efficiency. And so as we've shared in the past, we were really focused on improving the installation process. We had shared that there was a quite large backlog at the time of the acquisition. And to really address that backlog, we needed to improve the installation efficiency process, and we've been working on that, applying some of our lean expertise as well as making some adjustments in the software that would automate a lot of that and simplify the workload in the field. So we're seeing a lot of those efforts come to fruition. We did have very strong placements in Q2. That was part of the driver of MMS growth. We continue to see strong demand for the Pyxis ES platform, and we're equally looking forward to continued strong growth in the second half of the year in that, as Vince alluded to earlier. Then on the infusion side, we also are very pleased with the growth that we saw in the quarter here and have similar expectations for the back half of the year. As you know, we are the market leader in that space. We've continued to strengthen our position over the last several years. We expect to continue to strengthen our position in the market by about the same amount this year, as we have over the last couple of years. We do see customers continue to select the BD Alaris pumps in an incremental way really based on that interoperability and the power of one to be able to do all of their infusion needs across both large-volume infusions, syringes and narcotics, all in one product. It's the only item that can do that. So we're happy there. I would point out as well that as you look at our safety sales, particularly in the U.S., that was largely driven by growth in our -- in some of the connectors that are associated with our dedicated sets in the infusion category. And that's really a reflection of that strong performance in that infusion category and that renewing consumable stream that comes as we place pumps incrementally. Thank you."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost sy",93,"Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost synergies or on the revenue side? And obviously, you alluded to some of the products in registration. And then secondly, just on China, looks like, based on the numbers, we're going to need about -- some sort of teens acceleration, easier comps. But can you just elaborate on that?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, okay so I'll ask Chris to talk about the cost synergies.",12,"Yes, okay so I'll ask Chris to talk about the cost synergies."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So just a reminder that we raised the cost synergies earlier, assuming that...[Technical Difficulty]",16,"Sure. So just a reminder that we raised the cost synergies earlier, assuming that...
[Technical Difficulty]"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Is anybody able to hear us?",6,"Is anybody able to hear us?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Yes, we can hear you now.",6,"Yes, we can hear you now."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our",233,"Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our recent -- or our original model. I would also remind you that we increased the overall synergies from the standpoint of the tax rate improvements that we saw that we originally didn't contemplate, and that's another 3% accretion that we had mentioned. Really, the -- when you think about the synergies, we get initial synergies of duplicate public company costs. Then you move into the integration of systems and infrastructure, and we've gotten good traction on that and that led to the last increase. And then towards the end are the more difficult synergies to get, which are the distribution centers and manufacturing plants, and we actually saw some good initial improvements in that area or traction in that area that led to our last increase. So we really feel great about what we're driving. All-in all-in, it's significantly higher than our original expectations, particularly when you add the tax synergy. You see this year the EPS quarter-over-quarter was over 44% and, I think, is an indication of that. So we really feel good about our ability to drive those synergies and executing on those synergies."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of",74,"And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of the chain last year, so there is a favorable comparison in the fourth quarter. But Tom, do you want to comment on any of the product lines?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from",80,"No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from CareFusion into, and we're seeing some good traction in some of those items, particularly as we think about connectors and some of the oncology products coming over from CareFusion."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us.",28,"And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise with Stifel.",9,"Your next question is from Rick Wise with Stifel."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, maybe you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and w",103,"I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, maybe you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and what you're thinking about? And maybe just one for Chris on operating margin expansion. You've addressed it a little bit, but this acceleration in operating margin expansion can't go on forever. How do we think about the -- not for guidance, but how do we think about fiscal '17 and beyond? What's possible in terms of further operating margin expansion just directionally?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- the margins [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get down to the",159,"Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- the margins [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get down to the 3x leverage, and we're making excellent progress there. And so in the short run, we still have the flexibility to do plug-in acquisitions. And then as we have been stating, we're going to be really strategy driven. And we challenge both segments to look at their strategies. And as we look at the -- our ability to provide solutions to the marketplace and have a broader impact, that's what's going to drive our strategy. It'll be a mix of both internal development and continued looking on the outside, and we'll be very, very balanced here. But ultimately, it's about strategic impact plus value creation for shareholders, and that's how we're thinking about it."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies",277,"And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies and continuous improvement, a little bit of benefit from raw material prices, as we've talked in the past, from oil. But then, on the operating side, SSG&A really reflective of hitting on the synergies. It was a little bit of an easier compare in the second quarter because of the operating margin challenges in CareFusion in that quarter last year. So you won't expect 370. In fact, we expect about 170 to 190 for the year on the operating margin basis. I'd remind you that's on top of a 100 basis of margin improvement last year. So really improving the margins, as you point out. And as we think about going forward, as we execute on synergies, you would expect to see above normal. So we usually think 40 to 50 basis points of margin improvement. You're going to get more of that as we execute on the synergies in '17 and '18. You would also get a little bit of a lift from the fact that as we exit respiratory, which had challenging margins, you get a little bit of a lift. So not to give guidance on '17, but you're absolutely right. Directionally, we're going to see improved margins going forward in '17 and '18. And then, as you start lapping those synergies, I think somewhere beyond that, you start going back to that 40 to 50 basis points. That's a few years out."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Derik De Bruin of Bank of America.",13,"Your next question is coming from Derik De Bruin of Bank of America."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these movi",68,"Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these moving parts are on it? And do you still feel good about a 4% to 5% longer-term organic revenue growth rate for the company?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent pro",90,"Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent progress. I think you see the performance of the CareFusion businesses is quite strong. I think that the portfolio moves that we have made have been the right ones. So that still is our goal and I think we're making excellent progress."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can you guys hear me? So guys, kind of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist and the respiratory, I guess, when ex",80,"Can you guys hear me? So guys, kind of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist and the respiratory, I guess, when exactly do you expect all those to close? And if you have any updated views on the EPS and that kind of impact from an EPS standpoint for those initiatives."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then...",25,"Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then..."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed.",3,"Simplist is closed."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is done.",3,"Simplist is done."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad",162,"Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad commercialization in early FY '17. We are tracking towards -- by the end of this fiscal year, within this fiscal year, we will be doing a limited launch, and we've talked about this in the past, in which Medtronic will start providing the product to a set group of patients so that they can really understand the user insight at another level before they do the full-scale launch. And so we're moving forward, preparing to ship out the first product for that limited-scale launch in the back half of this fiscal year. That will occur, and then it would open up for a full commercial launch, we expect, at the start of FY '17."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14.",44,"And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks very much.",4,"Okay, thanks very much."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein with William Blair.",10,"Your next question comes from Brian Weinstein with William Blair."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current p",74,"On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current projects? Is it really putting that money to work in new projects? And any specific areas of focus that you would like to focus on with those dollars?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before",167,"Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before the medical device tax, in the back half of the year. It's the timing of things like clinical trials and whatnot. And so -- but in addition, the money that is being spent on the medical device tax is being spent in both segments, and it is a combination of some new things that we are doing. But mostly, it's current strategies where we are accelerating those strategies, where we had platforms where we could push them faster. And part of that, which is a bit new for us, is moving the informatics side of things quicker. So you can think of major platforms going faster and the informatics piece on top of that. Both sides of the company."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Richard Newitter with Leerink Partners.",10,"Your next question comes from Richard Newitter with Leerink Partners."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is kind of like an inning question, what innings are you in for 2 parts of your business that we frequently talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades",105,"This is kind of like an inning question, what innings are you in for 2 parts of your business that we frequently talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades for that product cycle? And then the second innings question, just the -- in your cytology business, your liquid-based Pap testing, can you just tell us what the trend is there? Are we kind of through the interval expansion impacts mostly at this point? And just comment on any pricing or volume trends for that business."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, let's start with the Pap first, and Linda can talk to you about that.",15,"Sure, let's start with the Pap first, and Linda can talk to you about that."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-di",100,"Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-digit performance. And then the entire platform, both in the U.S. and ex U.S., is being held by the Total automation we're doing across both our FocalPoint and our Totalys system. So complete control of the sample from collection through the result. So that's driving a lot of growth both in the U.S. and ex U.S. for us."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Linda. Okay.",4,"Okay. Thanks, Linda. Okay."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes.",42,"And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks for the question.",5,"Okay, thanks for the question."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth",152,"So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth. That would seemingly imply there's a positive offset for developed market growth. I believe this change in mix should benefit operating margin. It doesn't seem like your guidance reflects that margin mix dynamic. Am I wrong? And if not, why? And then the second question is for Tom. Regarding your plans for the 25-or-so additional CareFusion product registrations, what's the time line for those? And can you walk us through why those products take a bit longer to get registered? I'm just trying to get a better handle on the profile of those products versus the first 50 that are close to or have been registered."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Chris?",2,"Okay. Chris?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range.",49,"Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Tom?",2,"Okay. Tom?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think abo",163,"And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think about those as being ones that we submitted more recently and didn't work through certain regulatory processes. In other cases, it's a combination of they're in certain countries that have longer registration. China has longer registration processes than most of Europe, as an example. And then the other one is, is that certain product categories -- so ChloraPrep, for example, is registered as a drug in many markets. Particularly, let's say, Latin America, it's registered as a drug. Those typically sit in the regulatory process longer than medical devices. So it's kind of a combination of those 3 items, not one thing specific, and not unexpected at all. It's right in line with our projection."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much.",50,"And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar with Evercore ISI.",10,"Your next question comes from Vijay Kumar with Evercore ISI."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure, sort of is that a l",88,"Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure, sort of is that a little bit of conservatism on the part of management just because FX has been moving all over the place when you think about -- and then trying to put the Q in context of FX improving in the back half?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right",270,"Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right, we were up around $0.14 to $0.16. But we see that as timing, and the timing buckets are the medical device tax spending, which we know where we want to spend it, but because of the timing -- don't forget it happened in January and we couldn't ramp that quickly. So that past quarter, we really got a lift from that. But we fully intend to spend that in the back half of the year. Then you had timing on the tax rate. So the tax rate was lower than our 21% to 22%, and that's just lumpy throughout the year. We expect that to fall back within the rest of the year. So you had that piece. And then we had the pull-forward of some of the revenues from the third quarter to the second quarter and the impact of that. So all of that accounts for the bulk of that $0.14 to $0.16 on an FXN basis. The other thing I'd point out is we actually raised the FXN EPS guidance last quarter by $0.28. It was loss from the standpoint that at that point, FX was getting worse across the world and it offset that, but the FXN was raised prior. So you really got to think about it in those 2 buckets."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Our final question is coming from Matt Taylor of Barclays.",10,"Our final question is coming from Matt Taylor of Barclays."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes",69,"I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes partnership with Medtronic. Can you talk a little bit about those opportunities and maybe help us quantify the upside there?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Tom will address those. Tom, you want to start with diabetes?",13,"Sure. So Tom will address those. Tom, you want to start with diabetes?"
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see",228,"Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see more of the impact in the Diabetes Care business in FY '17. That remains unchanged. So we remain very excited about that opportunity. It's, of course, our first venture outside of the pen needles and syringes for the Diabetes Care business, moving into a fast-growing market with the market leader, Medtronic, and we're, I think, equally excited about the product technology and what it can do to help patients and the partnership and what the power of us working together can do to make an impact there. If you think about solutions, so we -- as we had, of course, shared before, we have announced the solutions partnership with Fresenius. We are looking at launching that not necessarily now in Q4 of '16 but more in early FY '17 just based on regulatory approval time lines there, but that does continue to move forward. And again, we had not shared a specific number there, but we said it would certainly make up for any reduction in BD Rx sales that we had planned over the coming horizon, and that remains right on track."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for any closing remarks.",15,"I will now turn the floor back over to Vince Forlenza for any closing remarks."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thank you very much for your participation on the call today. It was a real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and p",137,"Okay, thank you very much for your participation on the call today. It was a real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and progress with those businesses, the synergies, the teams in place and then lastly, the strategic partnerships that we're doing, including the Parker Institute relationship, the new products that are being launched. We didn't spend a lot of time on the Life Science business today. There weren't that many questions. But with BD MAX, with KIESTRA, all these things happening over there, very, very exciting. And of course, the new products on the Medical side. So thank you very much for your time and look forward to updating you next quarter."
103678,329827360,974139,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for",79,"Hello, and welcome to BD's Second Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through May 12, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 83710101. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is po",399,"Thank you, Christie. Good morning, everyone, and thank you for joining us to review our second fiscal quarter results. 
As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com. 
During today's call, we will make forward-looking statements and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our second fiscal quarter press release and in the MD&A sections of our recent SEC filings. 
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website. 
As a reminder, until we annualize the acquisition of CareFusion in the third quarter of fiscal year 2016, we will speak to our revenue results on a comparable currency-neutral basis, which includes BD and CareFusion in the current and prior year periods. We believe this provides additional visibility into the new BD. The comparable current period revenues are adjusted to exclude a small impact related to a purchase accounting adjustment to record CareFusion's deferred revenues at fair value as of the acquisition date. 
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules, in our press release or the appendix of the Investor Relations slides. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby, Executive Vice President and President of the Life Sciences segment. 
It is now my pleasure to turn the call over to Vince."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic an",671,"Well, thank you, Monique, and good morning, everyone. As we stated in our press release, we are very pleased with our second quarter growth profile. Our results this quarter highlight our consistent performance and the benefit of our diverse geographic and product portfolio with both segments contributing to revenue growth. We continue to drive strong underlying margin expansion through the achievement of operational efficiencies and continuous improvement coupled with the positive impact of cost synergies. 
As many of you already know, in March we celebrated the 1-year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration, and a significant amount of work has been driven by the integration teams across the businesses. 
In terms of talent retention, we have a strong team that's in place that's comprised of both legacy CareFusion and legacy BD associates. They've been helping drive the company through our next phase of growth as a combined entity. 
In terms of our customers, we are becoming increasingly more relevant as they look -- as they are looking for providers that can really help them improve the quality, efficiency and safety of processes. We have made good progress on this front 12 months post-close, and feedback from our customers has been extremely positive. 
Also, we have been actively working to create new growth opportunities for CareFusion products and expanding their global reach by leveraging BD's global infrastructure. We are well into the registration process with dozens of products across multiple geographies. I will provide more details on this later in the presentation. 
Lastly, we are seeing strong productivity as we are overdelivering on our initial cost synergy capture commitments. As you already know, we have increased our total cost synergy target by about $100 million over the deal's horizon. We are clearly advancing our strategy to improve medication management. The value we bring to customers around the world has become increasingly evident as we make progress integrating these 2 great companies. 
We're also pleased to inform you that the annual strategic review of our portfolio is now complete. In March, we announced that BD and Apax Partners, a private equity firm, will form a joint venture with the Respiratory Solutions business. Apax will establish and stand up a newco, enabling more strategic focus and investment to build a leading global respiratory company. 
And more recently, we announced the divestiture of our vertebral augmentation solutions business. This product line was not aligned with our strategy and we believe it can see more robust investment in growth under a different owner. 
The completion of our current strategic review process enables the company to remain focused on the areas we believe are high growth and aligned with our core capabilities. 
In addition, during our last call, we let you know about our intent to reinvest the savings from the suspension of the medical device tax that went into effect in January. Since that time, we have already allocated increased R&D dollars to highly strategic initiatives. Not only will this help to fund -- drive future growth for the company, but it will also enable better outcomes for our customers and their patients. 
Looking forward to the total year, we are confident in our outlook and are maintaining our fiscal 2016 currency-neutral revenue and EPS guidance. We are also increasing our adjusted guidance to reflect lower currency headwinds due to the weakening of the U.S. dollar relative to the euro and other currencies. 
Moving to Slide 5. I will review our second quarter revenue and EPS results, which I will speak to on a currency-neutral basis. 
Total company revenues grew 5.3% or 5.2% on a combined organic basis. 
Adjusted EPS of $2.18 was ahead of our expectations as the quarter benefited in part from some timing within the year. 
Now I'd like to turn things over to Chris for a more detailed discussion of our second quarter financial performance and our updated fiscal year 2016 guidance."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to our very solid second quarter results. Total second quarter revenues of approximately $3.1 billion grew 5.3% on a co",1855,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to our very solid second quarter results. 
Total second quarter revenues of approximately $3.1 billion grew 5.3% on a comparable basis or 5.2% on a combined organic basis. This was slightly ahead of our expectations as the quarter benefited by about 50 basis points from the timing of revenues, which occurred earlier than expected. I'll discuss this as I take you through the business results. 
BD Medical's second quarter revenues increased 6.1%, reflecting solid growth across the segment. Medication and Procedural Solutions growth was 4%, which reflects strength in Infusion Therapy, safety-engineered products and infection prevention. 
Medication Management Solutions revenues grew 6%, driven by strong dispensing capital installations with our Pyxis platform. Pyxis ES demand was strong in the quarter, driven by several large customer conversions, and we saw a positive impact from our efforts to simplify the installation process. 
We also saw solid growth in the infusion business, where we continue to expand our leadership position. Growth in Diabetes Care was 3.6%, driven by pen needles and syringes. Pharmaceutical Systems growth of 11% reflects a strong growth in SAIS. Performance in this business also reflected the favorable timing of customer orders that occurred 1 quarter earlier than we initially anticipated.  Respiratory Solutions revenues increased 10.9%, reflecting the timing of capital placements, which similarly benefited the quarter as the placements were expected to occur later in the fiscal year. 
BD Life Sciences second quarter revenues increased 3.4%, driven by solid growth in Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 5.7% was driven by safety-engineered products in the U.S. and solid growth in Europe and emerging markets. 
Diagnostic Systems growth of 4.6% was the result of strong growth in core microbiology, including IDAST and BD MAX assays. Growth was also aided in part by an increase in flu activity in the U.S. While the flu season is still mild in comparison to the prior year, the timing of the late flu season had a positive benefit year-over-year in the quarter of 10 basis points. Biosciences revenues were about flat when compared with last year's second quarter. Strong double-digit growth in the U.S. was driven by continued increased demand for high-parameter instruments and growth in research reagents. This was offset by a 7% decline in Europe due to a difficult comparison related to timing of orders in the prior year. In addition, growth was negatively impacted by clinical tender delays in Africa associated with our HIV monitoring related to the World Health Organization guidelines. 
Moving to Slide 8. I'll walk you through our geographic revenues for the second quarter on a currency-neutral basis. 
U.S. revenues increased 5.7%. This was primarily driven by strength in Medication Management Solutions, Medication and Procedural Solutions, Biosciences and Diagnostics and was aided in part by the aforementioned timing of revenues. 
BD Medical's performance reflects strong dispensing capital installations and solid growth in the infusion business as well as strength in infection prevention and interventional specialties. 
BD Life Sciences growth reflects continued strong performance in the Biosciences business, driven by demand for high-parameter research instruments and reagent sales. Diagnostic Systems had strong growth in microbiology, including KIESTRA and blood culture, BD MAX as well as a benefit from the increase in flu activity during the quarter. 
Moving on to international. Revenues grew 4.8%. This is below our normal growth rate and primarily reflects the aforementioned clinical tender delays in Africa. I'll provide more details on this in a moment. 
The Medical segment grew 6.9%. This reflects solid performance in Medication and Procedural Solutions driven by sales of safety-engineered products, particularly in China, and strong dispensing installations in Medication Management Solutions. Growth was aided in part by the aforementioned timing of customer ordering patterns and capital placements. 
The Life Sciences segment grew 1.4%. This reflects strong growth in Preanalytical Systems in Western Europe and Asia Pacific and strong growth in Western Europe and Latin America in Diagnostic Systems, driven by core microbiology. This was partially offset by the aforementioned tender delays in Africa and the difficult comparison in Europe in Biosciences. 
On Slide 9, emerging market revenues grew 5.1%, currency neutral, with developed markets growing 5.3%. The second quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by a decline in EMA. China growth for the second quarter was 9.4%. Double-digit revenue growth in our Medical segment was driven by continued strong demand for consumables across all of our businesses in the segment. Within our Life Sciences segment, strength in Preanalytical Systems was offset by the slowdown of capital spending in Diagnostic Systems as communicated on our call last quarter. For the total year, we continue to expect China to grow in the low double-digit range. 
We now expect total emerging markets to grow in the high single-digit range compared to our previous guidance of 9% to 10% growth. This is offset by stronger performance in developed markets, growing between 4% and 4.5% for the second half of the year. 
Our revised guidance for emerging markets reflects the aforementioned impact in Africa to our Biosciences unit from the WHO guidelines. In addition, since we last provided guidance in February, the government of Saudi Arabia announced the new austerity measures, which affect the health care industry. This has begun to impact our business in that particular region, and we saw a small impact in the second quarter. We view this situation in Saudi Arabia as temporary, though the timing of reversal may not occur within this fiscal year. 
Our new guidance range contemplates emerging markets growing between 10% and 12% for the second half of the year. 
Moving to global safety on Slide 10. Currency-neutral sales increased 6.7%. Safety revenues in the U.S. grew 4.5% and international sales also grew 9.9%, currency neutral, with continued strength in Europe as compliance with safety legislation continues. Safety revenues grew 15.6% in emerging markets. Medical Safety sales grew 8%, primarily driven by safety catheters. Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 4.6% in the quarter. 
Slide 11 recaps the second quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 5.3% on a comparable currency-neutral basis. Pricing was slightly positive in the quarter. 
Moving down the P&L, I will focus on the comparable basis figures, which include CareFusion's results in the prior year in order to give a better indication of our performance. 
Gross profit improved by 7.9%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency. 
SSG&A as a percentage of revenue was 24.5%. We are very pleased with the leverage we are getting, which includes the benefit of cost synergy capture. 
R&D as a percentage of revenue was 5.9%. Our expenditures in the quarter were slightly lower than our full year expectation of 6% to 6.5% of revenues due to the timing of spending. We continue to invest in new products and innovation and expect to further reinvest the benefit from the medical device tax suspension in the back half of the year. 
Operating income grew 24.8%, reflecting strong P&L leverage. In addition, as we had previously discussed, there were a number of items that negatively impacted operating margin in the prior year in the CareFusion business. I'll address the underlying growth in operating profit in more detail on the next slide. 
Our tax rate declined 70 basis points to 20.6%, below our full year expectation of 21% to 22% as the quarter included some timing benefits. 
As Vince discussed earlier, adjusted earnings per share were $2.18, which is a 44.7% increase versus the prior year. This reflects our solid growth profile and strong underlying margin expansion. In addition, growth benefited from the timing of revenues earlier than -- in the year than expected as well as timing within the year related to R&D expenditures and tax, as we just discussed. 
Slide 12 illustrates our gross profit and operating margin for the second quarter presented on a comparable basis. Strong gross profit margin performance of 170 basis points was primarily driven by robust operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. 
Strong operating margin performance of 370 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. In addition, timing of R&D expenses and the benefit of the medical device tax suspension aided operating margin in the quarter. Also, you will recall, several items drove lower second quarter operating margins for CareFusion in the prior year. 
Currency had a slightly negative impact on both gross profit margin and operating margins. 
Moving on to Slide 14. Since we provided guidance in February, the U.S. dollar has weakened against the euro and other currencies. As a result, we are raising our adjusted EPS guidance by 2% -- percentage points or $0.13 from a range of $8.37 to $8.44 to a range of $8.50 to $8.57. We are maintaining our currency-neutral adjusted EPS guidance of $9.01 to $9.08 as we expect the second quarter tax timing to reverse and R&D spend to ramp over the back half of the year, which includes reinvestment of the medical device tax. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments. 
Turning to Slide 15. I'd like you to walk you through the additional elements of our guidance for the full fiscal year 2016. 
In summary, we continue to expect comparable organic revenue growth of 4.5% to 5% on a currency-neutral basis, with the back half of the year growing between 5.5% and 6.5%. This contemplates the third quarter growth rate to be slightly lower than our full year guidance range and the fourth quarter to be well above the full year guidance range. 
On a reported basis, revenue growth for the total year is expected to be between 21.5% and 22%, which reflects a currency headwind of about 300 basis points, an improvement from our prior guidance of about 450 basis points of currency headwinds. 
The U.S. dollar has weakened against the euro and most currencies since we last provided guidance in February. While our guidance assumes a euro-to-dollar exchange rate of $1.13 for the rest of the year, which is better than the actual rate from the second half of last year, we see some remaining FX headwinds over the second half as non-euro currencies remain unfavorable year-over-year. 
We continue to expect growth of 4.5% to 5% in BD Medical and 4% to 4.5% in our Life Sciences segment. Based on our current view of the environment, we continue to expect pricing to be about flat for the year. Beyond revenue and EPS, all other P&L guidance from February remains unchanged. 
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems",733,"Thank you, Chris. Moving on to Slide 17 and our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. 
Starting with new product innovation. Within our Life Sciences business, our Preanalytical Systems business launched 2 new products this quarter. The UltraTouch Push Button Blood Collection sets will deliver significant improvements in patient outcomes and lab efficiency. The BD Barricor tubes use gel-free technology, which significantly improves sample quality and lab turnaround time. The initial market feedback on both these products has been extremely positive. 
In our Bioscience business, as evidenced by our U.S. growth rate this quarter, we have seen very positive market uptake of our high-parameter instrumentation, the FACSSymphony X-50 and X-20. In our genomics business, we anticipate launching our GenCell CLiC library preparation platform and our FACSseq Cell Sorter designed specifically for genomics applications later this year -- this fiscal year. 
Within strategic and business initiatives, as we discussed earlier, we have completed our current portfolio review, having recently announced the Respiratory Solutions joint venture and sale of the vertebral augmentation solutions business. We remain focused on the areas we believe are high growth and aligned with our core capabilities. 
We have also made progress with our product registrations, having successfully registered more than 50 CareFusion products in over 20 countries. In addition, we have submitted registrations and are awaiting approval for an additional 25 products. This is consistent with our plans to achieve revenue synergies, and we remain on track for them to begin to materialize in fiscal year 2017. 
And in the areas of partnerships and collaborations, we remain excited for the launch of our infusion set, which we expect will move to broad commercial release with Medtronic in early fiscal year 2017. We believe this product will improve the consistency of insulin delivery by significantly reducing flow interruptions, simplify the user's experience and increase a patient's overall satisfaction with insulin pumping. 
We recently entered into a strategic partnership with the Parker Institute for Cancer Immunotherapy, and we'll play a part in the Institute's vision of reducing cancer to a manageable disease. Support from the Parker Institute will help us advance our new cell sorter program while bringing our high-parameter cell analysis solutions to these researchers as they work to discover the next breakthrough in cancer immunotherapy. As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you as we continue to make progress.
Moving on to our business update on Slide 18. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the second quarter, and we made progress with our back-office functions and with harmonizing our IT infrastructure. 
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies as we exit fiscal year 2018. Contributing to our operational efficiencies is the benefit of sustained lower oil prices on raw material costs, as we discussed earlier. 
The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 170 to 190 basis points of expansion this fiscal year. 
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid second quarter. Both segments performed well and our performance highlights the benefits of our diverse portfolio, both from a product and geographic standpoint. 
Second, we have made significant progress on the acquisition of CareFusion. The value we can bring to customers around the world has become increasingly evident as we integrate these 2 great companies. 
Third, we have taken steps to optimize our portfolio. In doing so, we are positioning ourselves in higher-growth areas which are aligned with our core capabilities. By taking these actions, we are delivering the most value to our customers. 
Finally, we are confident in our outlook for the full fiscal year. We're maintaining our currency-neutral revenue guidance and raising our adjusted EPS. We believe we are well positioned to continue our track record of delivering value to our customers and shareholders. I look to the future with optimism. 
Thank you. We will now open the call to questions."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley.",13,"[Operator Instructions] Your first question is coming from David Lewis of Morgan Stanley."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one that the whole device industry is showing this quarter, which is this polarization between better U.S. perfor",91,"Vince, 2 questions. Maybe one for you and one for Chris. I guess the first one is, the theme that you're showing the last several quarters is one that the whole device industry is showing this quarter, which is this polarization between better U.S. performance and slightly softer ex U.S. performance, specifically emerging markets. Talk to us about how much of this in your mind is the quarter or just the trend that BD has been seeing for several quarters? And what's driving that strength in the U.S. in your opinion?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care",363,"Well, I think there's a couple of things driving the strength in the U.S. Number one is I think you have seen a stabilization in the U.S. marketplace in terms of health care, and I think there's a benefit out there from the people that do have health care coverage, especially the expansion of Medicaid. But the other thing that you are seeing is that our businesses are performing quite well. You heard us talk about in the Bioscience business, the launch of those new products. We have a whole series of new products coming out, and I mentioned -- and specifically the high-parameter work that's going on. So yes, that showed up in this quarter right now, but that's going to continue as we move through the year. You also saw good performance in Diagnostics because we're getting some traction in blood culture and KIESTRA, that is moving forward -- KIESTRA moving forward in the U.S. And then good performance across the Medical businesses, where we -- we're improving our competitive position in MMS. And so you see all of that coming together. And Europe, I think -- once again, I think, has stabilized, and it's really -- of course, you have to drop out the CareFusion factors, but there was negative timing in Biosciences. But you've got the same product launches that are occurring there. And quite frankly, Japan is forming -- is performing better for us as well. Now on the other side of the coin, the situation in China seems to have stabilized. We're seeing good performance on the medical device side of the business. And the situation really hasn't changed all that much on Diagnostics, on the capital side, but it has stabilized. And so we're getting good growth in China. We didn't mention it, we continue to get good growth in India. We're getting good growth in Latin America. There were some onetime events this quarter, which you heard in terms of Africa and Saudi Arabia. And Saudi Arabia is more of an impact in the back half of the year. So yes, this is slightly less in emerging markets, yes, but the mix is quite good."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Mike Weinstein of JPMorgan.",10,"Your next question is coming from Mike Weinstein of JPMorgan."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're 3 months later and you gre",139,"Let me start. If we went back a quarter, The Street was concerned about the performance in the fiscal first quarter. Revenues grew 1.8% organic and The Street was worried just about the ability to see the acceleration. Now we're 3 months later and you grew 5.3% organic this quarter. So essentially, what you said would happen happened. Can you just talk a little bit as you go into the back half of the year? I just want to make sure I understand the commentary on the cadence of the quarters. I know the comp, in some different respects, for the fourth quarter is easier than the third quarter, but I just want to understand the -- just the commentary relative to third quarter being a bit below the full year guidance and the fourth quarter being materially above."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through.",34,"Yes, Mike, I'll have Chris walk you through that because there are some complications here. You got to go back to last year to understand what was happening, but Chris will walk you through."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter b",173,"Yes. So the best way -- the key to understanding the second half growth trajectory is really to focus on the absolute dollars of revenue that we're achieving this year versus last year. We're actually up against the tough comparison in the third quarter because in terms of absolute dollars, that was our highest quarter last year. So you got to really look at those absolute dollars. Looking at growth rates is a little misleading because the growth rate last year was negative in CareFusion in the third quarter, but that was more about the compare to prior year. But the absolute dollars are the grow over. And then as you model out the year, based on the guidance that we just gave you in terms of growth rates for the third and fourth quarter, you'll see steadily improving sequential revenue dollars for all 4 quarters this year. So we really feel good about the trajectory, particularly on a sequential basis. This year, it's all about the compare to last year revenue dollars."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike, if you think about it, there were 2 events at CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate, with the first quarter being very high and the third quarter being very high. And then we had the flu.",92,"Yes, Mike, if you think about it, there were 2 events at CareFusion, 2 different compensation events that caused the pattern to be -- highly fluctuate, with the first quarter being very high and the third quarter being very high. And then we had the flu. So you got to go back and look at those absolute numbers, as Chris was saying, and then you'll see that our growth this year actually, as we look at the whole year, is actually quite smooth. But the growth rates jump around because of that."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks for your question, Mike.",5,"Thanks for your question, Mike."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from David Roman of Goldman Sachs.",10,"Your next question is from David Roman of Goldman Sachs."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then h",117,"Vincent, I wanted to follow up on your commentary regarding some of the registrations that you're getting outside the U.S. I guess firstly, can you maybe give us a little bit more flavor on what those products are, which businesses those sit in and then how we should start to evaluate the impact on a go-forward basis? And then for Chris, can you maybe help us understand why given the change in currency there's not a positive impact on the margin profile? It looks like you just flowed the dollars right down to EPS at the corporate margin guidance you previously provided. So why wouldn't we see an uplift in profitability associated with the change in rates?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?",43,"Sure. So let me ask Tom to comment first. And we'll give you more transparency in terms of the sales and sales impact next year, but why don't you talk to the products that are getting registered and which geographies we're talking about?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2",246,"Sure. This is Tom. So as Vince mentioned before, we've registered more than 50 products over 20 countries. We've got about 25 additional registrations submitted and awaiting approval. Essentially all of those products fall within either MPS or MMS, the 2 businesses that are -- came from legacy CareFusion, and the majority of those products are actually within MPS. So think disposables. And this is right in line with what we had talked about over the last several quarters, that as we think about the first products that would be able to help drive incremental revenue growth, it would be things like infusion sets, ChloraPrep, the consumables that fit very well with BD's traditional sales channels and market approaches and presence in the marketplaces, and those are the products that we focused on getting registrations for first. So I would say we're seeing some early signs of success as we've been launching these products, which is very consistent with our plans to achieve revenue synergies and really remain on track to start seeing them materialize more in 2017. But we do see sales now. And obviously, on a company the size of BD and a segment of Medical, we'll see those start showing up more materially as we roll into '17. But they have started. And I would just say that obviously, we're going to continue those product registration work. We're continuing the sales and marketing investments to support those initiatives. But overall, we're on track."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, althoug",144,"And to your second question, David, we did still see a little bit of a drag in the second quarter on growth -- the gross profit. It's 10 basis points of currency drag and 30 on operating margin. And the dynamic there is a couple of things. One is, although the euro has improved, the non-euro currencies year-over-year are still providing a bit of a drag. And then secondly, and probably more importantly, is the phenomenon of the profit and inventory that we've talked about in the past. So it didn't quite catch up in the second quarter. Certainly not much of a drag and it's starting to level off, and that, in my prepared remarks, was the commentary for the second half of the year. It doesn't really turn positive because of that phenomena, but it certainly lightens up in terms of headwinds."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Larry Keusch of Raymond James.",10,"Your next question comes from Larry Keusch of Raymond James."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installa",93,"I guess for Tom. Would you mind talking a little bit about infusion pumps, sort of the growth, the competitive landscape, kind of where you think you're going for the year? And then also, as alluded to in the prepared comments, it sounds like the installation process for MedStation ES is improving. I know there have been a number of software tweaks for that ES system over the past couple of years, and just also I want to understand if you're kind of getting to a point where that system is now stable."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the sof",424,"Yes. Sure, Larry. This is Tom. So let me start off with the good Pyxis question and then I'll address infusion pumps. So we are actually quite pleased with the progress that we're making on Pyxis as we actually just released another new version of the software, which we think really it makes some very significant progress and actually addresses -- will make a big step forward in terms of installation efficiency. And so as we've shared in the past, we were really focused on improving the installation process. We had shared that there was a quite large backlog at the time of the acquisition. And to really address that backlog, we needed to improve the installation efficiency process, and we've been working on that, applying some of our lean expertise as well as making some adjustments in the software that would automate a lot of that and simplify the workload in the field. So we're seeing a lot of those efforts come to fruition. We did have very strong placements in Q2. That was part of the driver of MMS growth. We continue to see strong demand for the Pyxis ES platform, and we're equally looking forward to continued strong growth in the second half of the year in that, as Vince alluded to earlier. Then on the infusion side, we also are very pleased with the growth that we saw in the quarter here and have similar expectations for the back half of the year. As you know, we are the market leader in that space. We've continued to strengthen our position over the last several years. We expect to continue to strengthen our position in the market by about the same amount this year, as we have over the last couple of years. We do see customers continue to select the BD Alaris pumps in an incremental way really based on that interoperability and the power of one to be able to do all of their infusion needs across both large-volume infusions, syringes and narcotics, all in one product. It's the only item that can do that. So we're happy there. I would point out as well that as you look at our safety sales, particularly in the U.S., that was largely driven by growth in our -- in some of the connectors that are associated with our dedicated sets in the infusion category. And that's really a reflection of that strong performance in that infusion category and that renewing consumable stream that comes as we place pumps incrementally. Thank you."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Bill Quirk of Piper Jaffray.",10,"Your next question is from Bill Quirk of Piper Jaffray."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost sy",93,"Vince, you and the team have done a really nice job in terms of executing on some of the identified cost synergy opportunities with CareFusion. Can you talk a little bit about the pace of identifying new opportunities either in terms of additional cost synergies or on the revenue side? And obviously, you alluded to some of the products in registration. And then secondly, just on China, looks like, based on the numbers, we're going to need about -- some sort of teens acceleration, easier comps. But can you just elaborate on that?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, okay so I'll ask Chris to talk about the cost synergies.",12,"Yes, okay so I'll ask Chris to talk about the cost synergies."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So just a reminder that we raised the cost synergies earlier, assuming that...[Technical Difficulty]",16,"Sure. So just a reminder that we raised the cost synergies earlier, assuming that...
[Technical Difficulty]"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Is anybody able to hear us?",6,"Is anybody able to hear us?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Yes, we can hear you now.",6,"Yes, we can hear you now."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay.",1,"Okay."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our",233,"Okay. Okay, so let me start again to that question. So on -- in terms of cost synergies, we did, I would remind you, improve cost synergies fairly recently up to the $325 million to $350 million, and that was identification of some new synergies from our recent -- or our original model. I would also remind you that we increased the overall synergies from the standpoint of the tax rate improvements that we saw that we originally didn't contemplate, and that's another 3% accretion that we had mentioned. Really, the -- when you think about the synergies, we get initial synergies of duplicate public company costs. Then you move into the integration of systems and infrastructure, and we've gotten good traction on that and that led to the last increase. And then towards the end are the more difficult synergies to get, which are the distribution centers and manufacturing plants, and we actually saw some good initial improvements in that area or traction in that area that led to our last increase. So we really feel great about what we're driving. All-in all-in, it's significantly higher than our original expectations, particularly when you add the tax synergy. You see this year the EPS quarter-over-quarter was over 44% and, I think, is an indication of that. So we really feel good about our ability to drive those synergies and executing on those synergies."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of",74,"And then for China, growth is going to be driven by the Medical side of the company, and there are multiple businesses on the Medical side that are doing well in China. And then in addition, there were several million dollars of inventory that came out of the chain last year, so there is a favorable comparison in the fourth quarter. But Tom, do you want to comment on any of the product lines?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from",80,"No, I think as you said, we see on -- the consumables across the board are holding in strongly. We do have -- again, while it may not be overly material for the company, China is one of the lead markets in which we launched some of those new products from CareFusion into, and we're seeing some good traction in some of those items, particularly as we think about connectors and some of the oncology products coming over from CareFusion."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us.",28,"And we don't talk about it much, but we also have launched flush in China. So that's another piece that has been growing quite nicely for us."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Rick Wise with Stifel.",9,"Your next question is from Rick Wise with Stifel."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, maybe you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and w",103,"I guess I'll ask sort of a 2-part question. Maybe, first, the big picture. Vince, maybe you can talk a little about your latest thoughts, evolving thoughts on capital deployment. You're through the post-CareFusion portfolio review. Maybe what's next and what you're thinking about? And maybe just one for Chris on operating margin expansion. You've addressed it a little bit, but this acceleration in operating margin expansion can't go on forever. How do we think about the -- not for guidance, but how do we think about fiscal '17 and beyond? What's possible in terms of further operating margin expansion just directionally?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- the margins [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get down to the",159,"Okay, that's fine. I'll start out and you guys get really good at your, well, single questions. So -- the margins [ph] are really fantastic. Let me just say from a capital deployment standpoint, of course, short run, we're still working to get down to the 3x leverage, and we're making excellent progress there. And so in the short run, we still have the flexibility to do plug-in acquisitions. And then as we have been stating, we're going to be really strategy driven. And we challenge both segments to look at their strategies. And as we look at the -- our ability to provide solutions to the marketplace and have a broader impact, that's what's going to drive our strategy. It'll be a mix of both internal development and continued looking on the outside, and we'll be very, very balanced here. But ultimately, it's about strategic impact plus value creation for shareholders, and that's how we're thinking about it."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies",277,"And then on the margins, Rick, to your point, the second quarter was really rich margin performance on operating margins, 370 basis points. That was driven again by the very strong gross profit margin, which is really going around operational efficiencies and continuous improvement, a little bit of benefit from raw material prices, as we've talked in the past, from oil. But then, on the operating side, SSG&A really reflective of hitting on the synergies. It was a little bit of an easier compare in the second quarter because of the operating margin challenges in CareFusion in that quarter last year. So you won't expect 370. In fact, we expect about 170 to 190 for the year on the operating margin basis. I'd remind you that's on top of a 100 basis of margin improvement last year. So really improving the margins, as you point out. And as we think about going forward, as we execute on synergies, you would expect to see above normal. So we usually think 40 to 50 basis points of margin improvement. You're going to get more of that as we execute on the synergies in '17 and '18. You would also get a little bit of a lift from the fact that as we exit respiratory, which had challenging margins, you get a little bit of a lift. So not to give guidance on '17, but you're absolutely right. Directionally, we're going to see improved margins going forward in '17 and '18. And then, as you start lapping those synergies, I think somewhere beyond that, you start going back to that 40 to 50 basis points. That's a few years out."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is coming from Derik De Bruin of Bank of America.",13,"Your next question is coming from Derik De Bruin of Bank of America."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these movi",68,"Another long single question, but you've done a number of portfolio reviews lately with respiratory and the Simplist portfolio. But can you sort of talk about is this a '17 organic revenue growth question and sort of like what the impact of all these moving parts are on it? And do you still feel good about a 4% to 5% longer-term organic revenue growth rate for the company?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent pro",90,"Yes, when we did the deal and we discussed what our revenue aspirations were, we said legacy BD was growing at around 5% and that CareFusion was at about 3.5%, and our goal was to bring the entire company up to about 5%. I think we're making excellent progress. I think you see the performance of the CareFusion businesses is quite strong. I think that the portfolio moves that we have made have been the right ones. So that still is our goal and I think we're making excellent progress."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Can you guys hear me? So guys, kind of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist and the respiratory, I guess, when ex",80,"Can you guys hear me? So guys, kind of a timing question on a few items. I guess, one, with the infusion sets, do you have kind of a specific launch for that, the diabetes the infusion set? And then on the BD Simplist and the respiratory, I guess, when exactly do you expect all those to close? And if you have any updated views on the EPS and that kind of impact from an EPS standpoint for those initiatives."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then...",25,"Yes. So Tom can talk to those things. But respiratory, I think, we're expecting to close at the end of this fiscal year. And then..."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed.",3,"Simplist is closed."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is done.",3,"Simplist is done."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad",162,"Simplist is closed. And as we've shared in the past on Simplist, we don't expect any impact on sales from that at all. It was small and the other opportunities will make up for that. In terms of the infusion set launch, as Vince mentioned, we expect broad commercialization in early FY '17. We are tracking towards -- by the end of this fiscal year, within this fiscal year, we will be doing a limited launch, and we've talked about this in the past, in which Medtronic will start providing the product to a set group of patients so that they can really understand the user insight at another level before they do the full-scale launch. And so we're moving forward, preparing to ship out the first product for that limited-scale launch in the back half of this fiscal year. That will occur, and then it would open up for a full commercial launch, we expect, at the start of FY '17."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14.",44,"And this is Chris. The only other thing I'd add is as we said with the respiratory announcement, the impact to '17, because it closes at the end of our fiscal year, there's no impact to '16. But for '17, it's $0.10 to $0.14."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks very much.",4,"Okay, thanks very much."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein with William Blair.",10,"Your next question comes from Brian Weinstein with William Blair."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current p",74,"On R&D, it did step down sequentially. You said that obviously, you're going to get the benefit of the device tax and reinvest that. So can you talk a little bit more specifically about the priorities within R&D? Is it about accelerating kind of current projects? Is it really putting that money to work in new projects? And any specific areas of focus that you would like to focus on with those dollars?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before",167,"Yes. Sure, Brian, and thanks for the question. First off, in this quarter, there was some timing in the R&D spending. It was that. We knew it was going to happen. Of course, that's timing. That's -- that money is going to get spent, and I'm talking before the medical device tax, in the back half of the year. It's the timing of things like clinical trials and whatnot. And so -- but in addition, the money that is being spent on the medical device tax is being spent in both segments, and it is a combination of some new things that we are doing. But mostly, it's current strategies where we are accelerating those strategies, where we had platforms where we could push them faster. And part of that, which is a bit new for us, is moving the informatics side of things quicker. So you can think of major platforms going faster and the informatics piece on top of that. Both sides of the company."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Richard Newitter with Leerink Partners.",10,"Your next question comes from Richard Newitter with Leerink Partners."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is kind of like an inning question, what innings are you in for 2 parts of your business that we frequently talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades",105,"This is kind of like an inning question, what innings are you in for 2 parts of your business that we frequently talk about. Particularly with ES, just can you just update us on where you are with the kind of the opportunity there to kind of get upgrades for that product cycle? And then the second innings question, just the -- in your cytology business, your liquid-based Pap testing, can you just tell us what the trend is there? Are we kind of through the interval expansion impacts mostly at this point? And just comment on any pricing or volume trends for that business."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, let's start with the Pap first, and Linda can talk to you about that.",15,"Sure, let's start with the Pap first, and Linda can talk to you about that."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-di",100,"Yes. So if you look at the liquid cytology business in the U.S., as you mentioned, we're really starting to see a flattening of that business. So the interval testing, we think we're mostly through. Outside the U.S., we're actually seeing strong double-digit performance. And then the entire platform, both in the U.S. and ex U.S., is being held by the Total automation we're doing across both our FocalPoint and our Totalys system. So complete control of the sample from collection through the result. So that's driving a lot of growth both in the U.S. and ex U.S. for us."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Linda. Okay.",4,"Okay. Thanks, Linda. Okay."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes.",42,"And on Pyxis ES, so we're -- about 25% of our base business has been converted over to ES. And so we continue to see strong demand there, and we still do have certainly a -- quite a wide runway ahead, yes."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thanks for the question.",5,"Okay, thanks for the question."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth",152,"So I don't have a multipart question, but I do have 2 questions, one for Chris and one for Tom. The good news is I think they're quick follow-ups. So for Chris, you reiterated full year revenue guidance. You reduced expectations for emerging market growth. That would seemingly imply there's a positive offset for developed market growth. I believe this change in mix should benefit operating margin. It doesn't seem like your guidance reflects that margin mix dynamic. Am I wrong? And if not, why? And then the second question is for Tom. Regarding your plans for the 25-or-so additional CareFusion product registrations, what's the time line for those? And can you walk us through why those products take a bit longer to get registered? I'm just trying to get a better handle on the profile of those products versus the first 50 that are close to or have been registered."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Chris?",2,"Okay. Chris?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range.",49,"Yes, just you're not wrong. But at this point in the year, the impact that it has is still within the range of guidance that we gave. So we had a fairly broad range and it's still in that range. So arguably, it's the higher end of the range."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Tom?",2,"Okay. Tom?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think abo",163,"And Doug, this is Tom. So the 25 is not kind of a straightforward answer, and the fact is it's really a combination of -- just think about -- of course, we couldn't submit all files simultaneously. So it just takes time to work through those. So think about those as being ones that we submitted more recently and didn't work through certain regulatory processes. In other cases, it's a combination of they're in certain countries that have longer registration. China has longer registration processes than most of Europe, as an example. And then the other one is, is that certain product categories -- so ChloraPrep, for example, is registered as a drug in many markets. Particularly, let's say, Latin America, it's registered as a drug. Those typically sit in the regulatory process longer than medical devices. So it's kind of a combination of those 3 items, not one thing specific, and not unexpected at all. It's right in line with our projection."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much.",50,"And you have to pull together the data for these files. And so certain product lines that may not have done that kind of clinical trial work for China, so we had to do some prework to get them into the funnel. That's all that is. Okay, thanks very much."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar with Evercore ISI.",10,"Your next question comes from Vijay Kumar with Evercore ISI."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure, sort of is that a l",88,"Just maybe one housekeeping question on the guidance, Chris. You beat the quarter pretty handily, $0.16, and it looks like FX came in better by 150 bps with the overall guidance sort of up $0.13 by the midpoint. Just want to make sure, sort of is that a little bit of conservatism on the part of management just because FX has been moving all over the place when you think about -- and then trying to put the Q in context of FX improving in the back half?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right",270,"Sure, Vijay. So what I'd say is you really have to look at the EPS guidance in 2 buckets. One is the FXN side. And then the FX impact. So what we did is we did flow through everything on the FX impact, and that was the $0.13. On an FXN basis, you're right, we were up around $0.14 to $0.16. But we see that as timing, and the timing buckets are the medical device tax spending, which we know where we want to spend it, but because of the timing -- don't forget it happened in January and we couldn't ramp that quickly. So that past quarter, we really got a lift from that. But we fully intend to spend that in the back half of the year. Then you had timing on the tax rate. So the tax rate was lower than our 21% to 22%, and that's just lumpy throughout the year. We expect that to fall back within the rest of the year. So you had that piece. And then we had the pull-forward of some of the revenues from the third quarter to the second quarter and the impact of that. So all of that accounts for the bulk of that $0.14 to $0.16 on an FXN basis. The other thing I'd point out is we actually raised the FXN EPS guidance last quarter by $0.28. It was loss from the standpoint that at that point, FX was getting worse across the world and it offset that, but the FXN was raised prior. So you really got to think about it in those 2 buckets."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Our final question is coming from Matt Taylor of Barclays.",10,"Our final question is coming from Matt Taylor of Barclays."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes",69,"I wanted to see if you could touch on a couple of kind of interesting projects that you've talked about in the last couple of quarters. One is the solutions that you're bringing in with the swap in the Simplist business. And then the other is the diabetes partnership with Medtronic. Can you talk a little bit about those opportunities and maybe help us quantify the upside there?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Tom will address those. Tom, you want to start with diabetes?",13,"Sure. So Tom will address those. Tom, you want to start with diabetes?"
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see",228,"Sure. This is Tom. So we haven't specifically sized the opportunity on infusion sets, but I think as we've said all year, we were expecting to get the product into some early-stage release in a controlled patient group this fiscal year and then really see more of the impact in the Diabetes Care business in FY '17. That remains unchanged. So we remain very excited about that opportunity. It's, of course, our first venture outside of the pen needles and syringes for the Diabetes Care business, moving into a fast-growing market with the market leader, Medtronic, and we're, I think, equally excited about the product technology and what it can do to help patients and the partnership and what the power of us working together can do to make an impact there. If you think about solutions, so we -- as we had, of course, shared before, we have announced the solutions partnership with Fresenius. We are looking at launching that not necessarily now in Q4 of '16 but more in early FY '17 just based on regulatory approval time lines there, but that does continue to move forward. And again, we had not shared a specific number there, but we said it would certainly make up for any reduction in BD Rx sales that we had planned over the coming horizon, and that remains right on track."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for any closing remarks.",15,"I will now turn the floor back over to Vince Forlenza for any closing remarks."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, thank you very much for your participation on the call today. It was a real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and p",137,"Okay, thank you very much for your participation on the call today. It was a real pleasure to talk about a very solid quarter and to raise our EPS guidance. It was also a pleasure to talk about the progress we're making on the CareFusion integration and progress with those businesses, the synergies, the teams in place and then lastly, the strategic partnerships that we're doing, including the Parker Institute relationship, the new products that are being launched. We didn't spend a lot of time on the Life Science business today. There weren't that many questions. But with BD MAX, with KIESTRA, all these things happening over there, very, very exciting. And of course, the new products on the Medical side. So thank you very much for your time and look forward to updating you next quarter."
103678,329827360,975007,"Becton, Dickinson and Company, Q2 2016 Earnings Call, May 05, 2016",2016-05-05,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 fo",77,"Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the BD.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 44231624.
[Operator Instructions] Beginning this call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",608,"Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations.
Factors that could cause such differences appear in our third fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualize the acquisition of CareFusion in March, and as such, our third quarter results reflect the new BD in both the current and prior year period.
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of [indiscernible] respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance.
Comparable organic revenues are adjusted to further exclude the impact of nonannualized acquisitions and closed divestitures. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules in our press release or the appendix of the Investor Relations slides. 
At this time, we would like to announce some leadership changes, which will take place on October 1. Jerry Hurwitz, Executive Vice President of HR and Chief Human Resources Officer, has announced his intention to retire from the company. We thank Jerry for his many contributions and his 24 years of service to BD. 
We are also very pleased to announce that Linda Tharby will be our next Executive Vice President of HR and Chief Human Resources Officer effective with Jerry's retirement. We are confident that Linda's drive for performance, combined with her strong strategic agility and passion for people development, will make her well suited to lead HR. 
Linda's appointment helps the company meet a unique business needs and enables Linda to gain personal developments on the functional leadership side. 
We also pleased to announce that Alberto Mas, currently the Worldwide President of Diagnostic Systems, will succeed Linda as Executive Vice President and President of the Life Sciences segment. Having served as President of 3 major business units during his 24-year career at BD, Alberto is uniquely positioned for this next step. Since assuming his position of Worldwide President of Diagnostic Systems in 2013, Alberto has focused the business on reinventing the labs through automation and standardization and advancing our position in the Molecular Diagnostics through differentiated assays. 
We are confident that both of these leaders will make major contributions to our future success as we build a bigger, better, bolder BD. 
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby in her current role as Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned. Over the past several years, we have continued to strengthe",356,"Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned. 
Over the past several years, we have continued to strengthen our leadership team through a diversity of experiences and perspectives to form a global team that helps ensure our future success and the continued development of our senior leaders. Our leadership team is designed to support the company's strategy and increase focus on growth as we develop more impactful solutions for our customers. We're extremely pleased to announce Linda and Alberto's new roles as they help lead the company through our next phase of growth. 
Now turning to Slide 4 and the company's results. We are pleased with our third quarter growth profile. Performance from both the Medical and Life Sciences segments contributed to solid organic revenue growth that was in line with our expectations. Our results this quarter continue to highlight our consistent performance and the benefit of our diverse portfolio. We continue to drive strong underlying margin expansion through the achievement of synergies, operational efficiencies and continuous improvement. 
We're also increasing our R&D investment in key strategic opportunities and expect to fully utilize the benefit of the medical device tax suspension. As we've shared with you, we have a robust pipeline and look forward to sharing new opportunities with you in the near future. Looking ahead, I feel good about the business, and our performance year-to-date gives us confidence in our full year outlook. 
Moving to Slide 5. I will review our third quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company organic revenues grew 4%, in line with our expectations. Adjusted EPS of $2.35 was ahead of our expectations. As I just mentioned, this was driven by strong operating performance, which enables us to invest incremental dollars in R&D. Chris will provide more details on this later in his remarks. 
Now I'd like to turn things over to Chris for a more detailed discussion of our third quarter financial performance and our updated fiscal year 2016 guidance."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results. Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. Thi",2004,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results. 
Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This was in line with the growth expectations we had outlined on last quarter's earnings call. As a reminder, the second fiscal quarter had benefited by about 50 basis points from the timing of revenues, which occurred earlier than originally anticipated. In turn, this negatively impacted the third quarter by about 50 basis points. I'll discuss this further as I take you through the business results. 
BD Medical third quarter revenues increased 3%, reflecting strong performance in Medication Management Solutions and Diabetes Care units and solid growth in the Medication and Procedural Solutions unit. As anticipated, performance in the Pharmaceutical Systems and Respiratory Solution units were negatively impacted, in part by customer ordering patterns and the timing of capital placements. These items occurred earlier than originally anticipated, benefiting the second fiscal quarter as communicated on last quarter's earnings call. 
Medication and Procedural Solutions growth was 2.1%, which reflects strengthen in Infusion Therapy and safety-engineered products but was negatively impacted by the divestiture of our spine business and a tough comparison to the prior year. Medication Management Solutions revenues grew 6.2%, driven by strong dispensing capital installations with our Pyxis platform. We also saw solid growth in the infusion business. 
Growth in Diabetes Care was 6.6%, driven by pen needles and a favorable comparison to the prior year. Pharmaceutical Systems growth of 1.5% reflects strong growth in SAIS and safety-engineered products, partially offset by the aforementioned timing of customer orders. 
Respiratory Solutions revenues decreased 3.3%, reflecting the aforementioned timing of capital placements. Respiratory Solutions had a negative impact of 60 basis points to the third quarter organic growth. Excluding the Respiratory Solutions business, total company organic growth was 4.6%. 
BD Life Sciences third quarter revenues increased 6%, primarily driven by strong growth in the Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 6.6% was driven by international market and safety-engineered products in the U.S. 
Diagnostic Systems growth of 9.5% was the result of strong growth in microbiology, led by the timing of BD KIESTRA installations as well as continued strength in blood culture and growth in BD MAX. Biosciences revenues grew 1.2% in the third quarter. We are seeing additional pressure in Africa related to our clinical HIV business, and we continue to monitor this situation. In the U.S., Biosciences had double-digit growth, driven by sales of research instruments. In addition, we experienced strong sales of research reagents globally. Growth was partially offset by funding delays, primarily in Western Europe and Japan. 
Moving to Slide 8. I'll walk you through our geographic revenues for the third quarter on a currency-neutral basis. U.S. revenues increased 3.4%, reflecting strength in both the Medical and Life Sciences segments. BD Medical's performance reflects strength in dispensing capital installations, which includes the benefit of a large customer installation as well as strong performance in infusion systems, which included double-digit growth in our disposables business. SAIS and safety-engineered products also contributed to growth in the quarter. 
BD Life Sciences growth in the U.S. reflects continued strength in our research business in Biosciences, led by the recently launched FACSSymphony and FACSCelesta instruments and a growing research reagent and surgeon dye portfolio, including our new optibuild platform for customized reagents. 
Diagnostic Systems was driven by strong growth in molecular, including BD MAX and growth in core blood culture. Preanalytical Systems also had solid performance across all 4 platforms during the quarter. 
Moving on to international. Revenues grew 4.6%. This is below our normal growth rate and primarily reflects some unfavorable timing events within the Medical segment. The Medical segment grew 2.6%. This reflects strength in China and sales of safety-engineered products and strong dispensing installations in Medication Management Solutions. This growth was partially offset by the timing events in Pharmaceutical Systems and Respiratory Solutions and softness in the Middle East as we expected. 
The Life Sciences segment grew 8.1%. Preanalytical Systems growth was very strong across all regions, primarily due to the continued expansion of safety-engineered products. Diagnostic Systems had strong growth in Western Europe, driven by KIESTRA installations in the quarter. Overall strength in core microbiology and cervical cancer-related sales also contributed to growth in Diagnostic Systems. The Biosciences business was negatively impacted by the aforementioned decline in the HIV business and funding delays. 
Now turning to Slide 9. Developed markets revenues grew 3.7%, and emerging markets revenues grew 5.2%. Third quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by declines in the Middle East and Africa as communicated on last quarter's earnings call. The Middle East and Africa had a negative impact of approximately 400 basis points. Excluding these regions, emerging markets grew approximately 9% in the quarter. China growth for the third quarter was 9.5%. Revenue growth across the Medical and Life Sciences segments was driven by continued strong demand for consumables. For the total year, we continue to expect China to grow in the low double-digit range. We now anticipate total emerging markets to grow in the mid-single-digit range. We expect as we exit fiscal year 2016, these headwinds in the Middle East and Africa will largely be behind us. It's important to note that we anticipate emerging markets growth of high single digits as we move forward. 
Moving to global safety on Slide 10. Currency-neutral sales increased 8.9%. Safety revenues in the U.S. grew 5.3%, and international sales grew 13.9% currency neutral, driven by strength in Asia Pacific and Europe. Safety revenues grew 19.6% in emerging markets. 
Medical Safety sales grew 9.6%, driven by a range of safety-engineered products, including safety catheters and strength in Pharmaceutical Systems. The benefits from EU safety legislation continued aid growth in the quarter. 
Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 7.6% in the quarter. 
Slide 11 recaps the third quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 4% on a comparable organic currency-neutral basis. Pricing was slightly positive in the quarter. 
Gross profit improved 6.3%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency. 
SSG&A as a percentage of revenues was 22.7%. We're very pleased with the leverage we're getting, which includes the benefit of cost synergy capture. The suspension of the medical device tax also had a positive impact on SSG&A that as we previously communicated, we intend to reinvest the savings in R&D, which you are beginning to see on the R&D line. 
R&D as a percentage of revenues was 6.5%. We continue to invest in new products and innovation and expect to incrementally reinvest approximately $25 million of the medical device tax in the fourth quarter. As a result, we expect R&D as a percentage of revenues in the fourth quarter to be above our full year guidance range. This brings our total year R&D dollars as a percentage of revenue closer to 6.5%. 
Operating income grew 12.8%, reflecting strong P&L leverage. Our tax rate declined 350 basis points to 21.3%, which is in line with our full year expectations of 21% to 22%. 
As Vince discussed earlier, adjusted earnings per share were $2.35, which is a 19.5% increase versus the prior year. This reflects our solid growth profile, strong underlying margin expansion and a lower tax rate. I'd also like to highlight that year-to-date, we have driven very strong earnings growth of 33.9%. 
Slide 12 illustrates our gross profit and operating margin for the third quarter. Foreign currency had an unfavorable impact of about 50 basis points on our gross profit margin in the quarter. On a performance basis, strong gross margin expansion of 160 basis points was primarily driven by operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. Strong operating margin performance of 210 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. These contributions were partially offset by increased R&D expenses we incurred following the medical device tax suspension. Foreign currency had an unfavorable impact of 60 basis points on operating margin in the quarter. 
Year-to-date, we have driven approximately 280 basis points of underlying operating margin expansion. This strong performance gives us the ability to raise our guidance for the year to a range of 200 to 210 basis points of underlying operating margin expansion. 
Moving on to Slide 14. To ensure consistency and clarity, I'd like to provide more color on revenue growth guidance. Last quarter, we noted there was approximately a 50 basis point benefit from the timing of revenues that occurred earlier than we anticipated. We expected that timing to bring down the third quarter growth rate a bit, and we had guided this quarter to be below our revenue growth range for the total year. 
The key to understanding our second half revenue growth trajectory is to focus on the absolute dollars we're achieving this year versus last year. We are up against a tough comparison this quarter because in terms of absolute dollars, that was our highest quarter last year. As you model out the total fiscal year, we have been steadily improving sequential revenue dollars every quarter. While our year-to-date performance implies a revenue growth rate of about 7% in the fourth quarter, you will see that in terms of absolute dollars, it's reasonable and achievable as illustrated on Slide 14. 
Moving on to Slide 15. We are maintaining our adjusted EPS guidance range of $8.50 to $8.57. Our strong performance in the third quarter and our full year outlook give us the confidence to raise our currency-neutral adjusted EPS guidance fiscal 2016 by 1 percentage point to a range of $9.08 to $9.15 while increasing our investment in R&D. Offsetting this increased performance are incremental currency headwinds of approximately 1 percentage point that have resulted from the U.S. dollar strengthening relative to the euro and other currencies since we provided guidance in May. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments. 
Turning to Slide 16. I'd like to walk through additional elements of our guidance for the full fiscal year 2016. We continue to expect growth of 4.5% to 5% in BD Medical. Due to the aforementioned challenges in Africa in our Biosciences business, we now expect revenues in BD Life Sciences to grow between 3.5% and 4%. This brings total BD to the bottom end of our revenue growth guidance range of 4.5% to 5% for the total year. 
On a reported basis, revenue growth for the total year is expected to be between 21% and 21.5%, which reflects a currency headwind of about 350 basis points, which is an incremental 50 basis point headwind compared to our prior guidance of about 300 basis points of currency headwinds. Based on our current view of the environment, we continue to expect pricing to be flat to slightly positive for the year. 
Our guidance assumes a euro-to-dollar exchange rate of $1.11 for the rest of the year. We see some remaining FX headwinds over the fourth quarter as noneuro currencies are also expected to be unfavorable year-over-year. 
Before I turn the call back over to Vince, I'd like to note that in June, we continued to deleverage as we paid down a $750 million debt maturity associated with the CareFusion acquisition. At the end of the third quarter, our leverage ratio was 3.4x, and we remain on track to achieve our commitment of 3x gross debt leverage within 24 months of close or March of 2017. 
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. Starting with new product innovation. Within our Medical business, we reached ove",779,"Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations. 
Starting with new product innovation. Within our Medical business, we reached over 100 hospitals with Alaris infusion pump interoperability. Bidirectional interoperability to a hospital's electronic medical records improves patient safety and care by reducing manual input of data and programming errors while also improving staff efficiency. 
Within our Life Science business, we are seeing strong performance from our recently launched research instruments, FACSSymphony and FACSCelesta. In addition, to complement the portfolio, we recently introduced the unique mid-level cell sorter, the FACSMelody, which has received positive customer feedback. The FACSMelody will have a full-scale commercial launch in the fourth quarter. 
All of these instruments are complemented by our Sirigen Dyes and recently launched optibuild customized reagents. 
In the area of Women's Health, we have continued to make good progress. We have already submitted our vaginitis and GC/CT assays and are now in the process of submitting our HPV assay to the FDA for approval. This assay is designed to provide physicians access to broader, high-risk HPV genotype information beyond type 16 and 18 to guide and inform treatment decisions for their patients. This is an important milestone for the company and is complementary to our current portfolio. 
As part of our menu expansion on BD MAX, we have completed an agreement with Check-Points B.V., a Netherlands-based company, which is focused on the development of rapid molecular test for the detection of carbapenem-resistant organisms. Check-Points currently has a CE Mark product optimized for the BD MAX that incorporates our Open System Reagents. 
Within strategic and business initiatives, we're pleased with the progress towards the creation of the Respiratory Solutions joint venture and remain on track to close late in fiscal year 2016 or early in fiscal 2017. As we told you last quarter, we have also continued to make good progress with our CareFusion product registration process. We remain on track with our plans to achieve revenue synergies and continue to expect them to begin to materialize in fiscal year 2017 in our Medication and Procedural Solutions business. 
And in the areas of partnerships and collaborations, we recently completed an in-depth launch planning meeting with Medtronic to integrate our commercial plans in operations as we anticipate the launch of our insulin infusion set. We remain on track for broad commercial release in early fiscal year 2017. 
As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you further at our Analyst Day in New York City in November. 
Moving on to our business update on Slide 19. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the third quarter. We're making progress expanding and leveraging global shared services and centers of excellence. We also continue to focus on implementing lean and efficient end-to-end processes with our corporate functions. 
During the quarter, we also announced plans to close 2 plants as we made progress with our footprint optimization. We continue to expect the majority of manufacturing-related synergies to be achieved in the latter part of our deal horizon. 
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies related to the CareFusion acquisition as we exit fiscal year 2018. 
Turning to operating margin expansion. The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 200 to 210 basis points of expansion this fiscal year. 
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid third quarter. Both segments performed well, and our results highlight the benefit of our diverse portfolio, both from a product and geographic standpoint. 
Second, we are delivering strong operating performance. Also, with respect to our operating efficiencies, cost leverage and cost synergy capture, are generating significant operating margin improvement as evidenced by our increased guidance for the total year. Also, we have many exciting opportunities in the pipeline, and we are incrementally investing in an R&D to fund those strategic opportunities. 
Finally, we are confident in our outlook for the full fiscal year. We remain very optimistic about BD's prospects for the future and our ability to continue to deliver strong returns to shareholders over time. 
Thank you. We will now open the call to questions."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel.",14,"[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess, I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually I'll start it differently. Becton has consistently",111,"I guess, I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually I'll start it differently. Becton has consistently for a long time every year done a good job of expanding margins, reducing costs, but this kind of performance we've seen in fiscal '15 and 2016, how do we think about the next 2 [ph] years? What are the opportunities that are remaining? And I mean, do you have a lot more to go in terms of consolidating plant manufacturing? Just give us some larger perspective to think about the future."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Rick. I'll take that. It's Chris. We're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. So it's good, continuous i",231,"Sure, Rick. I'll take that. It's Chris. We're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. So it's good, continuous improvement, and that's coming from 2 things. Obviously, the synergies are helping us on the operating margins, SSG&A and that type of thing, but we're also seeing very good performance on the gross profit line, and a lot of that is really coming from continuous improvement-type initiatives that we've had in place. So we feel good about that. And the good news is that, that continues going forward, particularly on the synergy piece. So you would expect to see, on top of the normal 40 to 50 basis points that we drive every year, you would expect to see an incremental 40 to 50 basis points just coming from the natural synergies that you get over the life of the deal horizon. On top of that, you would also think about the fact that with the respiratory going away and with that joint venture, you'll get a benefit on margins as well because as we've mentioned, the respiratory margins really were headwinds to the overall margins. So we feel good about the margin profile going out into the future over the next couple of years."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And you were asking about manufacturing, and what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the 3 25 to 3 50 really starts to hit towards the back end, and we've been giving that time",112,"And you were asking about manufacturing, and what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the 3 25 to 3 50 really starts to hit towards the back end, and we've been giving that time frame of kind of late '17 into '18. So we're really early on in kind of the footprint adjustment. We did mention the 2 plants, but there's a lot more work to be done, but I feel very good about the way the team has this organized. Tom and I have met with them, and I think we really have a solid plan."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great, and just as a follow-up, just thinking about 2 growth drivers, maybe you can give us more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there, and where you're investing in",57,"Great, and just as a follow-up, just thinking about 2 growth drivers, maybe you can give us more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there, and where you're investing in R&D and how we think about that potentially being incremental growth drivers as well."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I'll start with the R&D and ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really about. This is not",224,"I'll start with the R&D and ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really about. This is not about going after new areas. This is really about fortifying what we were doing and so it's spread over both the medication management strategy and over to the Life Science side of things. So I'll give you one example on the Life Science side. We've been doing very well with KIESTRA. We see enhancements that we can make to KIESTRA. We know that the market is going to like these, and so this is an opportunity to accelerate that work that would have taken us another year or 2 to get to. On the medication management side, what I would tell you is that where we're spending is core to that medication management strategy. We saw there's a great opportunity. There was an opportunity to get some technology at the same time. So we're a little opportunistic to do this in the fourth quarter, made all the sense in the world. So right down the middle of what we're doing is the way to think about that, Rick. So I'll turn that over Tom."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Rick, this is Tom. And just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 c",130,"Rick, this is Tom. And just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countries, and we had another 25 registrations submitted and are waiting approval. And since then over the last quarter, we've gained a number of approvals begin. We've actually submitted a number of additional registrations, and so as we shared before, we're on track with our expectations, begin seeing the initial sign of some of those synergies coming through in FY '17, and as we shared in the past, we expect those initial synergies to show up in our consumable medication management business, which is MPS."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks for your questions, Rick.",5,"Thanks for your questions, Rick."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of David Lewis with Morgan Stanley.",13,"Your next question comes from the line of David Lewis with Morgan Stanley."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions, guys. I guess, the first thing for Chris. I'm thinking about '16, Chris. So obviously, underlying earnings growth this year is extremely strong. It sets up more difficult comparison for '17. So I know it's early, but I wondered if you",133,"Two quick questions, guys. I guess, the first thing for Chris. I'm thinking about '16, Chris. So obviously, underlying earnings growth this year is extremely strong. It sets up more difficult comparison for '17. So I know it's early, but I wondered if you we're willing to comment on sort of comfort with consensus next year, which is sort of low double-digit sort of low teens and some of the factors that gets you that comfort if you're willing to provide it. And then just maybe for a second one for Chris just capital deployment priorities. You mentioned deleveraging here into this year and into next year. Just how are you thinking about capital priorities maybe it's also a question for Vince in terms of future M&A, share repurchase activity or further deleverage."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Great, David. Thanks for those questions. Absolutely as I think through fiscal year '17, I would take you back to our normal model, which is mid single digits, 5 percentage [ph] on the top and 10% on the bottom. Then on top of that, you get a couple hundr",519,"Great, David. Thanks for those questions. Absolutely as I think through fiscal year '17, I would take you back to our normal model, which is mid single digits, 5 percentage [ph] on the top and 10% on the bottom. Then on top of that, you get a couple hundred basis points coming from the synergies that we've talked about. And then I think you just have to take into consideration, and I'm not sure everybody's models shows this yet, the $0.10 to $0.14 that come from the respiratory dilution. So that gets you a number that is clearly in the low double digits, as you said. So I have a lot of confidence in that. What I'd also point to, though, is the variables of the headwinds and tailwinds, which generally come from FX and pension, and it's too early to call either of those, and we'll certainly give more guidance on that in November as we provide specific guidance. But right now, neither one of those seem too bad. If FX stayed where it is, it'd be pretty neutral. Pension right now interest rates are probably slight negative, but that could change between now and September when it gets measured. So bottom line, is we are really feeling good about that. Onto your second question in terms of capital allocation, you see that we are making great progress towards our 3x leverage. We're already down to 3.4. So we're well on our way. So thinking about the second half of next year, we will certainly be in a position where we can -- our cash flow is good. We'll be in a position to start redirecting some of that cash away from debt pay-down and back to the more traditional capital allocation methods that we have. I think what you could expect us to do is go back to a similar model that we had pre-CareFusion acquisition, where we look at tuck-in acquisitions. We make sure we're invested in the business clearly first. We have always been increasing our dividend, and we continue to increase the dividend, obviously, as we do the CareFusion transaction, and we've been increasing 10%. But because the bottom line's growing more than 10%, the payout ratios come down. So I think we've got to bring that more in the line and do a little bit of catch up there. And then obviously, that still leaves a lot of cash leftover. We would rather not have that build up on the balance sheet, and so we would likely go back to some share buyback. Having said that, I intend to go through that in November. We do have some time. I'm actually thinking of getting all of your input between now and March to let us know what you think, and so I'd encourage that. And as you know, we've been already beginning that kind of dialogue, and so the good news is I think we have a lot of cash and some positive things that we can do in terms of allocating that. So that's sort of a way to think about it."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or it's really about what is the strategy and how does that create shareholder value, and so just if you've seen us do that",65,"And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or it's really about what is the strategy and how does that create shareholder value, and so just if you've seen us do that in the past, that's the way we're going to approach it in the future. Thanks for your questions, David."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Larry Keusch with Raymond James.",13,"Your next question comes from the line of Larry Keusch with Raymond James."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting just from a high level just try to figure out what you guys I think about covering there.",45,"Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting just from a high level just try to figure out what you guys I think about covering there."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see, and so we're thinking that we have to cover both segments for yo",228,"Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see, and so we're thinking that we have to cover both segments for you. We have to get into in depth on medication, on management kind of across the care continuum for you. We really haven't had an in-depth discussion, and so that'll be a major focus, and then on the Life Science side, they're -- we have a lot to talk about in the core businesses and then the ramp up of things such as genomics. So we're going to make sure that you really understand these things. We know that we're a little difficult to understand because there's so much to cover. So we're going to try to be concise about it, and hopefully, we can give you a little sense of the capabilities we have been building at the same time to drive this new wave of innovation. So those are what we're really looking at. And then around the same time as Chris talk to you, we're going to focus on capital allocation maybe not in that meeting, but as we do the earnings call. So those are the big things that we want to talk to you about."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brian Weinstein with William Blair.",13,"Your next question comes from the line of Brian Weinstein with William Blair."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? In Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there and",55,"So question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? In Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there and how meaningful of a headwind is this for you guys right now?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda can address that question.",7,"Sure. So Linda can address that question."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Brian, it's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guideline. So what we ar",125,"Brian, it's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guideline. So what we are seeing is 2 things occurring. Number one, is tenders that have been previously issued, the amount of volume against those tenders we're seeing come down and then with the actual tenders themselves being canceled. So the impact on our quarter was roughly 200 basis points. And as we exit '16, we believe that the headwinds are largely behind us, the size of this business in Africa now I think has been under the -- around the $30 million range."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And Linda, the 200 basis points you were talking about was on...",12,"And Linda, the 200 basis points you were talking about was on..."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, the 200...",3,"Yes, the 200..."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Life Sciences.",2,"Life Sciences."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Was on the biosciences growth.",5,"Was on the biosciences growth."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","In Life Sciences as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point sort of about a $20 million kind of hit, and that we see that as largely behind us. So we don't carry that goi",59,"In Life Sciences as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point sort of about a $20 million kind of hit, and that we see that as largely behind us. So we don't carry that going into next year, and it's behind us."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Vijay Kumar with Evercore ISI.",13,"Your next question comes from the line of Vijay Kumar with Evercore ISI."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering as we're modeling 4Q right because it looks like the EPS g",76,"Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering as we're modeling 4Q right because it looks like the EPS guidance is a little light relative to what the street is modeling. Is this just because of how this comps move from 3Q to 4Q and the street is modeling?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, no, Vijay. You're pointing to Slide 14 to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different, and that's all about last year. So if you remember la",419,"Yes, no, Vijay. You're pointing to Slide 14 to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different, and that's all about last year. So if you remember last quarter, I mentioned this time we actually give you a chart that kind of demonstrates it because I think if you really study that chart, you can see that the growth rates moving around, but the dollars a nice sequential increases every quarter, and so that gives us the confidence that we can achieve that in the fourth quarter. To your point on EPS, it's really all about the fact that we let the overperformance in the third quarter, we let half of that flow through, and then the other half is what we're investing. If you do the math on that investment of R&D, that's about 20 -- that's $25 million. That takes you up close to 7.5% of revenue in the fourth quarter, and so that's the other half of the overachievement in the third quarter that we're going to spend. And when you think about that, it's really -- we couldn't really spend it in the second quarter. We just couldn't get the programs in place fast enough. We spent the fair share in the third quarter. That's 6.5% of revenues. So we started to getting some traction on reinvesting in Medical device there, and fourth quarter is really a catch up. So when you look at how much we're spending this year on R&D related to medical device tax, it's the entire amount of the medical device tax that we get in benefit. So think about that more as a catch-up. Now in addition to that, on EPS, we talked about headwinds from FX, and that's certainly the other piece of it. We get a little bit of a headwind from the euro going from 1 13 down to 1 11, but the bigger portion is the other currencies, and those other currencies are -- there's really 3 that are driving that impact. The yuan in China is significantly weakened against the dollar since May, about 3% weakness. The Mexican peso has weakened about 6% versus the dollar. And obviously, the British pounds we all know from Brexit impacted by about 9% from our May call, and those are the 3 that are driving the preponderance of the headwinds and FX in the fourth quarter. Thanks very much."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Derik De Bruin of Bank of America.",15,"Your next question comes from the line of Derik De Bruin of Bank of America."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I've got one housekeeping question and just a broader one. The housekeeping question is what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is since you mentioned Brexit, I guess, you talked ab",82,"So I've got one housekeeping question and just a broader one. The housekeeping question is what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is since you mentioned Brexit, I guess, you talked about some weakness in Eastern Europe. Can you sort of elaborate on what you're seeing on these market trends, and how do we think about the impact to some of the uncertainty in Europe going forward?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll take first...",5,"So I'll take first..."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","[indiscernible] The spine business is about $25 million business. So that should help you in terms of getting the sense of the size of that.",25,"[indiscernible] The spine business is about $25 million business. So that should help you in terms of getting the sense of the size of that."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow, but I think the U.",80,"And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow, but I think the U.K. business for us is around $250 million. But we expect the NHS is going to continue to buy products to support the country. So we don't see a big impact."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Jon Groberg with UBS.",12,"Your next question comes from the line of Jon Groberg with UBS."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great. So just an end market question for you, Vince or whoever you want to hand it off to. One, can you give us an update on China kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you'",98,"Great. So just an end market question for you, Vince or whoever you want to hand it off to. One, can you give us an update on China kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you're seeing generally in China, and then in the U.S., I think a lot of people are a little bit perplexed given what you see hospitals reporting and MLR ratios. Can you maybe just talk about what you're seeing from a utilization standpoint in the U.S.?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us, and so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the",119,"Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us, and so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the Life Science side of things, and some of the tenders that we had seen postponed are starting. So it gives us a little bit more confidence on that side, but we continue to see strong performance on the Medical side of the business, consistent with what we've been saying. So pretty stable there and optimistic as we look towards next year. And then what was the second piece you were asking about?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S.",2,"U.S."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.S. res",62,"So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.S. research market is doing quite well, and you saw that, of course, in the bioscience business."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brandon [ph] from Jefferies.",12,"Your next question comes from the line of Brandon [ph] from Jefferies."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","[indiscernible] for Brandon. Can you provide some color surrounding the strength in emerging markets safety and how much longer can the segment grow in the double digits?",27,"[indiscernible] for Brandon. Can you provide some color surrounding the strength in emerging markets safety and how much longer can the segment grow in the double digits?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","We still think we have a long runway there in the emerging markets, and Tom can give you a little bit of color, but a lot of what we saw this and core product was the catheter area. But Tom, maybe you want to talk about China and where they are in Brazil",62,"We still think we have a long runway there in the emerging markets, and Tom can give you a little bit of color, but a lot of what we saw this and core product was the catheter area. But Tom, maybe you want to talk about China and where they are in Brazil and Latin America that are real drivers for this."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Justin, this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and China. Within the U",170,"Sure. Justin, this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and China. Within the U.S., we saw growth in third quarter really driven by safety connectors on our fusion set. I know you didn't specifically asked about Europe, common question as well, and so we do see safety continuing to also perform well in Europe. Compliance with the regulation is continuing and is the major driver of that safety growth. We've shared in the past that we really see stronger conversion in the Infusion Therapy and still more Infusion Therapy as well as blood collection with less conversion in injection. So that's more room to go there, and overall, as you think about it in terms of what we still have ahead, we're still in the middle innings in European safety conversion let's say in that start of the fifth."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier.",2,"And earlier."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier.",2,"And earlier."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And starting in the first, second inning emerging markets.",9,"And starting in the first, second inning emerging markets."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","The next question comes from the line of Michael Weinstein, JPMorgan.",11,"The next question comes from the line of Michael Weinstein, JPMorgan."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook maybe focusing on revenue growth. So with some of the upcoming launches like infusion set early next year, some of the early CareFusion approvals in China, are you",79,"This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook maybe focusing on revenue growth. So with some of the upcoming launches like infusion set early next year, some of the early CareFusion approvals in China, are you expecting the top line to accelerate next year? And how should we be thinking about that? And if not, what are maybe some of the other puts and takes we should be considering?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16, and what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis",242,"Sure, let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16, and what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis points. You also get a lift from respiratory going away and the size that, the impact of respiratory this year for the full year, and it's choppy as we said, it was about 60 basis points in the third quarter. But over the course of the whole year, it's worth about 10 basis points, and so you get a little bit of a lift from that naturally. And we feel good about the rest of the business as we talked about emerging markets, we see getting back to the high single digits kind of range, which is really where we were this year if you exclude the issues in the Middle East, which was both Africa and in Saudi Arabia, which we talked about on the last call, and so we feel good about that. In developed markets, they're continuing to do very nicely. So we feel real good about our revenue guidance for next year. We clearly give you a lot more details as we get into the November call and give you a little bit more about the specific products that we have in the pipeline on the Analyst Meeting in November."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I mean, the only other thing I would add is as we think about it, Saudi Arabia we're expecting it to be stable. Going forward, we don't expect any major change there, and then on the Life Science side as we talked about, the situation in Africa I think is",63,"I mean, the only other thing I would add is as we think about it, Saudi Arabia we're expecting it to be stable. Going forward, we don't expect any major change there, and then on the Life Science side as we talked about, the situation in Africa I think is going to stabilize as well, too. So that's how we're thinking about it."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Bill Quirk with Piper Jaffray.",13,"Your next question comes from the line of Bill Quirk with Piper Jaffray."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great. So, I guess, 2 questions guys. First off, at the ACC this week, you had a new [indiscernible]. I was hoping you could  maybe elaborate a little bit on that in terms of, I guess, some product expectation kind of that what could possibly do increment",104,"Great. So, I guess, 2 questions guys. First off, at the ACC this week, you had a new [indiscernible]. I was hoping you could  maybe elaborate a little bit on that in terms of, I guess, some product expectation kind of that what could possibly do incrementally for margin structure, et cetera, and then also just want to highlight on the microbiology comment that you made, I'll be curious just kind of what you're seeing bigger picture there. There does appear to be, I guess, more interest in that category from investment standpoint within a lot of both domestic as well as European hospitals."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Linda.",2,"Okay. Linda."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So thanks so much, yes, the technology you're referring to EPS is called Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is next generation, uses no gel.",358,"Okay. So thanks so much, yes, the technology you're referring to EPS is called Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is next generation, uses no gel. It's a mechanical separator. So we're really looking forward if you think about what this drives for the lab is really drives a much higher quality, cleaner sample, think about all the breakdowns due to the gel in the clinical Diagnostic Systems think about that going away and then just driving better workflow efficiency and lower costs. So we've now rolled that product out outside of the U.S. We're seeing a lot of activity in terms of numbers of account that are validating this. The validations will take some time. So really start to see the impact of this in '17. And then we expect our U.S. launch to occur in '16. So really, excited about that one. Moving onto microbiology, broadly, of course, saw a lot of share gains over the course of the last year in our BACTEC. But if we think about what we're trying to do with a microbiology lab, it's really about our KIESTRA system and doing 2 things. So first thing we've done with KIESTRA acquisition a few years back is really focus on the full automation. So moving that plate right from start of streaking that plate through IDAST, KIESTRA links all of those systems completely together, and then over the course of the last year, we worked on our [indiscernible] program, which we now advise informatics around that platform, and of course, the first thing that we will do in that informatics side is launch our Veritor plus, which is our flu. It will be next-generation of Veritor for us, which will link into that system, which will launch in Q4 of this year. So hopefully that gives you good picture of both on the PAS side. We're really excited about the innovation. I talked about the tube side. We also have innovation on the needle side and then what we're doing in the microbiology lab."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","From your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things.",34,"From your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Doug Schenkel with Cowen.",12,"Your next question comes from the line of Doug Schenkel with Cowen."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","My first question is for Vince. Second is for Linda or Chris. Vince, we appreciate the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And should we think about this",143,"My first question is for Vince. Second is for Linda or Chris. Vince, we appreciate the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And should we think about this as a pull forward or more of the new normal or maybe a bit of both? And then again for Linda or Chris, regarding the cut in Life Science revenue growth guidance for the year, I think you only called out Africa and Middle East weakness as specific reasons for the cut. I think the reduction translates into about $200 million. I'm assuming my math is right. On the surface, it seems like this is a lot to attribute all to geographic weakness, especially at this point in the year. I'm just wondering if there's other dynamics worth calling out."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points.",35,"Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay, that makes more sense.",5,"Okay, that makes more sense."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year, and you don't start a program and finish it in 1 quarter. These things will cont",216,"There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year, and you don't start a program and finish it in 1 quarter. These things will continue. As I was mentioning, this is an acceleration of the strategy that we had when we've seen some really attractive opportunities to accelerate that strategy, both on the Life Sciences and on the Medical side. You are mentioning microbiology in your question, and we said that is one of the areas in terms of the automation that we felt, with the opportunity that we're seeing for that platform globally, that we could extend that platform. We had finished the technology feasibility. So we felt really good about it. So Linda took the opportunity to do that. Then on the other side, Tom had a series of opportunities in the medication management area, where he could accelerate his programs around medication management, including the informatics piece of that strategy, and there was some opportunity to get some technology from the outside, which we took advantage of, and so we're very happy that these things came together in that way. We think it positions us well going forward."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I just wanted to clear, Doug, I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%.",43,"I just wanted to clear, Doug, I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","The fourth quarter is a bit of an anomaly that's a bit of a catch-up.",16,"The fourth quarter is a bit of an anomaly that's a bit of a catch-up."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's a bit of a catch up, and there's a little bit of onetime.",15,"It's a bit of a catch up, and there's a little bit of onetime."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","What I was indicating with my opportunistic comment.",8,"What I was indicating with my opportunistic comment."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Matt Taylor with Barclays.",12,"Your next question comes from the line of Matt Taylor with Barclays."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I just wanted to ask emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds.",31,"I just wanted to ask emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","You've had better growth in that than the past. I guess, can you just talk about how you develop that forecast, the factors that go into it and what could be sources of upside or downside to that number?",40,"You've had better growth in that than the past. I guess, can you just talk about how you develop that forecast, the factors that go into it and what could be sources of upside or downside to that number?"
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break",469,"Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break that down then to look at business by business, what's happening on kind of the capital side of things as they're purchasing. That's more of an impact, obviously, on the Life Science than on the Medical side. And then we go back and look at the Medical piece in 2 ways course, what's the opportunity for core growth. And then as Tom was talking about earlier, all the product registrations we have for China and other marketplaces from the CareFusion acquisition. So that's China, number one. Number two, we're looking at India as a growth driver, and that has -- the last 2 years, that has picked up and been a good growth driver for us. Yes, there's pluses and minuses in India. We're seeing good fundamental demand there with the burgeoning middle class. We're expanding our distribution in India. So we will take that into account. There are some headwinds in India in terms of tariffs that are -- that have been put in place. So we make sure that's not any significant impact but -- so I would say we still find it as a very attractive marketplace for us. And Middle East and Africa, of course, we're much more careful about what's going on in Saudi Arabia. We follow what the government funding is. In this case, of course, the funding was not just in health care, but it was a significant change linked to the price of oil that we saw, and so the way we're thinking about that is kind of price of oil staying where it is, which means on the low side, which says that they're going to fund their health care, but it's not a big expansion of health care. That was going on in the first half of the year. That's not happening now. But they have to continue to provide care. That's what we're thinking about there. In Africa, we talked about the CD4 business and some of the shift in the guidelines. We believe we've seen the majority of that impact that's really driven by [indiscernible], not the entire marketplace. So it was a segment of that market. So we'll watch how that evolves as Linda said. Then Latin America, as you know, a mixture for us. Mexico's doing well. Brazil is doing okay is what we would say, and we watch the economy there and what's happening from an inflationary standpoint. And of course, funding -- but the other countries in Latin America contributing quite nicely. So that's how we build it up."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Richard Newitter with Leerink Partners.",13,"Your next question comes from the line of Richard Newitter with Leerink Partners."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Ravi in Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denominator",84,"This is Ravi in Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denominator behind that? I mean, is this sort of [indiscernible] all the registrations that you are doing? Or is there a lot more products that remain needs to go through that pathway? And then I have 2 [ph] follow-ups."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Tom will take that.",5,"Sure, Tom will take that."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Ravi, this is Tom. I wouldn't say the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available for that",212,"Sure, Ravi, this is Tom. I wouldn't say the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available for that you need to have additional data generated, and we're in existing formats that those markets would accept. Take, for example, as we think about pumps in some cases, we need to do translation and get the language done first, and that's an R&D program to get that ready. Some of the markets require infusion sets to be adapted a bit for local practices, and so what you saw come through first are, obviously, those products that meet the needs of specific geographies. We have the data ready, and we move forward and submit right away and so most of those also tend to be on the consumable side I shared earlier, which is why is we think about FY '17, we would expect those synergies to really be focused within our NPS business because that's where those more simple medical devices that are more universal in nature in terms of how they fit in with the health care system. That's where we tend to be focused."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Your next question comes from the line of Kristen Stewart with Deutsche Bank."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just as a follow-up to that. Tom, if you could give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast some of this ramp up or how meaningful, I guess, these registrations.",47,"Just as a follow-up to that. Tom, if you could give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast some of this ramp up or how meaningful, I guess, these registrations."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, as Chris mentioned, we think about it in tens of bps, not dramatically higher than that. And again just to put things in perspective, we're really pleased with the performance and outlook and even though we've gotten as early as in FY '16, of course,",248,"Yes, as Chris mentioned, we think about it in tens of bps, not dramatically higher than that. And again just to put things in perspective, we're really pleased with the performance and outlook and even though we've gotten as early as in FY '16, of course, as we have said, CareFusion was 3, 3.5 at best growth business as a stand-alone. We're holding at our 4.5% to 5% growth for the segment overall. And as you know, when you take a 3% grower and a nearly 5% grower, you don't get within the range that we are sharing, and so we are already -- we see some good performance this year already as a result of the 2 companies coming together. We've been some incremental improvements on that in FY '17 within the NPS business in that tens of bps as Chris described. The other thing as you also to keep in mind is that some geographies take a lot longer. So China although with the market that we are filing registrations in, once you file a registration in China, it's a 3-year process. So you can't get into certain markets that fast. More of the European Latin America Southeast Asian markets are those geographies that you can actually get into within an 18-month window, and so that's where you'll see us entering first. Those aren't necessarily as large a some of the markets in China, which will be later on in our 3-year kind of outlook horizon."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you.",2,"Thank you."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","At this time, there are no further questions, I will now turn the conference back over to Mr. Vince Forlenza.",20,"At this time, there are no further questions, I will now turn the conference back over to Mr. Vince Forlenza."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. This is Vince. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much.",31,"Okay. This is Vince. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you.",2,"Thank you."
103678,370563082,1024667,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 fo",79,"Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 44231624. [Operator Instructions]
Beginning this call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",611,"Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our third fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our third quarter results reflect the new BD in both the current and prior year period.
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance.
Comparable organic revenues are adjusted to further exclude the impact of nonannualized acquisitions and closed divestitures. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules in our press release or the appendix of the Investor Relations slides.
At this time, we would like to announce some leadership changes, which will take place on October 1. Jerry Hurwitz, Executive Vice President of HR and Chief Human Resources Officer, has announced his intention to retire from the company. We thank Jerry for his many contributions and his 24 years of service to BD.
We are also very pleased to announce that Linda Tharby will be our next Executive Vice President of HR and Chief Human Resources Officer effective with Jerry's retirement. We are confident that Linda's drive for performance, combined with her strong strategic agility and passion for people development, will make her well suited to lead HR. Linda's appointment helps the company meet a unique business need and enables Linda to gain personal development on the functional leadership side.
We are also pleased to announce that Alberto Mas, currently the Worldwide President of Diagnostic Systems, will succeed Linda as Executive Vice President and President of the Life Sciences segment. Having served as President of 3 major business units during his 24-year career at BD, Alberto is uniquely positioned for this next step. Since assuming his position of Worldwide President of Diagnostic Systems in 2013, Alberto has focused the business on reinventing the labs through automation and standardization and advancing our position in the molecular diagnostics through differentiated assays. We are confident that both of these leaders will make major contributions to our future success as we build a bigger, better, bolder BD.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby in her current role as Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.Over the past several years, we have continued to strengthen",355,"Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.
Over the past several years, we have continued to strengthen our leadership team through a diversity of experiences and perspectives to form a global team that helps ensure our future success and the continued development of our senior leaders. Our leadership team is designed to support the company's strategy and increase focus on growth as we develop more impactful solutions for our customers. We're extremely pleased to announce Linda and Alberto's new roles as they help lead the company through our next phase of growth.
Now turning to Slide 4 and the company's results. We're pleased with our third quarter growth profile. Performance from both the Medical and Life Sciences segments contributed to solid organic revenue growth that was in line with our expectations. Our results this quarter continue to highlight our consistent performance and the benefit of our diverse portfolio. We continue to drive strong underlying margin expansion through the achievement of synergies, operational efficiencies and continuous improvement. We're also increasing our R&D investment in key strategic opportunities and expect to fully utilize the benefit of the medical device tax suspension.
As we've shared with you, we have a robust pipeline and look forward to sharing new opportunities with you in the near future. Looking ahead, I feel good about the business, and our performance year-to-date gives us confidence in our full year outlook.
Moving to Slide 5. I will review our third quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company organic revenues grew 4%, in line with our expectations. Adjusted EPS of $2.35 was ahead of our expectations. As I just mentioned, this was driven by strong operating performance, which enables us to invest incremental dollars in R&D. Chris will provide more details on this later in his remarks.
Now I'd like to turn things over to Chris for a more detailed discussion of our third quarter financial performance and our updated fiscal year 2016 guidance."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This",2004,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.
Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This was in line with the growth expectations we had outlined on last quarter's earnings call. As a reminder, the second fiscal quarter had benefited by about 50 basis points from the timing of revenues, which occurred earlier than originally anticipated. In turn, this negatively impacted the third quarter by about 50 basis points. I'll discuss this further as I take you through the business results.
BD Medical third quarter revenues increased 3%, reflecting strong performance in Medication Management Solutions and Diabetes Care units and solid growth in the Medication and Procedural Solutions unit. As anticipated, performance in the Pharmaceutical Systems and Respiratory Solution units were negatively impacted, in part by customer ordering patterns and the timing of capital placements. These items occurred earlier than originally anticipated, benefiting the second fiscal quarter as communicated on last quarter's earnings call.
Medication and Procedural Solutions growth was 2.1%, which reflects strength in infusion therapy and safety-engineered products but was negatively impacted by the divestiture of our spine business and a tough comparison to the prior year. Medication Management Solution revenues grew 6.2%, driven by strong dispensing capital installations with our Pyxis platform. We also saw solid growth in the infusion business.
Growth in Diabetes Care was 6.6%, driven by pen needles and a favorable comparison to the prior year. Pharmaceutical Systems growth of 1.5% reflects strong growth in SAIS and safety-engineered products, partially offset by the aforementioned timing of customer orders.
Respiratory Solutions revenues decreased 3.3%, reflecting the aforementioned timing of capital placements. Respiratory Solutions had a negative impact of 60 basis points to the third quarter organic growth. Excluding the Respiratory Solutions business, total company organic growth was 4.6%.
BD Life Sciences third quarter revenues increased 6%, primarily driven by strong growth in the Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 6.6% was driven by international market and safety-engineered products in the U.S.
Diagnostic Systems growth of 9.5% was the result of strong growth in microbiology, led by the timing of BD KIESTRA installations as well as continued strength in blood culture and growth in BD MAX.
Biosciences revenues grew 1.2% in the third quarter. We are seeing additional pressure in Africa related to our clinical HIV business, and we continue to monitor this situation. In the U.S., Biosciences had double-digit growth, driven by sales of research instruments. In addition, we experienced strong sales of research reagents globally. Growth was partially offset by funding delays, primarily in Western Europe and Japan.
Moving to Slide 8. I'll walk you through our geographic revenues for the third quarter on a currency-neutral basis. U.S. revenues increased 3.4%, reflecting strength in both the Medical and Life Sciences segments. BD Medical's performance reflects strength in dispensing capital installations, which includes the benefit of a large customer installation as well as strong performance in infusion systems, which included double-digit growth in our disposables business. SAIS and safety-engineered products also contributed to growth in the quarter.
BD Life Sciences growth in the U.S. reflects continued strength in our research business and biosciences, led by the recently launched FACSSymphony and FACSCelesta instruments and a growing research reagent and Sirigen dye portfolio, including our new OptiBuild platform for customized reagents. 
Diagnostic Systems was driven by strong growth in molecular, including BD MAX and growth in core blood culture. Preanalytical Systems also had solid performance across all 4 platforms during the quarter.
Moving on to International. Revenues grew 4.6%. This is below our normal growth rate and primarily reflects some unfavorable timing events within the Medical segment. The Medical segment grew 2.6%. This reflects strength in China and sales of safety-engineered products and strong dispensing installations in Medication Management Solutions. This growth was partially offset by the timing events in Pharmaceutical Systems and Respiratory Solutions and softness in the Middle East as we expected.
The Life Sciences segment grew 8.1%. Preanalytical Systems growth was very strong across all regions, primarily due to continued expansion of safety-engineered products. Diagnostic Systems had strong growth in Western Europe, driven by KIESTRA installations in the quarter. Overall strength in core microbiology and cervical cancer-related sales also contributed to growth in Diagnostic Systems. The Biosciences business was negatively impacted by the aforementioned declines in the HIV business and funding delays.
Now turning to Slide 9. Developed markets revenues grew 3.7%, and emerging markets revenues grew 5.2%. Third quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by declines in the Middle East and Africa, as communicated on last quarter's earnings call. The Middle East and Africa had a negative impact of approximately 400 basis points. Excluding these regions, emerging markets grew approximately 9% in the quarter.
China growth for the third quarter was 9.5%. Revenue growth across the Medical and Life Sciences segments was driven by continued strong demand for consumables. For the total year, we continue to expect China to grow in the low double-digit range. We now anticipate total emerging markets to grow in the mid-single-digit range. We expect as we exit fiscal year 2016, these headwinds in the Middle East and Africa will largely be behind us. It's important to note that we anticipate emerging markets growth of high single digits as we move forward.
Moving to global safety on Slide 10. Currency-neutral sales increased 8.9%. Safety revenues in the U.S. grew 5.3%, and international sales grew 13.9% currency neutral, driven by strength in Asia Pacific and Europe. Safety revenues grew 19.6% in emerging markets.
Medical Safety sales grew 9.6%, driven by a range of safety-engineered products, including safety catheters and strength in Pharmaceutical Systems. The benefits from EU safety legislation continue to aid growth in the quarter.
Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 7.6% in the quarter.
Slide 11 recaps the third quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 4% on a comparable organic currency-neutral basis. Pricing was slightly positive in the quarter. Gross profit improved 6.3%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency.
SSG&A as a percentage of revenues was 22.7%. We're very pleased with the leverage we're getting, which includes the benefit of cost synergy capture. The suspension of the medical device tax also had a positive impact on SSG&A. As we previously communicated, we intend to reinvest the savings in R&D, which you are beginning to see on the R&D line.
R&D as a percentage of revenues was 6.5%. We continue to invest in new products and innovation and expect to incrementally reinvest approximately $25 million of the medical device tax in the fourth quarter. As a result, we expect R&D as a percentage of revenues in the fourth quarter to be above our full year guidance range. This brings our total year R&D dollars as a percentage of revenue closer to 6.5%.
Operating income grew 12.8%, reflecting strong P&L leverage. Our tax rate declined 350 basis points to 21.3%, which is in line with our full year expectations of 21% to 22%.
As Vince discussed earlier, adjusted earnings per share were $2.35, which is a 19.5% increase versus the prior year. This reflects our solid growth profile, strong underlying margin expansion and a lower tax rate. I'd also like to highlight that year-to-date, we have driven very strong earnings growth of 33.9%.
Slide 12 illustrates our gross profit and operating margin for the third quarter. Foreign currency had an unfavorable impact of about 50 basis points on our gross profit margin in the quarter. On a performance basis, strong gross margin expansion of 160 basis points was primarily driven by operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. Strong operating margin performance of 210 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. These contributions were partially offset by increased R&D expenses we incurred following the medical device tax suspension. Foreign currency had an unfavorable impact of 60 basis points on operating margin in the quarter.
Year-to-date, we have driven approximately 280 basis points of underlying operating margin expansion. This strong performance gives us the ability to raise our guidance for the year to a range of 200 to 210 basis points of underlying operating margin expansion.
Moving on to Slide 14. To ensure consistency and clarity, I'd like to provide more color on revenue growth guidance. Last quarter, we noted there was approximately a 50 basis point benefit from the timing of revenues that occurred earlier than we anticipated. We expected that timing to bring down the third quarter growth rate a bit, and we had guided this quarter to be below our revenue growth range for the total year.
The key to understanding our second half revenue growth trajectory is to focus on the absolute dollars we're achieving this year versus last year. We are up against a tough comparison this quarter because in terms of absolute dollars, that was our highest quarter last year. As you model out the total fiscal year, we have been steadily improving sequential revenue dollars every quarter. While our year-to-date performance implies a revenue growth rate of about 7% in the fourth quarter, you will see that in terms of absolute dollars, it's reasonable and achievable, as illustrated on Slide 14.
Moving on to Slide 15. We are maintaining our adjusted EPS guidance range of $8.50 to $8.57. Our strong performance in the third quarter and our full year outlook give us the confidence to raise our currency-neutral adjusted EPS guidance for fiscal 2016 by 1 percentage point to a range of $9.08 to $9.15 while increasing our investment in R&D. Offsetting this increased performance are incremental currency headwinds of approximately 1 percentage point that have resulted from the U.S. dollar strengthening relative to the euro and other currencies since we provided guidance in May. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 16. I'd like to walk through additional elements of our guidance for the full fiscal year 2016. We continue to expect growth of 4.5% to 5% in BD Medical. Due to the aforementioned challenges in Africa in our Biosciences business, we now expect revenues in BD Life Sciences to grow between 3.5% and 4%. This brings total BD to the bottom end of our revenue growth guidance range of 4.5% to 5% for the total year.
On a reported basis, revenue growth for the total year is expected to be between 21% and 21.5%, which reflects a currency headwind of about 350 basis points, which is an incremental 50 basis point headwind compared to our prior guidance of about 300 basis points of currency headwinds. Based on our current view of the environment, we continue to expect pricing to be flat to slightly positive for the year.
Our guidance assumes a euro-to-dollar exchange rate of $1.11 for the rest of the year. We see some remaining FX headwinds over the fourth quarter as non-euro currencies are also expected to be unfavorable year-over-year.
Before I turn the call back over to Vince, I'd like to note that in June, we continued to deleverage as we paid down a $750 million debt maturity associated with the CareFusion acquisition. At the end of the third quarter, our leverage ratio was 3.4x, and we remain on track to achieve our commitment of 3x gross debt leverage within 24 months of close or March of 2017.
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.Starting with new product innovation. Within our Medical business, we reached over",778,"Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.
Starting with new product innovation. Within our Medical business, we reached over 100 hospitals with Alaris infusion pump interoperability. Bidirectional interoperability to a hospital's electronic medical records improves patient safety and care by reducing manual input of data and programming errors while also improving staff efficiency.
Within our Life Science business, we are seeing strong performance from our recently launched research instruments, FACSSymphony and FACSCelesta. In addition, to complement the portfolio, we recently introduced the unique mid-level cell sorter, the FACSMelody, which has received positive customer feedback. The FACSMelody will have a full-scale commercial launch in the fourth quarter.
All of these instruments are complemented by our Sirigen dyes and recently launched OptiBuild customized reagents.
In the area of Women's Health, we have continued to make good progress. We have already submitted our vaginitis and GC/CT assays and are now in the process of submitting our HPV assay to the FDA for approval. This assay is designed to provide physicians access to broader, high-risk HPV genotype information beyond type 16 and 18 to guide and form treatment decisions for their patients. This is an important milestone for the company and is complementary to our current portfolio.
As part of our menu expansion on BD MAX, we have completed an agreement with Check-Points B.V., a Netherlands-based company which is focused on the development of rapid molecular test for the detection of carbapenem-resistant organisms. Check-Points currently has a CE Mark product optimized for the BD MAX that incorporates our open system reagents.
Within strategic and business initiatives, we're pleased with the progress towards the creation of the Respiratory Solutions joint venture and remain on track to close late in fiscal year 2016 or early in fiscal 2017.
As we told you last quarter, we have also continued to make good progress with our CareFusion product registration process. We remain on track with our plans to achieve revenue synergies and continue to expect them to begin to materialize in fiscal year 2017 in our Medication and Procedural Solutions business.
And in the areas of partnerships and collaborations, we recently completed an in-depth launch planning meeting with Medtronic to integrate our commercial plans and operations as we anticipate the launch of our insulin infusion set. We remain on track for broad commercial release in early fiscal year 2017.
As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you further at our Analyst Day in New York City in November.
Moving on to our business update on Slide 19. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the third quarter. We're making progress expanding and leveraging global shared services and centers of excellence. We also continue to focus on implementing lean and efficient end-to-end processes with our corporate functions.
During the quarter, we also announced plans to close 2 plants as we made progress with our footprint optimization. We continue to expect the majority of manufacturing-related synergies to be achieved in the latter part of our deal horizon.
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies related to the CareFusion acquisition as we exit fiscal year 2018.
Turning to operating margin expansion. The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 200 to 210 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid third quarter. Both segments performed well, and our results highlight the benefit of our diverse portfolio, both from a product and geographic standpoint. Second, we are delivering strong operating performance. Also, with respect to our operating efficiencies, cost leverage and cost synergy capture are generating significant operating margin improvement as evidenced by our increased guidance for the total year. Also, we have many exciting opportunities in the pipeline, and we are incrementally investing in R&D to fund those strategic opportunities. Finally, we are confident in our outlook for the full fiscal year. We remain very optimistic about BD's prospects for the future and our ability to continue to deliver strong returns to shareholders over time.
Thank you. We will now open the call to questions."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel.",14,"[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently",111,"I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently, for a long time, every year, done a good job of expanding margins, reducing costs. But this kind of performance we've seen in fiscal '15 and 2016, how do we think about the next 2 years? What are the opportunities that are remaining? And I mean, do you have a lot more to go in terms of consolidating plant manufacturing? Just give us some larger perspective to think about the future."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a",235,"Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a good, continuous improvement, and that's coming from 2 things. Obviously, the synergies are helping us on the operating margins, SSG&A and that type of thing, but we're also seeing very good performance on the gross profit line, and a lot of that is really coming from continuous improvement-type initiatives that we've had in place. So we feel good about that. And the good news is that, that continues going forward, particularly on the synergy piece. So you would expect to see, on top of the normal 40 to 50 basis points that we drive every year, you would expect to see an incremental 40 to 50 basis points just coming from the natural synergies that you get over the life of the deal horizon. On top of that, you would also think about the fact that with the respiratory going away and with that joint venture, you'll get a benefit on margins as well because as we've mentioned, the respiratory margins really were headwinds to the overall margins. So we feel good about the margin profile going out into the future over the next couple of years."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the 3 25 to 3 50 really starts to hit towards the back end, and we've been giving that time",112,"And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the 3 25 to 3 50 really starts to hit towards the back end, and we've been giving that time frame of kind of late '17 into '18. So we're really early on in kind of the footprint adjustment. We did mention the 2 plants. But there's a lot more work to be done, but I feel very good about the way the team has this organized. Tom and I have met with them, and I think we really have a solid plan."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investin",58,"Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investing in R&D and how we think about that potentially being incremental growth drivers as well."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really abo",227,"Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really about. This is not about going after new areas. This is really about fortifying what we were doing. And so it's spread over both the medication management strategy and over to the life science side of things. So I'll give you one example on the Life Science side. We've been doing very well with KIESTRA. We see enhancements that we can make to KIESTRA. We know that the market is going to like these, and so this is an opportunity to accelerate that work that would have taken us another year or 2 to get to. On the medication management side, what I would tell you is that where we're spending is core to that medication management strategy. We saw there's a great opportunity. There was an opportunity to get some technology at the same time. So we're a little opportunistic to do this in the fourth quarter, made all the sense in the world. So right down the middle of what we're doing is the way to think about that, Rick. So I'll turn that over to Tom."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countr",130,"This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countries, and we had another 25 registrations submitted and awaiting approval. And since then, over the last quarter, we've gained a number of approvals. We've gained -- we've actually submitted a number of additional registrations. And so as we shared before, we're on track with our expectations, begin seeing the initial sign of some of those synergies coming through in FY '17. And as we shared in the past, we expect those initial synergies to show up in our consumable medication management business, which is MPS."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of David Lewis with Morgan Stanley.",13,"Your next question comes from the line of David Lewis with Morgan Stanley."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but",138,"Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but I wondered if you were willing to comment on sort of comfort with consensus next year, which is sort of low double-digit sort of low teens and some of the factors that gets you that comfort, if you're willing to provide it. And then just maybe for a second one for Chris, just capital deployment priorities. You mentioned deleveraging here into this year and into next year. Just how are you thinking about capital priorities? Maybe it's also a question for Vince in terms of future M&A, share repurchase activity or further deleverage."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred b",520,"Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred basis points coming from the synergies that we've talked about. And then I think you just have to take into consideration, and I'm not sure everybody's model shows this yet, the $0.10 to $0.14 that come from the respiratory dilution. So that gets you to a number that is clearly in the low double digits, as you said. So I have a lot of confidence in that. What I'd also point to, though, is the variables of the headwinds and tailwinds which generally come from FX and pension. And it's too early to call either of those, and we'll certainly give more guidance on that in November as we provide specific guidance. But right now, neither one of those seem too bad. If FX stayed where it is, it'd be pretty neutral. Pension right now with interest rates are probably a slight negative, but that could change between now and September when it gets measured. So bottom line is we are really feeling good about that. Onto your second question in terms of capital allocation, you see that we are making great progress towards our 3x leverage. We're already down to 3.4. So we're well on our way. So thinking about the second half of next year, we will certainly be in a position where we can -- our cash flow is good. We'll be in a position to start redirecting some of that cash away from debt pay-down and back to the more traditional capital allocation methods that we have. I think what you could expect us to do is go back to a similar model that we had pre-CareFusion acquisition, where we look at tuck-in acquisitions. We make sure we're invested in the business clearly first. We have always been increasing our dividend, and we continued to increase the dividend, obviously, as we did the CareFusion transaction. And we've been increasing 10%. But because the bottom line is growing more than 10%, the payout ratios come down. So I think we've got to bring that more in the line and do a little bit of catch-up there. And then obviously, that still leaves a lot of cash leftover. We would rather not have that build up on the balance sheet, and so we would likely go back to some share buybacks. Having said that, I intend to go through that in November. We do have some time. I'm actually thinking of getting all of your input between now and March to let us know what you think, and so I'd encourage that. And as you know, we've been already beginning that kind of dialogue. And so the good news is I think we have a lot of cash and some positive things that we can do in terms of allocating that. So that's sort of a way to think about it."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do t",66,"And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do that in the past, that's the way we're going to approach it in the future. Thanks for your questions, David."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Larry Keusch with Raymond James.",13,"Your next question comes from the line of Larry Keusch with Raymond James."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there.",45,"Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for yo",227,"Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for you. We have to get into in depth on medication, on management, kind of across the care continuum for you. We really haven't had an in-depth discussion. And so that'll be a major focus. And then on the Life Science side, there -- we have a lot to talk about in the core businesses and then the ramp-up of things such as genomics. So we're going to make sure that you really understand these things. We know that we're a little difficult to understand because there's so much to cover. So we're going to try to be concise about it. And hopefully, we can give you a little sense of the capabilities we have been building at the same time to drive this new wave of innovation. So those are what we're really looking at. And then around the same time, as Chris talked to you, we're going to focus on capital allocation, maybe not in that meeting but as we do the earnings call. So those are the big things that we want to talk to you about."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brian Weinstein with William Blair.",13,"Your next question comes from the line of Brian Weinstein with William Blair."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there?",56,"So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there? And how meaningful of a headwind is this for you guys right now?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda can address that question.",7,"Sure. So Linda can address that question."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seei",124,"It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seeing is 2 things occurring. Number one is tenders that have been previously issued, the amount of volume against those tenders we're seeing come down and then the actual tenders themselves being canceled. So the impact on our quarter was roughly 200 basis points. And as we exit '16, we believe that the headwinds are largely behind us. The size of this business in Africa now, I think, has been under the -- around the $30 million range."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And Linda, the 200 basis points you were talking about was on...",12,"And Linda, the 200 basis points you were talking about was on..."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, the 200...",3,"Yes, the 200..."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Life Sciences.",2,"Life Sciences."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Was on the Biosciences growth within...",7,"Was on the Biosciences growth within..."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as l",67,"Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as largely behind us. So we don't carry that going into next year, and it's behind us."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Vijay Kumar with Evercore ISI.",13,"Your next question comes from the line of Vijay Kumar with Evercore ISI."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it",83,"Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it looks like the EPS guidance is a little light relative to what the Street is modeling. Is this just because of how these comps -- comp move from 3Q to 4Q? And is the Street mismodeling?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about l",427,"Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about last year. So if you remember, last quarter, I mentioned this, this time we thought we'd actually give you a chart that kind of demonstrates it because I think if you really study that chart, you can see that the growth rate is moving around, but the dollar is a nice sequential increases every quarter. And so that gives us the confidence that we can achieve that in the fourth quarter. To your point on EPS, it's really all about the fact that we let the overperformance in the third quarter -- we let half of that flow through, and then the other half is what we're investing. If you do the math on that investment of R&D, that's about $25 million. That takes you up close to 7.5% of revenue in the fourth quarter. And so that's the other half of the overachievement in the third quarter that we're going to spend. And when you think about that, it's really -- we couldn't really spend it in the second quarter. We just couldn't get the programs in place fast enough. We spent the fair share in the third quarter. That's 6.5% of revenues. So we started to getting some traction on reinvesting in medical device there. And fourth quarter is really a catch-up. So when you look at how much we're spending this year on R&D related to medical device tax, it's the entire amount of the medical device tax that we get in benefit. So think about that more as a catch-up. Now in addition to that, on EPS, we talked about headwinds from FX, and that's certainly the other piece of it. We get a little bit of a headwind from the euro going from $1.13 down to $1.11. But the bigger portion is the other currencies, and those other currencies are -- there's really 3 that are driving that impact. The yuan in China has significantly weakened against the dollar since May, about 3% weakness. The Mexican peso has weakened about 6% versus the dollar. And obviously, the British pound's, we all know from Brexit, impacted by about 9% from our May call. And those are the 3 that are driving the preponderance of the headwinds and FX in the fourth quarter. Thanks very much."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Derik De Bruin with Bank of America.",15,"Your next question comes from the line of Derik De Bruin with Bank of America."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked a",84,"So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked about some weaknesses in Eastern Europe. Can you sort of elaborate on what you're seeing in those market trends? And sort of how do we think about the impact to some of the uncertainty in Europe going forward?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","The spine business is about $25 million business. So that should help you in terms of getting the sense of the size of that.",24,"The spine business is about $25 million business. So that should help you in terms of getting the sense of the size of that."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.",80,"And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.K. business for us is around $250 million. But we expect the NHS is going to continue to buy products to support the country. So we don't see a big impact."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Jon Groberg with UBS.",12,"Your next question comes from the line of Jon Groberg with UBS."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you'",99,"So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you're seeing generally in China? And then in the U.S., I think a lot of people are a little bit perplexed given what you see hospitals are reporting and MLR ratios. Can you maybe just talk about what you're seeing from a utilization standpoint in the U.S.?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the",119,"Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the life science side of things, and some of the tenders that we had seen postponed are starting. So it gives us a little bit more confidence on that side. But we continue to see strong performance on the medical side of the business, consistent with what we've been saying. So pretty stable there and optimistic as we look towards next year. And then what was the second piece you were asking about?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S.",2,"U.S."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.",63,"U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.S. research market is doing quite well, and you saw that, of course, in the bioscience business."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brandon Couillard with Jefferies.",12,"Your next question comes from the line of Brandon Couillard with Jefferies."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?",30,"It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are in Brazi",63,"We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are in Brazil and Latin America that are real drivers for this."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and Ch",178,"Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and China. Within the U.S., we saw growth in the third quarter really driven by safety connectors on our infusion set. I know you didn't specifically ask about Europe, it's a common question as well. And so we do see safety continuing to also perform well in Europe. Compliance with the regulation is continuing and is the major driver of that safety growth. We've shared in the past that we really see stronger conversion in the infusion therapy and still more of infusion therapy as well as blood collection with less conversion in injection. So that's more room to go there. And overall, as you think about it in terms of what we still have ahead, we're still in the middle innings in European safety conversion, let's say in that start of the fifth."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And various, just starting in the first, second inning in the emerging markets.",13,"And various, just starting in the first, second inning in the emerging markets."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","The next question comes from the line of Michael Weinstein with JPMorgan.",12,"The next question comes from the line of Michael Weinstein with JPMorgan."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China,",81,"This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China, are you expecting the top line to accelerate next year? And how should we be thinking of that? And if not, what are maybe some of the other puts and takes we should be considering?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis",242,"Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis points. You also get a lift from respiratory going away and the size of that, the impact of respiratory this year for the full year, and it's choppy. As we said, it was about 60 basis points in the third quarter. But over the course of the whole year, it's worth about 10 basis points. And so you get a little bit of a lift from that naturally. And we feel good about the rest of business. As we talked about emerging markets, we see getting back to the high single digits kind of range, which is really where we were this year if you exclude the issues in the Middle East, which was both Africa and in Saudi Arabia, which we talked about on the last call. And so we feel good about that. And developed markets, they're continuing to do very nicely. So we feel real good about our revenue guidance for next year. We'll clearly give you a lot more details as we get into the November call and give you a little bit more about the specific products that we have in the pipeline on the Analyst Meeting in November."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is g",62,"And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is going to stabilize as well, too. So that's how we're thinking about it."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","The next question comes from the line of Bill Quirk with Piper Jaffray.",13,"The next question comes from the line of Bill Quirk with Piper Jaffray."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin",103,"So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin structure, et cetera. And then also, just want to highlight on the microbiology comment that you made. I'll be curious just kind of what you're seeing bigger picture there. There does appear to be, I guess, more interest in the category from an investment standpoint within a lot of both domestic as well as European hospitals."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Linda?",2,"Okay. Linda?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","All right. So thanks so much. Yes, the technology we were referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generat",368,"All right. So thanks so much. Yes, the technology we were referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generation, uses no gel. It's a mechanical separator. So we're really looking forward -- if you think about what this drives for the lab is really drives a much higher-quality, cleaner sample. Think about all the breakdowns due to the gel in the clinical diagnostic systems, think about that going away and then just driving better workflow efficiency and lower costs. So we've now rolled that product out outside of the U.S. We're seeing a lot of activity in terms of numbers of accounts that are validating this. So the validation cycle will take some time. So really start to see the impact of this in '17. And then we expect our U.S. launch to occur in '16. So really excited about that one. Moving on to microbiology, broadly, of course, saw a lot of share gains over the course of the last year in our BACTEC. But if we think about what we're trying to do in a microbiology lab, it's really about our KIESTRA system and doing 2 things. So first thing we've done with KIESTRA acquisition a few years back is really focus on the full automation. So moving that plate rate from start of streaking that plate rate through the IDAST. KIESTRA links all of those systems completely together. And then over the course of the last year, we worked on our Infostratus program, which we now advise informatics around that platform. And of course, the first thing that we will do on that informatics side is launch our Veritor Plus, which is our flu. It will be the next-generation Veritor for us, which will link into that system, which will launch in Q4 of this year. So hopefully, that gives you a good picture both on the PAS side. We're really excited about the innovation. I talked about the tube side. We also have innovation on the needle side and then what we're doing in the microbiology lab."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things.",35,"And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Doug Schenkel with Cowen.",12,"Your next question comes from the line of Doug Schenkel with Cowen."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And s",148,"I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And should we think about this as a pull forward or more of the new normal or maybe a bit of both? And then again, for Linda or Chris, regarding the cut in Life Science revenue growth guidance for the year, I think you only called out Africa and Middle East weakness as specific reasons for the cut. I think the reduction translates into about $200 million. Assuming my math is right, on the surface, it seems like this is a lot to attribute all to geographic weakness, especially at this point in the year. I'm just wondering if there's other dynamics worth calling out."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points.",36,"Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will cont",217,"There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will continue. As I was mentioning, this is an acceleration of the strategy that we had when we've seen some really attractive opportunities to accelerate that strategy, both on the Life Sciences and on the Medical side. You are mentioning microbiology in your question, and we said that is one of the areas in terms of the automation that we felt, with the opportunity that we're seeing for that platform globally, that we could extend that platform. We had finished the technology feasibility. So we felt really good about it. And so Linda took the opportunity to do that. Then on the other side, Tom had a series of opportunities in the medication management area, where he could accelerate his programs around medication management, including the informatics piece of that strategy. And there was some opportunity to get some technology from the outside, which we took advantage of. And so we're very happy that these things came together in that way. We think it positions us well going forward."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is",61,"I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is a bit of an anomaly that -- it's a bit of a catch-up."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment.",24,"It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Matt Taylor with Barclays.",12,"Your next question comes from the line of Matt Taylor with Barclays."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, c",74,"I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, can you just talk a little bit about how you develop that forecast, the factors that go into it? And what could be sources of upside or downside to that number?"
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break",473,"Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break that down then to look at business by business, what's happening on kind of the capital side of things as they're purchasing. That's more of an impact, obviously, on the Life Science side than on the Medical side. And then we go back and look at the Medical piece in 2 ways course, what's the opportunity for core growth, and then as Tom was talking about earlier, all the product registrations that we have for China and other marketplaces from the CareFusion acquisition. So that's China, number one. Number two, we're looking at India as a growth driver, and that has -- the last 2 years, that has picked up and been a good growth driver for us. Yes, there's pluses and minuses in India. We're seeing good fundamental demand there with the burgeoning middle class. We're expanding our distribution in India. So we will take that into account. There are some headwinds in India in terms of tariffs that are -- that have been put in place. So we make sure that that's not any significant impact, so I would say we still find it as a very attractive marketplace for us. And Middle East and Africa, of course, we're much more careful about what's going on in Saudi Arabia. We follow what the government funding is. In this case, of course, the funding was not just in health care, but it was a significant change linked to the price of oil that we saw. And so the way we're thinking about that is kind of price of oil staying where it is, which means on the low side, which says that they're going to fund their health care, but it's not a big expansion of health care. That was going on in the first half of the year. That's not happening now. But they have to continue to provide care. That's what we're thinking about there. In Africa, we talked about the CD4 business and some of the shift in the guidelines. We've seen -- we believe we've seen the majority of that impact that's really driven by Pepkor, not the entire marketplace. So it was a segment of that market. So we'll watch how that evolves, as Linda said. Then Latin America, as you know, a mixture for us. Mexico's doing well. Brazil is doing okay is what we would say, and we watch the economy there and what's happening from an inflationary standpoint. And of course, funding -- but the other countries in Latin America contributing quite nicely. So that's how we build it up."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Richard Newitter with Leerink Partners.",13,"Your next question comes from the line of Richard Newitter with Leerink Partners."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denomina",84,"This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denominator behind that? I mean, is this sort of the bullets of all the registrations that you're doing? Or is there a lot more products that remain to go through that pathway? And then I have 2 follow-ups."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Tom will take that.",5,"Sure, Tom will take that."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available",215,"Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available for, that you'd need to have additional data generated. And we're in existing formats that those markets would accept. Take, for example, as we think about pumps, in some cases, we need to do translation and get the language done first, and that's an R&D program to get that ready. Some of the markets require infusion sets to be adapted a bit for local practices. And so what you saw come through first are, obviously, those products that meet the needs of specific geographies. We have the data ready, and we move forward and submit right away. And so most of those also tend to be on the consumable side I shared earlier, which is why as we think about FY '17, we would expect those synergies to really be focused within our MPS business because that's where those more simple medical devices that are more universal in nature in terms of how they fit in with the health care system. That's where we tend to be focused."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Your next question comes from the line of Kristen Stewart with Deutsche Bank."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations.",50,"Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of",253,"Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of course, as we have said, CareFusion was 3%, 3.5% at best growth business as a stand-alone, all right. We're holding at our 4.5% to 5% growth for the segment overall. And as you know, when you take a 3% grower and a nearly 5% grower, you don't get within the range that we're sharing. And so we're already -- we see some good performance this year already as a result of the 2 companies coming together. We think some incremental improvements on that in FY '17, specifically within the MPS business in that tens of bps, as Chris described. The other thing as you -- also to keep in mind is that some geographies take a lot longer. So China, although it's a market that we are filing registrations in, once you file a registration in China, it's a 3-year process. So you can't get into certain markets that fast. Typically, more of the European, Latin America, Southeast Asia markets are those geographies that you can actually get into within an 18-month window. And so that's where you'll see us entering first. Those aren't necessarily as large as some of the markets like China, which will be later on in our 3-year kind of outlook horizon."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza.",20,"At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much.",33,"Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you.",2,"Thank you."
103678,370563082,1025017,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 fo",79,"Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 44231624. [Operator Instructions]
Beginning this call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",610,"Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our third fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our third quarter results reflect the new BD in both the current and prior year period.
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance.
Comparable organic revenues are adjusted to further exclude the impact of nonannualized acquisitions and closed divestitures. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules in our press release or the appendix of the Investor Relations slides.
At this time, we would like to announce some leadership changes which will take place on October 1. Jerry Hurwitz, Executive Vice President of HR and Chief Human Resources Officer, has announced his intention to retire from the company. We thank Jerry for his many contributions and his 24 years of service to BD.
We are also very pleased to announce that Linda Tharby will be our next Executive Vice President of HR and Chief Human Resources Officer effective with Jerry's retirement. We are confident that Linda's drive for performance, combined with her strong strategic agility and passion for people development, will make her well suited to lead HR. Linda's appointment helps the company meet a unique business need and enables Linda to gain personal development on the functional leadership side.
We are also pleased to announce that Alberto Mas, currently the Worldwide President of Diagnostic Systems, will succeed Linda as Executive Vice President and President of the Life Sciences segment. Having served as President of 3 major business units during his 24-year career at BD, Alberto is uniquely positioned for this next step. Since assuming his position of Worldwide President of Diagnostic Systems in 2013, Alberto has focused the business on reinventing the labs through automation and standardization and advancing our position in molecular diagnostics through differentiated assays. We are confident that both of these leaders will make major contributions to our future success as we build a bigger, better, bolder BD.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby in her current role as Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.Over the past several years, we have continued to strengthen",355,"Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.
Over the past several years, we have continued to strengthen our leadership team through a diversity of experiences and perspectives to form a global team that helps ensure our future success and the continued development of our senior leaders. Our leadership team is designed to support the company's strategy and increased focus on growth as we develop more impactful solutions for our customers. We're extremely pleased to announce Linda and Alberto's new roles as they help lead the company through our next phase of growth.
Now turning to Slide 4 and the company's results. We're pleased with our third quarter growth profile. Performance from both the Medical and Life Sciences segments contributed to solid organic revenue growth that was in line with our expectations. Our results this quarter continued to highlight our consistent performance and the benefit of our diverse portfolio. We continued to drive strong underlying margin expansion through the achievement of synergies, operational efficiencies and continuous improvement. We're also increasing our R&D investment in key strategic opportunities and expect to fully utilize the benefit of the medical device tax suspension.
As we've shared with you, we have a robust pipeline and look forward to sharing new opportunities with you in the near future. Looking ahead, I feel good about the business, and our performance year-to-date gives us confidence in our full year outlook.
Moving to Slide 5. I will review our third quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company organic revenues grew 4%, in line with our expectations. Adjusted EPS of $2.35 was ahead of our expectations. As I just mentioned, this was driven by strong operating performance, which enables us to invest incremental dollars in R&D. Chris will provide more details on this later in his remarks.
Now I'd like to turn things over to Chris for a more detailed discussion of our third quarter financial performance and our updated fiscal year 2016 guidance."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This",2006,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.
Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This was in line with the growth expectations we had outlined on last quarter's earnings call. As a reminder, the second fiscal quarter had benefited by about 50 basis points from the timing of revenues, which occurred earlier than originally anticipated. In turn, this negatively impacted the third quarter by about 50 basis points. I'll discuss this further as I take you through the business results.
BD Medical third quarter revenues increased 3%, reflecting strong performance in Medication Management Solutions and Diabetes Care units and solid growth in the Medication and Procedural Solutions unit. As anticipated, performance in the Pharmaceutical Systems and Respiratory Solution units were negatively impacted, in part by customer ordering patterns and the timing of capital placements. These items occurred earlier than originally anticipated, benefiting the second fiscal quarter as communicated on last quarter's earnings call.
Medication and Procedural Solutions growth was 2.1%, which reflects strength in infusion therapy and safety-engineered products but was negatively impacted by the divestiture of our spine business and a tough comparison to the prior year. Medication Management Solution revenues grew 6.2%, driven by strong dispensing capital installations with our Pyxis platform. We also saw solid growth in the infusion business.
Growth in Diabetes Care was 6.6%, driven by pen needles and a favorable comparison to the prior year. Pharmaceutical Systems growth of 1.5% reflects strong growth in SAIS and safety-engineered products, partially offset by the aforementioned timing of customer orders.
Respiratory Solutions revenues decreased 3.3%, reflecting the aforementioned timing of capital placements. Respiratory Solutions had a negative impact of 60 basis points to the third quarter organic growth. Excluding the Respiratory Solutions business, total company organic growth was 4.6%.
BD Life Sciences third quarter revenues increased 6%, primarily driven by strong growth in the Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 6.6% was driven by international market and safety-engineered products in the U.S.
Diagnostic Systems growth of 9.5% was the result of strong growth in microbiology, led by the timing of BD KIESTRA installations as well as continued strength in blood culture and growth in BD MAX.
Biosciences revenues grew 1.2% in the third quarter. We are seeing additional pressure in Africa related to our clinical HIV business, and we continue to monitor this situation. In the U.S., Biosciences had double-digit growth, driven by sales of research instruments. In addition, we experienced strong sales of research reagents globally. Growth was partially offset by funding delays, primarily in Western Europe and Japan.
Moving to Slide 8. I'll walk you through our geographic revenues for the third quarter on a currency-neutral basis. U.S. revenues increased 3.4%, reflecting strength in both the Medical and Life Sciences segments. BD Medical's performance reflects strength in dispensing capital installations, which includes the benefit of a large customer installation as well as strong performance in infusion systems, which included double-digit growth in our disposables business. SAIS and safety-engineered products also contributed to growth in the quarter.
BD Life Sciences growth in the U.S. reflects continued strength in our research business and biosciences, led by the recently launched FACSSymphony and FACSCelesta instruments and a growing research reagent and Sirigen dye portfolio, including our new OptiBuild platform for customized reagents. 
Diagnostic Systems was driven by strong growth in molecular, including BD MAX, and growth in core blood culture. Preanalytical Systems also had solid performance across all 4 platforms during the quarter.
Moving on to International. Revenues grew 4.6%. This is below our normal growth rate and primarily reflects some unfavorable timing events within the Medical segment. The Medical segment grew 2.6%. This reflects strength in China and sales of safety-engineered products and strong dispensing installations in Medication Management Solutions. This growth was partially offset by the timing events in Pharmaceutical Systems and Respiratory Solutions and softness in the Middle East as we expected.
The Life Sciences segment grew 8.1%. Preanalytical Systems growth was very strong across all regions, primarily due to continued expansion of safety-engineered products. Diagnostic Systems had strong growth in Western Europe, driven by KIESTRA installations in the quarter. Overall strength in core microbiology and cervical cancer-related sales also contributed to growth in Diagnostic Systems. The Biosciences business was negatively impacted by the aforementioned declines in the HIV business and funding delays.
Now turning to Slide 9. Developed markets revenues grew 3.7%, and emerging markets revenues grew 5.2%. Third quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by declines in the Middle East and Africa, as communicated on last quarter's earnings call. The Middle East and Africa had a negative impact of approximately 400 basis points. Excluding these regions, emerging markets grew approximately 9% in the quarter.
China growth for the third quarter was 9.5%. Revenue growth across the Medical and Life Sciences segments was driven by continued strong demand for consumables. For the total year, we continue to expect China to grow in the low double-digit range. We now anticipate total emerging markets to grow in the mid-single-digit range. We expect that as we exit fiscal year 2016, these headwinds in the Middle East and Africa will largely be behind us. It's important to note that we anticipate emerging markets growth of high single digits as we move forward.
Moving to global safety on Slide 10. Currency-neutral sales increased 8.9%. Safety revenues in the U.S. grew 5.3%, and international sales grew 13.9% currency neutral, driven by strength in Asia Pacific and Europe. Safety revenues grew 19.6% in emerging markets.
Medical Safety sales grew 9.6%, driven by a range of safety-engineered products, including safety catheters and strength in Pharmaceutical Systems. The benefits from EU safety legislation continue to aid growth in the quarter.
Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 7.6% in the quarter.
Slide 11 recaps the third quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 4% on a comparable organic currency-neutral basis. Pricing was slightly positive in the quarter. Gross profit improved 6.3%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency.
SSG&A as a percentage of revenues was 22.7%. We're very pleased with the leverage we're getting, which includes the benefit of cost synergy capture. The suspension of the medical device tax also had a positive impact on SSG&A, though as weve previously communicated, we intend to reinvest the savings in R&D, which you are beginning to see on the R&D line.
R&D as a percentage of revenues was 6.5%. We continue to invest in new products and innovation and expect to incrementally reinvest approximately $25 million of the medical device tax in the fourth quarter. As a result, we expect R&D as a percentage of revenues in the fourth quarter to be above our full year guidance range. This brings our total year R&D dollars as a percentage of revenue closer to 6.5%.
Operating income grew 12.8%, reflecting strong P&L leverage. Our tax rate declined 350 basis points to 21.3%, which is in line with our full year expectations of 21% to 22%.
As Vince discussed earlier, adjusted earnings per share were $2.35, which is a 19.5% increase versus the prior year. This reflects our solid growth profile, strong underlying margin expansion and a lower tax rate. I'd also like to highlight that year-to-date, we have driven very strong earnings growth of 33.9%.
Slide 12 illustrates our gross profit and operating margin for the third quarter. Foreign currency had an unfavorable impact of about 50 basis points on our gross profit margin in the quarter. On a performance basis, strong gross margin expansion of 160 basis points was primarily driven by operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. Strong operating margin performance of 210 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. These contributions were partially offset by increased R&D expenses we incurred following the medical device tax suspension. Foreign currency had an unfavorable impact of 60 basis points on operating margin in the quarter.
Year-to-date, we have driven approximately 280 basis points of underlying operating margin expansion. This strong performance gives us the ability to raise our guidance for the year to a range of 200 to 210 basis points of underlying operating margin expansion.
Moving on to Slide 14. To ensure consistency and clarity, I'd like to provide more color on revenue growth guidance. Last quarter, we noted there was approximately a 50 basis point benefit from the timing of revenues that occurred earlier than we anticipated. We expected that timing to bring down the third quarter growth rate a bit, and we had guided this quarter to be below our revenue growth range for the total year.
The key to understanding our second half revenue growth trajectory is to focus on the absolute dollars we're achieving this year versus last year. We are up against a tough comparison this quarter because in terms of absolute dollars, that was our highest quarter last year. As you model out the total fiscal year, we have been steadily improving sequential revenue dollars every quarter. While our year-to-date performance implies a revenue growth rate of about 7% in the fourth quarter, you will see that in terms of absolute dollars, it's reasonable and achievable, as illustrated on Slide 14.
Moving on to Slide 15. We are maintaining our adjusted EPS guidance range of $8.50 to $8.57. Our strong performance in the third quarter and our full year outlook give us the confidence to raise our currency-neutral adjusted EPS guidance for fiscal 2016 by 1 percentage point to a range of $9.08 to $9.15 while increasing our investment in R&D. Offsetting this increased performance are incremental currency headwinds of approximately 1 percentage point that have resulted from the U.S. dollar strengthening relative to the euro and other currencies since we provided guidance in May. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 16. I'd like to walk through additional elements of our guidance for the full fiscal year 2016. We continue to expect growth of 4.5% to 5% in BD Medical. Due to the aforementioned challenges in Africa in our Biosciences business, we now expect revenues in BD Life Sciences to grow between 3.5% and 4%. This brings total BD to the bottom end of our revenue growth guidance range of 4.5% to 5% for the total year.
On a reported basis, revenue growth for the total year is expected to be between 21% and 21.5%, which reflects a currency headwind of about 350 basis points, which is an incremental 50 basis point headwind compared to our prior guidance of about 300 basis points of currency headwinds. Based on our current view of the environment, we continue to expect pricing to be flat to slightly positive for the year.
Our guidance assumes a euro-to-dollar exchange rate of $1.11 for the rest of the year. We see some remaining FX headwinds over the fourth quarter as non-euro currencies are also expected to be unfavorable year-over-year.
Before I turn the call back over to Vince, I'd like to note that in June, we continued to deleverage as we paid down a $750 million debt maturity associated with the CareFusion acquisition. At the end of the third quarter, our leverage ratio was 3.4x, and we remain on track to achieve our commitment of 3x gross debt leverage within 24 months of close or March of 2017.
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.Starting with new product innovation. Within our Medical business, we reached over",778,"Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.
Starting with new product innovation. Within our Medical business, we reached over 100 hospitals with Alaris infusion pump interoperability. Bidirectional interoperability to a hospital's electronic medical records improves patient safety and care by reducing manual input of data and programming errors while also improving staff efficiency.
Within our Life Science business, we are seeing strong performance from our recently launched research instruments, FACSSymphony and FACSCelesta. In addition, to complement the portfolio, we recently introduced the unique mid-level cell sorter, the FACSMelody, which has received positive customer feedback. The FACSMelody will have a full-scale commercial launch in the fourth quarter.
All of these instruments are complemented by our Sirigen dyes and recently launched OptiBuild customized reagents.
In the area of Women's Health, we have continued to make good progress. We have already submitted our vaginitis and GC/CT assays and are now in the process of submitting our HPV assay to the FDA for approval. This assay is designed to provide physicians access to broader, high-risk HPV genotype information beyond type 16 and 18 to guide and form treatment decisions for their patients. This is an important milestone for the company and is complementary to our current portfolio.
As part of our menu expansion on BD MAX, we have completed an agreement with Check-Points B.V., a Netherlands-based company which is focused on the development of rapid molecular test for the detection of carbapenem-resistant organisms. Check-Points currently has a CE Mark product optimized for the BD MAX that incorporates our open system reagents.
Within strategic and business initiatives, we're pleased with the progress towards the creation of the Respiratory Solutions joint venture and remain on track to close late in fiscal year 2016 or early in fiscal 2017.
As we told you last quarter, we have also continued to make good progress with our CareFusion product registration process. We remain on track with our plans to achieve revenue synergies and continue to expect them to begin to materialize in fiscal year 2017 in our Medication and Procedural Solutions business.
And in the areas of partnerships and collaborations, we recently completed an in-depth launch planning meeting with Medtronic to integrate our commercial plans and operations as we anticipate the launch of our insulin infusion set. We remain on track for broad commercial release in early fiscal year 2017.
As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you further at our Analyst Day in New York City in November.
Moving on to our business update on Slide 19. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the third quarter. We're making progress expanding and leveraging global shared services and centers of excellence. We also continue to focus on implementing lean and efficient end-to-end processes with our corporate functions.
During the quarter, we also announced plans to close 2 plants as we made progress with our footprint optimization. We continue to expect the majority of manufacturing-related synergies to be achieved in the latter part of our deal horizon.
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies related to the CareFusion acquisition as we exit fiscal year 2018.
Turning to operating margin expansion. The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 200 to 210 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid third quarter. Both segments performed well, and our results highlight the benefit of our diverse portfolio, both from a product and geographic standpoint. Second, we are delivering strong operating performance. Also, with respect to our operating efficiencies, cost leverage and cost synergy capture are generating significant operating margin improvement as evidenced by our increased guidance for the total year. Also, we have many exciting opportunities in the pipeline, and we are incrementally investing in R&D to fund those strategic opportunities. Finally, we are confident in our outlook for the full fiscal year. We remain very optimistic about BD's prospects for the future and our ability to continue to deliver strong returns to shareholders over time.
Thank you. We will now open the call to questions."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel.",14,"[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently",111,"I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently, for a long time, every year, done a good job of expanding margins, reducing costs. But this kind of performance we've seen in fiscal '15 and 2016, how do we think about the next 2 years? What are the opportunities that are remaining? And I mean, do you have a lot more to go in terms of consolidating plant manufacturing? Just give us some larger perspective to think about the future."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a",235,"Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a good, continuous improvement, and that's coming from 2 things. Obviously, the synergies are helping us on the operating margins, SSG&A and that type of thing, but we're also seeing very good performance on the gross profit line, and a lot of that is really coming from continuous improvement-type initiatives that we've had in place. So we feel good about that. And the good news is that, that continues going forward, particularly on the synergy piece. So you would expect to see, on top of the normal 40 to 50 basis points that we drive every year, you would expect to see an incremental 40 to 50 basis points just coming from the natural synergies that you get over the life of the deal horizon. On top of that, you would also think about the fact that with the respiratory going away and with that joint venture, you'll get a benefit on margins as well because as we've mentioned, the respiratory margins really were headwinds to the overall margins. So we feel good about the margin profile going out into the future over the next couple of years."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the $325 million to $350 million really starts to hit towards the back end, and we've been g",112,"And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the $325 million to $350 million really starts to hit towards the back end, and we've been giving that time frame of kind of late '17 into '18. So we're really early on in kind of the footprint adjustment. We did mention the 2 plants. But there's a lot more work to be done, but I feel very good about the way the team has this organized. Tom and I have met with them, and I think we really have a solid plan."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investin",58,"Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investing in R&D and how we think about that potentially being incremental growth driver as well."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really abo",228,"Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really about. This is not about going after new areas. This is really about fortifying what we were doing. And so it's spread over both the medication management strategy and over to the life science side of things. So I'll give you one example on the Life Science side. We've been doing very well with KIESTRA. We see enhancements that we can make to KIESTRA. We know that the market is going to like these, and so this is an opportunity to accelerate that work that would have taken us another year or 2 to get to. On the medication management side, what I would tell you is that where we're spending is core to that medication management strategy. We saw there's a great opportunity, and there was an opportunity to get some technology at the same time. So we're a little opportunistic to do this in the fourth quarter, made all the sense in the world. So right down the middle of what we're doing is the way to think about that, Rick. So I'll turn that over to Tom."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countr",131,"This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countries, and we had another 25 registrations submitted and awaiting approval. And since then, over the last quarter, we've gained a number of new approvals. We've gained -- we've actually submitted a number of additional registrations. And so as we shared before, we're on track with our expectations, begin seeing the initial sign of some of those synergies coming through in FY '17. And as we shared in the past, we expect those initial synergies to show up in our consumable medication management business, which is MPS."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of David Lewis with Morgan Stanley.",13,"Your next question comes from the line of David Lewis with Morgan Stanley."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but",138,"Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but I wondered if you were willing to comment on sort of comfort with consensus next year, which is sort of low double-digit sort of low teens and some of the factors that gets you that comfort, if you're willing to provide it. And then just maybe for a second one for Chris, just capital deployment priorities. You mentioned deleveraging here into this year and into next year. Just how are you thinking about capital priorities? Maybe it's also a question for Vince in terms of future M&A, share repurchase activity or further deleverage."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred b",521,"Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred basis points coming from the synergies that we've talked about. And then I think you just have to take into consideration, and I'm not sure everybody's model shows this yet, the $0.10 to $0.14 that come from the respiratory dilution. So that gets you to a number that is clearly in the low double digits, as you said. So I have a lot of confidence in that. What I'd also point to, though, is the variables of the headwinds and tailwinds which generally come from FX and pension. And it's too early to call either of those, and we'll certainly give more guidance on that in November as we provide specific guidance. But right now, neither one of those seem too bad. If FX stayed where it is, it'd be pretty neutral. Pension right now with interest rates are probably a slight negative, but that could change between now and September when it gets measured. So bottom line is we are really feeling good about that. Onto your second question in terms of capital allocation, you see that we are making great progress towards our 3x leverage. We're already down to 3.4. So we're well on our way. So thinking about the second half of next year, we will certainly be in a position where we can -- our cash flow is good. We'll be in a position to start redirecting some of that cash away from debt pay-down and back to the more traditional capital allocation methods that we have. I think what you could expect us to do is go back to a similar model that we had pre-CareFusion acquisition, where we look at tuck-in acquisitions. We make sure we're invested in the business clearly first. We have always been increasing our dividend, and we continued to increase the dividend, obviously, as we did the CareFusion transaction. And we've been increasing 10%. But because the bottom line is growing more than 10%, the payout ratios come down. So I think we've got to bring that more in the line and do a little bit of catch-up there. And then obviously, that still leaves a lot of cash left over. We would rather not have that build up on the balance sheet, and so we would likely go back to some share buybacks. Having said that, I intend to go through that in November. We do have some time. I'm actually thinking of getting all of your input between now and March to let us know what you think, and so I'd encourage that. And as you know, we've been already beginning that kind of dialogue. And so the good news is I think we have a lot of cash and some positive things that we can do in terms of allocating that. So that's sort of a way to think about it."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do t",66,"And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do that in the past, that's the way we're going to approach it in the future. Thanks for your questions, David."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Larry Keusch with Raymond James.",13,"Your next question comes from the line of Larry Keusch with Raymond James."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there.",45,"Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for yo",227,"Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for you. We have to get into in depth on medication, on management, kind of across the care continuum for you. We really haven't had an in-depth discussion. And so that'll be a major focus. And then on the Life Science side, there -- we have a lot to talk about in the core businesses and then the ramp-up of things such as genomics. So we're going to make sure that you really understand these things. We know that we're a little difficult to understand because there's so much to cover. So we're going to try to be concise about it. And hopefully, we can give you a little sense of the capabilities we have been building at the same time to drive this new wave of innovation. So those are what we're really looking at. And then around the same time, as Chris talked to you, we're going to focus on capital allocation, maybe not in that meeting but as we do the earnings call. So those are the big things that we want to talk to you about."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brian Weinstein with William Blair.",13,"Your next question comes from the line of Brian Weinstein with William Blair."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there?",56,"So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there? And how meaningful of a headwind is this for you guys right now?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda can address that question.",7,"Sure. So Linda can address that question."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seei",123,"It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seeing is 2 things occurring. Number one is tenders that have been previously issued, the amount of volume against those tenders we're seeing come down and then the actual tenders themselves being canceled. So the impact on our quarter was roughly 200 basis points. And as we exit '16, we believe that the headwinds are largely behind us. The size of this business in Africa now think as been under the -- around the $30 million range."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And Linda, the 200 basis points you were talking about was on...",12,"And Linda, the 200 basis points you were talking about was on..."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, the 200...",3,"Yes, the 200..."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Life Sciences.",2,"Life Sciences."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Was on the Biosciences growth within...",7,"Was on the Biosciences growth within..."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as l",67,"Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as largely behind us. So we don't carry that going into next year, and it's behind us."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Vijay Kumar with Evercore ISI.",13,"Your next question comes from the line of Vijay Kumar with Evercore ISI."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it",83,"Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it looks like the EPS guidance is a little light relative to what the Street is modeling. Is this just because of how these comps -- comp move from 3Q to 4Q? And is the Street mismodeling?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about l",427,"Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about last year. So if you remember, last quarter, I mentioned this, this time we thought we'd actually give you a chart that kind of demonstrates it because I think if you really study that chart, you can see that the growth rate is moving around, but the dollar is a nice sequential increases every quarter. And so that gives us the confidence that we can achieve that in the fourth quarter. To your point on EPS, it's really all about the fact that we let the overperformance in the third quarter -- we let half of that flow through, and then the other half is what we're investing. If you do the math on that investment of R&D, that's about $25 million. That takes you up close to 7.5% of revenue in the fourth quarter. And so that's the other half of the overachievement in the third quarter that we're going to spend. And when you think about that, it's really -- we couldn't really spend it in the second quarter. We just couldn't get the programs in place fast enough. We spent the fair share in the third quarter. That's 6.5% of revenues. So we started to getting some traction on reinvesting in medical device there. And fourth quarter is really a catch-up. So when you look at how much we're spending this year on R&D related to medical device tax, it's the entire amount of the medical device tax that we get in benefit. So think about that more as a catch-up. Now in addition to that, on EPS, we talked about headwinds from FX, and that's certainly the other piece of it. We get a little bit of a headwind from the euro going from $1.13 down to $1.11. But the bigger portion is the other currencies, and those other currencies are -- there's really 3 that are driving that impact. The yuan in China has significantly weakened against the dollar since May, about 3% weakness. The Mexican peso has weakened about 6% versus the dollar. And obviously, the British pound, we all know from Brexit, impacted by about 9% from our May call. And those are the 3 that are driving the preponderance of the headwinds on FX in the fourth quarter. Thanks very much."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Derik De Bruin with Bank of America.",15,"Your next question comes from the line of Derik De Bruin with Bank of America."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked a",84,"So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked about some weaknesses in Eastern Europe. Can you sort of elaborate on what you're seeing in those market trends? And sort of how do we think about the impact to some of the uncertainty in Europe going forward?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","The spine business is about a $25 million business. So that should help you in terms of getting the sense of the size of that.",25,"The spine business is about a $25 million business. So that should help you in terms of getting the sense of the size of that."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.",80,"And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.K. business for us is around $250 million. But we expect the NHS is going to continue to buy products to support the country. So we don't see a big impact."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Jon Groberg with UBS.",12,"Your next question comes from the line of Jon Groberg with UBS."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you'",98,"So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you're seeing generally in China? And then in the U.S., I think a lot of people are a little bit perplexed given what you see hospitals reporting and MLR ratios. Can you maybe just talk about what you're seeing from a utilization standpoint in the U.S.?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the",119,"Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the life science side of things, and some of the tenders that we had seen postponed are starting. So it gives us a little bit more confidence on that side. But we continue to see strong performance on the medical side of the business, consistent with what we've been saying. So pretty stable there and optimistic as we look towards next year. And then what was the second piece you were asking about?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S.",2,"U.S."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.",63,"U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.S. research market is doing quite well, and you saw that, of course, in the bioscience business."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brandon Couillard with Jefferies.",12,"Your next question comes from the line of Brandon Couillard with Jefferies."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?",30,"It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are and Braz",63,"We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are and Brazil and Latin America that are real drivers for this."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and Ch",180,"Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and China. Within the U.S., we saw growth in the third quarter really driven by safety connectors on our infusion set. I know you didn't specifically ask about Europe, but it's a common question as well. And so we do see safety continuing to also perform well in Europe. Compliance with the regulation is continuing and is the major driver of that safety growth. We've shared in the past that we really see stronger conversion in the infusion therapy and still more often in infusion therapy as well as blood collection with less conversion in injection. So that's more room to go there. And overall, as you think about it in terms of what we still have ahead, we're still in the middle innings in European safety conversion, let's say in that start of the fifth."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And very -- just starting in the first, second inning in the emerging markets.",14,"And very -- just starting in the first, second inning in the emerging markets."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","The next question comes from the line of Michael Weinstein with JPMorgan.",12,"The next question comes from the line of Michael Weinstein with JPMorgan."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China,",81,"This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China, are you expecting the top line to accelerate next year? And how should we be thinking of that? And if not, what are maybe some of the other puts and takes we should be considering?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis",242,"Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis points. You also get a lift from respiratory going away and the size of that, the impact of respiratory this year for the full year, and it's choppy. As we said, it was about 60 basis points in the third quarter. But over the course of the whole year, it's worth about 10 basis points. And so you get a little bit of a lift from that naturally. And we feel good about the rest of business. As we talked about emerging markets, we see getting back to the high single digits kind of range, which is really where we were this year if you exclude the issues in the Middle East, which was both Africa and in Saudi Arabia, which we talked about on the last call. And so we feel good about that. And developed markets, they're continuing to do very nicely. So we feel real good about our revenue guidance for next year. We'll clearly give you a lot more details as we get into the November call and give you a little bit more about the specific products that we have in the pipeline on the Analyst Meeting in November."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is g",62,"And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is going to stabilize as well, too. So that's how we're thinking about it."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Bill Quirk with Piper Jaffray.",13,"Your next question comes from the line of Bill Quirk with Piper Jaffray."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin",103,"So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin structure, et cetera. And then also, just want to highlight on the microbiology comment that you made. I'll be curious just kind of what you're seeing bigger picture there. There does appear to be, I guess, more interest in the category from an investment standpoint within a lot of both domestic as well as European hospitals."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Linda?",2,"Okay. Linda?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","So thanks so much. Yes, the technology youre referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generation, uses",365,"So thanks so much. Yes, the technology youre referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generation, uses no gel. It's a mechanical separator. So we're really looking forward -- if you think about what this drives for the lab is really drives a much higher-quality, cleaner sample. Think about all the breakdowns due to the gel in the clinical diagnostic systems, think about that going away and then just driving better workflow efficiency and lower costs. So we've now rolled that product out outside of the U.S. We're seeing a lot of activity in terms of numbers of accounts that are validating this. So the validation cycle will take some time. So really start to see the impact of this in '17. And then we expect our U.S. launch to occur in '16. So really excited about that one. Moving on to microbiology, broadly, of course, saw a lot of share gains over the course of the last year in our BACTEC. But if we think about what we're trying to do in a microbiology lab, it's really about our KIESTRA system and doing 2 things. So first thing we've done with KIESTRA acquisition a few years back is really focus on the full automation. So moving that plate rate from start of streaking that plate rate through the IDAST. KIESTRA links all of those systems completely together. And then over the course of the last year, we worked on our Infostratus program, which will now drive informatics around that platform. And of course, the first thing that we will do on that informatics side is launch our Veritor Plus, which is our flu. It will be the next-generation Veritor for us, which will link into that system, which will launch in Q4 of this year. So hopefully, that gives you a good picture both on the PAS side. We're really excited about the innovation. I talked about the tube side. We also have innovation on the needle side and then what we're doing in the microbiology lab."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things.",35,"And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Doug Schenkel with Cowen.",12,"Your next question comes from the line of Doug Schenkel with Cowen."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And s",148,"I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And should we think about this as a pull forward or more of the new normal or maybe a bit of both? And then again, for Linda or Chris, regarding the cut in Life Science revenue growth guidance for the year, I think you only called out Africa and Middle East weakness as specific reasons for the cut. I think the reduction translates into about $200 million. Assuming my math is right, on the surface, it seems like this is a lot to attribute all to geographic weakness, especially at this point in the year. I'm just wondering if there's other dynamics worth calling out."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points.",36,"Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay. That makes more sense.",5,"Okay. That makes more sense."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will cont",217,"There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will continue. As I was mentioning, this is an acceleration of the strategy that we had when we've seen some really attractive opportunities to accelerate that strategy, both on the Life Sciences and on the Medical side. You were mentioning microbiology in your question, and we said that is one of the areas in terms of the automation that we felt, with the opportunity that we're seeing for that platform globally, that we could extend that platform. We had finished the technology feasibility. So we felt really good about it. And so Linda took the opportunity to do that. Then on the other side, Tom had a series of opportunities in the medication management area, where he could accelerate his programs around medication management, including the informatics piece of that strategy. And there was some opportunity to get some technology from the outside, which we took advantage of. And so we're very happy that these things came together in that way. We think it positions us well going forward."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is",61,"I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is a bit of an anomaly that -- it's a bit of a catch-up."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment.",24,"It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Matt Taylor with Barclays.",12,"Your next question comes from the line of Matt Taylor with Barclays."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, c",74,"I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, can you just talk a little bit about how you develop that forecast, the factors that go into it? And what could be sources of upside or downside to that number?"
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break",474,"Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break that down then to look at business by business, what's happening on kind of the capital side of things as they're purchasing. That's more of an impact, obviously, on the Life Science side than on the Medical side. And then we go back and look at the Medical piece in 2 ways, of course, what's the opportunity for core growth, and then as Tom was talking about earlier, all the product registrations that we have for China and other marketplaces from the CareFusion acquisition. So that's China, number one. Number two, we're looking at India as a growth driver, and that has -- the last 2 years, that has picked up and been a good growth driver for us. Yes, there's pluses and minuses in India. We're seeing good fundamental demand there with the burgeoning middle class. We're expanding our distribution in India. So we will take that into account. There are some headwinds in India in terms of tariffs that are -- that have been put in place. So we make sure that that's not any significant impact, so I would say we still find it as a very attractive marketplace for us. And Middle East and Africa, of course, we're much more careful about what's going on in Saudi Arabia. We follow what the government funding is. In this case, of course, the funding was not just in health care, but it was a significant change linked to the price of oil that we saw. And so the way we're thinking about that is kind of price of oil staying where it is, which means on the low side, which says that they're going to fund their health care, but it's not a big expansion of health care. That was going on in the first half of the year. That's not happening now. But they have to continue to provide care. That's what we're thinking about there. In Africa, we talked about the CD4 business and some of the shift in the guidelines. We've seen -- we believe we've seen the majority of that impact that's really driven by Pepkor, not the entire marketplace. So it was a segment of that market. So we'll watch how that evolves, as Linda said. Then Latin America, as you know, a mixture for us. Mexico's doing well. Brazil is doing okay is what we would say, and we watch the economy there and what's happening from an inflationary standpoint. And of course, funding -- but the other countries in Latin America contributing quite nicely. So that's how we build it up."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Richard Newitter with Leerink Partners.",13,"Your next question comes from the line of Richard Newitter with Leerink Partners."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denomina",84,"This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denominator behind that? I mean, is this sort of the bolus of all the registrations that you're doing? Or is there a lot more products that remain to go through that pathway? And then I have 2 follow-ups."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Tom will take that.",5,"Sure, Tom will take that."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available",216,"Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available for, that didnt need to have additional data generated and were in existing formats that those markets would accept. Take, for example, as we think about pumps, in some cases, we need to do translation and get the language done first, and that's an R&D program to get that ready. Some of the markets require infusion sets to be adapted a bit for local practices. And so what you saw come through first are, obviously, those products that meet the needs of specific geographies. We have the data ready, and we move forward and submit right away. And so most of those also tend to be on the consumable side as I shared earlier, which is why as we think about FY '17, we would expect those synergies to really be focused within our MPS business because that's where those more simple medical devices that are more universal in nature in terms of how they fit in with the health care system. That's where we tend to be focused."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Your next question comes from the line of Kristen Stewart with Deutsche Bank."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations.",50,"Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of",254,"Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of course, as we have said, CareFusion was 3%, 3.5% at best growth business as a stand-alone, all right. We're holding at our 4.5% to 5% growth for the segment overall. And as you know, when you take a 3% grower and a nearly 5% grower, you don't get within the range that we're sharing. And so we're already -- we see some good performance this year already as a result of the 2 companies coming together. We think some incremental improvements on that in FY '17, specifically within the MPS business in that tens of bps, as Chris described. The other thing as you -- also to keep in mind is that some geographies take a lot longer. So China, although it's a market that we are filing registrations in, once you file a registration in China, it's a 3-year process. So you can't get into certain markets that fast. Typically, more of the European, Latin America, Southeast Asia markets are those geographies that you can actually get into within an 18-month window. And so that's where you'll see us enter in first. Those aren't necessarily as large as some of the markets like China, which will be later on in our 3-year kind of outlook horizon."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza.",20,"At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much.",33,"Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you.",2,"Thank you."
103678,370563082,1025485,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 fo",79,"Hello, and welcome to BD's Third Fiscal Quarter 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through August 11, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and area code (404) 537-3406 for international calls using confirmation number 44231624. [Operator Instructions]
Beginning this call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted",610,"Thank you, Crystal. Good morning, everyone, and thank you for joining us to review our third fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our third fiscal quarter press release and in the MD&A sections of our recent SEC filings.
We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our third quarter results reflect the new BD in both the current and prior year period.
In addition, comparable prior year revenues are adjusted to exclude sales related to the terminated agreement with CareFusion for the sale of Fisher & Paykel's respiratory care products. The fiscal year 2016 comparable revenue guidance provided today will also exclude the year-over-year impact of this contract termination. The impact to the bottom line is not material and is included in our EPS guidance.
Comparable organic revenues are adjusted to further exclude the impact of nonannualized acquisitions and closed divestitures. Details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliation to GAAP measures in the financial schedules in our press release or the appendix of the Investor Relations slides.
At this time, we would like to announce some leadership changes which will take place on October 1. Jerry Hurwitz, Executive Vice President of HR and Chief Human Resources Officer, has announced his intention to retire from the company. We thank Jerry for his many contributions and his 24 years of service to BD.
We are also very pleased to announce that Linda Tharby will be our next Executive Vice President of HR and Chief Human Resources Officer effective with Jerry's retirement. We are confident that Linda's drive for performance, combined with her strong strategic agility and passion for people development, will make her well suited to lead HR. Linda's appointment helps the company meet a unique business need and enables Linda to gain personal development on the functional leadership side.
We are also pleased to announce that Alberto Mas, currently the Worldwide President of Diagnostic Systems, will succeed Linda as Executive Vice President and President of the Life Sciences segment. Having served as President of 3 major business units during his 24-year career at BD, Alberto is uniquely positioned for this next step. Since assuming his position of Worldwide President of Diagnostic Systems in 2013, Alberto has focused the business on reinventing the labs through automation and standardization and advancing our position in molecular diagnostics through differentiated assays. We are confident that both of these leaders will make major contributions to our future success as we build a bigger, better, bolder BD.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Executive Vice President, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Linda Tharby in her current role as Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.Over the past several years, we have continued to strengthen",355,"Thank you, Monique, and good morning, everyone. Before we discuss the company's performance in the quarter, I would like to comment briefly on the organizational changes Monique just mentioned.
Over the past several years, we have continued to strengthen our leadership team through a diversity of experiences and perspectives to form a global team that helps ensure our future success and the continued development of our senior leaders. Our leadership team is designed to support the company's strategy and increased focus on growth as we develop more impactful solutions for our customers. We're extremely pleased to announce Linda and Alberto's new roles as they help lead the company through our next phase of growth.
Now turning to Slide 4 and the company's results. We're pleased with our third quarter growth profile. Performance from both the Medical and Life Sciences segments contributed to solid organic revenue growth that was in line with our expectations. Our results this quarter continued to highlight our consistent performance and the benefit of our diverse portfolio. We continued to drive strong underlying margin expansion through the achievement of synergies, operational efficiencies and continuous improvement. We're also increasing our R&D investment in key strategic opportunities and expect to fully utilize the benefit of the medical device tax suspension.
As we've shared with you, we have a robust pipeline and look forward to sharing new opportunities with you in the near future. Looking ahead, I feel good about the business, and our performance year-to-date gives us confidence in our full year outlook.
Moving to Slide 5. I will review our third quarter revenue and EPS results, which I will speak to on a currency-neutral basis. Total company organic revenues grew 4%, in line with our expectations. Adjusted EPS of $2.35 was ahead of our expectations. As I just mentioned, this was driven by strong operating performance, which enables us to invest incremental dollars in R&D. Chris will provide more details on this later in his remarks.
Now I'd like to turn things over to Chris for a more detailed discussion of our third quarter financial performance and our updated fiscal year 2016 guidance."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This",2006,"Thanks, Vince, and good morning, everyone. As Vince just mentioned, the breadth and geographic diversity of our portfolio contributed to solid third quarter results.
Total third quarter revenues of $3.2 billion grew 4% on a comparable organic basis. This was in line with the growth expectations we had outlined on last quarter's earnings call. As a reminder, the second fiscal quarter had benefited by about 50 basis points from the timing of revenues, which occurred earlier than originally anticipated. In turn, this negatively impacted the third quarter by about 50 basis points. I'll discuss this further as I take you through the business results.
BD Medical third quarter revenues increased 3%, reflecting strong performance in Medication Management Solutions and Diabetes Care units and solid growth in the Medication and Procedural Solutions unit. As anticipated, performance in the Pharmaceutical Systems and Respiratory Solution units were negatively impacted, in part by customer ordering patterns and the timing of capital placements. These items occurred earlier than originally anticipated, benefiting the second fiscal quarter as communicated on last quarter's earnings call.
Medication and Procedural Solutions growth was 2.1%, which reflects strength in infusion therapy and safety-engineered products but was negatively impacted by the divestiture of our spine business and a tough comparison to the prior year. Medication Management Solution revenues grew 6.2%, driven by strong dispensing capital installations with our Pyxis platform. We also saw solid growth in the infusion business.
Growth in Diabetes Care was 6.6%, driven by pen needles and a favorable comparison to the prior year. Pharmaceutical Systems growth of 1.5% reflects strong growth in SAIS and safety-engineered products, partially offset by the aforementioned timing of customer orders.
Respiratory Solutions revenues decreased 3.3%, reflecting the aforementioned timing of capital placements. Respiratory Solutions had a negative impact of 60 basis points to the third quarter organic growth. Excluding the Respiratory Solutions business, total company organic growth was 4.6%.
BD Life Sciences third quarter revenues increased 6%, primarily driven by strong growth in the Preanalytical Systems and Diagnostic Systems units. Preanalytical Systems growth of 6.6% was driven by international market and safety-engineered products in the U.S.
Diagnostic Systems growth of 9.5% was the result of strong growth in microbiology, led by the timing of BD KIESTRA installations as well as continued strength in blood culture and growth in BD MAX.
Biosciences revenues grew 1.2% in the third quarter. We are seeing additional pressure in Africa related to our clinical HIV business, and we continue to monitor this situation. In the U.S., Biosciences had double-digit growth, driven by sales of research instruments. In addition, we experienced strong sales of research reagents globally. Growth was partially offset by funding delays, primarily in Western Europe and Japan.
Moving to Slide 8. I'll walk you through our geographic revenues for the third quarter on a currency-neutral basis. U.S. revenues increased 3.4%, reflecting strength in both the Medical and Life Sciences segments. BD Medical's performance reflects strength in dispensing capital installations, which includes the benefit of a large customer installation as well as strong performance in infusion systems, which included double-digit growth in our disposables business. SAIS and safety-engineered products also contributed to growth in the quarter.
BD Life Sciences growth in the U.S. reflects continued strength in our research business and biosciences, led by the recently launched FACSSymphony and FACSCelesta instruments and a growing research reagent and Sirigen dye portfolio, including our new OptiBuild platform for customized reagents. 
Diagnostic Systems was driven by strong growth in molecular, including BD MAX, and growth in core blood culture. Preanalytical Systems also had solid performance across all 4 platforms during the quarter.
Moving on to International. Revenues grew 4.6%. This is below our normal growth rate and primarily reflects some unfavorable timing events within the Medical segment. The Medical segment grew 2.6%. This reflects strength in China and sales of safety-engineered products and strong dispensing installations in Medication Management Solutions. This growth was partially offset by the timing events in Pharmaceutical Systems and Respiratory Solutions and softness in the Middle East as we expected.
The Life Sciences segment grew 8.1%. Preanalytical Systems growth was very strong across all regions, primarily due to continued expansion of safety-engineered products. Diagnostic Systems had strong growth in Western Europe, driven by KIESTRA installations in the quarter. Overall strength in core microbiology and cervical cancer-related sales also contributed to growth in Diagnostic Systems. The Biosciences business was negatively impacted by the aforementioned declines in the HIV business and funding delays.
Now turning to Slide 9. Developed markets revenues grew 3.7%, and emerging markets revenues grew 5.2%. Third quarter growth rate in emerging markets reflects solid growth in China and Latin America, partially offset by declines in the Middle East and Africa, as communicated on last quarter's earnings call. The Middle East and Africa had a negative impact of approximately 400 basis points. Excluding these regions, emerging markets grew approximately 9% in the quarter.
China growth for the third quarter was 9.5%. Revenue growth across the Medical and Life Sciences segments was driven by continued strong demand for consumables. For the total year, we continue to expect China to grow in the low double-digit range. We now anticipate total emerging markets to grow in the mid-single-digit range. We expect that as we exit fiscal year 2016, these headwinds in the Middle East and Africa will largely be behind us. It's important to note that we anticipate emerging markets growth of high single digits as we move forward.
Moving to global safety on Slide 10. Currency-neutral sales increased 8.9%. Safety revenues in the U.S. grew 5.3%, and international sales grew 13.9% currency neutral, driven by strength in Asia Pacific and Europe. Safety revenues grew 19.6% in emerging markets.
Medical Safety sales grew 9.6%, driven by a range of safety-engineered products, including safety catheters and strength in Pharmaceutical Systems. The benefits from EU safety legislation continue to aid growth in the quarter.
Life Sciences safety sales, which are driven by our Preanalytical Systems unit, grew 7.6% in the quarter.
Slide 11 recaps the third quarter income statement and highlights our currency-neutral results. As I mentioned a few moments ago, revenues grew 4% on a comparable organic currency-neutral basis. Pricing was slightly positive in the quarter. Gross profit improved 6.3%. I'll provide more color on gross profit on the next slide when we look at the underlying performance and the impact of currency.
SSG&A as a percentage of revenues was 22.7%. We're very pleased with the leverage we're getting, which includes the benefit of cost synergy capture. The suspension of the medical device tax also had a positive impact on SSG&A, though as weve previously communicated, we intend to reinvest the savings in R&D, which you are beginning to see on the R&D line.
R&D as a percentage of revenues was 6.5%. We continue to invest in new products and innovation and expect to incrementally reinvest approximately $25 million of the medical device tax in the fourth quarter. As a result, we expect R&D as a percentage of revenues in the fourth quarter to be above our full year guidance range. This brings our total year R&D dollars as a percentage of revenue closer to 6.5%.
Operating income grew 12.8%, reflecting strong P&L leverage. Our tax rate declined 350 basis points to 21.3%, which is in line with our full year expectations of 21% to 22%.
As Vince discussed earlier, adjusted earnings per share were $2.35, which is a 19.5% increase versus the prior year. This reflects our solid growth profile, strong underlying margin expansion and a lower tax rate. I'd also like to highlight that year-to-date, we have driven very strong earnings growth of 33.9%.
Slide 12 illustrates our gross profit and operating margin for the third quarter. Foreign currency had an unfavorable impact of about 50 basis points on our gross profit margin in the quarter. On a performance basis, strong gross margin expansion of 160 basis points was primarily driven by operational performance and continuous improvement initiatives and, to a lesser extent, from favorable raw material prices. Strong operating margin performance of 210 basis points was primarily driven by gross margin expansion combined with the achievement of operational efficiencies and the positive impact of cost synergies. These contributions were partially offset by increased R&D expenses we incurred following the medical device tax suspension. Foreign currency had an unfavorable impact of 60 basis points on operating margin in the quarter.
Year-to-date, we have driven approximately 280 basis points of underlying operating margin expansion. This strong performance gives us the ability to raise our guidance for the year to a range of 200 to 210 basis points of underlying operating margin expansion.
Moving on to Slide 14. To ensure consistency and clarity, I'd like to provide more color on revenue growth guidance. Last quarter, we noted there was approximately a 50 basis point benefit from the timing of revenues that occurred earlier than we anticipated. We expected that timing to bring down the third quarter growth rate a bit, and we had guided this quarter to be below our revenue growth range for the total year.
The key to understanding our second half revenue growth trajectory is to focus on the absolute dollars we're achieving this year versus last year. We are up against a tough comparison this quarter because in terms of absolute dollars, that was our highest quarter last year. As you model out the total fiscal year, we have been steadily improving sequential revenue dollars every quarter. While our year-to-date performance implies a revenue growth rate of about 7% in the fourth quarter, you will see that in terms of absolute dollars, it's reasonable and achievable, as illustrated on Slide 14.
Moving on to Slide 15. We are maintaining our adjusted EPS guidance range of $8.50 to $8.57. Our strong performance in the third quarter and our full year outlook give us the confidence to raise our currency-neutral adjusted EPS guidance for fiscal 2016 by 1 percentage point to a range of $9.08 to $9.15 while increasing our investment in R&D. Offsetting this increased performance are incremental currency headwinds of approximately 1 percentage point that have resulted from the U.S. dollar strengthening relative to the euro and other currencies since we provided guidance in May. We remain extremely pleased with our performance and our ability to execute and deliver on our commitments.
Turning to Slide 16. I'd like to walk through additional elements of our guidance for the full fiscal year 2016. We continue to expect growth of 4.5% to 5% in BD Medical. Due to the aforementioned challenges in Africa in our Biosciences business, we now expect revenues in BD Life Sciences to grow between 3.5% and 4%. This brings total BD to the bottom end of our revenue growth guidance range of 4.5% to 5% for the total year.
On a reported basis, revenue growth for the total year is expected to be between 21% and 21.5%, which reflects a currency headwind of about 350 basis points, which is an incremental 50 basis point headwind compared to our prior guidance of about 300 basis points of currency headwinds. Based on our current view of the environment, we continue to expect pricing to be flat to slightly positive for the year.
Our guidance assumes a euro-to-dollar exchange rate of $1.11 for the rest of the year. We see some remaining FX headwinds over the fourth quarter as non-euro currencies are also expected to be unfavorable year-over-year.
Before I turn the call back over to Vince, I'd like to note that in June, we continued to deleverage as we paid down a $750 million debt maturity associated with the CareFusion acquisition. At the end of the third quarter, our leverage ratio was 3.4x, and we remain on track to achieve our commitment of 3x gross debt leverage within 24 months of close or March of 2017.
Now I'd like to turn the call back over to Vince, who will provide you with an update on our key initiatives and product portfolio."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.Starting with new product innovation. Within our Medical business, we reached over",778,"Thank you, Chris. Moving on to Slide 18. I will walk through our updates on new product innovation, strategic and business initiatives and partnerships and collaborations.
Starting with new product innovation. Within our Medical business, we reached over 100 hospitals with Alaris infusion pump interoperability. Bidirectional interoperability to a hospital's electronic medical records improves patient safety and care by reducing manual input of data and programming errors while also improving staff efficiency.
Within our Life Science business, we are seeing strong performance from our recently launched research instruments, FACSSymphony and FACSCelesta. In addition, to complement the portfolio, we recently introduced the unique mid-level cell sorter, the FACSMelody, which has received positive customer feedback. The FACSMelody will have a full-scale commercial launch in the fourth quarter.
All of these instruments are complemented by our Sirigen dyes and recently launched OptiBuild customized reagents.
In the area of Women's Health, we have continued to make good progress. We have already submitted our vaginitis and GC/CT assays and are now in the process of submitting our HPV assay to the FDA for approval. This assay is designed to provide physicians access to broader, high-risk HPV genotype information beyond type 16 and 18 to guide and form treatment decisions for their patients. This is an important milestone for the company and is complementary to our current portfolio.
As part of our menu expansion on BD MAX, we have completed an agreement with Check-Points B.V., a Netherlands-based company which is focused on the development of rapid molecular test for the detection of carbapenem-resistant organisms. Check-Points currently has a CE Mark product optimized for the BD MAX that incorporates our open system reagents.
Within strategic and business initiatives, we're pleased with the progress towards the creation of the Respiratory Solutions joint venture and remain on track to close late in fiscal year 2016 or early in fiscal 2017.
As we told you last quarter, we have also continued to make good progress with our CareFusion product registration process. We remain on track with our plans to achieve revenue synergies and continue to expect them to begin to materialize in fiscal year 2017 in our Medication and Procedural Solutions business.
And in the areas of partnerships and collaborations, we recently completed an in-depth launch planning meeting with Medtronic to integrate our commercial plans and operations as we anticipate the launch of our insulin infusion set. We remain on track for broad commercial release in early fiscal year 2017.
As you can see, we are executing on our strategy and continue to have strong opportunities to drive growth and innovation. We look forward to updating you further at our Analyst Day in New York City in November.
Moving on to our business update on Slide 19. We continue to make progress with our cost synergy capture. Our G&A functional transformation continued in the third quarter. We're making progress expanding and leveraging global shared services and centers of excellence. We also continue to focus on implementing lean and efficient end-to-end processes with our corporate functions.
During the quarter, we also announced plans to close 2 plants as we made progress with our footprint optimization. We continue to expect the majority of manufacturing-related synergies to be achieved in the latter part of our deal horizon.
We remain on track to achieve our FY '16 cost synergies and continue to expect $325 million to $350 million in total cost synergies related to the CareFusion acquisition as we exit fiscal year 2018.
Turning to operating margin expansion. The consistent solid performance of our businesses, combined with operating efficiencies, cost leverage and cost synergy capture, is driving continued underlying operating margin expansion. In addition to the 100 basis points of operating margin expansion we achieved last year, we expect another 200 to 210 basis points of expansion this fiscal year.
Now I'd like to reiterate the key messages from our presentation today. First, this was a solid third quarter. Both segments performed well, and our results highlight the benefit of our diverse portfolio, both from a product and geographic standpoint. Second, we are delivering strong operating performance. Also, with respect to our operating efficiencies, cost leverage and cost synergy capture are generating significant operating margin improvement as evidenced by our increased guidance for the total year. Also, we have many exciting opportunities in the pipeline, and we are incrementally investing in R&D to fund those strategic opportunities. Finally, we are confident in our outlook for the full fiscal year. We remain very optimistic about BD's prospects for the future and our ability to continue to deliver strong returns to shareholders over time.
Thank you. We will now open the call to questions."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel.",14,"[Operator Instructions] Your first question comes from the line of Rick Wise with Stifel."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently",111,"I guess I'll start off with the operating margin expansion. I mean, you really are generating extraordinary margin expansion this year for multiple reasons. Maybe just stepping back, how much -- actually, I'll start it differently. Becton has consistently, for a long time, every year, done a good job of expanding margins, reducing costs. But this kind of performance we've seen in fiscal '15 and 2016, how do we think about the next 2 years? What are the opportunities that are remaining? And I mean, do you have a lot more to go in terms of consolidating plant manufacturing? Just give us some larger perspective to think about the future."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a",235,"Sure, Rick. I'll take that. It's Chris. Thanks. Yes, we're really happy with the margins that we're driving. Operating margin this year will be 200 to 210 basis points up, and I'll remind you that that's on top of 100 basis points last year. And so it's a good, continuous improvement, and that's coming from 2 things. Obviously, the synergies are helping us on the operating margins, SSG&A and that type of thing, but we're also seeing very good performance on the gross profit line, and a lot of that is really coming from continuous improvement-type initiatives that we've had in place. So we feel good about that. And the good news is that, that continues going forward, particularly on the synergy piece. So you would expect to see, on top of the normal 40 to 50 basis points that we drive every year, you would expect to see an incremental 40 to 50 basis points just coming from the natural synergies that you get over the life of the deal horizon. On top of that, you would also think about the fact that with the respiratory going away and with that joint venture, you'll get a benefit on margins as well because as we've mentioned, the respiratory margins really were headwinds to the overall margins. So we feel good about the margin profile going out into the future over the next couple of years."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the $325 million to $350 million really starts to hit towards the back end, and we've been g",112,"And you were asking about manufacturing. And what I was trying to indicate in my remarks, this is Vince, Rick, is that the manufacturing piece of the synergies in the $325 million to $350 million really starts to hit towards the back end, and we've been giving that time frame of kind of late '17 into '18. So we're really early on in kind of the footprint adjustment. We did mention the 2 plants. But there's a lot more work to be done, but I feel very good about the way the team has this organized. Tom and I have met with them, and I think we really have a solid plan."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investin",58,"Great. And just as a follow-up, just thinking about 2 growth drivers, maybe you can give us some more color. You talked about the 50 CareFusion products registered, 25 more on track. Maybe talk about the growth implications there and where you're investing in R&D and how we think about that potentially being incremental growth driver as well."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really abo",228,"Yes. So I'll start with the R&D, then I'll ask Tom to talk about the revenue synergies. So I really do think that this is a great opportunity for us with the suspension of the medical device tax to, Rick, accelerate our strategy is what this is really about. This is not about going after new areas. This is really about fortifying what we were doing. And so it's spread over both the medication management strategy and over to the life science side of things. So I'll give you one example on the Life Science side. We've been doing very well with KIESTRA. We see enhancements that we can make to KIESTRA. We know that the market is going to like these, and so this is an opportunity to accelerate that work that would have taken us another year or 2 to get to. On the medication management side, what I would tell you is that where we're spending is core to that medication management strategy. We saw there's a great opportunity, and there was an opportunity to get some technology at the same time. So we're a little opportunistic to do this in the fourth quarter, made all the sense in the world. So right down the middle of what we're doing is the way to think about that, Rick. So I'll turn that over to Tom."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countr",131,"This is Tom, and just to answer your question on revenue synergies, we continue to make good progress on our new product registrations. As you said, last quarter, we shared that we had gained regulatory approval for more than 50 products in over 20 countries, and we had another 25 registrations submitted and awaiting approval. And since then, over the last quarter, we've gained a number of new approvals. We've gained -- we've actually submitted a number of additional registrations. And so as we shared before, we're on track with our expectations, begin seeing the initial sign of some of those synergies coming through in FY '17. And as we shared in the past, we expect those initial synergies to show up in our consumable medication management business, which is MPS."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of David Lewis with Morgan Stanley.",13,"Your next question comes from the line of David Lewis with Morgan Stanley."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but",138,"Two quick questions, guys. I guess the first thing for Chris. I'm thinking about '16, Chris. And so obviously, the underlying earnings growth this year has been extremely strong. It sets up more of a difficult comparison for '17. So I know it's early, but I wondered if you were willing to comment on sort of comfort with consensus next year, which is sort of low double-digit sort of low teens and some of the factors that gets you that comfort, if you're willing to provide it. And then just maybe for a second one for Chris, just capital deployment priorities. You mentioned deleveraging here into this year and into next year. Just how are you thinking about capital priorities? Maybe it's also a question for Vince in terms of future M&A, share repurchase activity or further deleverage."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred b",521,"Great, David. Thanks for those questions. Absolutely, as I think through fiscal year '17, I would take you back to our normal model, which is mid-single digits, 5 percentage on the top and 10% on the bottom. Then on top of that, you get a couple hundred basis points coming from the synergies that we've talked about. And then I think you just have to take into consideration, and I'm not sure everybody's model shows this yet, the $0.10 to $0.14 that come from the respiratory dilution. So that gets you to a number that is clearly in the low double digits, as you said. So I have a lot of confidence in that. What I'd also point to, though, is the variables of the headwinds and tailwinds which generally come from FX and pension. And it's too early to call either of those, and we'll certainly give more guidance on that in November as we provide specific guidance. But right now, neither one of those seem too bad. If FX stayed where it is, it'd be pretty neutral. Pension right now with interest rates are probably a slight negative, but that could change between now and September when it gets measured. So bottom line is we are really feeling good about that. Onto your second question in terms of capital allocation, you see that we are making great progress towards our 3x leverage. We're already down to 3.4. So we're well on our way. So thinking about the second half of next year, we will certainly be in a position where we can -- our cash flow is good. We'll be in a position to start redirecting some of that cash away from debt pay-down and back to the more traditional capital allocation methods that we have. I think what you could expect us to do is go back to a similar model that we had pre-CareFusion acquisition, where we look at tuck-in acquisitions. We make sure we're invested in the business clearly first. We have always been increasing our dividend, and we continued to increase the dividend, obviously, as we did the CareFusion transaction. And we've been increasing 10%. But because the bottom line is growing more than 10%, the payout ratios come down. So I think we've got to bring that more in the line and do a little bit of catch-up there. And then obviously, that still leaves a lot of cash left over. We would rather not have that build up on the balance sheet, and so we would likely go back to some share buybacks. Having said that, I intend to go through that in November. We do have some time. I'm actually thinking of getting all of your input between now and March to let us know what you think, and so I'd encourage that. And as you know, we've been already beginning that kind of dialogue. And so the good news is I think we have a lot of cash and some positive things that we can do in terms of allocating that. So that's sort of a way to think about it."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do t",66,"And David, we haven't changed our philosophy on M&A. We're going to be very strategically driven, number one. We're not size driven or -- it's really about what is the strategy and how does that create shareholder value. And so just if you've seen us do that in the past, that's the way we're going to approach it in the future. Thanks for your questions, David."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Larry Keusch with Raymond James.",13,"Your next question comes from the line of Larry Keusch with Raymond James."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there.",45,"Two questions for you. I'm wondering if you could perhaps help us think a little bit about the agenda, if you will, for the November Analyst Meeting, just at a high level. Just trying to figure out what you guys are thinking about covering there."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for yo",227,"Well, we have a lot of new things in the pipeline. We've integrated a lot of things, and I don't think you've had the opportunity -- that the market hasn't had the opportunity to really see. And so we're thinking that we have to cover both segments for you. We have to get into in depth on medication, on management, kind of across the care continuum for you. We really haven't had an in-depth discussion. And so that'll be a major focus. And then on the Life Science side, there -- we have a lot to talk about in the core businesses and then the ramp-up of things such as genomics. So we're going to make sure that you really understand these things. We know that we're a little difficult to understand because there's so much to cover. So we're going to try to be concise about it. And hopefully, we can give you a little sense of the capabilities we have been building at the same time to drive this new wave of innovation. So those are what we're really looking at. And then around the same time, as Chris talked to you, we're going to focus on capital allocation, maybe not in that meeting but as we do the earnings call. So those are the big things that we want to talk to you about."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brian Weinstein with William Blair.",13,"Your next question comes from the line of Brian Weinstein with William Blair."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there?",56,"So a question on Africa, Middle East, the headwinds that you have there. Can you describe some of that in more detail? And Africa specifically, you said you're monitoring the CD4 viral load situation there, but what can you actually do proactively there? And how meaningful of a headwind is this for you guys right now?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. So Linda can address that question.",7,"Sure. So Linda can address that question."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seei",123,"It's Linda here. So as we discussed on our last call, the decline in the Africa HIV business is largely associated with now the regional health systems in Africa starting to implement the HIV viral load testing based on WHO guidelines. So what we are seeing is 2 things occurring. Number one is tenders that have been previously issued, the amount of volume against those tenders we're seeing come down and then the actual tenders themselves being canceled. So the impact on our quarter was roughly 200 basis points. And as we exit '16, we believe that the headwinds are largely behind us. The size of this business in Africa now think as been under the -- around the $30 million range."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And Linda, the 200 basis points you were talking about was on...",12,"And Linda, the 200 basis points you were talking about was on..."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, the 200...",3,"Yes, the 200..."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Life Sciences.",2,"Life Sciences."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Was on the Biosciences growth within...",7,"Was on the Biosciences growth within..."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences.",1,"Biosciences."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as l",67,"Biosciences growth. Yes, and on the -- on Life Sciences, as you saw, we took the guidance down. That was reflective of what was happening in Africa, and that was about a 50 basis point, sort of about a $20 million kind of hit. And that -- we see that as largely behind us. So we don't carry that going into next year, and it's behind us."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Vijay Kumar with Evercore ISI.",13,"Your next question comes from the line of Vijay Kumar with Evercore ISI."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it",83,"Maybe just one housekeeping question on -- I know in the last call, you guys spoke about comp metrics, the triggers for comp being changed from the June to September fiscal end. I'm just wondering, how was the -- as we're modeling 4Q, right -- because it looks like the EPS guidance is a little light relative to what the Street is modeling. Is this just because of how these comps -- comp move from 3Q to 4Q? And is the Street mismodeling?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about l",427,"Yes -- no, Vijay. So you're pointing to Slide 14, and I think we gave that to give you a sense that the revenue growth in the quarter just increases a little bit in the fourth quarter, but the growth rate is significantly different. And that's all about last year. So if you remember, last quarter, I mentioned this, this time we thought we'd actually give you a chart that kind of demonstrates it because I think if you really study that chart, you can see that the growth rate is moving around, but the dollar is a nice sequential increases every quarter. And so that gives us the confidence that we can achieve that in the fourth quarter. To your point on EPS, it's really all about the fact that we let the overperformance in the third quarter -- we let half of that flow through, and then the other half is what we're investing. If you do the math on that investment of R&D, that's about $25 million. That takes you up close to 7.5% of revenue in the fourth quarter. And so that's the other half of the overachievement in the third quarter that we're going to spend. And when you think about that, it's really -- we couldn't really spend it in the second quarter. We just couldn't get the programs in place fast enough. We spent the fair share in the third quarter. That's 6.5% of revenues. So we started to getting some traction on reinvesting in medical device there. And fourth quarter is really a catch-up. So when you look at how much we're spending this year on R&D related to medical device tax, it's the entire amount of the medical device tax that we get in benefit. So think about that more as a catch-up. Now in addition to that, on EPS, we talked about headwinds from FX, and that's certainly the other piece of it. We get a little bit of a headwind from the euro going from $1.13 down to $1.11. But the bigger portion is the other currencies, and those other currencies are -- there's really 3 that are driving that impact. The yuan in China has significantly weakened against the dollar since May, about 3% weakness. The Mexican peso has weakened about 6% versus the dollar. And obviously, the British pound, we all know from Brexit, impacted by about 9% from our May call. And those are the 3 that are driving the preponderance of the headwinds on FX in the fourth quarter. Thanks very much."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Derik De Bruin with Bank of America.",15,"Your next question comes from the line of Derik De Bruin with Bank of America."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked a",84,"So I've got one housekeeping question and just a broader one. The housekeeping question is, what's the overall impact of the spine divestiture? Can you give us a run rate? And then the follow-up on that is, since you mentioned Brexit, I guess you talked about some weaknesses in Eastern Europe. Can you sort of elaborate on what you're seeing in those market trends? And sort of how do we think about the impact to some of the uncertainty in Europe going forward?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","The spine business is about a $25 million business. So that should help you in terms of getting the sense of the size of that.",25,"The spine business is about a $25 million business. So that should help you in terms of getting the sense of the size of that."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.",80,"And then for Brexit, we don't see any significant impact to the business. It's very difficult to say exactly how this is going to play out. It's going to take years to play out. No one knows exactly which model they are going to follow. But I think the U.K. business for us is around $250 million. But we expect the NHS is going to continue to buy products to support the country. So we don't see a big impact."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Jon Groberg with UBS.",12,"Your next question comes from the line of Jon Groberg with UBS."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you'",98,"So just an end market question for you, Vince, or whoever you want to hand it off to. One, can you just give us an update on China, kind of where you are in terms of some of those inventory issues that you called out earlier in the year and just what you're seeing generally in China? And then in the U.S., I think a lot of people are a little bit perplexed given what you see hospitals reporting and MLR ratios. Can you maybe just talk about what you're seeing from a utilization standpoint in the U.S.?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the",119,"Yes. Well, starting on China, we had a strong quarter in China. So we think those inventory issues are behind us. And so we're not seeing a lot of change in the environment from quarter-to-quarter. What we did see was a little bit of strengthening on the life science side of things, and some of the tenders that we had seen postponed are starting. So it gives us a little bit more confidence on that side. But we continue to see strong performance on the medical side of the business, consistent with what we've been saying. So pretty stable there and optimistic as we look towards next year. And then what was the second piece you were asking about?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S.",2,"U.S."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.",63,"U.S. So U.S. utilization seems to be stable to maybe up a tick. I can't give you any real specific data on that, but just in talking to the organization, the U.S. organization, we're feeling quite good. That's the clinical market I'm talking about. The U.S. research market is doing quite well, and you saw that, of course, in the bioscience business."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Brandon Couillard with Jefferies.",12,"Your next question comes from the line of Brandon Couillard with Jefferies."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?",30,"It's Sachin in for Brandon. Can you provide some color surrounding the strength in emerging markets safety? And how much longer can the segment grow in the double digits?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are and Braz",63,"We think we still have a long runway there in the emerging markets. And Tom can give you a little bit of color. But a lot of what we saw this -- in core product was the catheter area. But Tom, maybe you want to talk about China and where they are and Brazil and Latin America that are real drivers for this."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and Ch",180,"Sure. Justin (sic) [ Sachin ], this is Tom. So as Chris had mentioned, at least specific to the Medical segment, we grew 9.6% in the quarter. As Vince just alluded to, safety catheters were a major contributor to that growth, particularly in Europe and China. Within the U.S., we saw growth in the third quarter really driven by safety connectors on our infusion set. I know you didn't specifically ask about Europe, but it's a common question as well. And so we do see safety continuing to also perform well in Europe. Compliance with the regulation is continuing and is the major driver of that safety growth. We've shared in the past that we really see stronger conversion in the infusion therapy and still more often in infusion therapy as well as blood collection with less conversion in injection. So that's more room to go there. And overall, as you think about it in terms of what we still have ahead, we're still in the middle innings in European safety conversion, let's say in that start of the fifth."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes.",1,"Yes."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And earlier in emerging markets.",5,"And earlier in emerging markets."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And very -- just starting in the first, second inning in the emerging markets.",14,"And very -- just starting in the first, second inning in the emerging markets."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","The next question comes from the line of Michael Weinstein with JPMorgan.",12,"The next question comes from the line of Michael Weinstein with JPMorgan."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China,",81,"This is Robbie Marcus in for Mike. Just wanted to follow up on the fiscal year '17 outlook, maybe focusing on revenue growth. So with some of the upcoming launches like the infusion set early next year and some of the early CareFusion approvals in China, are you expecting the top line to accelerate next year? And how should we be thinking of that? And if not, what are maybe some of the other puts and takes we should be considering?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis",242,"Sure. Let me take a shot at that, Robbie. Yes, we do expect acceleration next year from where we are in '16. And what contributes to that is we begin to see some acceleration in terms of revenue synergies from CareFusion. Think about that in tens of basis points. You also get a lift from respiratory going away and the size of that, the impact of respiratory this year for the full year, and it's choppy. As we said, it was about 60 basis points in the third quarter. But over the course of the whole year, it's worth about 10 basis points. And so you get a little bit of a lift from that naturally. And we feel good about the rest of business. As we talked about emerging markets, we see getting back to the high single digits kind of range, which is really where we were this year if you exclude the issues in the Middle East, which was both Africa and in Saudi Arabia, which we talked about on the last call. And so we feel good about that. And developed markets, they're continuing to do very nicely. So we feel real good about our revenue guidance for next year. We'll clearly give you a lot more details as we get into the November call and give you a little bit more about the specific products that we have in the pipeline on the Analyst Meeting in November."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is g",62,"And the only other thing I would add is as we think about it, Saudi Arabia, we're expecting it to be stable. Going forward, we don't expect any major change there. And then on the Life Science side, as we talked about, the situation in Africa I think is going to stabilize as well, too. So that's how we're thinking about it."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Bill Quirk with Piper Jaffray.",13,"Your next question comes from the line of Bill Quirk with Piper Jaffray."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin",103,"So I guess 2 questions guys. First off, at AACC this week, you had a new vacutainer. I was hoping you could maybe elaborate a little bit on that in terms of, I guess, some product expectations, kind of what that could possibly do incrementally for margin structure, et cetera. And then also, just want to highlight on the microbiology comment that you made. I'll be curious just kind of what you're seeing bigger picture there. There does appear to be, I guess, more interest in the category from an investment standpoint within a lot of both domestic as well as European hospitals."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Linda?",2,"Okay. Linda?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","So thanks so much. Yes, the technology youre referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generation, uses",365,"So thanks so much. Yes, the technology youre referring to in PAS is called the Barricor technology. So if you think about blood collection, we created the blood collection tube with our gel about 25-plus years ago. So this is the next generation, uses no gel. It's a mechanical separator. So we're really looking forward -- if you think about what this drives for the lab is really drives a much higher-quality, cleaner sample. Think about all the breakdowns due to the gel in the clinical diagnostic systems, think about that going away and then just driving better workflow efficiency and lower costs. So we've now rolled that product out outside of the U.S. We're seeing a lot of activity in terms of numbers of accounts that are validating this. So the validation cycle will take some time. So really start to see the impact of this in '17. And then we expect our U.S. launch to occur in '16. So really excited about that one. Moving on to microbiology, broadly, of course, saw a lot of share gains over the course of the last year in our BACTEC. But if we think about what we're trying to do in a microbiology lab, it's really about our KIESTRA system and doing 2 things. So first thing we've done with KIESTRA acquisition a few years back is really focus on the full automation. So moving that plate rate from start of streaking that plate rate through the IDAST. KIESTRA links all of those systems completely together. And then over the course of the last year, we worked on our Infostratus program, which will now drive informatics around that platform. And of course, the first thing that we will do on that informatics side is launch our Veritor Plus, which is our flu. It will be the next-generation Veritor for us, which will link into that system, which will launch in Q4 of this year. So hopefully, that gives you a good picture both on the PAS side. We're really excited about the innovation. I talked about the tube side. We also have innovation on the needle side and then what we're doing in the microbiology lab."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things.",35,"And from your question in terms of margin, the product will have attractive margins. So there's no big impact in terms of start-up costs next year. It's kind of in the regular course of things."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Doug Schenkel with Cowen.",12,"Your next question comes from the line of Doug Schenkel with Cowen."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And s",148,"I guess my first question is for Vince. My second is for, I think, Linda or Chris. Vince, we appreciate all the detail on operating investment in Q4. Could you share any detail on areas of prioritization associated with the increased R&D investment? And should we think about this as a pull forward or more of the new normal or maybe a bit of both? And then again, for Linda or Chris, regarding the cut in Life Science revenue growth guidance for the year, I think you only called out Africa and Middle East weakness as specific reasons for the cut. I think the reduction translates into about $200 million. Assuming my math is right, on the surface, it seems like this is a lot to attribute all to geographic weakness, especially at this point in the year. I'm just wondering if there's other dynamics worth calling out."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points.",36,"Yes. Let me address that one first before we get into the other piece. Your math is off by a decimal. It's about $20 million impact on a $4 billion business. It's about 50 basis points."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay. That makes more sense.",5,"Okay. That makes more sense."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will cont",217,"There you go. In terms of the R&D spend, you should assume that we will continue to spend the medical device tax as it is suspended and think about that going into next year. And you don't start a program and finish it in 1 quarter. These things will continue. As I was mentioning, this is an acceleration of the strategy that we had when we've seen some really attractive opportunities to accelerate that strategy, both on the Life Sciences and on the Medical side. You were mentioning microbiology in your question, and we said that is one of the areas in terms of the automation that we felt, with the opportunity that we're seeing for that platform globally, that we could extend that platform. We had finished the technology feasibility. So we felt really good about it. And so Linda took the opportunity to do that. Then on the other side, Tom had a series of opportunities in the medication management area, where he could accelerate his programs around medication management, including the informatics piece of that strategy. And there was some opportunity to get some technology from the outside, which we took advantage of. And so we're very happy that these things came together in that way. We think it positions us well going forward."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is",61,"I just wanted to be clear, Doug. I referenced the fourth quarter margin or the investment as about 7.5%. That's not the new normal. I think going forward, you would still think about R&D as a percentage of revenue in the 6% to 6.5%. But fourth quarter is a bit of an anomaly that -- it's a bit of a catch-up."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment.",24,"It's a bit of a catch-up, and there's a little bit of onetime, and that's what I was indicating with my opportunistic comment."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Matt Taylor with Barclays.",12,"Your next question comes from the line of Matt Taylor with Barclays."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, c",74,"I just wanted to ask an emerging market follow-up question. You talked about expecting high single-digit growth going forward when you look through some of the kind of near-term temporary headwinds. You've had better growth in that in the past. I guess, can you just talk a little bit about how you develop that forecast, the factors that go into it? And what could be sources of upside or downside to that number?"
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break",474,"Sure. When we think about emerging markets, obviously, we start with Asia. And within Asia, we start with China, and we're looking at health care spending in China and how that is unfolding. And what we're seeing is consistent spending in China. We break that down then to look at business by business, what's happening on kind of the capital side of things as they're purchasing. That's more of an impact, obviously, on the Life Science side than on the Medical side. And then we go back and look at the Medical piece in 2 ways, of course, what's the opportunity for core growth, and then as Tom was talking about earlier, all the product registrations that we have for China and other marketplaces from the CareFusion acquisition. So that's China, number one. Number two, we're looking at India as a growth driver, and that has -- the last 2 years, that has picked up and been a good growth driver for us. Yes, there's pluses and minuses in India. We're seeing good fundamental demand there with the burgeoning middle class. We're expanding our distribution in India. So we will take that into account. There are some headwinds in India in terms of tariffs that are -- that have been put in place. So we make sure that that's not any significant impact, so I would say we still find it as a very attractive marketplace for us. And Middle East and Africa, of course, we're much more careful about what's going on in Saudi Arabia. We follow what the government funding is. In this case, of course, the funding was not just in health care, but it was a significant change linked to the price of oil that we saw. And so the way we're thinking about that is kind of price of oil staying where it is, which means on the low side, which says that they're going to fund their health care, but it's not a big expansion of health care. That was going on in the first half of the year. That's not happening now. But they have to continue to provide care. That's what we're thinking about there. In Africa, we talked about the CD4 business and some of the shift in the guidelines. We've seen -- we believe we've seen the majority of that impact that's really driven by Pepkor, not the entire marketplace. So it was a segment of that market. So we'll watch how that evolves, as Linda said. Then Latin America, as you know, a mixture for us. Mexico's doing well. Brazil is doing okay is what we would say, and we watch the economy there and what's happening from an inflationary standpoint. And of course, funding -- but the other countries in Latin America contributing quite nicely. So that's how we build it up."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Richard Newitter with Leerink Partners.",13,"Your next question comes from the line of Richard Newitter with Leerink Partners."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denomina",84,"This is Ravi in for Rich. Just wanted to build on some of the other questions that have been asked. Just in terms of the CareFusion, the growth registrations that you're going through right now, could you maybe just give us a look into what's the denominator behind that? I mean, is this sort of the bolus of all the registrations that you're doing? Or is there a lot more products that remain to go through that pathway? And then I have 2 follow-ups."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, Tom will take that.",5,"Sure, Tom will take that."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available",216,"Yes. Ravi, this is Tom. So I wouldn't say this is the bolus of them. The numbers that we cited are certainly less than half of the products that we intend to have registered outside. We obviously started with those products that we have the data available for, that didnt need to have additional data generated and were in existing formats that those markets would accept. Take, for example, as we think about pumps, in some cases, we need to do translation and get the language done first, and that's an R&D program to get that ready. Some of the markets require infusion sets to be adapted a bit for local practices. And so what you saw come through first are, obviously, those products that meet the needs of specific geographies. We have the data ready, and we move forward and submit right away. And so most of those also tend to be on the consumable side as I shared earlier, which is why as we think about FY '17, we would expect those synergies to really be focused within our MPS business because that's where those more simple medical devices that are more universal in nature in terms of how they fit in with the health care system. That's where we tend to be focused."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from the line of Kristen Stewart with Deutsche Bank.",13,"Your next question comes from the line of Kristen Stewart with Deutsche Bank."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations.",50,"Just as a follow-up to that. Tom, if you could just give us a sense for just how much of an acceleration we should expect to see from some of these filings and how fast can some of this ramp up or how meaningful, I guess, are these registrations."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of",254,"Yes. As Chris mentioned, we think about it in tens of bps, not in -- dramatically higher than that. And again, just to put things in perspective, we're really pleased with the performance and outlook. And even though we've gotten as early as in FY '16, of course, as we have said, CareFusion was 3%, 3.5% at best growth business as a stand-alone, all right. We're holding at our 4.5% to 5% growth for the segment overall. And as you know, when you take a 3% grower and a nearly 5% grower, you don't get within the range that we're sharing. And so we're already -- we see some good performance this year already as a result of the 2 companies coming together. We think some incremental improvements on that in FY '17, specifically within the MPS business in that tens of bps, as Chris described. The other thing as you -- also to keep in mind is that some geographies take a lot longer. So China, although it's a market that we are filing registrations in, once you file a registration in China, it's a 3-year process. So you can't get into certain markets that fast. Typically, more of the European, Latin America, Southeast Asia markets are those geographies that you can actually get into within an 18-month window. And so that's where you'll see us enter in first. Those aren't necessarily as large as some of the markets like China, which will be later on in our 3-year kind of outlook horizon."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza.",20,"At this time, there are no further questions. I will now turn the conference back over to Mr. Vince Forlenza."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much.",33,"Okay. This is Vince. All right. Listen, thank you all for your questions and comments on the call. We look forward to briefing you at the end of next quarter. Thanks very much."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you.",2,"Thank you."
103678,370563082,1026314,"Becton, Dickinson and Company, Q3 2016 Earnings Call, Aug 04, 2016",2016-08-04,"Earnings Calls","Becton, Dickinson and Company","Operator","This concludes today's conference call. You may now disconnect.",10,"This concludes today's conference call. You may now disconnect."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by ph",81,"Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 94169710. [Operator Instructions] Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter fiscal results.As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation",387,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter fiscal results.
As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth fiscal quarter press release and in the MD&A sections of our recent SEC filings. We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our fourth quarter results reflect the new BD in both the current and prior year periods. In addition, comparable prior year revenues are adjusted to exclude the sales related to the terminated agreement with CareFusion for the sale of F&P's respiratory care products. The impact to the bottom line is not material. Comparable organic revenues are adjusted to further exclude the impact of non-annualized acquisition and closed divestitures. The fiscal 2017 comparable revenue guidance provided today will exclude revenues of closed divestitures, most notably the Respiratory Solutions business that was divested in October of 2016 just after our fiscal year-end. 
In the fourth quarter, the company recorded a noncash impairment charge for capitalized internal use IT software assets. This charge, along with the details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in and reconciliations to GAAP measures in the financial schedules in our press release or the appendix of Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical segment; and Alberto Mas, Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. Moving on to my presentation. As we stated in our press release, we are",593,"Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. 
Moving on to my presentation. As we stated in our press release, we are extremely proud of our accomplishments in our first full fiscal year as the new BD. As you already know, the acquisition of CareFusion 18 months ago significantly accelerated our strategy, and the powerful combination of BD and CareFusion continues to deliver positive results. We've seen significant benefits as a result of this transaction from a customer, employee and shareholder standpoint, and we think there's more to come. 
Turning to Slide 4. I'd like to highlight some key achievements in fiscal year 2016.
First, our results reflect our consistent performance and the benefit of our diverse geographic and product portfolio. Legacy BD remains solid, and the CareFusion portfolio has performed in line with our expectations. 
Second, emerging markets continue to be a key growth driver for the company. We experienced some headwinds this year, particularly in the Middle East and Africa, but remain confident that emerging markets are well-positioned for continued growth. We also continue to create new growth opportunities for CareFusion products in these markets and expand their global reach by leveraging BD's international infrastructure. 
We're on track with our new product approval and submission plans and look forward to providing more color at our analyst meeting later this month. Developed markets continued to show stabilization, and growth has accelerated over the past year. 
Third, we made key strategic decisions to optimize our portfolio. This included the divestitures of BD Rx and the spine business in conjunction with the joint venture for the respiratory business, which we just completed in October. These actions further enabled the organization to prioritize and invest in the most important opportunities for future growth. We were deliberate in increasing our R&D investment in targeted high-growth areas and fully utilized the benefit of the medical device tax suspension.
Fourth, we remain focused on our operating effectiveness and efficiency initiatives, which have generated significant margin expansion. This year, we drove approximately 200 basis points of underlying margin expansion, which includes approximately $120 million in cost synergies. We also delivered robust earnings growth of almost 30%, which is greater than our initial expectations.
Lastly, we closed our first full year as the new BD, having achieved all important milestones and also demonstrated that we are successfully executing on our acquisition of CareFusion. As we look forward, we continue to build on our solid foundation and look to fiscal year 2017 and beyond with confidence. 
Moving to Slide 5. You will see the guidance for fiscal year 2017 on a currency-neutral basis. For the fiscal year 2017, we expect currency-neutral revenue growth of 4.5% to 5% based on our current view of the environment and various macroeconomic factors. There are a number of items that could bring us to the top or bottom end of that range, including a stronger or weaker flu season than expected, the performance of new product launches, emerging market growth and pricing. On the bottom line, we will continue to deliver high-quality earnings growth. For fiscal year 2017, we expect EPS of $9.45 to $9.55 or $9.62 to $9.72 currency neutral, which reflects growth of 12% to 13%.
Now I'd like to turn the call over to Chris, who will walk you through our financial performance in the fourth quarter and full year, along with the additional details about our fiscal year 2017 guidance."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approx",2260,"Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approximately $3.2 billion grew 6.4% on a comparable basis. Fully diluted adjusted EPS came in ahead of our expectations at $2.12, growing at 16.5% over the prior year. 
As Vince mentioned earlier, we are very pleased with our solid finish to the year, the first full year as a combined entity with CareFusion. For the total year, revenues grew 4.3%. We significantly expanded our margins and captured approximately $120 million in synergy cost savings. Adjusted EPS of $8.59 exceeded our expectations, driven by solid revenues, margin expansion and an improved tax rate. In addition to the cost synergies, tax synergies have materialized sooner and have exceeded the benefits we anticipated in the early days of the transaction. We are also pleased to announce that we have continued to delever as we reduced the debt associated with the acquisition of CareFusion. We are currently at 3.3x gross leverage and remain on track to achieve our commitment of 3x gross leverage by March of 2017.
On Slide 8, I'll review our revenue growth by segment on a currency-neutral basis. Fourth quarter revenue growth was 6.4% for the total company in the quarter, pricing was about flat. BD Medical fourth quarter revenues increased 7.9%. Medication and Procedural Solutions growth was 6.6%, which reflects strength in flush, ChloraPrep and safety-engineered products. Revenues in Medication Management Solutions or MMS grew 12.8%. This was driven by double-digit growth in both dispensing and infusion sales.  
Respiratory Solution revenues increased 12.7%, as expected. This reflects strong capital installations and a favorable comparison to the prior year period.
Growth in Diabetes Care was 3.6%. This reflects solid growth in pen needles, which was partially offset by an unfavorable comparison to the prior year period. Pharmaceutical Systems growth of 5.1% reflects strength in our self-injection platform. For the total year, BD Medical grew 4.7%. 
BD Life Sciences fourth quarter revenues increased 2.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Diagnostic System revenues were about flat compared to the prior year. This reflects continued strength in core microbiology and BD MAX, which grew double digits in the quarter. This growth was offset by the timing of KIESTRA installations outside of the U.S., which I'll speak to in just a moment. For the total year, we are extremely pleased with our microbiology business, with KIESTRA growing at about 19%.
Preanalytical Systems growth of 4% was driven by safety-engineered products and growth in the U.S. and emerging markets. BD Biosciences growth of 4% was driven by continued strong research instrument placements in the U.S. and reagent sales. For the total year, Life Sciences grew 3.4%. The headwinds we experienced in Africa negatively impacted segment results by 60 basis points, bringing underlying growth to 4% for the total year.  
Moving to Slide 9. I'll walk you through our geographic revenues for the fourth quarter on a currency-neutral basis. U.S. growth was very strong at 7.2%. This was comprised of BD Medical growing at 7.7% and BD Life Sciences growing at 5.8%. BD Medical's performance reflects strong growth in capital placements and a wide range of infusion disposable products in our Medication and Procedural Solutions business. Growth was also driven by our Pharmaceutical Systems business. 
BD Life Sciences growth reflects strong performance across the segment in the U.S. The growth in our Biosciences business was driven by high-parameter research instruments, including FACSSymphony, our FACSCelesta mid-level analyzer and the launch of the FACSMelody. Our U.S. Diagnostics business saw continued growth in microbiology, including KIESTRA and the BD MAX molecular platform. The Preanalytical Systems business grew 5%, driven by safety-engineered products.
Moving on to international. Revenues grew 5.2%. This is below our normal growth rate, which is primarily related to the Life Sciences segment. The Medical segment grew 8.2%. This was driven by strong performance from infusion disposal products in the MPS business and strong performance in China. Growth was also driven by medication management, reflecting double-digit growth in both dispensing and infusion.
Growth in the Life Science segment was about flat compared to the prior year. We experienced a decline in Diagnostic Systems due to the timing of KIESTRA installations. Increased installations in the third fiscal quarter negatively impacted the fourth fiscal quarter in conjunction with the tough comparison to the prior year fourth quarter. Biosciences growth was lower in the quarter due to continued declines in Africa, as we anticipated. The Preanalytical Systems business grew 2.9%, driven by strength in China, which was partially offset by a tough comparison to the prior year period.
On Slide 10, developed markets grew a healthy 5.8%, bringing the total year growth to 4.1%. Emerging market revenues grew 8.5% currency neutral, bringing our year-to-date growth rate to 5.3%. China growth for the fourth quarter was 17.7%, bringing the total year growth rate to 10.1%. Growth in emerging markets this fiscal year was lower than initially expected in the Middle East and Africa, and we believe those challenges are largely behind us after we exit the first quarter of fiscal year 2017. Emerging markets remain an important growth driver, and given our robust international footprint, we are well positioned to drive growth well into the future.
Looking into fiscal year 2017. We expect emerging markets to grow high single digits, driven by a diversified base, with China growing low double digits, continued strength in Latin America and fewer headwinds in EMA and Africa. In terms of developed markets, we believe the stability we have seen in the market over the past 12 to 18 months will continue, yielding a growth rate of about 4%.
Moving to global safety on Slide 11. Currency-neutral sales increased 5.9% and grew to $783 million in the quarter. Safety revenues in the U.S. grew 5.7%. This reflects continued strength of safety catheters as well as a benefit from the timing of orders across our hypodermic products.
International sales grew 6.2% currency neutral. International performance in the Medical segment was driven by the continued strength in China, and safety revenues grew 13.8% in emerging markets.
Medical safety sales grew 7%, driven by infusion disposables, catheters and a range of safety-engineered products. Life Sciences safety sales, which were driven by our Preanalytical Systems unit, grew 4% in the quarter.
Slide 12 recaps the fourth quarter income statement and highlights our currency-neutral results. Revenues grew a strong 6.4% in the quarter. Gross profit was strong, growing faster than revenues, at 7.9%. And I'll provide more details on gross profit in just a moment. 
SSG&A as a percentage of revenue was 24.4%. We are very pleased with the leverage we are getting, which is masked in this quarter by key strategic investments in product launches in both segments. R&D as a percentage of revenues was 7.8%, which is higher than normal due to the timing of spend as anticipated. As a result of the medical device tax suspension, we were able to make additional investments in a number of high-growth areas. After normalizing for this significant additional investment in R&D, underlying operating income would have grown about 10% in the quarter.
Our tax rate declined to 16.2% in the quarter due to the reinstatement of the R&D tax credit, tax synergies materializing earlier than expected and continued favorable geographic mix. In the quarter, adjusted earnings per share were $2.12, which is a 16.5% increase versus the prior year.
Turning to Slide 13 and our gross profit and operating margins for the fourth quarter. On a performance basis, gross profit margin improved by 90 basis points, driven by continuous improvement initiatives. This was more than offset by significant currency headwinds of 110 basis points. On an operating margin basis, we are extremely pleased to have delivered about 100 basis points of underlying margin expansion. As I mentioned on the previous slide, the leverage we are getting in SSG&A as we continue to drive cost synergies is being masked in the quarter by investments in key product launches. In addition, margin expansion was partially offset by significant R&D investments, as expected, and unfavorable currency. 
I'd like to take a moment on Slide 14 to highlight some of our key operational achievements for fiscal year 2016. The acquisition of CareFusion provided BD a unique opportunity to leverage the transaction to optimize the combined organization through functional transformations, and we have made significant progress in this area. All of our efforts have yielded results, and we are on track to deliver continued synergies. In aggregate, we have achieved over $170 million in total cost synergies to date. 
We have also driven significant margin expansion on a multiyear trajectory. Starting with fiscal year 2015, we delivered 100 basis points of operating margin expansion. This year, we achieved another 200 basis points, and we believe we are well positioned to deliver another 175 to 225 basis points in fiscal year 2017. Over those 3 years, we will have driven over 500 basis points of cumulative margin expansion, and I believe that we continue to drive robust performance with additional synergies in conjunction with continuous improvement going forward. We're extremely proud of the organization's ability to continue improving on our skills and expertise by executing against our synergy commitment initiatives through these transformations.
Moving on to Slide 15. I'd like to highlight our robust EPS growth, which exceeded our expectations this year. Starting with 2015 EPS of $7.16, we had communicated last November that we would grow EPS 22% to 23% on a currency-neutral basis. Beyond our initial expectations, we delivered an incremental 400 basis points from margin improvement. We also realized incremental benefits from our tax rate improvement, which yielded 300 basis points, bringing EPS to $9.24. Unfavorable currency headwinds impacted earnings per share by 900 basis points. Despite that significant headwind, we were still able to deliver $8.59 of earnings. On a currency-neutral basis, earnings grew 29.1%, which we believe demonstrates our ability to deliver on our commitment.
Moving on to Slide 17. There are a number of factors to consider when discussing our earnings per share in fiscal year 2017. For modeling purposes and to ensure consistency, I'd like to provide more color on our EPS guidance. First, as I mentioned, we are extremely pleased with strong EPS growth this year. Looking forward, we expect currency-neutral EPS to grow between 12% and 13%. This is partially muted by the impact of the respiratory JV, as we previously communicated. Pension also presents a headwind next year of approximately 100 basis points. 
Contributing to EPS growth is approximately 200 basis points from the adoption of a new accounting standard related to the tax accounting on our stock compensation programs. In addition, we estimate that currency will once again present a headwind. Our guidance assumes a euro to dollar exchange rate of $1.10. On an adjusted basis, we expect to achieve very strong earnings of $9.45 to $9.55.
Turning to Slide 18. I'd like to walk you through the balance of our guidance expectations for the full fiscal year 2017. As Vince mentioned earlier in the presentation, we expect revenue growth of 4.5% to 5%, with BD Medical growing 4.5% to 5% and Life Sciences growing between 4% to 5%. Growth in both segments contemplates a small amount of pricing pressure. 
From a phasing perspective, we expect currency-neutral revenue growth in the first quarter to be below this range. This is primarily due to some lingering softness in the EMA region and the timing of tenders in our Biosciences business. This will result in a currency-neutral revenue growth of about 4% in the first fiscal quarter. We expect revenue growth to return back to our guidance range in the second fiscal quarter, with continued acceleration over the back half of the year. We expect gross profit margin to be between 53% and 54%, which is a significant milestone for BD.
SSG&A as a percentage of sales is expected to be between 23.5% and 24%. Our guidance also reflects continued investments in emerging markets as well as costs related to new product launches and registration costs. We expect our R&D investments to be in line with fiscal year 2016 at about 6% to 6.5% of revenues as we continue to invest in new products and platforms. 
As a result of the items I just detailed, operating margin is expected to be between 23% and 24% of revenues, up from 20.8% this year. Excluding the unfavorable impact of foreign currency, we expect our underlying operating margin to improve by 175 to 225 basis points. This also excludes slight pension headwinds.
We expect our tax rate to be between 17% and 19%, driven by tax synergies, favorable geographic mix and a benefit from accounting change in our stock compensation program. For fiscal year 2017, we anticipate our average fully diluted share count to be approximately 219 million. Cash flow is expected to remain strong, with operating cash flow of about $2.7 billion in fiscal year 2017. Capital expenditures are expected to be about $700 million. 
In summary, we have good momentum exiting this fiscal year, and looking forward into 2017, we are building off a solid foundation. I'm confident that fiscal year 2017 will be another strong year of performance, positioning us well for continued success. 
Now I'd like to turn the call back over to Vince, who'll provide you with our concluding remarks."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few.",509,"Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few. 
On the Medical side of the business, we are pleased that our partner, Fresenius, received their first FDA approval for IV solution products. Additional approvals are expected, and we are on track to start shipping these products late in the first half of the year. Last quarter, we received our first orders for FlowSmart, our new insulin infusion set, where Medtronic serves as our distribution partner. Early patient feedback has been extremely positive. 
On the life side -- Life Science side of the business, we're pleased that the FDA has approved the BD MAX Vaginal Panel and also the GC/CT/TV assay. We launched our new Phoenix IDAST instrument. We launched the FACSMelody and received approval for Barricor in the U.S. We plan to share more about our pipeline on November 17 at our upcoming Analyst Day.
Also on Analyst Day, we will discuss the company's strategy and vision for the future and how we are helping to address health care's most pressing challenges. The segment leaders will do a deep dive into our business units, which will include some key product launches that we will be unveiling for the first time. We will conclude the day with a financial framework that will outline our plans for sustainable revenue growth, continued margin expansion, strong cash flow generation and capital deployment and, ultimately, demonstrate how all of those things will drive long-term value not only for our customers and patients they serve but also for our employees and our shareholders.
Moving on to Slide 21. I would like to reiterate the key messages from our presentation today. First, we're extremely pleased with our first fiscal year as the new BD. We believe that we have demonstrated that we can successfully execute on the integration of the largest transaction in the company's history.  Second, the diversity of our portfolio from a product and geographic perspective provides consistent and reliable earnings growth. Third, we continue to invest in key strategic areas and, at the same time, deliver significant margin expansion and double-digit earnings growth. 
We're looking forward to sharing more details about our pipeline at our Analyst Day in 2 weeks. We believe we have the most robust pipeline in the company's history, and we look to fiscal year 2017 and beyond with confidence.
Finally, I would like to say thank you to all of our associates around the world for our successful first full fiscal year as a combined company with CareFusion. It's a testament to the hard work of all of our employees that we delivered on our commitments. I believe we have a tremendous opportunity to create a true industry leader as we continue to advance the world of health. 
So with that, thank you. We will now open the call to questions."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan.",12,"[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit mo",134,"So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit more challenged. And so maybe just focusing a bit on the more challenged businesses first. Can you just talk a little bit about some of the headwinds that you saw, particularly international, in the Life Sciences business this quarter, this year and how you think about some of those end markets in FY '17? And then if you think about that in aggregate, that 4.5% to 5% revenue growth target for FY '17, what gets you to the higher end of that range?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue, which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So f",639,"Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue, which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So from a market perspective, let me just start with the developed markets. The developed markets certainly have stabilized, and you've seen that -- our growth rate going up in the developed markets and the U.S. The U.S. was very strong. By the way, including Biosciences, Europe was good, Japan was good. So we feel good about our position in developed markets and the product pipeline we have for those marketplaces. If I come to emerging markets, the issue really this year was, number one, Saudi Arabia, where we saw the government do a 35% cut of all types of expenses, not just health care. And that will annualize during the year. We already saw a stabilization in Saudi Arabia. In terms of Africa, Africa was basically CD4 testing. And CD4 testing was driven by, one, some conversion to viral load; and two, actually, confusion over a change in the purchasing organization for CD4 and viral load. And we think we have one more quarter of that. We did start to see some CD4 orders come in the fourth quarter and a little bit of a rebound. But we know we have that in the first quarter and then that annualizes and improves. Coming back to opportunities. On China, you saw the strong growth in China in the fourth quarter. If you actually go back and look at China after the first quarter, where we had some inventory take-down, China was strong for the other 3 quarters. We expect that to continue. It was especially strong this year on the Medical side of the business, and we think we're well positioned with the work that Tom and the regulatory team have been doing with the CareFusion product lines there. And as I've mentioned on previous calls, we've started with some of those product lines kind of the simpler disposables, and I'm sure Tom will talk more about that later on in the call. If there was any softness in China this year from a true demand standpoint, it was on the Life Science side, and it was related to those anticorruption campaign. What we saw was stabilization starting in the third quarter and continuing into the fourth quarter. And Alberto can mention to you he's starting to get ramped up the Bruker deal in China as well, which was a whole new thing for us. We had to learn how to do that and work our way through some submissions. So we feel good about China. The rest of Asia has been good. Latin America has performed well this year. In spite of all those issues in Brazil, it's been -- the rest of the geography has done fine. Coming back to the 4.5% to 5%. Then the other element that you have to think about is 2 other things. One is we will not have respiratory anymore, and that has been a bit of a headwind for the company. And then we think, in the back half of the year, you'll start to see more traction with our product launches. Things like Barricor, they have to do the validation first, so that takes a little while to get going. Customer feedback has been excellent. Alberto can talk about the product launches that you heard for BD MAX. Those are really critical assays to that program. We're excited about them. And so there's a whole list of these things, and we'll show you more about that as we do the Analyst Day. So that's the way we're thinking about it."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the",127,"One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the first quarter because they really came up in the second quarter -- second, third and fourth of this year. So we still have a little bit of a tough compare in the first quarter that we talked about, particularly in Saudi and Africa. But once we get through that with the new product launches that we're seeing, the strength of the rest of the business, we feel real good about our prospects for '17."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, th",71,"So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, that would take us up, too. Those are probably the 2 factors that I see. So thanks, Mike, for the question."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from David Lewis of Morgan Stanley.",10,"Your next question comes from David Lewis of Morgan Stanley."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions I'll just throw [ph] at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team reaching your target here at least 2 years earlier from our models. So Chris, is this a structural kind of new low?",129,"Two quick questions I'll just throw [ph] at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team reaching your target here at least 2 years earlier from our models. So Chris, is this a structural kind of new low? Can you do better? And obviously, you're reinvesting these savings both in the fourth quarter and next year. Can you give us a sense of where the '17 reinvestment is going? And can you do better than these levels long term? And then for Vince or Tom, OUS Pyxis and Alaris, very strong this particular quarter. Can you talk about the drivers and sort of update us on how those numbers relate to progress on the CareFusion cross-sell?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last",191,"Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last call, the tax synergies coming from CareFusion happened faster and greater than we ever expected, and so we're seeing the benefit of that. So as we look out into next year, we see that bringing us to the high teens. And then we've got the benefit of the stock comp accounting adjustment. That brings us down to the 17% to 19% range. So this move down is part of the march down in the tax rate that we've been seeing, coupled with the benefits that we're getting from the synergies from CareFusion. And so we really feel good about that. We've also closed out a lot of tax exams in multiple jurisdictions. We're part of the IRS' CAP program, so they're auditing us on a real-time basis. So the sustainability of this tax rate is extremely strong, and we feel real good about it."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Chris. Tom, you want to pick up on the second part?",13,"Okay. Thanks, Chris. Tom, you want to pick up on the second part?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very wel",231,"So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very well. We talked earlier in the year about some of the process improvements we had made to accelerate the installation process. I think you're seeing the results of that work come to fruition now with faster installations, getting those systems in. We now have over 1,100 sites live on ES or about 1/3 of our installed base is now upgraded to the ES platform. And the receptivity is very solid, and we extract -- expect strong demand on that going forward. Alaris, we continue to gain about 2 to 3 points of category share this past year in FY '16, and we're looking at kind of a similar progress outlook for FY '17 as well. And so we certainly do have organizations that are cross-selling those as an integrated offering. You'll see at Analyst Day us talk about some new informatic capabilities and other new products coming out that will further strengthen the integration and the value that we can deliver to customers who are using that complete end-to-end offering. And so we look forward to talking to you about that very shortly."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Kristen Stewart of Deutsche Bank.",10,"Your next question comes from Kristen Stewart of Deutsche Bank."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether o",64,"Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether or not you'd be willing to do another larger deal. Or would it be back to doing just more share repurchase activity?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to",164,"So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to March, we're pretty sure that we're going to be meeting our requirements to the rating agencies. What I would say is that gives us more flexibility around those strategic imperatives. And so we believe we now have the capability to do large and, of course, continue to have that capability to do tuck-ins and a little bit more flexibility to do the tuck-ins in the short run than we've had over the last 2 years. And so I'm not sitting here saying we're going back to do a large one. We'll be strategy driven around this with increased flexibility and capability that we have built over the last couple of years. Chris, you want to talk about share buybacks?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x",262,"Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x leverage, we're getting a lot of increased flexibility. So as we think about the use of that cash flow, we'll probably do something on the dividend rate. You know that the payout ratio has come down a little bit. We increased 10% a year for the last couple of years. The good news is our EPS is going up over 20%. So the payout ratio has come down a little bit, and we will have to address that going forward. I think CapEx, as you think about it, will be in the $700 million range. That's pretty consistent with where it has been. So that leaves a lot of cash left over. We'll allocate some of that to tuck-in acquisitions, and that will still leave a lot of cash left over. And we're not going to let that cash build up on the balance sheet. So we'll return to doing some share buybacks. You will hear more about that at Analyst Day. And certainly, as we approach the March period of getting to the 3x leverage, we'll be giving a little bit more specificity on where we're going. But the good news is we have really good strong cash flow and a really solid balance sheet with a lot of flexibility."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?",40,"Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marke",76,"So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marketplace. So I think we're being prudent in terms of how we're thinking about this, and we'll continue to work as we have in the past to offset it."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing.",26,"And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Rick Wise of Stifel.",9,"Your next question comes from Rick Wise of Stifel."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. A",70,"I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. And maybe talk about the drivers, volume, cost, mix. I mean, what gets us to those higher levels I have no doubt you aspire to?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute",256,"Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute on within our operations group over the last few years. And as we look forward, the guidance that we gave of 53% to 54%, and that would be inclusive of FX headwinds and pricing headwinds, et cetera, is extremely strong. It's a significant milestone for us to hit that 53% to 54%. We do see a little bit of -- more synergies coming because as we execute on the synergies that affect gross profit and cost of goods sold, which we said would come towards the latter end of our synergies, and that is the way that's playing out, but, again, continued -- continuous improvement in that area. So we feel really good about the gross profit margin. Also, that flows down to the operating margin. So as we mentioned, this year, 200 basis points; last year, 100 basis points; next year, in that 200 basis points kind of range, 500 basis points in total, again, driven both from execution of the synergies as well as continuous improvement initiatives. So feel real good about that. and As we look forward even past next year, '18 will Have Continued cost synergies, and you'll see some benefits from that. So all in all, really strong margin improvement, and we feel really good about that."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about how Alaris, but I was wondering if you could give some thoughts around Fresenius IV solution that was approved, a little bit about what you do anticipate",74,"Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about how Alaris, but I was wondering if you could give some thoughts around Fresenius IV solution that was approved, a little bit about what you do anticipate launching towards the end of the first half? And what drives that share gain for the year [indiscernible] suggesting 200 [ph] to 300 basis points?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Larry, this is Tom. That share gain we saw this year is consistent with the share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the platform around the power of",249,"Larry, this is Tom. That share gain we saw this year is consistent with the share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the platform around the power of one, the ability to do not just large volume but also syringe base and narcotic infusion off the same platform as well as in leading interoperability position with electronic medical records, are some of the key reasons why people have been choosing it at a higher rate and continue to do so going forward. Again, we do have some new technologies being added to the platform, which we'll share also at the upcoming Analyst Meeting. So we're very positive on the outlook there. But as we think about IV solutions as we mentioned before, you're going to see, I would expect, a rolling series of approvals on that platform. This is the first -- of course, there's numbers of different formations of IV solutions as well as bag sizes when you think about building out a portfolio that customers really need to run their institution. And so what you just saw get approved was a first in a series of products that we would expect the additional products to be coming out over the months ahead, and that leads us up to where we have a really critical massive portfolio for launch at the end of the first half of the year."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar of Evercore ISI.",10,"Your next question comes from Vijay Kumar of Evercore ISI."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","It looks like the number for a lot better than that it seemed like at first [ph] quarter [ph]. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just tal",91,"It looks like the number for a lot better than that it seemed like at first [ph] quarter [ph]. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk about the quarterly cadence because obviously, this year was a back half loaded on the revenue front and given the flat share count and your comments around free cash generation, it looks like maybe there are some upside from cap deployment potentially?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Pricing is just slightly negative in the plan and as Chris said, it's already in the guidance.",17,"Pricing is just slightly negative in the plan and as Chris said, it's already in the guidance."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, which is no different then the beginning of just about any year. You got to look at that The pricing environment has been, as Vince said, it hasn't really changed. And so then I think the next part of your question came to the phasing of revenue goin",284,"Yes, which is no different then the beginning of just about any year. You got to look at that The pricing environment has been, as Vince said, it hasn't really changed. And so then I think the next part of your question came to the phasing of revenue going forward. As we said, we do see some headwinds continuing as we annualize the headwinds from Saudi and Africa. That will bring us down in the area of about 4% in the first quarter, plus or minus 20 basis points, particularly as that's a high quarter for the flu. So it could go one way or the other on us. But then the ramp in the second quarter brings us back well within the range -- the high end of the range. And the ramping of new products that we see in the second half of the year bring us back to a strong 4.5% to 5% range. So that feels really good. In terms of capital deployment, the share buybacks, we're committed to not buyback any shares other than what we've already done for respiratory, which we've talked about. But we're not looking to do anything until we get to the 3x leverage. We want to hit that commitment that we have, and that brings us through March. So halfway through the year. And then from that point on, you're right, there could be some -- if you look at the full year impact of that at that point, so more to come on that. But there is some potential as we buy back shares. It had a little bit of impact in '17 but probably more likely, the impact would be on '18."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein of William Blair.",10,"Your next question comes from Brian Weinstein of William Blair."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to ask about kind of U.S. headwind that we've heard about from others, specifically flu year-over-year was a tough comp for a lot of people. Utilization seems a bit weaker. We're hearing about things getting -- taking longer on capital projects w",90,"I wanted to ask about kind of U.S. headwind that we've heard about from others, specifically flu year-over-year was a tough comp for a lot of people. Utilization seems a bit weaker. We're hearing about things getting -- taking longer on capital projects worked on inventory distributors. How you guys think about those and how do you think about kind of the U.S. market going forward? What are the positive offset that you're seeing to those? And are you guys seeing any of those same headwinds that I described?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We're generally not procedural driven and Alaris conversion to make the hospitals safer and more effective. They're not being driven by this on the margin procedures, and in fact, Tom was talking about interoperability before and just to give an example,",142,"We're generally not procedural driven and Alaris conversion to make the hospitals safer and more effective. They're not being driven by this on the margin procedures, and in fact, Tom was talking about interoperability before and just to give an example, Brian, we were at one [ph] account, we're saving 5 million keystrokes a year. It's a kind of thing that you want to do in this environment. It was a very intentional part of our strategy. So what I would say is generally across the board, we're seeing pretty good stability and some increase. We're just getting started with KIESTRA, for example, in the U.S., which is a major cost saving, withers in the hospital market or in the clinical lab market. And so we don't have a lot of exposure to do kind of headwinds that you were mentioning."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company which was strong in both segments. 7.7% in Medical and 5.8% in life science. That also point to Biosciences is growing in the U.S. around 8% for the quarter an",77,"I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company which was strong in both segments. 7.7% in Medical and 5.8% in life science. That also point to Biosciences is growing in the U.S. around 8% for the quarter and for the year. A lot of that was new product introductions of Symphony, Celeste, the new Melody introduction or whatever. So U.S. is doing particularly strong for our business."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Vince, the first Analyst Day coming up November since 2011, and I know you don't want to give away all details, but may be big picture maybe can help us understand what you hope people take away from the meeting?",40,"Vince, the first Analyst Day coming up November since 2011, and I know you don't want to give away all details, but may be big picture maybe can help us understand what you hope people take away from the meeting?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, I hope that they take away a true understanding of when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to a complete solutions. What that means from a portfolio sta",255,"Yes, I hope that they take away a true understanding of when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to a complete solutions. What that means from a portfolio standpoint. And when I'm saying that we have the most robust populations shift the company, I want you to understand what that all means. And we will lay that out for you in a lot of detail. So that's number one on the list, that you understand why we have that confidence going forward. And i think it' going to be fun, quite frankly. It was fun doing this 5 years ago, so I'm looking forward to it. And then we're going to take that, and Chris is going to kind of give you a financial model of how this all holds together. And lastly, we're going to talk about the capabilities that it's going to require to do all this. We're going to show you how you were able to capabilities foundationally over the last 5 years and then how we build upon them. Tom mentioned informatics for example, but we'll also get into how we approach the emerging markets, what's different about our strategy and why we see that continuing to work. And some of the other capabilities that we will be bringing to bear, which all is extension of work we've done over 5 years. That's the kind of day and look forward to seeing you there, Jon."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Bill Quirk of Piper Jaffray.",10,"Your next question comes from Bill Quirk of Piper Jaffray."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A couple of questions. First off, international safety, you mentioned China, in particular, is a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, which relative to Medical, has been a",86,"A couple of questions. First off, international safety, you mentioned China, in particular, is a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, which relative to Medical, has been a little less predictable, and we certainly appreciate all the product launches both n launch as well as near-term development. Do you think this can improve the ability of the business? Or do you think we may have to look at some tuck-in deals for consistency."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So let me just take Life Sciences first. And the lumpiness that we've seen a Life Sciences, there's 2 elements. One is just KIESTRA, which is positive thing. These are big installations $2 million and you're seeing some quarterly jumps around as consumers",136,"So let me just take Life Sciences first. And the lumpiness that we've seen a Life Sciences, there's 2 elements. One is just KIESTRA, which is positive thing. These are big installations $2 million and you're seeing some quarterly jumps around as consumers are ready for us to install because there's some major changes that the may have to make to the laboratory, number one. Number two, we've had this issue with Africa, and that's been a bit of a problem. We think there's going to rationalize. Are interested in tuck-in acquisitions there? Absolutely as we are in on the Medical side. I'm just going to ask Alberto to comment on Kiestra and kind of what you're seeing from a pipeline standpoint of how you see the U.S. market evolving because we just got started there."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, where we're seeing the most growth in positive growth is in the U.S. market. Traditionally, this has been an acquisition was based in Europe and the market plus most developed there. But we're beginning to see some significant traction here in the U.",121,"Yes, where we're seeing the most growth in positive growth is in the U.S. market. Traditionally, this has been an acquisition was based in Europe and the market plus most developed there. But we're beginning to see some significant traction here in the U.S. In fact, the sales this last year doubled versus the previous quarter. Admittedly on a very small base, but we're seeing a lot of positive momentum especially as we build the platform. And you'll hear the capabilities of the platform that you'll hear about the end Analyst Day. So we will continue to build off those capabilities, and that gets the customer very excited about the future of the platform, not only the price of the platform."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And so the second part of the question was on where are we in the Europe from safety standpoint. And then if I remember Tom Polen gave you baseball analogy last quarter. So what inning are we in, Tom?",39,"And so the second part of the question was on where are we in the Europe from safety standpoint. And then if I remember Tom Polen gave you baseball analogy last quarter. So what inning are we in, Tom?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So we're in the middle innings when it comes to EU safety and maybe it will be in over time as well as it was last night. But overall, we saw safety continue to perform well in Europe. Compliance with regulations certainly is fueling that. We see implemen",147,"So we're in the middle innings when it comes to EU safety and maybe it will be in over time as well as it was last night. But overall, we saw safety continue to perform well in Europe. Compliance with regulations certainly is fueling that. We see implementation strongest in the conventional hospital setting. A little weaker in the alternate setting, that's true in most markets where individual doctor compliance may be less than a large governed hospital setting. Strongest conversion rates we see infusion and therapy and blood collection a little bit lagging in injection. That's also the same trend that we saw in the U.S. so still good growth plus was there and we're in the middle innings. You also mentioned China. Overall energy markets, we're seeing safety in very early innings at less than 15% conversions, so still quite a ways to go."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Derik De Bruin of Bank of America.",12,"Your next question comes from Derik De Bruin of Bank of America."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A lot of questions have been answered, but I just want a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook the growth over the year -- or during 2016 [ph] like the Middle E",87,"A lot of questions have been answered, but I just want a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook the growth over the year -- or during 2016 [ph] like the Middle East situation. But what gives you confidence that that's going to reaccelerate this year other than tougher comps or easier comps? What are you sort of seeing right now you're not going to have to face another year?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think you have to start with Saudi Arabia, which is a major impact to our emerging market growth this year. And as I said, government policy was to cut all expenses by 35%. Now you're going to run your health care system, you just can't stop buying prod",200,"I think you have to start with Saudi Arabia, which is a major impact to our emerging market growth this year. And as I said, government policy was to cut all expenses by 35%. Now you're going to run your health care system, you just can't stop buying product, number one. So our expectation was they were running down their inventories and then they will start to buy. What we've seen in this quarter was stabilization there. And so it didn't come all the way back to positive growth, but with significant improvement. So that gives us a sense that our hypothesis in this case is right, number one. Number two, it' really Africa and the annualization of Africa. It was still negative, but we started to see -- and Alberto can give you some more details, some CD4 orders starting to come in, which we did not see. So and then we saw good performance across Asia, as I was mentioning before. I expect that to keep happening, I expect Latin America, that Brazil is going to remain status quo, and we're going to continue to see strong growth in the other marketplaces. But Alberto, other comments on CD4?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, I just want to go back on comment I said before in terms of the change in the supply chain could be a little bit of instability in the ordering process in the delivery created a little bit more variance that we had anticipated.",45,"Yes, I just want to go back on comment I said before in terms of the change in the supply chain could be a little bit of instability in the ordering process in the delivery created a little bit more variance that we had anticipated."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Where people didn't know how to order. That's behind now.",11,"Where people didn't know how to order. That's behind now."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","The other point in China we saw a little bit inventory adjustment in the first quarter of last year. But since then as Vince mentioned earlier, it' been growing very nicely. And you see the fourth quarter growth extremely nicely, a little bit of an easier",103,"The other point in China we saw a little bit inventory adjustment in the first quarter of last year. But since then as Vince mentioned earlier, it' been growing very nicely. And you see the fourth quarter growth extremely nicely, a little bit of an easier compare there, but still very strong. Vince and I and Tom just got back from China. I can tell you that there's a lot of enthusiasm for some of the newer product we're bringing in, so we see a good a lot of stability and as we mentioned, lookings at low double-digits on China into next year."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation but more than obviously for the emerging markets.",36,"And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation but more than obviously for the emerging markets."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just try to get out how much of the synergies respiratory mix, et cetera. And then second, on the topic of your products, what was new product contr",90,"Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just try to get out how much of the synergies respiratory mix, et cetera. And then second, on the topic of your products, what was new product contribution to 2016 revenue growth? Looking ahead to 2017, it seems like new product contribution to organic growth should account for a bigger part of overall growth as you accelerate revenue synergies important launches such as the infusion sets. Can you comment on that?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","This is Chris. On the first  part of the question as we look at margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff; another 50 basis points coming from cos",96,"This is Chris. On the first  part of the question as we look at margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff; another 50 basis points coming from cost synergies and about 100 basis points coming from the respiratory JV coming off our income statement so we got benefit there. On the gross profit, it' roughly the same kind of area that benefit from respiratory, about half coming of it respiratory, about half of it from CI and synergy."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation. So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they really ha",171,"In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation. So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they really haven't gotten traction yet. Barricor, people are just starting to validate Barricor. The approvals on BD MAX, we just got in the last month or so. So they really haven't hit. And then you're talking about tens of basis points in terms of the CareFusion products in the emerging markets at this point in time. We haven't completed the work, let me say that way, in terms of trying to get a really good analysis around breaking out new product from the entire company. As we're going through the CareFusion integration, we haven't counted the geographic extension of those products as new products. But we're working our way through that, and you'll have a better sense after the Analyst Day of how this is coming together."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Matt Taylor of Barclays.",9,"Your next question comes from Matt Taylor of Barclays."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I was wondering if you could comment given you do have some bigger product cycles here coming up in the full year and one of the more robust pipelines at the company. Could you comment on some of the bigger opportunities like fluid, diabetes and some of t",75,"I was wondering if you could comment given you do have some bigger product cycles here coming up in the full year and one of the more robust pipelines at the company. Could you comment on some of the bigger opportunities like fluid, diabetes and some of the launches in terms of how we should expect the revenue contribution from that to flow? Can you help us size them and just your thoughts on timing?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll ask Tom to start talking about diabetes and FlowSmart. Okay?",13,"So I'll ask Tom to start talking about diabetes and FlowSmart. Okay?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Matt, this is Tom. Certainly we're excited about the upcoming launch or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the mini med process with our FlowSmart technology. Medtronic has begun shipping t",159,"Matt, this is Tom. Certainly we're excited about the upcoming launch or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the mini med process with our FlowSmart technology. Medtronic has begun shipping that to patients, and the feedback that we're hearing is very positive. And there's been a number of buyers actually write their experience. You can look that up online, but it's very, very good feedback has moved into the marketplace just over the last couple of months. We do expect that, that will expand to a broader full launch in early Q2. And that's well on track. So I think back to one of the earlier questions as we think about within the Diabetes Care business, we do expect don't give guidance by business unit but we expect an uptick in '17 in Diabetes Care, driven by that FlowSmart launch. And that's on track, proceeding as planned."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay, so Alberto, why don't you comment on BD MAX and Barricor in terms of kind of phasing on those things?",21,"Okay, so Alberto, why don't you comment on BD MAX and Barricor in terms of kind of phasing on those things?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, so for the BD MAX, the 2 approvals we got in the U.S. FDA approvals, we're excited about because they're very unique assays. They're differentiated assays that will bring value to the market. The CTTV assay is the first one that is integrated, which",175,"Yes, so for the BD MAX, the 2 approvals we got in the U.S. FDA approvals, we're excited about because they're very unique assays. They're differentiated assays that will bring value to the market. The CTTV assay is the first one that is integrated, which is the guideline for the CDC to do the 3 test all in one, and we're the only ones that have it on the same essay. The Vaginal Panel will be a significant improvement versus -- the only approved essay that we have out there will be better accuracy, more targets and much improved performance from that side. That will take a little bit of time to be built into the sales as people evaluate an account evaluate and compare to this. But we're very optimistic. The interest has been very high in both accounts. And on Barricor, a similar thing. Their evaluations are beginning to happen. There's more than 50 accounts currently evaluating the Barricor products, and that momentum we anticipate to continue through the rest of the year."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So if you think about it Alberto from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?",24,"So if you think about it Alberto from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, between -- the quickest 45 to it can be 200 days [indiscernible].",13,"Yes, between -- the quickest 45 to it can be 200 days [indiscernible]."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","200 days, and then you've got to work do inventory and whatnot. Now the last piece we haven't mentioned it and we will talk to you about at the Analyst Day, of course, is genomics. And genomics, where we stand there is, for BD, we are putting our first in",106,"200 days, and then you've got to work do inventory and whatnot. Now the last piece we haven't mentioned it and we will talk to you about at the Analyst Day, of course, is genomics. And genomics, where we stand there is, for BD, we are putting our first instruments as early access into customer accounts. So they will just start to do their validations as well. And so I do expect that to be a big contributor this year. I expect such new technology it' going to take a little longer, but we're also starting to get good feedback. Anything else you want to add?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","We will be issuing and launching new protocols as well, new assay protocols as we go along the year. That will build momentum at the same time.",27,"We will be issuing and launching new protocols as well, new assay protocols as we go along the year. That will build momentum at the same time."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, really coming into I think '18 with those protocols.",10,"Yes, really coming into I think '18 with those protocols."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is coming from Richard Newitter with Leerink Partners.",11,"Your final question is coming from Richard Newitter with Leerink Partners."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","You've now has some time to kind of digest all the opportunities that maybe you had in front of you or that CareFusion had in front of it but didn't have the means to exploit. I'm thinking a little more about the dispensing business in Europe. And I know",129,"You've now has some time to kind of digest all the opportunities that maybe you had in front of you or that CareFusion had in front of it but didn't have the means to exploit. I'm thinking a little more about the dispensing business in Europe. And I know the business model in that part of the world is just different, and it has historically worked well. But I do believe you have begun to talk up a little bit of our rolloff in leveraging that technology. I'm just wondering if that's going to factor in 2017 in the cross sell of the synergy phase of the acquisition integration and any kind of thoughts there? Is that something that we can hear more about at the Analyst Day?"
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, you will hear more about it at the Analyst Day. It's not so much cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line look",68,"Yes, you will hear more about it at the Analyst Day. It's not so much cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line looks like for you, and there's multiple aspects to that. So yes, we'll be happy to talk about that. Thanks for the question."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for closing remarks.",14,"I will now turn the floor back over to Vince Forlenza for closing remarks."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and",53,"Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and we'll see you there."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,403765314,1071912,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Thank you. This does conclude today's conference. Please disconnect your lines at this time, and have a wonderful day.",19,"Thank you. This does conclude today's conference. Please disconnect your lines at this time, and have a wonderful day."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by ph",81,"Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 94169710. [Operator Instructions] 
Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is poste",385,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth fiscal quarter press release and in the MD&A sections of our recent SEC filings. We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our fourth quarter results reflect the new BD in both the current and prior year periods. In addition, comparable prior year revenues are adjusted to exclude the sales related to the terminated agreement with CareFusion for the sale of F&P's respiratory care products. The impact to the bottom line is not material. Comparable organic revenues are adjusted to further exclude the impact of non-annualized acquisitions and closed divestitures. The fiscal 2017 comparable revenue guidance provided today will exclude revenues of closed divestitures, most notably the Respiratory Solutions business that was divested in October of 2016 just after our fiscal year-end. 
In the fourth quarter, the company recorded a noncash impairment charge for capitalized internal-use IT software assets. This charge, along with the details of the purchase accounting and other smaller adjustments and the comparable basis revenue results can be found in the reconciliations to GAAP measures in the financial schedules, in our press release or the appendix of Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical Segment; and Alberto Mas, Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. Moving on to my presentation. As we stated in our press release, we are",594,"Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. 
Moving on to my presentation. As we stated in our press release, we are extremely proud of our accomplishments in our first full fiscal year as the new BD. As you already know, the acquisition of CareFusion 18 months ago significantly accelerated our strategy, and the powerful combination of BD and CareFusion continues to deliver positive results. We've seen significant benefits as a result of this transaction from a customer, employee and shareholder standpoint, and we think there's more to come. 
Turning to Slide 4. I'd like to highlight some key achievements in fiscal year 2016. First, our results reflect our consistent performance and the benefit of our diverse geographic and product portfolio. Legacy BD remains solid, and the CareFusion portfolio has performed in line with our expectations. 
Second, emerging markets continue to be a key growth driver for the company. We experienced some headwinds this year, particularly in the Middle East and Africa, but remain confident that emerging markets are well positioned for continued growth. We also continue to create new growth opportunities for CareFusion products in these markets and expand their global reach by leveraging BD's international infrastructure. We're on track with our new product approval and submission plans and look forward to providing more color at our Analyst Meeting later this month. Developed markets continued to show stabilization, and growth has accelerated over the past year. 
Third, we made key strategic decisions to optimize our portfolio. This included the divestitures of BD Rx and the spine business in conjunction with the joint venture for the respiratory business, which we just completed in October. These actions further enabled the organization to prioritize and invest in the most important opportunities for future growth. We were deliberate in increasing our R&D investment in targeted high-growth areas and fully utilized the benefit of the medical device tax suspension.
Fourth, we remain focused on our operating effectiveness and efficiency initiatives, which have generated significant margin expansion. This year, we drove approximately 200 basis points of underlying margin expansion, which includes approximately $120 million in cost synergies. We also delivered robust earnings growth of almost 30%, which is greater than our initial expectations.
Lastly, we closed our first full year as the new BD, having achieved all important milestones and also demonstrated that we are successfully executing on our acquisition of CareFusion. As we look forward, we continue to build on our solid foundation and look to fiscal year 2017 and beyond with confidence. 
Moving to Slide 5. You will see the guidance for fiscal year 2017 on a currency-neutral basis. For the fiscal year 2017, we expect currency-neutral revenue growth of 4.5% to 5% based on our current view of the environment and various macroeconomic factors. There are a number of items that could bring us to the top or bottom end of that range, including a stronger or weaker flu season than expected, the performance of new product launches, emerging market growth and pricing. On the bottom line, we will continue to deliver high-quality earnings growth. For fiscal year 2017, we expect EPS of $9.45 to $9.55 or $9.62 to $9.72 currency neutral, which reflects growth of 12% to 13%.
Now I'd like to turn the call over to Chris, who will walk you through our financial performance in the fourth quarter and full year, along with the additional details about our fiscal year 2017 guidance."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approx",2260,"Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approximately $3.2 billion grew 6.4% on a comparable basis. Fully diluted adjusted EPS came in ahead of our expectations at $2.12, growing at 16.5% over the prior year. 
As Vince mentioned earlier, we are very pleased with our solid finish to the year, the first full year as a combined entity with CareFusion. For the total year, revenues grew 4.3%. We significantly expanded our margins and captured approximately $120 million in synergy cost savings. Adjusted EPS of $8.59 exceeded our expectations, driven by solid revenues, margin expansion and an improved tax rate. In addition to the cost synergies, tax synergies have materialized sooner and have exceeded the benefits we anticipated in the early days of the transaction. We are also pleased to announce that we have continued to delever as we reduced the debt associated with the acquisition of CareFusion. We are currently at 3.3x gross leverage and remain on track to achieve our commitment of 3x gross leverage by March of 2017.
On Slide 8, I'll review our revenue growth by segment on a currency-neutral basis. Fourth quarter revenue growth was 6.4% for the total company in the quarter, pricing was about flat. BD Medical fourth quarter revenues increased 7.9%. Medication and Procedural Solutions growth was 6.6%, which reflects strength in flush, ChloraPrep and safety-engineered products. Revenues in Medication Management Solutions or MMS grew 12.8%. This was driven by double-digit growth in both dispensing and infusion sales.  
Respiratory Solution revenues increased 12.7%, as expected. This reflects strong capital installations and a favorable comparison to the prior year period.
Growth in Diabetes Care was 3.6%. This reflects solid growth in pen needles, which was partially offset by an unfavorable comparison to the prior year period. Pharmaceutical Systems growth of 5.1% reflects strength in our self-injection platform. For the total year, BD Medical grew 4.7%. 
BD Life Sciences fourth quarter revenues increased 2.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Diagnostic System revenues were about flat compared to the prior year. This reflects continued strength in core microbiology and BD MAX, which grew double digits in the quarter. This growth was offset by the timing of KIESTRA installations outside of the U.S., which I'll speak to in just a moment. For the total year, we are extremely pleased with our microbiology business, with KIESTRA growing at about 19%.
Preanalytical Systems growth of 4% was driven by safety-engineered products and growth in the U.S. and emerging markets. BD Biosciences growth of 4% was driven by continued strong research instrument placements in the U.S. and reagent sales. For the total year, Life Sciences grew 3.4%. The headwinds we experienced in Africa negatively impacted segment results by 60 basis points, bringing underlying growth to 4% for the total year.  
Moving to Slide 9. I'll walk you through our geographic revenues for the fourth quarter on a currency-neutral basis. U.S. growth was very strong at 7.2%. This was comprised of BD Medical growing at 7.7% and BD Life Sciences growing at 5.8%. BD Medical's performance reflects strong growth in capital placements and a wide range of infusion disposable products in our Medication and Procedural Solutions business. Growth was also driven by our Pharmaceutical Systems business. 
BD Life Sciences growth reflects strong performance across the segment in the U.S. The growth in our Biosciences business was driven by high-parameter research instruments, including FACSSymphony, our FACSCelesta mid-level analyzer and the launch of the FACSMelody. Our U.S. Diagnostics business saw continued growth in microbiology, including KIESTRA and the BD MAX molecular platform. The Preanalytical Systems business grew 5%, driven by safety-engineered products.
Moving on to international. Revenues grew 5.2%. This is below our normal growth rate, which is primarily related to the Life Sciences segment. The Medical segment grew 8.2%. This was driven by strong performance from infusion disposal products in the MPS business and strong performance in China. Growth was also driven by medication management, reflecting double-digit growth in both dispensing and infusion.
Growth in the Life Science segment was about flat compared to the prior year. We experienced a decline in Diagnostic Systems due to the timing of KIESTRA installations. Increased installations in the third fiscal quarter negatively impacted the fourth fiscal quarter in conjunction with the tough comparison to the prior year fourth quarter. Biosciences growth was lower in the quarter due to continued declines in Africa, as we anticipated. The Preanalytical Systems business grew 2.9%, driven by strength in China, which was partially offset by a tough comparison to the prior year period.
On Slide 10, developed markets grew a healthy 5.8%, bringing the total year growth to 4.1%. Emerging market revenues grew 8.5% currency neutral, bringing our year-to-date growth rate to 5.3%. China growth for the fourth quarter was 17.7%, bringing the total year growth rate to 10.1%. Growth in emerging markets this fiscal year was lower than initially expected in the Middle East and Africa, and we believe those challenges are largely behind us after we exit the first quarter of fiscal year 2017. Emerging markets remain an important growth driver, and given our robust international footprint, we are well positioned to drive growth well into the future.
Looking into fiscal year 2017. We expect emerging markets to grow high single digits, driven by a diversified base, with China growing low double digits, continued strength in Latin America and fewer headwinds in EMA and Africa. In terms of developed markets, we believe the stability we have seen in the market over the past 12 to 18 months will continue, yielding a growth rate of about 4%.
Moving to global safety on Slide 11. Currency-neutral sales increased 5.9% and grew to $783 million in the quarter. Safety revenues in the U.S. grew 5.7%. This reflects continued strength of safety catheters as well as a benefit from the timing of orders across our hypodermic products.
International sales grew 6.2% currency neutral. International performance in the Medical segment was driven by the continued strength in China, and safety revenues grew 13.8% in emerging markets.
Medical safety sales grew 7%, driven by infusion disposables, catheters and a range of safety-engineered products. Life Sciences safety sales, which were driven by our Preanalytical Systems unit, grew 4% in the quarter.
Slide 12 recaps the fourth quarter income statement and highlights our currency-neutral results. Revenues grew a strong 6.4% in the quarter. Gross profit was strong, growing faster than revenues, at 7.9%. And I'll provide more details on gross profit in just a moment. 
SSG&A as a percentage of revenue was 24.4%. We are very pleased with the leverage we are getting, which is masked in this quarter by key strategic investments in product launches in both segments. R&D as a percentage of revenues was 7.8%, which is higher than normal due to the timing of spend as anticipated. As a result of the medical device tax suspension, we were able to make additional investments in a number of high-growth areas. After normalizing for this significant additional investment in R&D, underlying operating income would have grown about 10% in the quarter.
Our tax rate declined to 16.2% in the quarter due to the reinstatement of the R&D tax credit, tax synergies materializing earlier than expected and continued favorable geographic mix. In the quarter, adjusted earnings per share were $2.12, which is a 16.5% increase versus the prior year.
Turning to Slide 13 and our gross profit and operating margins for the fourth quarter. On a performance basis, gross profit margin improved by 90 basis points, driven by continuous improvement initiatives. This was more than offset by significant currency headwinds of 110 basis points. On an operating margin basis, we are extremely pleased to have delivered about 100 basis points of underlying margin expansion. As I mentioned on the previous slide, the leverage we are getting in SSG&A as we continue to drive cost synergies is being masked in the quarter by investments in key product launches. In addition, margin expansion was partially offset by significant R&D investments, as expected, and unfavorable currency. 
I'd like to take a moment on Slide 14 to highlight some of our key operational achievements for fiscal year 2016. The acquisition of CareFusion provided BD a unique opportunity to leverage the transaction to optimize the combined organization through functional transformations, and we have made significant progress in this area. All of our efforts have yielded results, and we are on track to deliver continued synergies. In aggregate, we have achieved over $170 million in total cost synergies to date. 
We have also driven significant margin expansion on a multiyear trajectory. Starting with fiscal year 2015, we delivered 100 basis points of operating margin expansion. This year, we achieved another 200 basis points, and we believe we are well positioned to deliver another 175 to 225 basis points in fiscal year 2017. Over those 3 years, we will have driven over 500 basis points of cumulative margin expansion, and I believe that we continue to drive robust performance with additional synergies in conjunction with continuous improvement going forward. We're extremely proud of the organization's ability to continue improving on our skills and expertise by executing against our synergy commitment initiatives through these transformations.
Moving on to Slide 15. I'd like to highlight our robust EPS growth, which exceeded our expectations this year. Starting with 2015 EPS of $7.16, we had communicated last November that we would grow EPS 22% to 23% on a currency-neutral basis. Beyond our initial expectations, we delivered an incremental 400 basis points from margin improvement. We also realized incremental benefits from our tax rate improvement, which yielded 300 basis points, bringing EPS to $9.24. Unfavorable currency headwinds impacted earnings per share by 900 basis points. Despite that significant headwind, we were still able to deliver $8.59 of earnings. On a currency-neutral basis, earnings grew 29.1%, which we believe demonstrates our ability to deliver on our commitment.
Moving on to Slide 17. There are a number of factors to consider when discussing our earnings per share in fiscal year 2017. For modeling purposes and to ensure consistency, I'd like to provide more color on our EPS guidance. First, as I mentioned, we are extremely pleased with strong EPS growth this year. Looking forward, we expect currency-neutral EPS to grow between 12% and 13%. This is partially muted by the impact of the respiratory JV, as we previously communicated. Pension also presents a headwind next year of approximately 100 basis points. 
Contributing to EPS growth is approximately 200 basis points from the adoption of a new accounting standard related to the tax accounting on our stock compensation programs. In addition, we estimate that currency will once again present a headwind. Our guidance assumes a euro to dollar exchange rate of $1.10. On an adjusted basis, we expect to achieve very strong earnings of $9.45 to $9.55.
Turning to Slide 18. I'd like to walk you through the balance of our guidance expectations for the full fiscal year 2017. As Vince mentioned earlier in the presentation, we expect revenue growth of 4.5% to 5%, with BD Medical growing 4.5% to 5% and Life Sciences growing between 4% to 5%. Growth in both segments contemplates a small amount of pricing pressure. 
From a phasing perspective, we expect currency-neutral revenue growth in the first quarter to be below this range. This is primarily due to some lingering softness in the EMA region and the timing of tenders in our Biosciences business. This will result in a currency-neutral revenue growth of about 4% in the first fiscal quarter. We expect revenue growth to return back to our guidance range in the second fiscal quarter, with continued acceleration over the back half of the year. We expect gross profit margin to be between 53% and 54%, which is a significant milestone for BD.
SSG&A as a percentage of sales is expected to be between 23.5% and 24%. Our guidance also reflects continued investments in emerging markets as well as costs related to new product launches and registration costs. We expect our R&D investments to be in line with fiscal year 2016 at about 6% to 6.5% of revenues as we continue to invest in new products and platforms. 
As a result of the items I just detailed, operating margin is expected to be between 23% and 24% of revenues, up from 20.8% this year. Excluding the unfavorable impact of foreign currency, we expect our underlying operating margin to improve by 175 to 225 basis points. This also excludes slight pension headwinds.
We expect our tax rate to be between 17% and 19%, driven by tax synergies, favorable geographic mix and a benefit from accounting change in our stock compensation program. For fiscal year 2017, we anticipate our average fully diluted share count to be approximately 219 million. Cash flow is expected to remain strong, with operating cash flow of about $2.7 billion in fiscal year 2017. Capital expenditures are expected to be about $700 million. 
In summary, we have good momentum exiting this fiscal year, and looking forward into 2017, we are building off a solid foundation. I'm confident that fiscal year 2017 will be another strong year of performance, positioning us well for continued success. 
Now I'd like to turn the call back over to Vince, who'll provide you with our concluding remarks."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few.",509,"Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few. 
On the Medical side of the business, we are pleased that our partner, Fresenius, received their first FDA approval for IV solution products. Additional approvals are expected, and we are on track to start shipping these products late in the first half of the year. Last quarter, we received our first orders for FlowSmart, our new insulin infusion set, where Medtronic serves as our distribution partner. Early patient feedback has been extremely positive. 
On the life side -- Life Science side of the business, we're pleased that the FDA has approved the BD MAX Vaginal Panel and also the GC/CT/TV assay. We launched our new Phoenix IDAST instrument. We launched the FACSMelody and received approval for Barricor in the U.S. We plan to share more about our pipeline on November 17 at our upcoming Analyst Day.
Also on Analyst Day, we will discuss the company's strategy and vision for the future and how we are helping to address health care's most pressing challenges. The segment leaders will do a deep dive into our business units, which will include some key product launches that we will be unveiling for the first time. We will conclude the day with a financial framework that will outline our plans for sustainable revenue growth, continued margin expansion, strong cash flow generation and capital deployment and, ultimately, demonstrate how all of those things will drive long-term value not only for our customers and patients they serve but also for our employees and our shareholders.
Moving on to Slide 21. I would like to reiterate the key messages from our presentation today. First, we're extremely pleased with our first fiscal year as the new BD. We believe that we have demonstrated that we can successfully execute on the integration of the largest transaction in the company's history.  Second, the diversity of our portfolio from a product and geographic perspective provides consistent and reliable earnings growth. Third, we continue to invest in key strategic areas and, at the same time, deliver significant margin expansion and double-digit earnings growth. 
We're looking forward to sharing more details about our pipeline at our Analyst Day in 2 weeks. We believe we have the most robust pipeline in the company's history, and we look to fiscal year 2017 and beyond with confidence.
Finally, I would like to say thank you to all of our associates around the world for our successful first full fiscal year as a combined company with CareFusion. It's a testament to the hard work of all of our employees that we delivered on our commitments. I believe we have a tremendous opportunity to create a true industry leader as we continue to advance the world of health. 
So with that, thank you. We will now open the call to questions."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan.",12,"[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit mo",134,"So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit more challenged. And so maybe just focusing a bit on the more challenged businesses first. Can you just talk a little bit about some of the headwinds that you saw, particularly international, in the Life Sciences business this quarter, this year and how you think about some of those end markets in FY '17? And then if you think about that in aggregate, that 4.5% to 5% revenue growth target for FY '17, what gets you to the higher end of that range?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue, which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So f",639,"Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue, which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So from a market perspective, let me just start with the developed markets. The developed markets certainly have stabilized, and you've seen that -- our growth rate going up in the developed markets and the U.S. The U.S. was very strong. By the way, including Biosciences, Europe was good, Japan was good. So we feel good about our position in developed markets and the product pipeline we have for those marketplaces. If I come to emerging markets, the issue really this year was, number one, Saudi Arabia, where we saw the government do a 35% cut of all types of expenses, not just health care. And that will annualize during the year. We already saw a stabilization in Saudi Arabia. In terms of Africa, Africa was basically CD4 testing. And CD4 testing was driven by, one, some conversion to viral load; and two, actually, confusion over a change in the purchasing organization for CD4 and viral load. And we think we have one more quarter of that. We did start to see some CD4 orders come in the fourth quarter and a little bit of a rebound. But we know we have that in the first quarter and then that annualizes and improves. Coming back to opportunities. On China, you saw the strong growth in China in the fourth quarter. If you actually go back and look at China after the first quarter, where we had some inventory take-down, China was strong for the other 3 quarters. We expect that to continue. It was especially strong this year on the Medical side of the business, and we think we're well positioned with the work that Tom and the regulatory team have been doing with the CareFusion product lines there. And as I've mentioned on previous calls, we've started with some of those product lines kind of the simpler disposables, and I'm sure Tom will talk more about that later on in the call. If there was any softness in China this year from a true demand standpoint, it was on the Life Science side, and it was related to those anticorruption campaign. What we saw was stabilization starting in the third quarter and continuing into the fourth quarter. And Alberto can mention to you he's starting to get ramped up the Bruker deal in China as well, which was a whole new thing for us. We had to learn how to do that and work our way through some submissions. So we feel good about China. The rest of Asia has been good. Latin America has performed well this year. In spite of all those issues in Brazil, it's been -- the rest of the geography has done fine. Coming back to the 4.5% to 5%. Then the other element that you have to think about is 2 other things. One is we will not have respiratory anymore, and that has been a bit of a headwind for the company. And then we think, in the back half of the year, you'll start to see more traction with our product launches. Things like Barricor, they have to do the validation first, so that takes a little while to get going. Customer feedback has been excellent. Alberto can talk about the product launches that you heard for BD MAX. Those are really critical assays to that program. We're excited about them. And so there's a whole list of these things, and we'll show you more about that as we do the Analyst Day. So that's the way we're thinking about it."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the",127,"One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the first quarter because they really came up in the second quarter -- second, third and fourth of this year. So we still have a little bit of a tough compare in the first quarter that we talked about, particularly in Saudi and Africa. But once we get through that with the new product launches that we're seeing, the strength of the rest of the business, we feel real good about our prospects for '17."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, th",71,"So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, that would take us up, too. Those are probably the 2 factors that I see. So thanks, Mike, for the question."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from David Lewis of Morgan Stanley.",10,"Your next question comes from David Lewis of Morgan Stanley."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team reaching your target here at least 2 years earlier from our models. So Chris, is this a structural",132,"Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team reaching your target here at least 2 years earlier from our models. So Chris, is this a structural kind of new low? Can you do better? And obviously, you're reinvesting these savings both in the fourth quarter and next year. Can you give us a sense of where the '17 reinvestment is going? And can you do better than these levels long term? And then for Vince or Tom, OUS Pyxis and Alaris, very strong this particular quarter. Can you talk about the drivers and sort of update us on how those numbers relate to progress on the CareFusion cross-sell?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last",191,"Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last call, the tax synergies coming from CareFusion happened faster and greater than we ever expected, and so we're seeing the benefit of that. So as we look out into next year, we see that bringing us to the high teens. And then we've got the benefit of the stock comp accounting adjustment. That brings us down to the 17% to 19% range. So this move down is part of the march down in the tax rate that we've been seeing, coupled with the benefits that we're getting from the synergies from CareFusion. And so we really feel good about that. We've also closed out a lot of tax exams in multiple jurisdictions. We're part of the IRS' CAP program, so they're auditing us on a real-time basis. So the sustainability of this tax rate is extremely strong, and we feel real good about it."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Chris. Tom, you want to pick up on the second part?",13,"Okay. Thanks, Chris. Tom, you want to pick up on the second part?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very wel",231,"So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very well. We talked earlier in the year about some of the process improvements we had made to accelerate the installation process. I think you're seeing the results of that work come to fruition now with faster installations, getting those systems in. We now have over 1,100 sites live on ES or about 1/3 of our installed base is now upgraded to the ES platform. And the receptivity is very solid, and we extract -- expect strong demand on that going forward. Alaris, we continue to gain about 2 to 3 points of category share this past year in FY '16, and we're looking at kind of a similar progress outlook for FY '17 as well. And so we certainly do have organizations that are cross-selling those as an integrated offering. You'll see at Analyst Day us talk about some new informatic capabilities and other new products coming out that will further strengthen the integration and the value that we can deliver to customers who are using that complete end-to-end offering. And so we look forward to talking to you about that very shortly."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Kristen Stewart of Deutsche Bank.",10,"Your next question comes from Kristen Stewart of Deutsche Bank."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether o",64,"Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether or not you'd be willing to do another larger deal. Or would it be back to doing just more share repurchase activity?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to",164,"So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to March, we're pretty sure that we're going to be meeting our requirements to the rating agencies. What I would say is that gives us more flexibility around those strategic imperatives. And so we believe we now have the capability to do large and, of course, continue to have that capability to do tuck-ins and a little bit more flexibility to do the tuck-ins in the short run than we've had over the last 2 years. And so I'm not sitting here saying we're going back to do a large one. We'll be strategy driven around this with increased flexibility and capability that we have built over the last couple of years. Chris, you want to talk about share buybacks?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x",262,"Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x leverage, we're getting a lot of increased flexibility. So as we think about the use of that cash flow, we'll probably do something on the dividend rate. You know that the payout ratio has come down a little bit. We increased 10% a year for the last couple of years. The good news is our EPS is going up over 20%. So the payout ratio has come down a little bit, and we will have to address that going forward. I think CapEx, as you think about it, will be in the $700 million range. That's pretty consistent with where it has been. So that leaves a lot of cash left over. We'll allocate some of that to tuck-in acquisitions, and that will still leave a lot of cash left over. And we're not going to let that cash build up on the balance sheet. So we'll return to doing some share buybacks. You will hear more about that at Analyst Day. And certainly, as we approach the March period of getting to the 3x leverage, we'll be giving a little bit more specificity on where we're going. But the good news is we have really good strong cash flow and a really solid balance sheet with a lot of flexibility."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?",40,"Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marke",76,"So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marketplace. So I think we're being prudent in terms of how we're thinking about this, and we'll continue to work as we have in the past to offset it."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing.",26,"And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Rick Wise of Stifel.",9,"Your next question comes from Rick Wise of Stifel."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. A",70,"I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. And maybe talk about the drivers, volume, cost, mix. I mean, what gets us to those higher levels I have no doubt you aspire to?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute",256,"Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute on within our operations group over the last few years. And as we look forward, the guidance that we gave of 53% to 54%, and that would be inclusive of FX headwinds and pricing headwinds, et cetera, is extremely strong. It's a significant milestone for us to hit that 53% to 54%. We do see a little bit of -- more synergies coming because as we execute on the synergies that affect gross profit and cost of goods sold, which we said would come towards the latter end of our synergies, and that is the way that's playing out, but, again, continued -- continuous improvement in that area. So we feel really good about the gross profit margin. Also, that flows down to the operating margin. So as we mentioned, this year, 200 basis points; last year, 100 basis points; next year, in that 200 basis points kind of range, 500 basis points in total, again, driven both from execution of the synergies as well as continuous improvement initiatives. So feel real good about that. And as we look forward even past next year, '18 will have continued cost synergies, and you'll see some benefits from that. So all in all, really strong margin improvement, and we feel real good about that."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do antici",79,"Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do anticipate launching with towards the end of the first half. And what drives that share gain for the year that you're sort of suggesting of 200 to 300 basis points?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the",257,"Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the platform around the power of one, the ability to do not just large volume but also syringe-based and narcotic infusions off the same platform as well as its leading interoperability position with electronic medical records, are some of the key reasons why people have been choosing it at a higher rate and continue to do so going forward. Again, we do have some new technologies being added to the platform, which we'll share also at the upcoming Analyst Meeting. So we're very positive on the outlook there. I think, as we think about IV solutions, and we've mentioned before that you're going to see, I would expect, a rolling series of approvals on that platform. This is the first -- of course, there's a number of different formulations of IV solutions as well as bag sizes when you think about building out a portfolio that customers really need to run their institution. And so what you just saw get approved was the first in a series of products, and we would expect the additional products to be coming out over the months ahead. And that leads us up to where we'll have a really critical kind of massive portfolio for launch at the end of the first half of the year."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar of Evercore ISI.",10,"Your next question comes from Vijay Kumar of Evercore ISI."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk",89,"It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk about the quarterly cadence, Chris? Because, obviously, this year was back half loaded on the revenue front and given the flat share count and your comments on free cash generation, it looks like maybe there's some upside from cap deployment potentially."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance.",18,"Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of revenue going forward.",284,"Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of revenue going forward. And as we said, we do see some headwinds continuing as we annualize the headwinds from Saudi and Africa. That will bring us down in the area of about 4% in the first quarter plus or minus 20 basis points, particularly as that's a high quarter for the flu. So it could go one way or the other on us. But then the ramp in the second quarter brings us back well within the range -- the high end of the range. And the ramping of new products we see in the second half of the year bring us back to a strong 4.5% to 5% range. So that feels real good. In terms of capital deployment, the share buybacks, we are committed to not buy back any shares other than what we've already done for respiratory, which we've talked about. But we're not looking to do anything until we get to the 3x leverage. We want to hit that commitment that we had, and that brings us through March, so halfway through the year. And then from that point on, you're right, there could be some -- but you don't get the full year impact of that at that point, so more to come on that. But there is some potential as we buy back shares. It will have a little bit of impact on '17, but probably, more likely, the impact would be on '18."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein of William Blair.",10,"Your next question comes from Brian Weinstein of William Blair."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get thr",100,"I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get through committees on capital projects and work down of inventory distributors. So how do you guys think about those and how do you think about kind of the U.S. market going forward? What are the positive offsets that you're seeing to those? And are you guys seeing any of those same headwinds that I described?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give an ex",141,"Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give an example, Brian, we were -- at one account, we're saving 5 million keystrokes a year. It's the kind of thing that you want to do in this environment, and it was a very intentional part of our strategy. So what I would say is, generally, across the board, we're seeing pretty good stability and some increase. We're just getting started with KIESTRA, for example, in the U.S., which is a major cost saving, whether it's the hospital market or in the clinical lab market. And so we don't have a lot of exposure to the kind of headwinds that you were mentioning."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments, 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences is growing in the U.S. around 8% for the quarte",78,"I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments, 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences is growing in the U.S. around 8% for the quarter and for the year. A lot of that was new product introductions of Symphony, Celesta, the new Melody introduction or whatever. So U.S. is feeling particularly strong for our business."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting.",49,"So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio stan",261,"Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio standpoint. And when I'm saying that we have the most robust pipeline in the history of the company, I want you to understand what that all means. And we will lay that out for you in a lot of detail. So that's number one on the list, that you understand why we have that confidence going forward. And I think it's going to be fun, quite frankly. It was fun doing this 5 years ago, so I'm looking forward to it. And then we're going to take that and we're -- Chris is going to kind of give you a financial model of how this all holds together. And lastly, we're going to talk about the capabilities that it's going to require to do all this. We're going to show you how we built the capabilities foundationally over the last 5 years and then how we build upon them. Tom mentioned informatics for example, but we'll also get into how we approach emerging markets, what's different about our strategy and why we see that continuing to work and some of the other capabilities that we will be bringing to bear, which all is an extension of the work we've done over the 5 years. So that's the kind of day, and look forward to seeing you there, Jon."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Bill Quirk of Piper Jaffray.",10,"Your next question comes from Bill Quirk of Piper Jaffray."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, is a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medi",91,"A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, is a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medical, has been a little less predictable, and we certainly appreciate all new product launches, both in launch as well as near-term development. Do you think this can improve the predictability of the business? Or do you think we may have to look at some tuck-in deals to improve the consistency?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump a",137,"Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump around as customers are ready for us to install because there's some major changes that they have to make to the laboratory, number one. Number two, we've had this issue with Africa, and that's been a bit of a problem. We think that's going to annualize. Are we interested in tuck-in acquisitions there? Absolutely, as we are on the Medical side. I'm just going to ask Alberto to comment on KIESTRA and kind of what you're seeing from a pipeline standpoint, how you see the U.S. market evolving because we just got started there."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in",121,"Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in the U.S. In fact, the sales this last year doubled versus the previous one, admittedly on a small base, but we're seeing a lot of positive momentum, especially as we build the platform. And you'll hear the capabilities of the platform that you'll hear about in the Analyst Day. So we would continue to build on those capabilities, and that gets our customers very excited about the future of the platform, not only the price of the platform."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?",41,"And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling",150,"Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling that. We see implementation strongest in the conventional hospital settings. It's a little weaker in the alternate settings. That's true in most markets where individual doctor compliance may be less than a large governed hospital setting. Strongest conversion rates we see in infusion therapy and blood collection, a little bit lagging in injection. That's also the exact same trend that we saw in the U.S. So still good growth prospects there, and we're in the middle innings. You also mentioned China. Overall in emerging markets, we see safety in the very early innings at less than 15% conversion, so still quite a ways to go."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Derik De Bruin of Bank of America.",12,"Your next question comes from Derik De Bruin of Bank of America."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Midd",105,"A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Middle East situation. But I just -- what sort of  gives you confidence that, that's going to reaccelerate this year other than tougher comps -- or easier comps? So what are you sort of seeing right now that gives you confidence that, that's going -- you're not going to have to face another sort of year?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was to cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop b",213,"Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was to cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop buying product, number one. So our expectation was they were running down their inventories and then -- and they would start to buy. What we've seen in this quarter was stabilization there. And so it didn't come all the way back to as positive growth, but it was significant improvement. So that gives us a sense that our hypothesis in this case is right, number one. Number two, it's really Africa and the annualization of Africa. It was still negative, but we started to see -- and Alberto could give you some more details, some CD4 orders starting to come in, which we did not see. So -- and then we saw good performance across Asia, as I was mentioning before. I expect that to keep happening. I expect that Latin America -- that Brazil is going to remain status quo, and we're going to continue to see strong growth in the other marketplaces. But Alberto, any more -- any other comments on CD4?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that could lead into a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipa",50,"Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that could lead into a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipated."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, where people didn't know how to order. And that's behind them.",12,"Yes, where people didn't know how to order. And that's behind them."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a littl",108,"I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a little bit of an easier compare there, but still very strong. Vince and I and Tom just got back from China. I can tell you there's a lot of enthusiasm for some of the newer products that we're bringing in. So we see a lot of good stability, and as we mentioned, we're looking at low double digits on China into next year."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets.",38,"And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was",96,"Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was new product contribution to 2016 revenue growth? And looking ahead to 2017, it seems like new product contribution to organic growth should account for a bigger part of overall growth as you accelerate revenue synergies and some important launches, such as the infusion sets. Could you comment on that?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming",104,"So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming from cost synergies and about 100 basis points coming from the respiratory JV coming off our income statement, so we get a benefit there. And on the gross profit, it's roughly the same kind of area. There's a benefit from respiratory -- about half of it coming from respiratory, about half of it coming from CI and synergy."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they rea",177,"In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they really haven't gotten traction yet. Barricor, people are just starting to validate Barricor. The approvals on BD MAX we just got in the last month or so. So they really haven't hit. And then you're talking about tens of basis points in terms of the CareFusion products in the emerging markets at this point in time. We haven't done -- we haven't completed the work, let me say it that way, in terms of trying to get a really good analysis around breaking out new product from the entire company. As we're going through the CareFusion integration, we haven't counted the geographic extension of those products as new products. But we're working our way through that, and you'll have a better sense, after the Analyst Day, of how this is coming together."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Matt Taylor of Barclays.",9,"Your next question comes from Matt Taylor of Barclays."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluid, diabetes and",78,"I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluid, diabetes and some of the diagnostic launches in terms of how we should expect the revenue contributions from those to flow? Help us size them and just give us some thoughts on timing."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?",14,"So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begu",168,"Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begun shipping that to patients, and the feedback that we're hearing is very positive. And there's been a number of bloggers actually write their experience. You can look that up online, but it's very, very good feedback as that moved into the marketplace just over the last couple of months. We do expect that, that probably will expand to a broader full launch in early Q2. And that's well on track. So I think back to one of the earlier questions, as we think about -- within the Diabetes Care business, we do expect -- and I obviously don't give guidance by business unit, but we expect an uptick in '17 in Diabetes Care, driven by that FlowSmart launch. And that's on track, proceeding as planned."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things.",23,"Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first o",190,"Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first one that is integrated, which is a guideline from the CDC to do the 3 tests all in one, and we're the only ones that will have it in the same assay. The vaginal panel will be a significant improvement versus the only approved assay, the Affirm assay, that we have out there, will be better accuracy, more targets and much improved performance from that side. That will take a little bit of time to be built into the sales as people evaluate and -- accounts evaluate and convert to this. But we are very, very optimistic. And all -- the interest has been very high in both accounts. And on Barricor, a similar thing. The evaluations are beginning to happen. There's more than 50 accounts currently evaluating the Barricor products, and that momentum we anticipate to continue in the rest of the year."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally, 90 days?",24,"So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally, 90 days?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, between -- yes. Let's say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there.",23,"Yes, between -- yes. Let's say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot. The last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- f",119,"To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot. The last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- for BD CLiC, we are putting our first instruments as early access into customer accounts. So they will just start to do their validations as well, and so I don't expect that to be a big contributor this year. I expect, since it's such new technology, it's going to take a little longer, but we're also starting to get good feedback there. Anything else you want to add?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time.",29,"And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question.",17,"Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is coming from Richard Newitter with Leerink Partners.",11,"Your final question is coming from Richard Newitter with Leerink Partners."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Eur",133,"Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Europe. And I know the business model in that part of the world is just different, and it hasn't historically lent itself well. But I do believe you had begun to talk a little bit about Rowa and leveraging that technology. I'm just wondering if that's going to factor in, in 2017 in the cross-sell or the synergy phase of the acquisition integration. And any kind of thoughts there? And is that something that we could hear more about at the Analyst Day?"
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line lo",69,"Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line looks like for you, and there's multiple aspects to that. So yes, we'll be happy to talk about that. Thanks for the question."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for closing remarks.",14,"I will now turn the floor back over to Vince Forlenza for closing remarks."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and",53,"Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and we'll see you there."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,403765314,1071918,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",18,"This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by ph",81,"Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 94169710. [Operator Instructions] 
Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is poste",385,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth fiscal quarter press release and in the MD&A sections of our recent SEC filings. We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our fourth quarter results reflect the new BD in both the current and prior year periods. In addition, comparable prior year revenues are adjusted to exclude the sales related to the terminated agreement with CareFusion for the sale of F&P's respiratory care products. The impact to the bottom line is not material. Comparable organic revenues are adjusted to further exclude the impact of non-annualized acquisitions and closed divestitures. The fiscal 2017 comparable revenue guidance provided today will exclude revenues of closed divestitures, most notably the Respiratory Solutions business that was divested in October of 2016 just after our fiscal year-end. 
In the fourth quarter, the company recorded a noncash impairment charge for capitalized internal-use IT software assets. This charge, along with the details of the purchase accounting and other smaller adjustments and the comparable basis revenue results, can be found in the reconciliations to GAAP measures in the financial schedules, in our press release or the appendix of Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical Segment; and Alberto Mas, Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. Moving on to my presentation. As we stated in our press release, we are",594,"Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. 
Moving on to my presentation. As we stated in our press release, we are extremely proud of our accomplishments in our first full fiscal year as the new BD. As you already know, the acquisition of CareFusion 18 months ago significantly accelerated our strategy, and the powerful combination of BD and CareFusion continues to deliver positive results. We've seen significant benefits as a result of this transaction from a customer, employee and shareholder standpoint, and we think there's more to come. 
Turning to Slide 4. I'd like to highlight some key achievements in fiscal year 2016. First, our results reflect our consistent performance and the benefit of our diverse geographic and product portfolio. Legacy BD remains solid, and the CareFusion portfolio has performed in line with our expectations. 
Second, emerging markets continue to be a key growth driver for the company. We experienced some headwinds this year, particularly in the Middle East and Africa, but remain confident that emerging markets are well positioned for continued growth. We also continue to create new growth opportunities for CareFusion products in these markets and expand their global reach by leveraging BD's international infrastructure. We're on track with our new product approval and submission plans and look forward to providing more color at our Analyst Meeting later this month. Developed markets continued to show stabilization, and growth has accelerated over the past year. 
Third, we made key strategic decisions to optimize our portfolio. This included the divestitures of BD Rx and the spine business in conjunction with the joint venture for the respiratory business, which we just completed in October. These actions further enabled the organization to prioritize and invest in the most important opportunities for future growth. We were deliberate in increasing our R&D investment in targeted high-growth areas and fully utilized the benefit of the medical device tax suspension.
Fourth, we remain focused on our operating effectiveness and efficiency initiatives, which have generated significant margin expansion. This year, we drove approximately 200 basis points of underlying margin expansion, which includes approximately $120 million in cost synergies. We also delivered robust earnings growth of almost 30%, which is greater than our initial expectations.
Lastly, we closed our first full year as the new BD having achieved all important milestones and also demonstrated that we are successfully executing on our acquisition of CareFusion. As we look forward, we continue to build on our solid foundation and look to fiscal year 2017 and beyond with confidence. 
Moving to Slide 5. You will see the guidance for fiscal year 2017 on a currency-neutral basis. For the fiscal year 2017, we expect currency-neutral revenue growth of 4.5% to 5% based on our current view of the environment and various macroeconomic factors. There are a number of items that could bring us to the top or bottom end of that range, including a stronger or weaker flu season than expected, the performance of new product launches, emerging market growth and pricing. On the bottom line, we will continue to deliver high-quality earnings growth. For fiscal year 2017, we expect EPS of $9.45 to $9.55 or $9.62 to $9.72 currency neutral, which reflects growth of 12% to 13%.
Now I'd like to turn the call over to Chris, who will walk you through our financial performance in the fourth quarter and full year, along with the additional details about our fiscal year 2017 guidance."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approx",2259,"Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approximately $3.2 billion grew 6.4% on a comparable basis. Fully diluted adjusted EPS came in ahead of our expectations at $2.12, growing at 16.5% over the prior year. 
As Vince mentioned earlier, we are very pleased with our solid finish to the year, the first full year as a combined entity with CareFusion. For the total year, revenues grew 4.3%. We significantly expanded our margins and captured approximately $120 million in synergy cost savings. Adjusted EPS of $8.59 exceeded our expectations, driven by solid revenues, margin expansion and an improved tax rate. In addition to the cost synergies, tax synergies have materialized sooner and have exceeded the benefits we anticipated in the early days of the transaction. We are also pleased to announce that we have continued to delever as we reduced the debt associated with the acquisition of CareFusion. We are currently at 3.3x gross leverage and remain on track to achieve our commitment of 3x gross leverage by March of 2017.
On Slide 8, I'll review our revenue growth by segment on a currency-neutral basis. Fourth quarter revenue growth was 6.4% for the total company. In the quarter, pricing was about flat. BD Medical fourth quarter revenues increased 7.9%. Medication and Procedural Solutions growth was 6.6%, which reflects strength in flush, ChloraPrep and safety-engineered products. Revenues in Medication Management Solutions or MMS grew 12.8%. This was driven by double-digit growth in both dispensing and infusion sales.  
Respiratory Solution revenues increased 12.7%, as expected. This reflects strong capital installations and a favorable comparison to the prior-year period.
Growth in Diabetes Care was 3.6%. This reflects solid growth in pen needles, which was partially offset by an unfavorable comparison to the prior year period. Pharmaceutical Systems growth of 5.1% reflects strength in our self-injection platform. For the total year, BD Medical grew 4.7%. 
BD Life Sciences fourth quarter revenues increased 2.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Diagnostic System revenues were about flat compared to the prior year. This reflects continued strength in core microbiology and BD MAX, which grew double digits in the quarter. This growth was offset by the timing of KIESTRA installations outside of the U.S., which I'll speak to in just a moment. For the total year, we are extremely pleased with our microbiology business, with KIESTRA growing at about 19%.
Preanalytical Systems growth of 4% was driven by safety-engineered products and growth in the U.S. and emerging markets. BD Biosciences growth of 4% was driven by continued strong research instrument placements in the U.S. and reagent sales. For the total year, Life Sciences grew 3.4%. The headwinds we experienced in Africa negatively impacted segment results by 60 basis points, bringing underlying growth to 4% for the total year.  
Moving to Slide 9. I'll walk you through our geographic revenues for the fourth quarter on a currency-neutral basis. U.S. growth was very strong at 7.2%. This was comprised of BD Medical growing at 7.7% and BD Life Sciences growing at 5.8%. BD Medical's performance reflects strong growth in capital placements and a wide range of infusion disposable products in our Medication and Procedural Solutions business. Growth was also driven by our Pharmaceutical Systems business. 
BD Life Sciences growth reflects strong performance across the segment in the U.S. The growth in our Biosciences business was driven by high-parameter research instruments, including FACSSymphony, our FACSCelesta mid-level analyzer and the launch of the FACSMelody. Our U.S. Diagnostics business saw continued growth in microbiology, including KIESTRA and the BD MAX molecular platform. The Preanalytical Systems business grew 5%, driven by safety-engineered products.
Moving on to international. Revenues grew 5.2%. This is below our normal growth rate, which is primarily related to the Life Sciences segment. The Medical segment grew 8.2%. This was driven by strong performance from infusion disposal products in the MPS business and strong performance in China. Growth was also driven by medication management, reflecting double-digit growth in both dispensing and infusion.
Growth in the Life Science segment was about flat compared to the prior year. We experienced a decline in Diagnostic Systems due to the timing of KIESTRA installations. Increased installations in the third fiscal quarter negatively impacted the fourth fiscal quarter in conjunction with the tough comparison to the prior year fourth quarter. Biosciences growth was lower in the quarter due to continued declines in Africa, as we anticipated. The Preanalytical Systems business grew 2.9%, driven by strength in China, which was partially offset by a tough comparison to the prior year period.
On Slide 10, developed markets grew a healthy 5.8%, bringing the total year growth to 4.1%. Emerging market revenues grew 8.5% currency neutral, bringing our year-to-date growth rate to 5.3%. China growth for the fourth quarter was 17.7%, bringing the total year growth rate to 10.1%. Growth in emerging markets this fiscal year was lower than initially expected in the Middle East and Africa, and we believe those challenges are largely behind us after we exit the first quarter of fiscal year 2017. Emerging markets remain an important growth driver, and given our robust international footprint, we are well positioned to drive growth well into the future.
Looking into fiscal year 2017. We expect emerging markets to grow high single digits, driven by a diversified base, with China growing low double digits, continued strength in Latin America and fewer headwinds in EMA and Africa. In terms of developed markets, we believe the stability we have seen in the market over the past 12 to 18 months will continue, yielding a growth rate of about 4%.
Moving to global safety on Slide 11. Currency-neutral sales increased 5.9% and grew to $783 million in the quarter. Safety revenues in the U.S. grew 5.7%. This reflects continued strength of safety catheters as well as a benefit from the timing of orders across our hypodermic products.
International sales grew 6.2% currency neutral. International performance in the Medical segment was driven by the continued strength in China, and safety revenues grew 13.8% in emerging markets.
Medical safety sales grew 7%, driven by infusion disposables, catheters and a range of safety-engineered products. Life Sciences safety sales, which were driven by our Preanalytical Systems unit, grew 4% in the quarter.
Slide 12 recaps the fourth quarter income statement and highlights our currency-neutral results. Revenues grew a strong 6.4% in the quarter. Gross profit was strong, growing faster than revenues, at 7.9%. And I'll provide more details on gross profit in just a moment. 
SSG&A as a percentage of revenue was 24.4%. We are very pleased with the leverage we are getting, which is masked in this quarter by key strategic investments in product launches in both segments. R&D as a percentage of revenues was 7.8%, which is higher than normal due to the timing of spend as anticipated. As a result of the medical device tax suspension, we were able to make additional investments in a number of high-growth areas. After normalizing for this significant additional investment in R&D, underlying operating income would have grown about 10% in the quarter.
Our tax rate declined to 16.2% in the quarter due to the reinstatement of the R&D tax credit, tax synergies materializing earlier than expected and continued favorable geographic mix. In the quarter, adjusted earnings per share were $2.12, which is a 16.5% increase versus the prior year.
Turning to Slide 13 and our gross profit and operating margins for the fourth quarter. On a performance basis, gross profit margin improved by 90 basis points, driven by continuous improvement initiatives. This was more than offset by significant currency headwinds of 110 basis points. On an operating margin basis, we are extremely pleased to have delivered about 100 basis points of underlying margin expansion. As I mentioned on the previous slide, the leverage we are getting in SSG&A as we continue to drive cost synergies is being masked in the quarter by investments in key product launches. In addition, margin expansion was partially offset by significant R&D investments, as expected, and unfavorable currency. 
I'd like to take a moment on Slide 14 to highlight some of our key operational achievements for fiscal year 2016. The acquisition of CareFusion provided BD a unique opportunity to leverage the transaction to optimize the combined organization through functional transformations, and we have made significant progress in this area. All of our efforts have yielded results, and we are on track to deliver continued synergies. In aggregate, we have achieved over $170 million in total cost synergies to date. 
We have also driven significant margin expansion on a multiyear trajectory. Starting with fiscal year 2015, we delivered 100 basis points of operating margin expansion. This year, we achieved another 200 basis points, and we believe we are well positioned to deliver another 175 to 225 basis points in fiscal year 2017. Over those 3 years, we will have driven over 500 basis points of cumulative margin expansion, and I believe that we continue to drive robust performance with additional synergies in conjunction with continuous improvement going forward. We're extremely proud of the organization's ability to continue improving on our skills and expertise by executing against our synergy commitment initiatives through these transformations.
Moving on to Slide 15. I'd like to highlight our robust EPS growth, which exceeded our expectations this year. Starting with 2015 EPS of $7.16, we had communicated last November that we would grow EPS 22% to 23% on a currency-neutral basis. Beyond our initial expectations, we delivered an incremental 400 basis points from margin improvement. We also realized incremental benefits from our tax rate improvement, which yielded 300 basis points, bringing EPS to $9.24. Unfavorable currency headwinds impacted earnings per share by 900 basis points. Despite that significant headwind, we were still able to deliver $8.59 of earnings. On a currency-neutral basis, earnings grew 29.1%, which we believe demonstrates our ability to deliver on our commitment.
Moving on to Slide 17. There are a number of factors to consider when discussing our earnings per share in fiscal year 2017. For modeling purposes and to ensure consistency, I'd like to provide more color on our EPS guidance. First, as I mentioned, we are extremely pleased with strong EPS growth this year. Looking forward, we expect currency-neutral EPS to grow between 12% and 13%. This is partially muted by the impact of the respiratory JV, as we previously communicated. Pension also presents a headwind next year of approximately 100 basis points. 
Contributing to EPS growth is approximately 200 basis points from the adoption of a new accounting standard related to the tax accounting on our stock compensation programs. In addition, we estimate that currency will once again present a headwind. Our guidance assumes a euro to dollar exchange rate of $1.10. On an adjusted basis, we expect to achieve very strong earnings of $9.45 to $9.55.
Turning to Slide 18. I'd like to walk you through the balance of our guidance expectations for the full fiscal year 2017. As Vince mentioned earlier in the presentation, we expect revenue growth of 4.5% to 5%, with BD Medical growing 4.5% to 5% and Life Sciences growing between 4% to 5%. Growth in both segments contemplates a small amount of pricing pressure. 
From a phasing perspective, we expect currency-neutral revenue growth in the first quarter to be below this range. This is primarily due to some lingering softness in the EMA region and the timing of tenders in our Biosciences business. This will result in a currency-neutral revenue growth of about 4% in the first fiscal quarter. We expect revenue growth to return back to our guidance range in the second fiscal quarter, with continued acceleration over the back half of the year. We expect gross profit margin to be between 53% and 54%, which is a significant milestone for BD.
SSG&A as a percentage of sales is expected to be between 23.5% and 24%. Our guidance also reflects continued investments in emerging markets as well as costs related to new product launches and registration costs. We expect our R&D investments to be in line with fiscal year 2016 at about 6% to 6.5% of revenues as we continue to invest in new products and platforms. 
As a result of the items I just detailed, operating margin is expected to be between 23% and 24% of revenues, up from 20.8% this year. Excluding the unfavorable impact of foreign currency, we expect our underlying operating margin to improve by 175 to 225 basis points. This also excludes slight pension headwinds.
We expect our tax rate to be between 17% and 19%, driven by tax synergies, favorable geographic mix and a benefit from accounting change in our stock compensation program. For fiscal year 2017, we anticipate our average fully diluted share count to be approximately 219 million. Cash flow is expected to remain strong, with operating cash flow of about $2.7 billion in fiscal year 2017. Capital expenditures are expected to be about $700 million. 
In summary, we have good momentum exiting this fiscal year, and looking forward into 2017, we are building off a solid foundation. I'm confident that fiscal year 2017 will be another strong year of performance, positioning us well for continued success. 
Now I'd like to turn the call back over to Vince, who'll provide you with our concluding remarks."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few.",509,"Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few. 
On the Medical side of the business, we are pleased that our partner, Fresenius, received their first FDA approval for IV solution products. Additional approvals are expected, and we are on track to start shipping these products late in the first half of the year. Last quarter, we received our first orders for FlowSmart, our new insulin infusion set, where Medtronic serves as our distribution partner. Early patient feedback has been extremely positive. 
On the life side -- Life Science side of the business, we're pleased that the FDA has approved the BD MAX Vaginal Panel and also the GC/CT/TV assay. We launched our new Phoenix IDAST instrument. We launched the FACSMelody and received approval for Barricor in the U.S. We plan to share more about our pipeline on November 17 at our upcoming Analyst Day.
Also on Analyst Day, we will discuss the company's strategy and vision for the future and how we are helping to address health care's most pressing challenges. The segment leaders will do a deep dive into our business units, which will include some key product launches that we will be unveiling for the first time. We will conclude the day with a financial framework that will outline our plans for sustainable revenue growth, continued margin expansion, strong cash flow generation and capital deployment and, ultimately, demonstrate how all of those things will drive long-term value not only for our customers and patients they serve but also for our employees and our shareholders.
Moving on to Slide 21. I would like to reiterate the key messages from our presentation today. First, we're extremely pleased with our first fiscal year as the new BD. We believe that we have demonstrated that we can successfully execute on the integration of the largest transaction in the company's history.  Second, the diversity of our portfolio from a product and geographic perspective provides consistent and reliable earnings growth. Third, we continue to invest in key strategic areas and, at the same time, deliver significant margin expansion and double-digit earnings growth. 
We're looking forward to sharing more details about our pipeline at our Analyst Day in 2 weeks. We believe we have the most robust pipeline in the company's history, and we look to fiscal year 2017 and beyond with confidence.
Finally, I would like to say thank you to all of our associates around the world for our successful first full fiscal year as a combined company with CareFusion. It's a testament to the hard work of all of our employees that we delivered on our commitments. I believe we have a tremendous opportunity to create a true industry leader as we continue to advance the world of health. 
So with that, thank you. We will now open the call to questions."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan.",12,"[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit mo",134,"So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit more challenged. And so maybe just focusing a bit on the more challenged businesses first. Can you just talk a little bit about some of the headwinds that you saw, particularly internationally in the Life Sciences business this quarter, this year and how you think about some of those end markets in FY '17? And then if you think about that in aggregate, that 4.5% to 5% revenue growth target for FY '17, what gets you to the higher end of that range?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So fr",638,"Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So from a market perspective, let me just start with the developed markets. The developed markets certainly have stabilized, and you've seen that -- our growth rate going up in the developed markets and the U.S. The U.S. was very strong. By the way, including Biosciences, Europe was good, Japan was good. So we feel good about our position in developed markets and the product pipeline we have for those marketplaces. If I come to emerging markets, the issue really this year was, number one, Saudi Arabia, where we saw the government do a 35% cut of all types of expenses, not just health care. And that will annualize during the year. We already saw a stabilization in Saudi Arabia. In terms of Africa, Africa was basically CD4 testing. And CD4 testing was driven by, one, some conversion to viral load; and two, actually, confusion over a change in the purchasing organization for CD4 and viral load. And we think we have one more quarter of that. We did start to see some CD4 orders coming in the fourth quarter and a little bit of a rebound. But we know we have that in the first quarter and then that annualizes and improves. Coming back to opportunities. On China, you saw the strong growth in China in the fourth quarter. If you actually go back and look at China after the first quarter, where we had some inventory take-down, China was strong for the other 3 quarters. We expect that to continue. It was especially strong this year on the Medical side of the business, and we think we're well positioned with the work that Tom and the regulatory team have been doing with the CareFusion product lines there. And as I've mentioned on previous calls, we've started with some of those product lines, kind of the simpler disposables, and I'm sure Tom will talk more about that later on in the call. If there was any softness in China this year from a true demand standpoint, it was on the Life Science side, and it was related to those anticorruption campaign. What we saw was stabilization starting in the third quarter and continuing into the fourth quarter. And Alberto can mention to you he's starting to get ramped up the Bruker deal in China as well, which was a whole new thing for us. We had to learn how to do that and work our way through some submissions. So we feel good about China. The rest of Asia has been good. Latin America has performed well this year. In spite of all those issues in Brazil, it's been the rest of the geography has done fine. Coming back to the 4.5% to 5%. Then the other element that you have to think about is 2 other things. One is we will not have respiratory anymore, and that has been a bit of a headwind for the company. And then we think, in the back half of the year, you'll start to see more traction with our product launches. Things like Barricor, they have to do the validation first, so that takes a little while to get going. Customer feedback has been excellent. Alberto can talk about the product launches that you heard for BD MAX. Those are really critical assays to that program. We're excited about them. And so there's a whole list of these things, and we'll show you more about that as we do the Analyst Day. So that's the way we're thinking about it."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the",127,"One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the first quarter because they really came up in the second quarter -- second, third and fourth of this year. So we still have a little bit of a tough compare in the first quarter that we talked about, particularly in Saudi and Africa. But once we get through that with the new product launches that we're seeing, the strength of the rest of the business, we feel real good about our prospects for '17."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, th",71,"So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, that would take us up, too. Those are probably the 2 factors that I see. So thanks, Mike, for the question."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from David Lewis of Morgan Stanley.",10,"Your next question comes from David Lewis of Morgan Stanley."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team in reaching your target here at least 2 years earlier from our models. So Chris, is this a structu",133,"Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team in reaching your target here at least 2 years earlier from our models. So Chris, is this a structural kind of new low? Can you do better? And obviously, you're reinvesting these savings both in the fourth quarter and next year. Can you give us a sense of where the '17 reinvestment is going? And can you do better than these levels long term? And then for Vince or Tom, OUS Pyxis and Alaris, very strong this particular quarter. Can you talk about the drivers and sort of update us on how those numbers relate to progress on the CareFusion cross-sell?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last",190,"Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last call, the tax synergies coming from CareFusion happened faster and greater than we ever expected, and so we're seeing the benefit of that. So as we look out into next year, we see that bringing us to the high teens. Then we've got the benefit of the stock comp accounting adjustment that brings us down to the 17% to 19% range. So this move down is part of the march down in the tax rate that we've been seeing, coupled with the benefits that we're getting from the synergies from CareFusion. And so we really feel good about that. We've also closed out a lot of tax exams in multiple jurisdictions. We're part of the IRS' CAP program, so they're auditing us on a real-time basis. So the sustainability of this tax rate is extremely strong, and we feel real good about it."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Chris. Tom, you want to pick up on the second part?",13,"Okay. Thanks, Chris. Tom, you want to pick up on the second part?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very wel",231,"So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very well. We talked earlier in the year about some of the process improvements we had made to accelerate the installation process. I think you're seeing the results of that work come to fruition now with faster installations, getting those systems in. We now have over 1,100 sites live on ES or about 1/3 of our installed base is now upgraded to the ES platform. And the receptivity is very solid, and we extract -- expect strong demand on that going forward. Alaris, we continue to gain about 2 to 3 points of category share this past year in FY '16, and we're looking at kind of a similar progress outlook for FY '17 as well. And so we certainly do have organizations that are cross-selling those as an integrated offering. You'll see at Analyst Day us talk about some new informatic capabilities and other new products coming out that will further strengthen the integration and the value that we can deliver to customers who are using that complete end-to-end offering. And so we look forward to talking to you about that very shortly."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Kristen Stewart of Deutsche Bank.",10,"Your next question comes from Kristen Stewart of Deutsche Bank."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether o",64,"Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether or not you'd be willing to do another larger deal. Or would it be back to doing just more share repurchase activity?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to",164,"So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to March, we're pretty sure that we're going to be meeting our requirements to the rating agencies. What I would say is that gives us more flexibility around those strategic imperatives. And so we believe we now have the capability to do large and, of course, continue to have that capability to do tuck-ins and a little bit more flexibility to do the tuck-ins in the short run than we've had over the last 2 years. And so I'm not sitting here saying we're going back to do a large one. We'll be strategy driven around this with increased flexibility and capability that we have built over the last couple of years. Chris, you want to talk about share buybacks?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x",261,"Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x leverage, we're getting a lot of increased flexibility. So as we think about the use of that cash flow, we'll probably do something on the dividend rate. You know that the payout ratio has come down a little bit. We increased 10% a year for the last couple of years. The good news is our EPS is going up over 20%. So the payout ratio has come down a little bit, and we will have to address that going forward. I think CapEx, as you think about it, will be in the $700 million range. That's pretty consistent with where it has been. So that leaves a lot of cash left over. We'll allocate some of that to tuck-in acquisitions, and that will still leave a lot of cash left over. And we're not going to let that cash build up on the balance sheet. So we'll return to doing some share buybacks. You'll hear more about that at Analyst Day. And certainly, as we approach the March period of getting to the 3x leverage, we'll be giving a little bit more specificity on where we're going. But the good news is we have really good strong cash flow and a really solid balance sheet with a lot of flexibility."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?",40,"Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marke",76,"So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marketplace. So I think we're being prudent in terms of how we're thinking about this, and we'll continue to work as we have in the past to offset it."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing.",26,"And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Rick Wise of Stifel.",9,"Your next question comes from Rick Wise of Stifel."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. A",71,"I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. And maybe talk about the drivers -- volume, cost, mix. I mean, what gets us to those higher levels I have no doubt you aspire to?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute",258,"Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute on within our operations group over the last few years. And as we look forward, the guidance that we gave of 53% to 54% -- and that would be inclusive of FX headwinds and pricing headwinds, et cetera -- is extremely strong. It's a significant milestone for us to hit that 53% to 54%. We do see a little bit of -- more synergies coming because as we execute on the synergies that affect gross profit and cost of goods sold, which we said would come towards the latter end of our synergies, and that is the way that's playing out, but, again, continued -- continuous improvement in that area. So we feel really good about the gross profit margin. Also, that flows down to the operating margin. So as we mentioned, this year, 200 basis points; last year, 100 basis points; next year, in that 200 basis points kind of range, 500 basis points in total, again, driven both from execution of the synergies as well as continuous improvement initiatives. So feel real good about that. And as we look forward even past next year, '18 will have continued cost synergies, and you'll see some benefits from that. So all in all, really strong margin improvement, and we feel real good about it."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do antici",79,"Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do anticipate launching with towards the end of the first half. And what drives that share gain for the year that you're sort of suggesting of 200 to 300 basis points?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the",257,"Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the platform around the power of, one, the ability to do not just large volume but also syringe-based and narcotic infusions off the same platform as well as its leading interoperability position with electronic medical records, are some of the key reasons why people have been choosing it at a higher rate and continue to do so going forward. Again, we do have some new technologies being added to the platform, which we'll share also at the upcoming Analyst Meeting. So we're very positive on the outlook there. And as we think about IV solutions, as we've mentioned before that you're going to see, I would expect, a rolling series of approvals on that platform. This is the first -- of course, there's a number of different formulations of IV solutions as well as bag sizes when you think about building out a portfolio that customers really need to run their institution. And so what you just saw get approved was the first in a series of products, and we would expect additional products to be coming out over the months ahead. And that leads us up to where we'll have a really critical kind of mass of a portfolio for launch at the end of the first half of the year."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar of Evercore ISI.",10,"Your next question comes from Vijay Kumar of Evercore ISI."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk",89,"It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk about the quarterly cadence, Chris? Because, obviously, this year was back half loaded on the revenue front and given the flat share count and your comments on free cash generation, it looks like maybe there's some upside from cap deployment potentially."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance.",18,"Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of the revenue going forw",286,"Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of the revenue going forward. And as we said, we do see some headwinds continuing as we annualize the headwinds from Saudi and Africa. That will bring us down in the area of about 4% in the first quarter plus or minus 20 basis points, particularly as that's a high quarter for the flu. So it could go one way or the other on us. But then the ramp in the second quarter brings us back well within the range -- the high end of the range. And the ramping of new products we see in the second half of the year bring us back to a strong 4.5% to 5% range. So that feels real good. In terms of capital deployment, the share buybacks, we are committed to not buy back any shares other than what we've already done for respiratory, which we've talked about. But we're not looking to do anything until we get to the 3x leverage. We want to hit that commitment that we had, and that brings us through March, so halfway through the year. And then from that point on, you're right, there could be some -- but you don't get the full year impact of that at that point, so more to come on that. But there is some potential as we buy back shares, that it will have a little bit of impact on '17, but probably, more likely, the impact would be on '18."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein of William Blair.",10,"Your next question comes from Brian Weinstein of William Blair."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get thr",100,"I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get through committees on capital projects and work down of inventory distributors. So how do you guys think about those and how do you think about kind of the U.S. market going forward? What are the positive offsets that you're seeing to those? And are you guys seeing any of those same headwinds that I described?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give you a",142,"Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give you an example, Brian, we were at one account and we're saving 5 million keystrokes a year. It's the kind of thing that you want to do in this environment, that was a very intentional part of our strategy. So what I would say is, generally, across the board, we're seeing pretty good stability and some increase. We're just getting started with KIESTRA, for example, in the U.S., which is a major cost saving, whether it's in the hospital market or in the clinical lab market. And so we don't have a lot of exposure to the kind of headwinds that you were mentioning."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments -- 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences growing in the U.S. around 8% for the quarter",78,"I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments -- 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences growing in the U.S. around 8% for the quarter and for the year. A lot of that was new product introductions of Symphony, Celesta, the new Melody introduction or whatever. So U.S. is feeling particularly strong for our business."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting.",49,"So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio stan",263,"Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio standpoint. And when I'm saying that we have the most robust pipeline in the history of the company, I want you to understand what that all means. And we will lay that out for you in a lot of detail. So that's number one on the list, that you understand why we have that confidence going forward. And I think it's going to be fun, quite frankly. It was fun doing this 5 years ago, so I'm looking forward to it. And then we're going to take that and we're -- and Chris is going to kind of give you a financial model of how this all holds together. And lastly, we're going to talk about the capabilities that it's going to require to do all this. And we're going to show you how we built the capabilities foundationally over the last 5 years and then how we build upon them. Tom mentioned informatics for example, but we'll also get into how we approach emerging markets, what's different about our strategy and why we see that continuing to work and some of the other capabilities that we will be bringing to bear, which all is an extension of the work we've done over the 5 years. So that's the kind of day, and look forward to seeing you there, Jon."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Bill Quirk of Piper Jaffray.",10,"Your next question comes from Bill Quirk of Piper Jaffray."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, as a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medi",90,"A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, as a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medical, has been a little less predictable, and we certainly appreciate all new product launches, both in-launch as well as near-term development. Do you think this can improve the predictability of the business? Or do you think we may have to look at some tuck-in deals to improve the consistency?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump a",137,"Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump around as customers are ready for us to install because there's some major changes that they have to make to the laboratory, number one. Number two, we've had this issue with Africa, and that's been a bit of a problem. We think that's going to annualize. Are we interested in tuck-in acquisitions there? Absolutely, as we are on the Medical side. I'm just going to ask Alberto to comment on KIESTRA and kind of what you're seeing from a pipeline standpoint, how you see the U.S. market evolving because we just got started there."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in",121,"Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in the U.S. In fact, the sales this last year doubled versus the previous one, admittedly on a small base, but we're seeing a lot of positive momentum, especially as we build the platform. And you'll hear the capabilities of the platform that you'll hear about on the Analyst Day. So we would continue to build on those capabilities, and that gets our customers very excited about the future of the platform, not only the price of the platform."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?",41,"And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling",150,"Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling that. We see implementation strongest in the conventional hospital settings. It's a little weaker in the alternate settings. That's true in most markets where individual doctor compliance may be less than a large governed hospital setting. Strongest conversion rates we see in infusion therapy and blood collection, a little bit lagging in injection. That's also the exact same trend that we saw in the U.S. So still good growth prospects there, and we're in the middle innings. You also mentioned China. Overall in emerging markets, we see safety in the very early innings at less than 15% conversion, so still quite a ways to go."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Derik De Bruin of Bank of America.",12,"Your next question comes from Derik De Bruin of Bank of America."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Midd",104,"A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Middle East situation. But I just -- what sort of gives you confidence that, that's going to reaccelerate this year other than tougher comps -- or easier comps? So what are you sort of seeing right now that gives you confidence that, that's going -- you're not going to have to face another slower year?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop buyi",211,"Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop buying product, number one. So our expectation was they were running down their inventories and then -- and they would start to buy. What we've seen in this quarter was stabilization there. And so it didn't come all the way back to positive growth, but it was significant improvement. So that gives us a sense that our hypothesis in this case is right, number one. Number two, it's really Africa and the annualization of Africa. It was still negative, but we started to see -- and Alberto could give you some more details, some CD4 orders starting to come in, which we did not see. So -- and then we saw good performance across Asia, as I was mentioning before. I expect that to keep happening. I expect that Latin America -- that Brazil is going to remain status quo, and we're going to continue to see strong growth in the other marketplaces. But Alberto, any more -- any other comments on CD4?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that created a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipated.",48,"Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that created a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipated."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, where people didn't know how to order. And that's behind them.",12,"Yes, where people didn't know how to order. And that's behind them."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a littl",108,"I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a little bit of an easier compare there, but still very strong. Vince and I and Tom just got back from China. I can tell you there's a lot of enthusiasm for some of the newer products that we're bringing in. So we see a lot of good stability, and as we mentioned, we're looking at low double digits on China into next year."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets.",38,"And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was",96,"Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was new product contribution to 2016 revenue growth? And looking ahead to 2017, it seems like new product contribution to organic growth should account for a bigger part of overall growth as you accelerate revenue synergies and some important launches, such as the infusion sets. Could you comment on that?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming",103,"So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming from cost synergies and about 100 basis points coming from the respiratory JV coming off our income statement, so we get benefit there. And on the gross profit, it's roughly the same kind of area. There's a benefit from respiratory -- about half of it coming from respiratory, about half of it coming from CI and synergy."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they rea",179,"In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they really haven't gotten traction yet. Barricor, people are just starting to validate Barricor. The approvals on BD MAX we just got in the last month or so. So they really haven't hit. And then you're talking about tens of basis points in terms of the CareFusion products in the emerging markets at this point in time. We haven't done the work -- we haven't completed the work, let me say it that way, in terms of trying to get a really good analysis around breaking out new product from the entire company. As we're going through the CareFusion integration, we haven't counted the geographic extension of those products as new products. But we're working our way through that, and you'll have a better sense, after the Analyst Day, of how this is coming together."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Matt Taylor of Barclays.",9,"Your next question comes from Matt Taylor of Barclays."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluids, diabetes an",80,"I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluids, diabetes and some of the diagnostic launches in terms of how we should expect the revenue contributions from those to flow? Can you help us size them and just give us some thoughts on timing?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?",14,"So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begu",168,"Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begun shipping that to patients, and the feedback that we're hearing is very positive. And there's been a number of bloggers actually write their experience. You can look that up online, but it's very, very good feedback as that's moved into the marketplace just over the last couple of months. We do expect that, that probably will expand to a broader full launch in early Q2. And that's well on track. So I think back to one of the earlier questions, as we think about -- within the Diabetes Care business, we do expect -- and obviously we don't give guidance by business unit, but we expect an uptick in '17 in Diabetes Care, driven by that FlowSmart launch. And that's on track, proceeding as planned."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things.",23,"Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first o",190,"Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first one that is integrated, which is a guideline from the CDC to do the 3 tests all in one, and we're the only ones that will have it in the same assay. The vaginal panel will be a significant improvement versus the only approved assay, the Affirm assay, that we have out there; will be better accuracy, more targets and much improved performance from that side. That will take a little bit of time to be built into the sales as people evaluate and -- accounts evaluate and convert to this. But we are very, very optimistic. And all -- the interest has been very high in both accounts. And on Barricor, a similar thing. The evaluations are beginning to happen. There's more than 50 accounts currently evaluating the Barricor products, and that momentum we anticipate to continue in the rest of the year."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?",24,"So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, between -- yes, I would say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there.",24,"Yes, between -- yes, I would say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot.",20,"To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Right.",1,"Right."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And the last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- for BD CLiC, we are putting our first instruments as early access into customer accounts. So",101,"And the last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- for BD CLiC, we are putting our first instruments as early access into customer accounts. So they will just start to do their validations as well, and so I don't expect that to be a big contributor this year. I expect, since it's such new technology, it's going to take a little longer, but we're also starting to get good feedback there. Anything else you want to add?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time.",29,"And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question.",17,"Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is coming from Richard Newitter with Leerink Partners.",11,"Your final question is coming from Richard Newitter with Leerink Partners."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Eur",133,"Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Europe. And I know the business model in that part of the world is just different, and it hasn't historically lent itself well. But I do believe you had begun to talk a little bit about Rowa and leveraging that technology. I'm just wondering if that's going to factor in, in 2017 in the cross-sell or the synergy phase of the acquisition integration. And any kind of thoughts there? And is that something that we could hear more about at the Analyst Day?"
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line lo",69,"Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line looks like for you, and there's multiple aspects to that. So yes, we'll be happy to talk about that. Thanks for the question."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for closing remarks.",14,"I will now turn the floor back over to Vince Forlenza for closing remarks."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and",53,"Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and we'll see you there."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,403765314,1072178,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",18,"This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by ph",81,"Hello, and welcome to BD's Fourth Fiscal Quarter and Full Fiscal Year 2016 Earnings Call. At the request of BD, today's call is being recorded. It will be available for replay through November 10, 2016, on the Investors page of the bd.com website or by phone at (800) 585-8367 for domestic calls and (404) 537-3406 for international calls using confirmation number 94169710. [Operator Instructions] 
Beginning today's call is Ms. Monique Dolecki, Vice President of Investor Relations. Ms. Dolecki, you may begin."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is poste",385,"Thank you, Christy. Good morning, everyone, and thank you for joining us to review our fourth fiscal quarter results. As we referenced in our press release, we are presenting a set of slides to accompany our remarks on this call. The presentation is posted on the Investor Relations page of our website at bd.com.
During today's call, we will make forward-looking statements, and it is possible that actual results could differ from our expectations. Factors that could cause such differences appear in our fourth fiscal quarter press release and in the MD&A sections of our recent SEC filings. We will also discuss some non-GAAP financial measures with respect to our performance. A reconciliation to GAAP measures can be found in our press release and its related financial schedules and in the slides. A copy of the release, including the financial schedules, is posted on the bd.com website.
As a reminder, we annualized the acquisition of CareFusion in March, and as such, our fourth quarter results reflect the new BD in both the current and prior year periods. In addition, comparable prior year revenues are adjusted to exclude the sales related to the terminated agreement with CareFusion for the sale of F&P's respiratory care products. The impact to the bottom line is not material. Comparable organic revenues are adjusted to further exclude the impact of non-annualized acquisitions and closed divestitures. The fiscal 2017 comparable revenue guidance provided today will exclude revenues of closed divestitures, most notably the Respiratory Solutions business that was divested in October of 2016 just after our fiscal year-end. 
In the fourth quarter, the company recorded a noncash impairment charge for capitalized internal-use IT software assets. This charge, along with the details of the purchase accounting and other smaller adjustments and the comparable basis revenue results, can be found in the reconciliations to GAAP measures in the financial schedules, in our press release or the appendix of Investor Relations slides.
Leading the call this morning is Vince Forlenza, Chairman, Chief Executive Officer and President. Also joining us are Chris Reidy, Chief Financial Officer and Chief Administrative Officer; Tom Polen, Executive Vice President and President of the Medical Segment; and Alberto Mas, Executive Vice President and President of the Life Sciences segment.
It is now my pleasure to turn the call over to Vince."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. Moving on to my presentation. As we stated in our press release, we are",594,"Thank you, Monique, and good morning, everyone. First, congratulations to the Cubs fans out there, especially the BD associates in Chicago. In the words of Brian Weinstein, go Cubs. 
Moving on to my presentation. As we stated in our press release, we are extremely proud of our accomplishments in our first full fiscal year as the new BD. As you already know, the acquisition of CareFusion 18 months ago significantly accelerated our strategy, and the powerful combination of BD and CareFusion continues to deliver positive results. We've seen significant benefits as a result of this transaction from a customer, employee and shareholder standpoint, and we think there's more to come. 
Turning to Slide 4. I'd like to highlight some key achievements in fiscal year 2016. First, our results reflect our consistent performance and the benefit of our diverse geographic and product portfolio. Legacy BD remains solid, and the CareFusion portfolio has performed in line with our expectations. 
Second, emerging markets continue to be a key growth driver for the company. We experienced some headwinds this year, particularly in the Middle East and Africa, but remain confident that emerging markets are well positioned for continued growth. We also continue to create new growth opportunities for CareFusion products in these markets and expand their global reach by leveraging BD's international infrastructure. We're on track with our new product approval and submission plans and look forward to providing more color at our Analyst Meeting later this month. Developed markets continued to show stabilization, and growth has accelerated over the past year. 
Third, we made key strategic decisions to optimize our portfolio. This included the divestitures of BD Rx and the spine business in conjunction with the joint venture for the respiratory business, which we just completed in October. These actions further enabled the organization to prioritize and invest in the most important opportunities for future growth. We were deliberate in increasing our R&D investment in targeted high-growth areas and fully utilized the benefit of the medical device tax suspension.
Fourth, we remain focused on our operating effectiveness and efficiency initiatives, which have generated significant margin expansion. This year, we drove approximately 200 basis points of underlying margin expansion, which includes approximately $120 million in cost synergies. We also delivered robust earnings growth of almost 30%, which is greater than our initial expectations.
Lastly, we closed our first full year as the new BD having achieved all important milestones and also demonstrated that we are successfully executing on our acquisition of CareFusion. As we look forward, we continue to build on our solid foundation and look to fiscal year 2017 and beyond with confidence. 
Moving to Slide 5. You will see the guidance for fiscal year 2017 on a currency-neutral basis. For the fiscal year 2017, we expect currency-neutral revenue growth of 4.5% to 5% based on our current view of the environment and various macroeconomic factors. There are a number of items that could bring us to the top or bottom end of that range, including a stronger or weaker flu season than expected, the performance of new product launches, emerging market growth and pricing. On the bottom line, we will continue to deliver high-quality earnings growth. For fiscal year 2017, we expect EPS of $9.45 to $9.55 or $9.62 to $9.72 currency neutral, which reflects growth of 12% to 13%.
Now I'd like to turn the call over to Chris, who will walk you through our financial performance in the fourth quarter and full year, along with the additional details about our fiscal year 2017 guidance."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approx",2259,"Thanks, Vince, and good morning, everyone. Moving on to Slide 7. I'd like to begin by discussing our fourth quarter revenue and EPS results as well as the key financial highlights for the quarter and the total year. Total fourth quarter revenues of approximately $3.2 billion grew 6.4% on a comparable basis. Fully diluted adjusted EPS came in ahead of our expectations at $2.12, growing at 16.5% over the prior year. 
As Vince mentioned earlier, we are very pleased with our solid finish to the year, the first full year as a combined entity with CareFusion. For the total year, revenues grew 4.3%. We significantly expanded our margins and captured approximately $120 million in synergy cost savings. Adjusted EPS of $8.59 exceeded our expectations, driven by solid revenues, margin expansion and an improved tax rate. In addition to the cost synergies, tax synergies have materialized sooner and have exceeded the benefits we anticipated in the early days of the transaction. We are also pleased to announce that we have continued to delever as we reduced the debt associated with the acquisition of CareFusion. We are currently at 3.3x gross leverage and remain on track to achieve our commitment of 3x gross leverage by March of 2017.
On Slide 8, I'll review our revenue growth by segment on a currency-neutral basis. Fourth quarter revenue growth was 6.4% for the total company. In the quarter, pricing was about flat. BD Medical fourth quarter revenues increased 7.9%. Medication and Procedural Solutions growth was 6.6%, which reflects strength in flush, ChloraPrep and safety-engineered products. Revenues in Medication Management Solutions or MMS grew 12.8%. This was driven by double-digit growth in both dispensing and infusion sales.  
Respiratory Solution revenues increased 12.7%, as expected. This reflects strong capital installations and a favorable comparison to the prior-year period.
Growth in Diabetes Care was 3.6%. This reflects solid growth in pen needles, which was partially offset by an unfavorable comparison to the prior year period. Pharmaceutical Systems growth of 5.1% reflects strength in our self-injection platform. For the total year, BD Medical grew 4.7%. 
BD Life Sciences fourth quarter revenues increased 2.7%, primarily driven by growth in Preanalytical Systems and Biosciences. Diagnostic System revenues were about flat compared to the prior year. This reflects continued strength in core microbiology and BD MAX, which grew double digits in the quarter. This growth was offset by the timing of KIESTRA installations outside of the U.S., which I'll speak to in just a moment. For the total year, we are extremely pleased with our microbiology business, with KIESTRA growing at about 19%.
Preanalytical Systems growth of 4% was driven by safety-engineered products and growth in the U.S. and emerging markets. BD Biosciences growth of 4% was driven by continued strong research instrument placements in the U.S. and reagent sales. For the total year, Life Sciences grew 3.4%. The headwinds we experienced in Africa negatively impacted segment results by 60 basis points, bringing underlying growth to 4% for the total year.  
Moving to Slide 9. I'll walk you through our geographic revenues for the fourth quarter on a currency-neutral basis. U.S. growth was very strong at 7.2%. This was comprised of BD Medical growing at 7.7% and BD Life Sciences growing at 5.8%. BD Medical's performance reflects strong growth in capital placements and a wide range of infusion disposable products in our Medication and Procedural Solutions business. Growth was also driven by our Pharmaceutical Systems business. 
BD Life Sciences growth reflects strong performance across the segment in the U.S. The growth in our Biosciences business was driven by high-parameter research instruments, including FACSSymphony, our FACSCelesta mid-level analyzer and the launch of the FACSMelody. Our U.S. Diagnostics business saw continued growth in microbiology, including KIESTRA and the BD MAX molecular platform. The Preanalytical Systems business grew 5%, driven by safety-engineered products.
Moving on to international. Revenues grew 5.2%. This is below our normal growth rate, which is primarily related to the Life Sciences segment. The Medical segment grew 8.2%. This was driven by strong performance from infusion disposal products in the MPS business and strong performance in China. Growth was also driven by medication management, reflecting double-digit growth in both dispensing and infusion.
Growth in the Life Science segment was about flat compared to the prior year. We experienced a decline in Diagnostic Systems due to the timing of KIESTRA installations. Increased installations in the third fiscal quarter negatively impacted the fourth fiscal quarter in conjunction with the tough comparison to the prior year fourth quarter. Biosciences growth was lower in the quarter due to continued declines in Africa, as we anticipated. The Preanalytical Systems business grew 2.9%, driven by strength in China, which was partially offset by a tough comparison to the prior year period.
On Slide 10, developed markets grew a healthy 5.8%, bringing the total year growth to 4.1%. Emerging market revenues grew 8.5% currency neutral, bringing our year-to-date growth rate to 5.3%. China growth for the fourth quarter was 17.7%, bringing the total year growth rate to 10.1%. Growth in emerging markets this fiscal year was lower than initially expected in the Middle East and Africa, and we believe those challenges are largely behind us after we exit the first quarter of fiscal year 2017. Emerging markets remain an important growth driver, and given our robust international footprint, we are well positioned to drive growth well into the future.
Looking into fiscal year 2017. We expect emerging markets to grow high single digits, driven by a diversified base, with China growing low double digits, continued strength in Latin America and fewer headwinds in EMA and Africa. In terms of developed markets, we believe the stability we have seen in the market over the past 12 to 18 months will continue, yielding a growth rate of about 4%.
Moving to global safety on Slide 11. Currency-neutral sales increased 5.9% and grew to $783 million in the quarter. Safety revenues in the U.S. grew 5.7%. This reflects continued strength of safety catheters as well as a benefit from the timing of orders across our hypodermic products.
International sales grew 6.2% currency neutral. International performance in the Medical segment was driven by the continued strength in China, and safety revenues grew 13.8% in emerging markets.
Medical safety sales grew 7%, driven by infusion disposables, catheters and a range of safety-engineered products. Life Sciences safety sales, which were driven by our Preanalytical Systems unit, grew 4% in the quarter.
Slide 12 recaps the fourth quarter income statement and highlights our currency-neutral results. Revenues grew a strong 6.4% in the quarter. Gross profit was strong, growing faster than revenues, at 7.9%. And I'll provide more details on gross profit in just a moment. 
SSG&A as a percentage of revenue was 24.4%. We are very pleased with the leverage we are getting, which is masked in this quarter by key strategic investments in product launches in both segments. R&D as a percentage of revenues was 7.8%, which is higher than normal due to the timing of spend as anticipated. As a result of the medical device tax suspension, we were able to make additional investments in a number of high-growth areas. After normalizing for this significant additional investment in R&D, underlying operating income would have grown about 10% in the quarter.
Our tax rate declined to 16.2% in the quarter due to the reinstatement of the R&D tax credit, tax synergies materializing earlier than expected and continued favorable geographic mix. In the quarter, adjusted earnings per share were $2.12, which is a 16.5% increase versus the prior year.
Turning to Slide 13 and our gross profit and operating margins for the fourth quarter. On a performance basis, gross profit margin improved by 90 basis points, driven by continuous improvement initiatives. This was more than offset by significant currency headwinds of 110 basis points. On an operating margin basis, we are extremely pleased to have delivered about 100 basis points of underlying margin expansion. As I mentioned on the previous slide, the leverage we are getting in SSG&A as we continue to drive cost synergies is being masked in the quarter by investments in key product launches. In addition, margin expansion was partially offset by significant R&D investments, as expected, and unfavorable currency. 
I'd like to take a moment on Slide 14 to highlight some of our key operational achievements for fiscal year 2016. The acquisition of CareFusion provided BD a unique opportunity to leverage the transaction to optimize the combined organization through functional transformations, and we have made significant progress in this area. All of our efforts have yielded results, and we are on track to deliver continued synergies. In aggregate, we have achieved over $170 million in total cost synergies to date. 
We have also driven significant margin expansion on a multiyear trajectory. Starting with fiscal year 2015, we delivered 100 basis points of operating margin expansion. This year, we achieved another 200 basis points, and we believe we are well positioned to deliver another 175 to 225 basis points in fiscal year 2017. Over those 3 years, we will have driven over 500 basis points of cumulative margin expansion, and I believe that we continue to drive robust performance with additional synergies in conjunction with continuous improvement going forward. We're extremely proud of the organization's ability to continue improving on our skills and expertise by executing against our synergy commitment initiatives through these transformations.
Moving on to Slide 15. I'd like to highlight our robust EPS growth, which exceeded our expectations this year. Starting with 2015 EPS of $7.16, we had communicated last November that we would grow EPS 22% to 23% on a currency-neutral basis. Beyond our initial expectations, we delivered an incremental 400 basis points from margin improvement. We also realized incremental benefits from our tax rate improvement, which yielded 300 basis points, bringing EPS to $9.24. Unfavorable currency headwinds impacted earnings per share by 900 basis points. Despite that significant headwind, we were still able to deliver $8.59 of earnings. On a currency-neutral basis, earnings grew 29.1%, which we believe demonstrates our ability to deliver on our commitment.
Moving on to Slide 17. There are a number of factors to consider when discussing our earnings per share in fiscal year 2017. For modeling purposes and to ensure consistency, I'd like to provide more color on our EPS guidance. First, as I mentioned, we are extremely pleased with strong EPS growth this year. Looking forward, we expect currency-neutral EPS to grow between 12% and 13%. This is partially muted by the impact of the respiratory JV, as we previously communicated. Pension also presents a headwind next year of approximately 100 basis points. 
Contributing to EPS growth is approximately 200 basis points from the adoption of a new accounting standard related to the tax accounting on our stock compensation programs. In addition, we estimate that currency will once again present a headwind. Our guidance assumes a euro to dollar exchange rate of $1.10. On an adjusted basis, we expect to achieve very strong earnings of $9.45 to $9.55.
Turning to Slide 18. I'd like to walk you through the balance of our guidance expectations for the full fiscal year 2017. As Vince mentioned earlier in the presentation, we expect revenue growth of 4.5% to 5%, with BD Medical growing 4.5% to 5% and Life Sciences growing between 4% to 5%. Growth in both segments contemplates a small amount of pricing pressure. 
From a phasing perspective, we expect currency-neutral revenue growth in the first quarter to be below this range. This is primarily due to some lingering softness in the EMA region and the timing of tenders in our Biosciences business. This will result in a currency-neutral revenue growth of about 4% in the first fiscal quarter. We expect revenue growth to return back to our guidance range in the second fiscal quarter, with continued acceleration over the back half of the year. We expect gross profit margin to be between 53% and 54%, which is a significant milestone for BD.
SSG&A as a percentage of sales is expected to be between 23.5% and 24%. Our guidance also reflects continued investments in emerging markets as well as costs related to new product launches and registration costs. We expect our R&D investments to be in line with fiscal year 2016 at about 6% to 6.5% of revenues as we continue to invest in new products and platforms. 
As a result of the items I just detailed, operating margin is expected to be between 23% and 24% of revenues, up from 20.8% this year. Excluding the unfavorable impact of foreign currency, we expect our underlying operating margin to improve by 175 to 225 basis points. This also excludes slight pension headwinds.
We expect our tax rate to be between 17% and 19%, driven by tax synergies, favorable geographic mix and a benefit from accounting change in our stock compensation program. For fiscal year 2017, we anticipate our average fully diluted share count to be approximately 219 million. Cash flow is expected to remain strong, with operating cash flow of about $2.7 billion in fiscal year 2017. Capital expenditures are expected to be about $700 million. 
In summary, we have good momentum exiting this fiscal year, and looking forward into 2017, we are building off a solid foundation. I'm confident that fiscal year 2017 will be another strong year of performance, positioning us well for continued success. 
Now I'd like to turn the call back over to Vince, who'll provide you with our concluding remarks."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few.",509,"Thank you, Chris. Moving on to Slide 20. We are pleased with the progress we continue to make on our pipeline and believe we have the most robust pipeline in the company's history. We have recently obtained a number of approvals. I'll touch on just a few. 
On the Medical side of the business, we are pleased that our partner, Fresenius, received their first FDA approval for IV solution products. Additional approvals are expected, and we are on track to start shipping these products late in the first half of the year. Last quarter, we received our first orders for FlowSmart, our new insulin infusion set, where Medtronic serves as our distribution partner. Early patient feedback has been extremely positive. 
On the life side -- Life Science side of the business, we're pleased that the FDA has approved the BD MAX Vaginal Panel and also the GC/CT/TV assay. We launched our new Phoenix IDAST instrument. We launched the FACSMelody and received approval for Barricor in the U.S. We plan to share more about our pipeline on November 17 at our upcoming Analyst Day.
Also on Analyst Day, we will discuss the company's strategy and vision for the future and how we are helping to address health care's most pressing challenges. The segment leaders will do a deep dive into our business units, which will include some key product launches that we will be unveiling for the first time. We will conclude the day with a financial framework that will outline our plans for sustainable revenue growth, continued margin expansion, strong cash flow generation and capital deployment and, ultimately, demonstrate how all of those things will drive long-term value not only for our customers and patients they serve but also for our employees and our shareholders.
Moving on to Slide 21. I would like to reiterate the key messages from our presentation today. First, we're extremely pleased with our first fiscal year as the new BD. We believe that we have demonstrated that we can successfully execute on the integration of the largest transaction in the company's history.  Second, the diversity of our portfolio from a product and geographic perspective provides consistent and reliable earnings growth. Third, we continue to invest in key strategic areas and, at the same time, deliver significant margin expansion and double-digit earnings growth. 
We're looking forward to sharing more details about our pipeline at our Analyst Day in 2 weeks. We believe we have the most robust pipeline in the company's history, and we look to fiscal year 2017 and beyond with confidence.
Finally, I would like to say thank you to all of our associates around the world for our successful first full fiscal year as a combined company with CareFusion. It's a testament to the hard work of all of our employees that we delivered on our commitments. I believe we have a tremendous opportunity to create a true industry leader as we continue to advance the world of health. 
So with that, thank you. We will now open the call to questions."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan.",12,"[Operator Instructions] Our first question is coming from Mike Weinstein with JPMorgan."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit mo",134,"So as a starting point, Vince, I'd love to hear your thoughts, just as you look to FY '17, about some of your end markets. And some of the businesses, as I look over the quarter and the full year '16, did a little bit better. Some businesses were a bit more challenged. And so maybe just focusing a bit on the more challenged businesses first. Can you just talk a little bit about some of the headwinds that you saw, particularly internationally in the Life Sciences business this quarter, this year and how you think about some of those end markets in FY '17? And then if you think about that in aggregate, that 4.5% to 5% revenue growth target for FY '17, what gets you to the higher end of that range?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So fr",638,"Yes, Mike. Sure, happy to do that. I feel good about the 4.5% to 5%. And let me walk through the markets, and I'll hit the Bioscience issue which you brought up, which was really the real drag along with, quite frankly, the flu early on in the year. So from a market perspective, let me just start with the developed markets. The developed markets certainly have stabilized, and you've seen that -- our growth rate going up in the developed markets and the U.S. The U.S. was very strong. By the way, including Biosciences, Europe was good, Japan was good. So we feel good about our position in developed markets and the product pipeline we have for those marketplaces. If I come to emerging markets, the issue really this year was, number one, Saudi Arabia, where we saw the government do a 35% cut of all types of expenses, not just health care. And that will annualize during the year. We already saw a stabilization in Saudi Arabia. In terms of Africa, Africa was basically CD4 testing. And CD4 testing was driven by, one, some conversion to viral load; and two, actually, confusion over a change in the purchasing organization for CD4 and viral load. And we think we have one more quarter of that. We did start to see some CD4 orders coming in the fourth quarter and a little bit of a rebound. But we know we have that in the first quarter and then that annualizes and improves. Coming back to opportunities. On China, you saw the strong growth in China in the fourth quarter. If you actually go back and look at China after the first quarter, where we had some inventory take-down, China was strong for the other 3 quarters. We expect that to continue. It was especially strong this year on the Medical side of the business, and we think we're well positioned with the work that Tom and the regulatory team have been doing with the CareFusion product lines there. And as I've mentioned on previous calls, we've started with some of those product lines, kind of the simpler disposables, and I'm sure Tom will talk more about that later on in the call. If there was any softness in China this year from a true demand standpoint, it was on the Life Science side, and it was related to those anticorruption campaign. What we saw was stabilization starting in the third quarter and continuing into the fourth quarter. And Alberto can mention to you he's starting to get ramped up the Bruker deal in China as well, which was a whole new thing for us. We had to learn how to do that and work our way through some submissions. So we feel good about China. The rest of Asia has been good. Latin America has performed well this year. In spite of all those issues in Brazil, it's been the rest of the geography has done fine. Coming back to the 4.5% to 5%. Then the other element that you have to think about is 2 other things. One is we will not have respiratory anymore, and that has been a bit of a headwind for the company. And then we think, in the back half of the year, you'll start to see more traction with our product launches. Things like Barricor, they have to do the validation first, so that takes a little while to get going. Customer feedback has been excellent. Alberto can talk about the product launches that you heard for BD MAX. Those are really critical assays to that program. We're excited about them. And so there's a whole list of these things, and we'll show you more about that as we do the Analyst Day. So that's the way we're thinking about it."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the",127,"One way to sum that up, this is Chris, is that if you back out the light flu season and the headwinds from Africa and Saudi, the rest of the business would -- was at the high end of the 4.5% to 5% this year alone. We see those headwinds abating after the first quarter because they really came up in the second quarter -- second, third and fourth of this year. So we still have a little bit of a tough compare in the first quarter that we talked about, particularly in Saudi and Africa. But once we get through that with the new product launches that we're seeing, the strength of the rest of the business, we feel real good about our prospects for '17."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, th",71,"So what takes you to the top end of the range? Obviously, if those product launches, we get faster traction on them, number one. Two, with flu, flu was very mild last year. It's hard to believe that it would be milder. So if we got a strong flu season, that would take us up, too. Those are probably the 2 factors that I see. So thanks, Mike, for the question."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from David Lewis of Morgan Stanley.",10,"Your next question comes from David Lewis of Morgan Stanley."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team in reaching your target here at least 2 years earlier from our models. So Chris, is this a structu",133,"Two quick questions. I'll just -- so I'll throw them both at you here and jump back in queue. So I guess, first off, hats off to Antoinette and the tax team in reaching your target here at least 2 years earlier from our models. So Chris, is this a structural kind of new low? Can you do better? And obviously, you're reinvesting these savings both in the fourth quarter and next year. Can you give us a sense of where the '17 reinvestment is going? And can you do better than these levels long term? And then for Vince or Tom, OUS Pyxis and Alaris, very strong this particular quarter. Can you talk about the drivers and sort of update us on how those numbers relate to progress on the CareFusion cross-sell?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last",190,"Sure, David. Thanks for the question, and thanks for the call out to Antoinette and team. We've been talking about taking the tax rate down to the high teens for some time now, and we've been making great progress against that. As we mentioned on the last call, the tax synergies coming from CareFusion happened faster and greater than we ever expected, and so we're seeing the benefit of that. So as we look out into next year, we see that bringing us to the high teens. Then we've got the benefit of the stock comp accounting adjustment that brings us down to the 17% to 19% range. So this move down is part of the march down in the tax rate that we've been seeing, coupled with the benefits that we're getting from the synergies from CareFusion. And so we really feel good about that. We've also closed out a lot of tax exams in multiple jurisdictions. We're part of the IRS' CAP program, so they're auditing us on a real-time basis. So the sustainability of this tax rate is extremely strong, and we feel real good about it."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Thanks, Chris. Tom, you want to pick up on the second part?",13,"Okay. Thanks, Chris. Tom, you want to pick up on the second part?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very wel",231,"So as you mentioned, MMS had a very strong quarter, a little under 13% growth in the quarter, about 7% growth for the full year. And maybe just to touch base on the 2 areas that you mentioned, Pyxis and Alaris. Certainly, Pyxis ES continues to go very well. We talked earlier in the year about some of the process improvements we had made to accelerate the installation process. I think you're seeing the results of that work come to fruition now with faster installations, getting those systems in. We now have over 1,100 sites live on ES or about 1/3 of our installed base is now upgraded to the ES platform. And the receptivity is very solid, and we extract -- expect strong demand on that going forward. Alaris, we continue to gain about 2 to 3 points of category share this past year in FY '16, and we're looking at kind of a similar progress outlook for FY '17 as well. And so we certainly do have organizations that are cross-selling those as an integrated offering. You'll see at Analyst Day us talk about some new informatic capabilities and other new products coming out that will further strengthen the integration and the value that we can deliver to customers who are using that complete end-to-end offering. And so we look forward to talking to you about that very shortly."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Kristen Stewart of Deutsche Bank.",10,"Your next question comes from Kristen Stewart of Deutsche Bank."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether o",64,"Just wondering, as you're approaching your, I guess, targeted debt levels, how you guys are thinking about M&A kind of beyond that. Are you guys looking at doing some strategic tuck-ins? Or just given the success that you've had with CareFusion, whether or not you'd be willing to do another larger deal. Or would it be back to doing just more share repurchase activity?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to",164,"So Kristen, thanks for the question. When we think about M&A, we are strategy driven and shareholder value driven, and so the size of the transaction actually follows from the strategy. As Chris mentioned, we're about 3.3x right now. By the time we get to March, we're pretty sure that we're going to be meeting our requirements to the rating agencies. What I would say is that gives us more flexibility around those strategic imperatives. And so we believe we now have the capability to do large and, of course, continue to have that capability to do tuck-ins and a little bit more flexibility to do the tuck-ins in the short run than we've had over the last 2 years. And so I'm not sitting here saying we're going back to do a large one. We'll be strategy driven around this with increased flexibility and capability that we have built over the last couple of years. Chris, you want to talk about share buybacks?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x",261,"Yes, sure. So what I would say though is, in addition to that, the continued strong cash flow is terrific. So we have a lot of flexibility. And as Vince mentioned, the balance sheet will be very strong. It is strong now at the 3.3x, but when we get to 3x leverage, we're getting a lot of increased flexibility. So as we think about the use of that cash flow, we'll probably do something on the dividend rate. You know that the payout ratio has come down a little bit. We increased 10% a year for the last couple of years. The good news is our EPS is going up over 20%. So the payout ratio has come down a little bit, and we will have to address that going forward. I think CapEx, as you think about it, will be in the $700 million range. That's pretty consistent with where it has been. So that leaves a lot of cash left over. We'll allocate some of that to tuck-in acquisitions, and that will still leave a lot of cash left over. And we're not going to let that cash build up on the balance sheet. So we'll return to doing some share buybacks. You'll hear more about that at Analyst Day. And certainly, as we approach the March period of getting to the 3x leverage, we'll be giving a little bit more specificity on where we're going. But the good news is we have really good strong cash flow and a really solid balance sheet with a lot of flexibility."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?",40,"Okay, great. And then just one other question. You had mentioned building a little bit more pricing pressure into the forecast. Can you maybe comment on where you're seeing a little bit more pricing pressure or expecting that to occur?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marke",76,"So I -- we haven't really seen the environment change all that much. We know that there's going to be pricing pressure. We've talked a lot about it being in Europe. And of course, over the last few years, we continue to see consolidation in the U.S. marketplace. So I think we're being prudent in terms of how we're thinking about this, and we'll continue to work as we have in the past to offset it."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing.",26,"And it's already built into the range of guidance that we're giving. So it's kind of the -- part of the range is the pricing."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Rick Wise of Stifel.",9,"Your next question comes from Rick Wise of Stifel."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. A",71,"I'll start off with the gross margin. Chris, you emphasized -- underscored the excellent gross margins and hitting significant milestones. I'd just be curious to hear your thoughts on your aspirational goals from here over the next 2 to 4, 3 to 5 years. And maybe talk about the drivers -- volume, cost, mix. I mean, what gets us to those higher levels I have no doubt you aspire to?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute",258,"Sure. Thank you, Rick. We are really pleased with what we've seen this year. The FXN growth rate was 140 basis points. That's a little bit of synergy from CareFusion, but more it's just a continuous improvement that we've demonstrated that we can execute on within our operations group over the last few years. And as we look forward, the guidance that we gave of 53% to 54% -- and that would be inclusive of FX headwinds and pricing headwinds, et cetera -- is extremely strong. It's a significant milestone for us to hit that 53% to 54%. We do see a little bit of -- more synergies coming because as we execute on the synergies that affect gross profit and cost of goods sold, which we said would come towards the latter end of our synergies, and that is the way that's playing out, but, again, continued -- continuous improvement in that area. So we feel really good about the gross profit margin. Also, that flows down to the operating margin. So as we mentioned, this year, 200 basis points; last year, 100 basis points; next year, in that 200 basis points kind of range, 500 basis points in total, again, driven both from execution of the synergies as well as continuous improvement initiatives. So feel real good about that. And as we look forward even past next year, '18 will have continued cost synergies, and you'll see some benefits from that. So all in all, really strong margin improvement, and we feel real good about it."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question is from Larry Keusch of Raymond James.",10,"Your next question is from Larry Keusch of Raymond James."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do antici",79,"Just wondering if we could go back and expand a little bit on -- I know Tom talked a little bit about Alaris, but I was wondering if you could weave in some thoughts around the Fresenius IV solution that was approved, a little bit about what you do anticipate launching with towards the end of the first half. And what drives that share gain for the year that you're sort of suggesting of 200 to 300 basis points?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the",257,"Sure. Larry, this is Tom. So that share gain that we saw this year is actually relatively consistent with share trajectory that we've seen over the last, let's call it, 4 to 5 years within the Alaris platform. I think what customers certainly value in the platform around the power of, one, the ability to do not just large volume but also syringe-based and narcotic infusions off the same platform as well as its leading interoperability position with electronic medical records, are some of the key reasons why people have been choosing it at a higher rate and continue to do so going forward. Again, we do have some new technologies being added to the platform, which we'll share also at the upcoming Analyst Meeting. So we're very positive on the outlook there. And as we think about IV solutions, as we've mentioned before that you're going to see, I would expect, a rolling series of approvals on that platform. This is the first -- of course, there's a number of different formulations of IV solutions as well as bag sizes when you think about building out a portfolio that customers really need to run their institution. And so what you just saw get approved was the first in a series of products, and we would expect additional products to be coming out over the months ahead. And that leads us up to where we'll have a really critical kind of mass of a portfolio for launch at the end of the first half of the year."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Vijay Kumar of Evercore ISI.",10,"Your next question comes from Vijay Kumar of Evercore ISI."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk",89,"It looks like the numbers were actually a lot better than what it seemed like at first blush. So just maybe a couple of questions on the guidance, Chris or Vince. What does the guidance assume from a pricing assumption for next year? And can you just talk about the quarterly cadence, Chris? Because, obviously, this year was back half loaded on the revenue front and given the flat share count and your comments on free cash generation, it looks like maybe there's some upside from cap deployment potentially."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance.",18,"Yes. Pricing is just slightly negative in the plan, and as Chris said, it's already in the guidance."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of the revenue going forw",286,"Yes, which is no different than the beginning of just about any year. You got to look at that. The pricing environment, as Vince said, hasn't really changed. And so then, I think the next part of your question came to the phasing of the revenue going forward. And as we said, we do see some headwinds continuing as we annualize the headwinds from Saudi and Africa. That will bring us down in the area of about 4% in the first quarter plus or minus 20 basis points, particularly as that's a high quarter for the flu. So it could go one way or the other on us. But then the ramp in the second quarter brings us back well within the range -- the high end of the range. And the ramping of new products we see in the second half of the year bring us back to a strong 4.5% to 5% range. So that feels real good. In terms of capital deployment, the share buybacks, we are committed to not buy back any shares other than what we've already done for respiratory, which we've talked about. But we're not looking to do anything until we get to the 3x leverage. We want to hit that commitment that we had, and that brings us through March, so halfway through the year. And then from that point on, you're right, there could be some -- but you don't get the full year impact of that at that point, so more to come on that. But there is some potential as we buy back shares, that it will have a little bit of impact on '17, but probably, more likely, the impact would be on '18."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Brian Weinstein of William Blair.",10,"Your next question comes from Brian Weinstein of William Blair."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get thr",100,"I wanted to ask about kind of U.S. headwinds that we've heard about from others. Specifically, flu year-over-year was a tough comp for a lot of people. Utilization seems to be a little weaker. We're hearing about things getting -- taking longer to get through committees on capital projects and work down of inventory distributors. So how do you guys think about those and how do you think about kind of the U.S. market going forward? What are the positive offsets that you're seeing to those? And are you guys seeing any of those same headwinds that I described?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give you a",142,"Well, we're generally not procedural driven. An Alaris conversion to make the hospitals safer and more effective, they're not being driven by this on-the-margin procedures. And in fact, Tom was talking about interoperability before. And just to give you an example, Brian, we were at one account and we're saving 5 million keystrokes a year. It's the kind of thing that you want to do in this environment, that was a very intentional part of our strategy. So what I would say is, generally, across the board, we're seeing pretty good stability and some increase. We're just getting started with KIESTRA, for example, in the U.S., which is a major cost saving, whether it's in the hospital market or in the clinical lab market. And so we don't have a lot of exposure to the kind of headwinds that you were mentioning."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments -- 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences growing in the U.S. around 8% for the quarter",78,"I think what demonstrates that, Brian, is the 7.2% growth we saw in the U.S. across the company, which was strong in both segments -- 7.7% in Medical and 5.8% in Life Science. And I'd also point to Biosciences growing in the U.S. around 8% for the quarter and for the year. A lot of that was new product introductions of Symphony, Celesta, the new Melody introduction or whatever. So U.S. is feeling particularly strong for our business."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Jon Groberg of UBS.",9,"Your next question comes from Jon Groberg of UBS."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting.",49,"So Vince, it's the first Analyst Day coming up since -- in November here since 2011, and I know you don't want to give away all the details. But just kind of big picture, maybe you can help us understand what you hope people take away from the meeting."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio stan",263,"Yes. I hope that they take away a true understanding of, when we are talking about this move to complete solutions for the customer based on anchor products and value-added services, all the way to complete solutions, what that means from a portfolio standpoint. And when I'm saying that we have the most robust pipeline in the history of the company, I want you to understand what that all means. And we will lay that out for you in a lot of detail. So that's number one on the list, that you understand why we have that confidence going forward. And I think it's going to be fun, quite frankly. It was fun doing this 5 years ago, so I'm looking forward to it. And then we're going to take that and we're -- and Chris is going to kind of give you a financial model of how this all holds together. And lastly, we're going to talk about the capabilities that it's going to require to do all this. And we're going to show you how we built the capabilities foundationally over the last 5 years and then how we build upon them. Tom mentioned informatics for example, but we'll also get into how we approach emerging markets, what's different about our strategy and why we see that continuing to work and some of the other capabilities that we will be bringing to bear, which all is an extension of the work we've done over the 5 years. So that's the kind of day, and look forward to seeing you there, Jon."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Bill Quirk of Piper Jaffray.",10,"Your next question comes from Bill Quirk of Piper Jaffray."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, as a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medi",90,"A couple of questions here. First off, international safety, Vince, you mentioned China, in particular, as a standout. Just remind us where we are on the ongoing European conversion. And then secondly, the Life Sciences business, at least relative to Medical, has been a little less predictable, and we certainly appreciate all new product launches, both in-launch as well as near-term development. Do you think this can improve the predictability of the business? Or do you think we may have to look at some tuck-in deals to improve the consistency?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump a",137,"Well, let me just take Life Sciences first. And the lumpiness that we've seen on Life Sciences, there's 2 elements. One is just KIESTRA, which is a positive thing. These are big installations. They're $2 million. And so you're seeing some quarterly jump around as customers are ready for us to install because there's some major changes that they have to make to the laboratory, number one. Number two, we've had this issue with Africa, and that's been a bit of a problem. We think that's going to annualize. Are we interested in tuck-in acquisitions there? Absolutely, as we are on the Medical side. I'm just going to ask Alberto to comment on KIESTRA and kind of what you're seeing from a pipeline standpoint, how you see the U.S. market evolving because we just got started there."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in",121,"Yes. Where we're seeing the most growth and positive growth is in the U.S. market. Traditionally, this has been an acquisition that was based in Europe, and that market was most developed there. But we're beginning to see some significant traction here in the U.S. In fact, the sales this last year doubled versus the previous one, admittedly on a small base, but we're seeing a lot of positive momentum, especially as we build the platform. And you'll hear the capabilities of the platform that you'll hear about on the Analyst Day. So we would continue to build on those capabilities, and that gets our customers very excited about the future of the platform, not only the price of the platform."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?",41,"And so the second part of the question was on where are we in Europe from a safety conversion standpoint. And if I remember right, Tom Polen gave you a baseball analogy last quarter. So what inning are we in, Tom?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling",150,"Bill, Tom. So we're in the middle innings when it comes to EU safety, and maybe there'll be an overtime as well, like there was last night. But overall, we see safety continue to perform well in Europe. Compliance with the regulation certainly is fueling that. We see implementation strongest in the conventional hospital settings. It's a little weaker in the alternate settings. That's true in most markets where individual doctor compliance may be less than a large governed hospital setting. Strongest conversion rates we see in infusion therapy and blood collection, a little bit lagging in injection. That's also the exact same trend that we saw in the U.S. So still good growth prospects there, and we're in the middle innings. You also mentioned China. Overall in emerging markets, we see safety in the very early innings at less than 15% conversion, so still quite a ways to go."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Derik De Bruin of Bank of America.",12,"Your next question comes from Derik De Bruin of Bank of America."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Midd",104,"A lot of questions have been answered, but I just wanted a little bit more color on some of your emerging market expectations. I mean, there was a number of reductions in terms of the outlook on the growth over the year -- or during 2016, like in the Middle East situation. But I just -- what sort of gives you confidence that, that's going to reaccelerate this year other than tougher comps -- or easier comps? So what are you sort of seeing right now that gives you confidence that, that's going -- you're not going to have to face another slower year?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop buyi",211,"Well, I think you have to start with Saudi Arabia, which was a major impact to our emerging market growth this year. And as I said, government policy was cut all expenses by 35%. Now if you're going to run your health care system, you can't just stop buying product, number one. So our expectation was they were running down their inventories and then -- and they would start to buy. What we've seen in this quarter was stabilization there. And so it didn't come all the way back to positive growth, but it was significant improvement. So that gives us a sense that our hypothesis in this case is right, number one. Number two, it's really Africa and the annualization of Africa. It was still negative, but we started to see -- and Alberto could give you some more details, some CD4 orders starting to come in, which we did not see. So -- and then we saw good performance across Asia, as I was mentioning before. I expect that to keep happening. I expect that Latin America -- that Brazil is going to remain status quo, and we're going to continue to see strong growth in the other marketplaces. But Alberto, any more -- any other comments on CD4?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that created a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipated.",48,"Yes. I just want to go back to a comment I'd said before in terms of the change in the supply chain that created a little bit of instability in the ordering process and the delivery. And that created a little bit more variance than we had anticipated."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, where people didn't know how to order. And that's behind them.",12,"Yes, where people didn't know how to order. And that's behind them."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a littl",108,"I think the other point is that China, we saw a little bit of inventory adjustments in the first quarter of last year. But since then, as Vince mentioned earlier, it's been growing very nicely. And you see the fourth quarter grow extremely nicely, a little bit of an easier compare there, but still very strong. Vince and I and Tom just got back from China. I can tell you there's a lot of enthusiasm for some of the newer products that we're bringing in. So we see a lot of good stability, and as we mentioned, we're looking at low double digits on China into next year."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets.",38,"And then the last piece is that we do expect to start getting some traction with the CareFusion products. And that's tens of basis points for the corporation, but it's more than that, obviously, for the emerging markets."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Doug Schenkel of Cowen and Company.",11,"Your next question comes from Doug Schenkel of Cowen and Company."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was",96,"Just a couple of topics. First, could you provide a bridge for 2017 operating margin guidance? I guess I'm just trying to get at how much of this is synergies, removal of respiratory, mix, et cetera. And then second, on the topic of new products, what was new product contribution to 2016 revenue growth? And looking ahead to 2017, it seems like new product contribution to organic growth should account for a bigger part of overall growth as you accelerate revenue synergies and some important launches, such as the infusion sets. Could you comment on that?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming",103,"So this is Chris. On the first part of that question, as we look at the margin next year, the roughly 200 basis points of operating margin, about 50 basis points of that from the normal continuous improvement kind of stuff, another 50 basis points coming from cost synergies and about 100 basis points coming from the respiratory JV coming off our income statement, so we get benefit there. And on the gross profit, it's roughly the same kind of area. There's a benefit from respiratory -- about half of it coming from respiratory, about half of it coming from CI and synergy."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they rea",179,"In terms of new products, the growth that you're seeing in Biosciences is really driven by the new product instrumentation, okay? So I can point you directly to that. But in terms of the other major new product launches that we are talking about, they really haven't gotten traction yet. Barricor, people are just starting to validate Barricor. The approvals on BD MAX we just got in the last month or so. So they really haven't hit. And then you're talking about tens of basis points in terms of the CareFusion products in the emerging markets at this point in time. We haven't done the work -- we haven't completed the work, let me say it that way, in terms of trying to get a really good analysis around breaking out new product from the entire company. As we're going through the CareFusion integration, we haven't counted the geographic extension of those products as new products. But we're working our way through that, and you'll have a better sense, after the Analyst Day, of how this is coming together."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your next question comes from Matt Taylor of Barclays.",9,"Your next question comes from Matt Taylor of Barclays."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluids, diabetes an",80,"I was wondering if you could comment -- given that you do have some bigger product cycles here coming up in the fiscal year and one of the more robust pipelines of the company, could you comment on some of the bigger opportunities like fluids, diabetes and some of the diagnostic launches in terms of how we should expect the revenue contributions from those to flow? Can you help us size them and just give us some thoughts on timing?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?",14,"So I'll ask Tom to start with talking about diabetes and FlowSmart, okay?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begu",168,"Okay. Matt, this is Tom. So certainly, we're excited about the upcoming launch -- or the recent launch of the infusion set. In September, we did make our first shipments to Medtronic on the MiniMed Pro-set with our FlowSmart technology. Medtronic has begun shipping that to patients, and the feedback that we're hearing is very positive. And there's been a number of bloggers actually write their experience. You can look that up online, but it's very, very good feedback as that's moved into the marketplace just over the last couple of months. We do expect that, that probably will expand to a broader full launch in early Q2. And that's well on track. So I think back to one of the earlier questions, as we think about -- within the Diabetes Care business, we do expect -- and obviously we don't give guidance by business unit, but we expect an uptick in '17 in Diabetes Care, driven by that FlowSmart launch. And that's on track, proceeding as planned."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things.",23,"Okay. So Alberto, why don't you comment on BD MAX and Barricor as well in terms of kind of phasing on those things."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first o",190,"Yes. So for the BD MAX, the 2 approvals that we got in the U.S., FDA approvals, we're very excited about because they're very unique assays. They're very differentiated assays that will bring a lot of value to the market. The CT/GC/TV assay is the first one that is integrated, which is a guideline from the CDC to do the 3 tests all in one, and we're the only ones that will have it in the same assay. The vaginal panel will be a significant improvement versus the only approved assay, the Affirm assay, that we have out there; will be better accuracy, more targets and much improved performance from that side. That will take a little bit of time to be built into the sales as people evaluate and -- accounts evaluate and convert to this. But we are very, very optimistic. And all -- the interest has been very high in both accounts. And on Barricor, a similar thing. The evaluations are beginning to happen. There's more than 50 accounts currently evaluating the Barricor products, and that momentum we anticipate to continue in the rest of the year."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?",24,"So if you think about it, Alberto, from a cycle standpoint, an evaluation of a new assay takes about how long generally? 90 days?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, between -- yes, I would say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there.",24,"Yes, between -- yes, I would say between the quickest, 45, to -- it can be up to 100 days, so somewhere in there."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot.",20,"To 100 days, yes. And then you have to -- they got to work off their old inventory and whatnot."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Right.",1,"Right."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And the last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- for BD CLiC, we are putting our first instruments as early access into customer accounts. So",101,"And the last piece we haven't mentioned at all and we will talk to you about at the Analyst Day, of course, is genomics. In genomics, where we stand there, is -- for BD CLiC, we are putting our first instruments as early access into customer accounts. So they will just start to do their validations as well, and so I don't expect that to be a big contributor this year. I expect, since it's such new technology, it's going to take a little longer, but we're also starting to get good feedback there. Anything else you want to add?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time.",29,"And we will be issuing and launching new protocols as well, new assay protocols, as we go along the year. That will build up momentum at the same time."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question.",17,"Yes, really coming into, I think, '18 with those protocols. Okay. Thanks very much for the question."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","Your final question is coming from Richard Newitter with Leerink Partners.",11,"Your final question is coming from Richard Newitter with Leerink Partners."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Analysts","Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Eur",133,"Just you've now had some time to kind of digest all the opportunities that maybe you had in front of you -- or that CareFusion had in front of it but didn't have the means to exploit. And I'm thinking a little bit more about the dispensing business in Europe. And I know the business model in that part of the world is just different, and it hasn't historically lent itself well. But I do believe you had begun to talk a little bit about Rowa and leveraging that technology. I'm just wondering if that's going to factor in, in 2017 in the cross-sell or the synergy phase of the acquisition integration. And any kind of thoughts there? And is that something that we could hear more about at the Analyst Day?"
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line lo",69,"Yes, you will hear more about it at the Analyst Day. It's not so much a cross-selling opportunity, but an additional opportunity is the way that I would think about that. And we will share that because we haven't kind of detailed what that product line looks like for you, and there's multiple aspects to that. So yes, we'll be happy to talk about that. Thanks for the question."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","I will now turn the floor back over to Vince Forlenza for closing remarks.",14,"I will now turn the floor back over to Vince Forlenza for closing remarks."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and",53,"Well, thank you all for your participation on the call today. It was a pleasure going through what was a strong year for BD, to talk about 2017. And we're looking forward to getting together with you at the Analyst Day in 2 weeks. So thanks very much, and we'll see you there."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Executives","Thanks, everyone.",2,"Thanks, everyone."
103678,403765314,1073676,"Becton, Dickinson and Company, Q4 2016 Earnings Call, Nov 03, 2016",2016-11-03,"Earnings Calls","Becton, Dickinson and Company","Operator","This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day.",18,"This does conclude today's teleconference. Please disconnect your lines at this time, and have a wonderful day."
